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G-protein coupled receptors (GPCRs) play an essential role in the ability of a cell to react to its 
environment. The presence of these receptors on the cell membrane allow the external environment 
of a cell to affect the intracellular signalling that takes place. For this reason GPCRs are an attractive 
drug target. Targeting of class B GPCRs through the GLP-1 receptor (GLP1R) agonists is an already 
approved therapy for the treatment of Type 2 Diabetes. Class A rhodopsin-like GPCRs are currently 
the most popular drug targets for current FDA approved drugs. GPCRs are also attractive drug 
targets due to the wide range of ligands that bind to GPCRs such as free fatty acids during digestion. 
This thesis examined the effects of activation of both synthetic and endogenous ligands for GPR39, 
GPR55, GPR75, GPR119 and GPR120 on the secretion of the incretin hormones GLP-1 and GIP. 
The insulinotropic effects of these receptors was also investigated. GLP-1 and GIP secretion were 
studied using GLUTag and pGIPneo STC-1 cells respectively while insulin secretion was assessed 
in BRIN-BD11 cells and isolated pancreatic islets. The cytotoxicity of GPCR agonists was 
determined using MTT assay in GLUTag and pGIPneo STC-1 cells and Alamar blue assay in BRIN-
BD11 cells. Membrane integrity was further studied using LDH assay. The expression and cellular 
localisation of GPCRs and intestinal hormones was determined using qPCR and double 
immunohistochemistry in both cell lines and small intestine. The acute in vivo effects of intestinal 
GPCR activation on blood glucose as well as plasma GLP-1, GIP and insulin were examined in 
male Swiss TO mice. The chronic effects biological effects of GPR55 agonist Abn-CBD and 
GPR119 agonist GPR119 as a monotherapy and combination therapy with the DPP-IV inhibitor 
Sitagliptin were assessed. 
GPCR agonists were able to demonstrate GLP-1, GIP and insulin secretory ability both in vitro and 
in vivo. The expression of GPCRs in the L and K cells of the intestine were confirmed using 
immunohistochemistry. Oral administration of GPCR agonists as a monotherapy or combination 
therapy resulted increased incretin hormone and insulin secretion as well as reduced blood glucose. 
The effects of chronic treatment of AS1269574 and Abn-CBD in streptozotocin induced diabetic 
mice improved glucose homeostasis. 
Overall this thesis identified the ability of GPCR ligands to affect glucose homeostasis through the 
incretin hormone pathway as well as through direct action on the pancreas. The work carried out in 
this thesis demonstrates that GPCR based therapies have anti-diabetic potential and may be an 
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Diabetes mellitus is a metabolic disorder which is defined by chronic hyperglycaemia which is 
caused by either defective insulin secretion, reduced sensitivity to insulin in peripheral tissues or 
both (Karamanou et al. 2015). In 2015, 415 million people were estimated to have diabetes with 
this number expected to rise to 642 million people in 2040 (Ogurtsova et al. 2017). A large number 
of people with diabetes have yet to be diagnosed (Shi, Hu 2014). Unchecked, hyperglycaemia leads 
to a range of complications including diabetic ketoacidosis and hyperosmolar hyperglycemic state 
(Kitabchi et al. 2009). Diabetes appears to be linked with increased cancer rates, however the 
mechanisms through which they are both linked are not yet understood (Shi, Hu 2014). Diabetes is 
also linked with cardiovascular diseases as well as complications in the eyes, kidneys and nerves 
due to damage to the small blood vessels (Emerging Risk Factors Collaboration et al. 2010).  
 
1.1.1: Classification of diabetes 
Diabetes was first classified into insulin-sensitive and insulin-insensitive types (Himsworth 2011). 
Up to 3 million people in the USA are estimated to be living with Type 1 Diabetes which is the 
insulin sensitive type described by Himsworth in 1936 (Chiang et al. 2014). It is estimated that 
around 190000 youths under 20 years of age have Type 1 Diabetes in the USA (Pettitt et al. 2014). 
In Type 1 Diabetes, lymphocytes target the β-cells of the pancreas leading to reduced insulin 
secretion (Craig, Hattersley & Donaghue 2009). Clinical symptoms of Type 1 Diabetes present 
themselves whenever T-cell mediated destruction of the β-cells has destroyed 90% of β-cell 
population in the pancreas (Gepts 1965). It can be hard to diagnose late onset Type 1 Diabetes, 
however 8.8% of people with this type of diabetes produce GAD antibodies (Hawa et al. 2013) 
while one in three people have residual C-peptide levels especially in those diagnosed later in life 
(Davis et al. 2015). Clinical symptoms of Type 1 Diabetes include polyuria, polydipsia, and 
ketonemia with the most dangerous side effect of these being the rapid onset of ketoacidosis (Chiang et 
al. 2014). Type 1 Diabetes accounts for approximately 5-10% of all diabetes cases (Mealey, Oates 
& American Academy of Periodontology 2006).  
When Himsworth was describing the insulin-insensitive diabetes in 1936, he was most likely 
describing individuals with Type 2 Diabetes. This is the most prevalent form of diabetes with 
estimates suggesting 90% of all diabetes sufferers having Type 2 Diabetes (Zimmet, Alberti & Shaw 
2001). The highest proportion of individuals with Type 2 Diabetes are those who have adopted a 
Western lifestyle while people from developing countries appear to be affected in lower numbers 
(Forouhi, Wareham 2014). Type 2 Diabetes is increasing in prevalence globally and there are 
expected to be approximately 600 million people diagnosed with Type 2 Diabetes by 2035 (Forouhi, 
Wareham 2014). The symptoms of Type 2 Diabetes include polyuria, polydipsia, polyphagia, and 
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weight loss (Vijan 2010). One of the main complications of Type 2 Diabetes is reduced glucose 
tolerance of the peripheral tissues due to reduced glucose uptake in these tissues during episodes of 
hyperinsulinemia and this complication can appear before the full development of Type 2 Diabetes 
(Lillioja et al. 1988, Warram et al. 1990, Lillioja et al. 1993). The most severe complications with 
Type 2 Diabetes are the hyperosmolar hyperglycemic state (HHS) and diabetic ketoacidosis, 
however diabetic ketoacidosis is rarely seen in people with Type 2 Diabetes (Pasquel, Umpierrez 
2014, Fasanmade, Odeniyi & Ogbera 2008). Other complications seen in individuals with Type 2 
Diabetes include altered lipid metabolism, retinopathy, nephropathy, neuropathy, impotence, 
acanthosis nigricans, or frequent infections (Vijan 2010, Nolan, Damm & Prentki 2011). These 
complications are strongly linked with obesity which has led to the development of the term 
“diabesity” (Shafrir 1996). The therapies used to control the complications of Type 2 Diabetes 
include diet and drugs however if this doesn’t work then direct injection of insulin is required 
(Zimmet, Alberti & Shaw 2001). 
The other main form of diabetes is gestational diabetes which occurs in pregnant women who are 
intolerant to glucose (American Diabetes Association 2004). It was originally described as a form 
of diabetes which increased foetal mortality however the same risk was not transferred to the mother 
(White 1949). Increased infant mortality is not the only risk for children as offspring from mothers 
affected by gestational diabetes are larger when born (Nolan 2011). Estimates suggest that 7% of 
all pregnant women are affected by gestational diabetes however estimates also vary from 1% to 
14% of all pregnancies (American Diabetes Association 2004). Like Type 2 Diabetes, gestational 
diabetes is linked to obesity with heavier mothers being at greater risk of gestational diabetes (Chu 
et al. 2007a) however blood glucose is regulated better in women with reduced carbohydrate intake 
(Major et al. 1998). Gestational diabetes is also linked to an increased risk of developing Type 2 
Diabetes in later life (Ross 2006).  
 
1.1.2 Pathophysiology of type 2 diabetes 
The development of Type 2 Diabetes has classically been attributed to 3 main causes of 
hyperglycaemia (Codario 2011). These are increased hepatic gluconeogenesis and glycogenolysis, 
impaired insulin secretion from the β-cells of the pancreas and resistance to insulin in the muscle 
and adipose cells of the body (Robert 1996). Despite several studies identifying loci which may 
confer an increased risk for Type 2 Diabetes (Hanis et al. 1996, Sladek et al. 2007), no single genetic 
cause has been identified (Codario 2011).  On top of the 3 classical causes of hyperglycaemia in 
individuals with Type 2 Diabetes, a fourth cause, impaired incretin secretion, has been identified 
(Codario 2011). Evidence for insulin resistance was presented in 1960 in a study which 
demonstrated diabetic individuals having hyperinsulinemia as well as hyperglycaemia (Yalow & 
Berson 1960). Due to the complex nature of the pathophysiology of Type 2 Diabetes, there are 
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various treatments which are prescribed depending on the mechanisms causing hyperglycaemia or 
insulin resistance. These therapies are discussed in more detail below. 
Increased gluconeogenesis has previously been described as the main cause of fasting 
hyperglycaemia (Consoli 1992). This is further backed as Metformin, the front line in Type 2 
Diabetes treatment, exerts its mechanism of action through reduced gluconeogenesis (Hundal et al. 
2000). Meanwhile, insulin resistance can occur naturally during different stages of the life cycle 
including puberty (Moran et al. 1999), aging (DeFronzo 1979) and pregnancy in women (Buchanan 
et al. 1990). The effects of insulin resistance have been shown to be reduced when physical activity 
is increased (Goodyear, Kahn 1998). The mechanism through which insulin resistance is increased 
appears to be through reduced GLUT4 expression and increased retinol binding protein-4 (RBP4) 
expression in adipocytes (Yang et al. 2005). Increased plasma free fatty acid levels have also been 
linked with insulin resistance (Boden 1997). Interestingly the function of the β-cells of the pancreas 
is mediated by the sensitivity of the peripheral tissues in the body to insulin (Kahn et al. 2006). 
There is further evidence for the link between insulin sensitivity and the functionality of pancreatic 
β-cells as healthy β-cells respond to insulin resistance to maintain normal glycaemic levels, however 
when β-cells are dysfunctional, glucose homeostasis is impaired (Kahn et al. 2006). Dysfunctional 
β-cells lose function in various ways as they are unable to secrete insulin in response to both 
increased glucose levels and nonglucose secretagogues (Kahn 2001). Furthermore individuals with 
Type 2 Diabetes have exhibited reduced β-cell mass due to increased apoptosis resulting in the 
pancreas being unable to adequately respond to insulin secretory stimuli (Butler et al. 2003). The 
hyperglycaemia exhibited in Type 2 Diabetes may also play a role in β-cell dysfunction due to the 
toxic effects of elevated glucose levels on the β-cell (Garvey et al. 1985). 
 
1.1.3: Current therapies 
Before drug prescription for the treatment for Type 2 Diabetes, most people will try to use a form 
of dietary intervention to try and reduce chronic hyperglycaemia. Reduction in energy intake has 
been shown to normalise blood glucose values as well as reduce pancreatic fat (Lim et al. 2011). 
Undertaking a very-low-calorie diet (VLCD) of 600-700 calories a day can reverse Type 2 Diabetes 
in a very short timeframe however the long term effects of this diet are unknown (Steven et al. 
2016). Other methods for weight loss include surgical intervention through bariatric surgery and 
this has shown to have positive effects on liver fat levels, insulin sensitivity, blood glucose levels, 
plasma insulin levels and body weight (Taylor 2008, Kashyap et al. 2010). These effects may be 
due to the area of the small intestine that is bypassed (Pories et al. 1987, Rubino et al. 2006). 
Bariatric surgery may be preferable to dieting as the long term weight loss through this method is 
sustainable (Pories et al. 1987) however this has to be measured against the potential for 
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complications during the surgery. When dietary intervention is unable to control the symptoms of 
Type 2 Diabetes, a pharmaceutical drug is prescribed and these are discussed in more detail below. 
 
1.1.4: Biguanides 
Biguanides were first used in medieval times through the use of the French lilac as an anti-diabetic 
therapy and became prominent in the 1960s (Witters 2001). The main biguanide used is metformin 
which is an oral drug which was approved by the FDA for the treatment of Type 2 Diabetes in 1995 
(Hundal, Inzucchi 2003) however it was used in the UK from 1958 (Malek et al. 2013). Other 
biguanides such as phenformin and buformin had severe side effects which led to their withdrawal 
as an anti-diabetic treatment in the 1970s (Witters 2001). One of these side effects, lactic acidosis, 
is seen at far lower levels when metformin is administered (Sirtori et al. 1978) however it is more 
likely to occur in people with poor renal function (Lipska, Bailey & Inzucchi 2011). Metformin 
increases the insulin sensitivity of the liver and peripheral tissues as well as reducing hepatic glucose 
output (Dunn 2005, Hundal et al. 2000). The reduction of gluconeogenesis from the liver is insulin 
dependent and is regulated through the AMPK pathway (Malek et al. 2013). Metformin 
monotherapy is usually the first treatment adopted when a person is diagnosed with Type 2 Diabetes 
although combination therapies with insulin and other drugs are being investigated (Hemmingsen 
et al. 2012, Maruthur et al. 2016). 
 
1.1.5: Sulphonylureas 
Sulphonylureas have a direct effect on the insulin secreting β-cells of the pancreas (Rendell 2004). 
As a result of this one of the main complications with the use of sulphonylureas is hypoglycaemia 
(van Dalem et al. 2016). There are 3 forms of sulphonylurea receptor, SUR1, SUR2A and SUR2B 
(Matsuo et al. 2000) with the SUR1 receptor being expressed in the pancreas (Donley et al. 2005). 
Sulphonylureas bind to SUR1 which is a crucial component of ATP-sensitive potassium ion 
channels along with Kir6.2 subunits (Reis, Velho 2002). Four Kir6.2 subunits form the inner pore 
of the KATP channel through which potassium ions can enter the cell with each subunit being 
attached to a separate SUR subunit which ATP binds to (Nichols 2006). ATP binding to SUR1 is 
dependent on magnesium ions (Matsuo et al. 2000). These KATP channels are inwardly rectifying 
potassium channels which allow potassium to enter β-cells of the pancreas (Hibino et al. 2010). 
Sulphonylureas attach to these receptors, forcing them to close and as a result potassium can no 
longer enter the β-cell. This leads to membrane depolarisation, the influx of extracellular calcium 
into the cell and thus insulin secretion (Gribble, Reimann 2003). Knockout of either the Kir6.2 or 
SUR1 subunits of the KATP channel results in neonatal hypoglycaemia (Miki et al. 1998, Seghers et 
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al. 2000). Single nucleotide polymorphisms in either the Kir6.2 or SUR1 subunits can lead to 
hyperinsulinemic hypoglycaemia in infants as well as an increased risk in Type 2 Diabetes which 




Like sulphonylureas, meglitinides increase insulin secretion through direction action on the KATP 
channels of the β-cells of the pancreas (Blickle 2006). Repaglinide was the first meglitinide used as 
an anti-diabetic therapy followed closely by nateglinide (Landgraf 2000). Oral administration of 
meglitinides leads to a rapid increase in insulin secretion from the pancreas and reduces postprandial 
hyperglycaemia (Black et al. 2007). They also do not have long lasting effects on the pancreas as 
they are rapidly metabolised in the liver (Landgraf 2000). This makes it meglitinides a viable 
alternative to those who cannot use metformin due to renal impairment (Blickle 2006). Meglitinides 
have also been shown to reduce glycosylated HbA1c with repaglinide outperforming nateglinide 
(Black et al. 2007). Compared to sulphonylureas, meglitinide administration confers an increased 
risk of hypoglycaemia (Gerich et al. 2005) while there was increased weight gain compared to 
metformin administration (Black et al. 2007). Due to their rapid degradation in the liver, 
meglitinides need to be taken in more frequent dosages than other anti-diabetic medications 
(Inzucchi et al. 2012). 
 
1.1.7: Thiazolidinediones (TZDs) 
TZDs, which are also known as glitazones, are similar to metformin as they increase insulin 
sensitivity of fat, liver and muscle cells (Hauner 2002). Administration of pioglitazone was shown 
to have no detrimental effects on cardiovascular risk and it has been shown to reduce coronary 
atherosclerosis (Mannucci et al. 2008, Nissen et al. 2008). It is thought that the reason for these 
beneficial side effects is due to the activation of the peroxisome proliferator-activated receptor 
gamma (PPAR-γ) by TZDs which in turn alters the expression of a range of genes involved in 
metabolism (Hauner 2002). TZDs can be administered as a monotherapy or as a combination 
therapy with other Type 2 Diabetes therapeutic drugs (Rosenstock et al. 2007). Side effects of TZDs 
include weight gain, water retention, increased risk of myocardial infraction and there is also data 
to suggest that there is an increased risk of bladder cancer (Nathan et al. 2006, Nissen, Wolski 2010, 




1.1.8: α-glucosidase inhibitors 
α-glucosidase inhibitors prevent postprandial hyperglycaemia through the reduction in the rate of 
gastric emptying by reducing the rate of polysaccharide digestion (Nathan et al. 2006). As α-
glucosidase inhibitors work in the intestine, they have no direct effect on insulin secretion from the 
pancreas and thus are unlikely to cause hypoglycaemia (Van de Laar et al. 2005). They have been 
shown to exhibit positive effects on glycated HbA1c, fasting blood glucose and postprandial blood 
glucose (Van de Laar et al. 2005). Acarbose has also been shown to have positive results in the 
reduction of myocardial infraction, hypertension and other cardiovascular events (Chiasson et al. 
2003). Due to their effects on the intestine, the main detrimental side effects of these inhibitors are 
found in the gastrointestinal tract and include flatulence, diarrhea and stomach ache (Van de Laar 
et al. 2005). 
 
1.1.9: GLP-1 mimetics 
As discussed above, incretin hormones are important regulators of glucose homeostasis however 
they are rapidly degraded by DPP-IV. Also described above are the GLP-1 receptor agonists 
Exenatide and Liraglutide. GLP-1 receptor agonists are an attractive area of research in Type 2 
Diabetes research due to the ability of GLP-1 to increase β-cell mass through the generation of new 
β-cells and the reduction of β-cell apoptosis (Lund, Knop & Vilsboll 2011). GLP-1 mimetics are 
preferred to native GLP-1 as they avoid the rapid cleavage that GLP-1 undergoes by DPP-IV. 
Exenatide (marketed as Byetta) is based off the peptide Exendin-4 which was first extracted from 
Heloderma suspectum venom and has 53% sequence homology with GLP-1 (Eng et al. 1992). 
Despite the differences in sequence between Exendin-4 and GLP-1, there does not appear to be any 
differences in the potency of each agonist for the GLP-1 receptor (Lund, Knop & Vilsboll 2011). 
Liraglutide (which is marketed as Victoza) has 97% sequence homology with GLP-1 but avoids 
DPP-IV degradation through the addition of a 16-carbon fatty acid chain at Lys26 and the 
substitution of a Lysine residue with an Arginine residue at position 34 of the polypeptide chain 
(Neumiller et al. 2010). Exenatide was the first GLP-1 mimetic to be used as a therapy for Type 2 
Diabetes with FDA approval being granted in 2005 with Liraglutide being granted this in 2010 
(Lund, Knop & Vilsboll 2011). The first generation of GLP1R agonists have to be injected either 
once or twice daily which has led to the development of longer lasting agonists which are injected 
once a week such as Bydureon, Lixisenatide, Albiglutide, Dulaglutide and Semaglutide (Lund, 
Knop & Vilsboll 2011, Lund, Knop & Vilsboll 2014). The side effects of GLP1R agonists mostly 
stem from the gastrointestinal tract and include diarrhea, nausea and vomiting while spells of 
dizziness have also been reported (Agerso et al. 2002, Neumiller et al. 2010). The anti-diabetic 
effects of GLP-1 mimetics include reduced glycated HbA1c, fasting glucose and body weight (Buse 
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et al. 2004, DeFronzo et al. 2005, Kendall et al. 2005, Feinglos et al. 2005). GLP-1 mimetics may 
also have beneficial effects on fatty liver disease and inflammation (Lee et al. 2012, Samson, Bajaj 
2013, Wang et al. 2014). 
  
1.1.10: DPP-IV inhibitors 
DPP-IV inhibitors improve glycaemic control through a reduction in the degradation of native GLP-
1 (Pathak, Bridgeman 2010). The quick half-life of native GLP-1 in the body directed researchers 
towards the targeting of DPP-IV (Verspohl 2009). The first approved DPP-IV inhibitor was 
Sitagliptin which was approved by the FDA in 2006 (Dicker 2011). The effects of these compounds 
appears to be only through the incretin hormones and not a direct action on the pancreas as the use 
of DPP-IV inhibitors in double incretin receptor knockout (DIRKO) mice had no effect on glucose 
homeostasis (Hansotia et al. 2004). In high fat fed rats, DPP-IV inhibition reduced hyperglycaemia 
and increased insulin secretion through the incretin pathway after being challenged with glucose 
(Mitani et al. 2002). DPP-IV inhibitors have also shown the ability to reduce glycated HbA1c, 
fasting blood glucose, postprandial blood glucose, mean blood glucose and postprandial glucose 
levels as well as increase mean and postprandial GLP-1 levels (Ahren et al. 2004b, Dicker 2011). 
They can also be used as a monotherapy but are also used as a combination therapy with other 
treatments (Ahren et al. 2004a, Dicker 2011). Unlike GLP-1 mimetics, DPP-IV inhibitors can be 
administered orally (Verspohl 2009). There are a range of adverse side effects caused by DPP-IV 
inhibitors which include headaches, respiratory tract infection, urinary tract infection and, like 
metformin, should not be administered to people with renal impairment (Pathak, Bridgeman 2010). 
 
1.1.11: Sodium-glucose cotransporter 2 (SGLT2) inhibitors 
SGLT2 inhibitors are a relatively recent discovery for the treatment of Type 2 Diabetes and they 
have been recommended as a second option for individuals who do not respond or cannot use 
Metformin (Cefalu, Riddle 2015). SGLT2 inhibitors tend to be used as a double or triple 
combination therapy in conjunction with other diabetic medicines (Rosenstock et al. 2007, Lewin 
et al. 2015) and they have potential as a combination therapy with Metformin as SGLT2 inhibitors 
convey a protective effect on the kidneys (Fioretto et al. 2016). SGLT2 inhibitors were targeted as 
a therapy for Type 2 Diabetes as blood glucose is reabsorbed in the kidneys and inhibition of this 
reabsorption should lead to reduced blood glucose and better control of hyperglycaemia (Han et al. 
2008). They have proven to be useful in the treatment of Type 2 Diabetes through the reduction of 
glycated HbA1c, body weight and systolic blood pressure (Leiter et al. 2015, Matthaei et al. 2015). 
The first SGLT2 inhibitor identified was dapagliflozin which reduced blood glucose in 
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hyperglycaemic rats (Meng et al. 2008). Other SGLT2 inhibitors have been identified and some of 
these have been shown to reduce blood pressure and hypertension in individuals with Type 2 
Diabetes (Tikkanen et al. 2015). Care must be taken when administering SGLT2 inhibitors as they 
may cause diabetic ketoacidosis despite no dramatic increase in blood glucose (Rosenstock, 
Ferrannini 2015, Taylor, Blau & Rother 2015). 
 
1.1.12: Amylin analogues 
There is only one amylin analogue that is currently approved for use in the treatment of both Type 
1 and Type 2 Diabetes and this is known as pramlintide (Jones 2007). There are 3 different 
substitutions which amylin undergoes in order to form pramlintide. The alanine at position 25 and 
serine residues at positions 28 and 29 in amylin are substituted for a proline residue in each position 
(Edelman, Maier & Wilhelm 2008). One of the major issues with medication for Type 2 Diabetes 
is the resulting weight gain, however pramlintide has shown that it can reduce the body weight as 
well as glycated HbA1c in obese individuals (Hollander et al. 2004). One of the issues with 
pramlintide is that it has to be administered via subcutaneous injection and as a result it is normally 
administered alongside insulin (Hollander et al. 2004, Ryan, Jobe & Martin 2005, Edelman, Maier 
& Wilhelm 2008). Further complications include nausea and hypoglycaemia (Ryan, Jobe & Martin 
2005). It may also not be appropriate for those with poor renal function as pramlintide is broken 
down in the kidneys (Edelman, Maier & Wilhelm 2008). 
 
1.2: Small intestine 
The small intestine runs from the stomach to the caecum and is over 20ft long with the length of the 
intestine being correlated with the individual person’s height (Underhill 1955). The surface area of 
the small intestine has been described to be a similar size to that of a tennis court (260-300m2) 
(Niess, Reinecker 2006) however more recent measurements describe a surface area that is 10 times 
less than this figure (30m2) (Helander, Fändriks 2014). The small intestine has numerous villi which 
project into the lumen of the gut through their finger-like shape (Clevers 2013). Villi are lined 
mainly with epithelial cells that provide a barrier to infection while also being closely linked to the 
vascular system which allows for the absorption of nutrients (Clevers 2013). At the bottom of the 
villi are the crypts of Lieberkühn where populations of intestinal stem-cells reside. These stem cells 
travel up the epithelial lining of the villi thus providing a self-renewal function for intestinal villi 
(Clevers 2013). Stem cells can be identified by the intestinal stem cell marker Lgr5 (van, Clevers 
2009). The first part of the intestine, the duodenum, was first described by Herophilus of chalcedon 
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who was one of the first people to carry out autopsies on humans (Bay, Bay 2010). It is named as 
such due to the fact that it was found to be 12 finger widths long (Helander, Fändriks 2014). The 
duodenum is distinct from the jejunum and ileum due to the presence of Brunner’s glands (Krause 
2000). The jejunum is the middle part of the intestine and is 2/3 the length of the ileum (Cornes 
1965). The ileum is distinct from the other sections of the intestine due to the presence of Peyer’s 
patches, however these are sometimes observed in the distal duodenum and the distal jejunum 
(Cornes 1965). The function of Peyer’s patches is important for the role of the small intestine as a 
barrier to infection as the main function of these patches is mucosal immunity (Lelouard et al. 2012). 
Recently a new organ which interacts with the small intestine, known as the mesentery, has been 
described however further studies will need to be carried out to determine what role this organ plays 
in small intestinal function (Coffey, O'Leary 2016). The composition of the lining of the villi is not 
as simple as stem cells in the crypts of Lieberkühn while epithelial cells line the walls of the villi. 
Instead the nutrient absorbing epithelial cells are interspersed with enteroendocrine, goblet, Paneth, 
tuft and M cells (Clevers 2013) all of which arise from stem cells in the crypts of Lieberkühn 
(Gordon 1993) and all of which are described in more detail below (Figure 1.1). 
Figure 1.1 
Adapted from Crosnier, Stamataki & Lewis 2006. Paneth 
cells (dark green) which secrete antimicrobial peptides 
reside at the bottom of the intestinal crypt. Stem cells (red) 
are also found in the crypt and these cells can differentiate 
into any of the cell types found in the villi. This 
differentiation occurs in the region labelled the transit-
amplifying cells (pink) which is just above the bottom of 
the crypt. After the crypt, the villi protrudes into the lumen 
of the small intestine in a finger like conformation. Cells 
on the outer surface are determined to have an open 
conformation and these are mainly epithelial cells (in blue) 
which allow for the absorption of nutrients from digested 
food travelling through the intestine. Interspersed 
throughout the epithelial cells are goblet cells (light green) 
which secrete mucus to help with the transport of food 
along the lumen. Also interspersed throughout the 




1.2.1: Enteroendocrine Cells 
The gastrointestinal tract secretes a wide variety of hormones with over 30 different gastrointestinal 
hormones having been described (Gunawardene, Corfe & Staton 2011). Despite the large number 
of hormones secreted from the intestine, the enteroendocrine cells of the intestine only make up a 
small (less than 1%) proportion of the intestinal cell population (Sternini, Anselmi & Rozengurt 
2008, Gunawardene, Corfe & Staton 2011) and are scattered individually throughout the intestine 
(Schonhoff, Giel-Moloney & Leiter 2004). The enteroendocrine cells can be further divided into G, 
X/A-like, D, I, K, L and enterochromaffin cells (Sternini, Anselmi & Rozengurt 2008) which are 
described in more detail below. Cells can be described as ‘open’ or ‘closed’ which describes their 
position on the villi. Open cells protrude into the lumen while closed cells do not (Sternini, Anselmi 
& Rozengurt 2008). 
 
1.2.2: G cells  
The G cells of the intestine secrete gastrin and are found in the upper duodenum as well as the 
stomach (Walsh, Grossman 1975). Secretion from G cells is potently stimulated by individual 
amino acids, phenylalanaine and tryptophan in particular (Taylor et al. 1982) as well as extracellular 
calcium ions (Levant, Walsh & Isenberg 1973). Interestingly secretion from G cells is not 
influenced by the concentration of calcium ions in plasma. The reason for this is that extracellular 
calcium activates a calcium sensing receptor which in turn activates phospholipase C. This opens 
other cation receptors on the cell membrane thus allowing for the influx of calcium into the cell and 
thus secretion from intestinal G cells (Buchan et al. 2001). G cells are located on villi so project 
into the lumen and as a result are affected by the entry of nutrients into the lumen (Dockray, Varro 
& Dimaline 1996).  
 
1.2.3: X/A-like cells  
The naming of X/A-like cells has arisen due to their similarity to α-cells of the pancreas (thus the 
A-like name) and due to the inability to determine their function in rats (X cells) (Stengel, Tache 
2009). Ghrelin, a hormone which is secreted in appetite regulation, was localised to the X/A-like 
cells in the gastrointestinal tract as well as the stomach thus providing some light on the function of 
these cells (Date et al. 2000). It was later elucidated that these cell also contain obestatin, a hormone 
which reduces appetite and was originally thought to be an agonist for GPR39 (Zhang et al. 2005a). 
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These cells are mainly located in the upper part of the gastrointestinal tract (Rindi et al. 2004) and 
are described as closed due to their unavailability to the lumen (Stengel, Tache 2009). 
 
1.2.4: D cells  
D cells secrete somatostatin and are found throughout both the small and large intestine (Sjolund et 
al. 1983). They appear less often than other enteroendocrine cell types as they make up 
approximately 3-5% of all enteroendocrine cells (Gunawardene, Corfe & Staton 2011). They are 
mainly found in the pancreas as discussed below. 
 
1.2.5: I cells 
I cells secrete CCK in response to fatty acids and proteins as they travel along the villi of the small 
intestine (Sternini, Anselmi & Rozengurt 2008). They are situated mainly in the duodenum and 
jejunum (Figure 1.2) and have the open conformation on the villi wall that allows them to interact 
with the contents of the lumen (Liddle 1997). There has been previous little research on I cells alone 
due to the difficulty in isolating these cells (Sykaras et al. 2012b). The lumen sensing mechanism 
of I cells has yet to be fully elucidated, however this is proposed to be through G-protein coupled 
receptors (GPCRs) and GPR40 has been identified on I cells in the intestine (Liou et al. 2011). This 
same research used GPR40 knockout mice to show that the phospholipase C pathway was the likely 
signalling mechanism for these cells. Another G-protein coupled receptor through which I cells may 
be activated is GPR120 however the role of this receptor in CCK secretion has yet to be fully 
understood (Sykaras et al. 2012b). There is also evidence that GPR41 and GPR43 may be other 
potential G-protein coupled receptor on I cells (Samuel et al. 2008, Sykaras et al. 2012b) 
 
1.2.6: K cells 
Originally K cells were thought to be functional stages of other enteroendocrine cells, however in 
1975 they were discovered to be the GIP secreting cell of the intestine which are present in both the 
duodenum and jejunum (Buffa et al. 1975). While K cells are considered to be a distinct cell type 
from other enteroendocrine cells, there is a small proportion of cells in the intestine which secrete 
both GIP and GLP-1 which is usually secreted from L cells (Mortensen et al. 2003). GIP secretion 
from K cells appears to be controlled through 2 separate pathways, with the nutrient sensing 
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pathway leads to AMPK-kinase regulation while the neuronal pathway activates protein kinase C 
(Li, Wice 2005). The receptors present of the membrane of the K cell appear to provide clues to 
which nutrients stimulate GIP secretion with both glucose sensing and fatty acid sensing receptors 
being present (Parker et al. 2008). K cells are of interest in diabetes research not only for their GIP 
secreting effects, with recent studies engineering them to produce insulin as a possible therapy 
(Mojibian et al. 2014) 
 
1.2.7: L cells 
Intestinal L cells secrete both GLP-1, PYY and GLP-2 and are more numerous in the ileal portion 
of the small intestine than the duodenal section (Sternini, Anselmi & Rozengurt 2008, Habib et al. 
2012, Petersen et al. 2014). L cells are normally distinguished from other enteroendocrine cells due 
to the expression of the preproglucagon gene however there is research showing that the location of 
the cell is of more importance than the genes produced (Habib et al. 2012). The presence of glucose 
can affect L cell secretion due to the depolarisation of the membrane leading to increased 
intracellular calcium (Reimann et al. 2008) with the knockout of the GLUT2 receptor leading to 
reduced GLP-1 secretion (Cani et al. 2007). The presence of fatty acid receptors on the L cell 
membrane provide evidence that fatty acids also regulate L cell secretion (Reimann et al. 2008) 
while L cell secretion can also be regulated through the cAMP pathway (Tolhurst et al. 2011a). 
 
1.2.8 Enteroendocrine cell plasticity 
The enteroendocrine cells of the intestine have classically been categorised into cell types based on 
their function and hormonal secretion as described above. Recent advances have suggested that 
segregation of enteroendocrine cells into distinct cell sub types does not accurately describe the 
nature of enteroendocrine cells. Differentiation of stem cells in the intestinal crypt into endocrine 
cells of the epithelium is regulated by a number of transcriptional factors such as Math1, Neuro3, 
NeuroD and Hes1 (May, Kaestner 2009, Li et al. 2011). Enteroendocrine cell differentiation is also 
regulated by various transcription factors along the cephalocaudal axis of the intestine with factors 
such as PDX-1, CDX-2, GATA-4, GATA-5, GATA-6, HNF-1α, HNF-1β and CDP all showing 
distinct expression patterns in different areas of the intestine (Fang, Olds & Sibley 2006, 
Middendorp et al. 2014). A number of studies have identified co-expression of hormones in 
enteroendocrine cells of the intestine outside of enteroendocrine cell classifications based on 
hormonal secretion (Habib et al. 2012, Egerod et al. 2012, Svendsen et al. 2015, Cho et al. 2015). 
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Knockout models have demonstrated that the absence of these transcription factors can lead to 
changes in the population of enteroendocrine cells in the villi (Larsson et al. 1996, Jepeal, Boylan 
& Wolfe 2003, Jepeal et al. 2005). Manipulation of these factors may have potential in changing 
the enteroendocrine cell population of the intestine (Gribble, Reimann 2016). 
 
1.2.9: Enterochromaffin cells  
Enterochromaffin cells are neuroendocrine cells which make up less than 1% of the intestine 
(Bellono et al. 2017). These cells secrete serotonin which was described in 1948 (Rapport, Green 
& Page 1948) and produce histamine (Hakanson et al. 1986, Delwaide et al. 1991). One of the main 
characteristics of enterochromaffin cells is the electron dense core of the secretory granules present 
within the cell (Hakanson et al. 1992). These cells are also sensitive to circulating gastrin levels, 
with high levels of gastrin resulting in the secretion of histamine while high levels of circulating 
somatostatin may have a paracrine effect on these cells (Hakanson et al. 1992). Long term exposure 
to high levels of gastrin leads to enterochromaffin cell hypertrophy (Bottcher et al. 1989) and 
hyperplasia if this effect is sustained (Hakanson et al. 1992). The histamine secretory role of 
enterochromaffin cells is of particular importance as long term inhibition of histamine secretion 
resulted in inhibition of gastric acid secretion and cancerous tumours in the enterochromaffin cells 
of the stomach (Havu 1986). The mechanism that gastrin uses to increase histamine secretion 
appears to be through binding to a membrane receptor which releases calcium into the cytoplasm 
and also depolarises the membrane to increase intracellular calcium (Prinz et al. 1993). This same 
study also demonstrated an effect of CCK-8 on these cells. This is not the only mechanism through 
which histamine is released as further research has shown that enterochromaffin cells are able to 
receive signals from the nervous system (Bellono et al. 2017). 
 
1.2.10: Goblet cells 
The main role of goblet cells in the intestine is to secrete mucus into the lumen of the intestine which 
provides lubrication and protection to the villi (Forstner 1978). They have been named goblet cells 
due to their cup-like shape which occurs when the supranuclear portion of the cell fills with mucus 
(Birchenough et al. 2015). Unlike the stomach and large intestine, the small intestine has one mucus 
layer which protects the cells of the villi (Ermund et al. 2013). Goblet cells arise from 2 main 
precursor cells in the small intestine. One precursor cell is the oligomucous cell which are cells 
which contain small amounts of mucus but can become mature goblet cells as the migrate up the 
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villi (Cheng 1974). Oligomucous cells are present in the base of the crypts of Lieberkühn and the 
lower half of the midcrypt compartment while mature goblet cells appeared higher in the crypt and 
also appeared in the villi (Cheng 1974). Oligomucous cells account for around half of all mucous 
containing cells in the intestine. Therefore there must be another pathway for the development of 
mature goblet cells. The other half of the goblet cell population appears to arise from columnar stem 
cells which exist at the bottom of the crypts (Cheng, Leblond 1974). Further evidence for goblet 
cell development occurring through two pathways is that goblet cells travel up the villi and 
eventually disperse into the lumen once at the tip and the oligomucous cell pathway is unable to 
keep up with the rate of goblet cell turnover (Merzel, Leblond 1969). The amount of mucus stored 
in goblet cells increases from the duodenum until around midway through the jejunum, after which 
mucus levels stay relatively constant (Kemper, Specian 1991). One source for mucus secreted from 
goblin cells is glucose and the mucus they secrete is produced at a constant rate (Neutra, Leblond 
1966). There are approximately 50 proteins which make up the proteome of intestinal mucus with 
the major component MUC2 being the best understood (Birchenough et al. 2015). One of the main 
stimulators of mucus secretion from goblet cells is acetylcholine (Specian, Neutra 1980) while 
secretion is also stimulated by histamine (Halm, Halm 2000). 
 
1.2.11: Paneth cells 
As described above, goblet cells provide a protective mucus layer which prevents direct contact 
between cells of the villi and bacteria which live in the gut. However, in diseases such as 
inflammatory bowel disease this defence is broken down and bacteria can have a detrimental effect 
on the epithelial lining of the small intestine (Xavier, Podolsky 2007). There is a second defence 
mechanism in the intestine, which lies at the bottom of the crypts of Lieberkühn, and these are 
bacterial sensing cells that secrete antimicrobial peptides known as Paneth cells (Ayabe et al. 2000). 
The majority of the secreted peptides are alpha-defensins which were shown to protect the intestine 
from a range of pathogens (Ayabe et al. 2000) while angiogenin, lysozyme and intestinal 
phospholipase A2 proteins are also secreted (Satoh et al. 1988, Harwig et al. 1995, Hooper et al. 
2003). The mechanism through which Paneth cells recognise bacterial pathogens is the MyD88-
dependent toll-like receptor (TLR) which activated through direct contact with bacteria (Vaishnava 
et al. 2008). The position of Paneth cells in the crypts of Lieberkühn suggests that their main defence 
role is the protection of intestinal stem cells which are also present at the bottom of the crypt (Ganz 
1999). This could also be defined as a self-protective role as Paneth cells arise from the stem cells 
which they protect (Ganz 2000, Cheng, Leblond 1974). Another defining feature of Paneth cells is 
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that the epithelial cells of the small intestine have a high turnover rate, whereas Paneth cells are able 
to survive up to 30 days (Clevers, Bevins 2013).  
 
1.2.12: Tuft cells 
Tuft cells were first visualised in rat duodenum in 1973 (Isomaki 1973). One of the defining 
characteristics of tuft cells is the presence of numerous microvilli which extend into the lumen of 
the intestine from the apical surface of the membrane (Hoover et al. 2017). Like the cell types 
described above, the presence of the Lgr5 marker shows that these cells are derived from stem cells 
at the bottom of the crypts of Lieberkühn (Gerbe et al. 2011). Tuft cells can be distinguished from 
other intestinal cell types due to the DCLK1 expression (Gerbe et al. 2011). Despite the 
identification of intestinal tuft cells in 1973, only recently have there been studies carried out to 
determine their function. This may be due to the difficulty in identifying the different cells in the 
epithelial layer of the villi of the small intestine (Gerbe et al. 2009). One function which has been 
suggested is the secretion of opiod proteins (Kokrashvili et al. 2009). While the turnover of tuft 
cells in the villi is normally less than 2 weeks, there is a subpopulation that are long lived and are 
oncogenic when induced by inflammation (Westphalen et al. 2013). Another outstanding feature of 
tuft cells is their interaction with the nuclei of neighbouring cells using cryospinules (Hoover et al. 
2017) and there is an absence of secretory granules within the cytoplasm of these cells (Morroni, 
Cangiotti & Cinti 2007). A second function for tuft cells that has been suggested is as the 
chemoreceptor cells of the intestine due to the presence of α-gustducin which is a component of the 












The enteroendocrine cells are spread throughout the gastrointestinal tract. K cells, G cells, I cells 
and X/ A like cells are spread throughout the upper and middle of the small intestine and are also 
found in the stomach. Meanwhile L cells are found further down the small intestine and are mainly 
situated in the ileum. 
 
1.3: Gastrointestinal hormones 
 
1.3.1: Gastric inhibitory peptide/ Glucose-dependent insulinotropic peptide (GIP) 
GIP is secreted from the nutrient sensing K cells of the small intestine primarily in the duodenum 
in response to digestion of fatty acids and carbohydrates (Cleator, Gourlay 1975). GIP is a 42 amino 
acid polypeptide which is derived from a 153 amino acid long polypeptide precursor known as 
preproGIP (Takeda et al. 1987). GIP was first isolated in 1969 with further isolation in 1970 
confirming the ability of GIP to inhibit gastric secretion (Brown et al. 1969, Brown, Mutt & 
Pederson 1970). This activity is why GIP received one of its monikers. Initially a 43 amino acid 
sequence for GIP was elucidated in 1971 (Brown, Dryburgh 1971) however this was corrected and 
after the removal of a glutamine residue at position 29, the currently accepted 42 amino acid 
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conformation was derived (Jörnvall et al. 1981). As the alternative name for GIP suggests, it is a 
hormone with insulinotropic activity. This was first described in 1973 which showed that GIP 
administration to healthy humans resulted in increased insulin secretion (Dupre et al. 1973). Further 
research into this effect showed that GIP secretion is glucose sensitive and relies on hyperglycaemic 
conditions regardless of the level of insulin secretion (Andersen et al. 1978). The removal of GIP 
from rat gut extracts which were then administered to rats resulted in maintenance of more than 
50% of the incretin effect (Ebert, Unger & Creutzfeldt 1983). This research suggested that GIP was 
not the only incretin hormone which led to the later discovery of glucagon-like peptide 1 (GLP-1). 
The actions of GIP are regulated in the body through a proteolytic enzyme dipeptidyl peptidase IV 
(DPP-IV) which cleaves GIP at the alanine residue in position 2 of the polypeptide chain, resulting 
in the inactive GIP (3-42) (Figure 1.4) and a short half-life of around 7 minutes (Kieffer, McIntosh 
& Pederson 1995). 
The insulinotropic effect of GIP makes GIP-based therapies, such as GIP mimetics, an attractive 
prospect in Type 2 Diabetes therapeutics. However, research in individuals with Type 2 Diabetes 
has shown that GIP loses its insulinotropic action and this is one reason GIP mimetics are not more 
extensively studied (Nauck et al. 1993, Seino, Fukushima & Yabe 2010). This research discovered 
that after oral glucose administration, GIP secretory levels were not different between diabetic and 
non-diabetic subjects. This was the first work to demonstrate a decreased incretin effect in people 
affected by Type 2 Diabetes.  
 
1.3.2: Glucagon-like peptide 1 (GLP-1) 
GLP-1 is secreted from intestinal L cells in response to fatty acid and carbohydrate digestion 
(Hansen et al. 2013). Intestinal L cells are dispersed throughout the intestine however the highest 
concentration can be found in the distal ileum in the small intestine while the colon has lower 
concentrations than those found in the rectum (Adrian et al. 1985). The gene which codes for the 
GLP-1 protein, the proglucagon gene, codes for a precursor protein from which a number of 
peptides can be cleaved (Jin 2008). One interesting feature of the GLP-1 precursor protein is that 
the main hormone cleaved in the intestine, GLP-1, has the opposite function to that of the main 
hormone cleaved in the pancreas, glucagon. In order for these different hormones to be cleaved, 
they must undergo different post translational processing. In the intestine, post translational 
processing is regulated by the prohormone convertase-1 (PC-1) enzyme (Drucker, Nauck 2006). In 
the pancreas this processing is carried out by PC2 as described above (Rouille et al. 1994). The 
proglucagon gene is expressed throughout the body with mRNA transcripts being expressed in the 
brainstem, pancreas, and intestine, however post translational processing is tissue specific (Lee, 
Brubaker & Drucker 1990). Three main forms of GLP-1 circulate in the body – the full length 37 
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amino acid transcript known as GLP-1(1-37), the 31 amino acid long GLP-1(7-37) and the 30 amino 
acid GLP-1(7-36). All three forms of the peptide have been shown to increase insulin secretion 
(Drucker et al. 1987, Nauck et al. 1993, Suzuki, Nakauchi & Taniguchi 2003) while the GLP-1(7-
37) form of GLP-1 increasing insulin gene expression in rats (Drucker et al. 1987) and GLP-1(7-
36) has been suggested as a neuropeptide (Blazquez et al. 1998). GLP-1 was first described as an 
incretin in 1987 in non-diabetic human volunteers (Kreymann et al. 1987) where administration of 
GLP-1(7-36) increased plasma insulin as well as decreased blood glucose and glucagon. The 
insulinotropic effect of GLP-1(7-36) was determined to be greater than the other recognised 
incretin, GIP.  
As described above, GIP loses its insulinotropic effects in individuals with Type 2 Diabetes despite 
no changes in GIP secretion levels. However, both GLP-1(7-36) and GLP-1(7-37) maintain their 
insulinotropic ability in individuals with Type 2 Diabetes. This was confirmed through studies 
between people with Type 2 Diabetes and people who were able to regulate their glucose 
homeostasis (Nathan et al. 1992, Nauck et al. 1993). This confirmed the previous effects seen in 
healthy human volunteers (Drucker et al. 1987, Nauck et al. 1993, Suzuki, Nakauchi & Taniguchi 
2003). The insulinotropic effect of GLP-1 in individuals with Type 2 Diabetes make it an interesting 
therapeutic target. In fact GLP-1 mimetics have been adopted as clinical therapies since 2005 
(Ahren 2009) with DPP-IV inhibitors being approved shortly thereafter in 2006 (Dicker 2011). 
GLP-1 has a short half-life due to its rapid cleavage by DPP-IV into the inactive GLP-1(7-36) and 
GLP-1(9-37) forms (Figure 1.4). In order to try and avoid the effects of DPP-IV, compounds which 
mimic GLP-1 but have slightly different structures, GLP-1 mimetics, have been developed. The 
two main GLP-1 mimetics used as therapeutic treatments targeting Type 2 Diabetes are exenatide 
and liraglutide (Lee et al. 2014). In order to avoid the cleavage effects of DPP-IV, the second 
position of the polypeptide chain in exenatide is modified as a Glycine residue replaces an Alanine 
residue. For Liraglutide, the effects of DPP-IV cleavage is reduced through two modifications. 
Firstly in the 34th position of the polypeptide chain Arginine is replaced with Lysine. The second 
modification seen is at position 26 of the polypeptide chain, where a Glutamate residue connected 
to a 16 carbon fatty acid chain is added.  
The continued insulinotropic effect of GLP-1 in individuals with Type 2 Diabetes is not the only 
attractive feature of GLP-1 based therapeutics. The receptor through which GLP-1 is active, the 
GLP-1 receptor (GLP1R), is expressed in both α- and β-cells whereas the receptor through with 
GIP is active, the GIP receptor (GIPr), is only found on β-cells (Drucker, Nauck 2006). As GLP-1 
can reduce glucagon secretion through the α-cells, it may help reduce the hyperglycaemia seen in 
Type 2 Diabetes. Another complication in Type 2 Diabetes is a reduction in β-cell mass and GLP-
1 has been shown to reduce β-cell apoptosis adding to the mounting evidence of GLP-1 based 
therapies being a useful tool against Type 2 Diabetes (Farilla et al. 2003). Furthermore, Type 2 
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Diabetes has strongly linked to obesity and GLP-1 slows gastric emptying and reduces appetite 
making GLP-1 mimetics which retain this ability desirable (Nauck, Meier 2005). Currently GLP-1 
mimetics depend on blood glucose levels meaning GLP-1 mimetics will only work in 
hyperglycaemic conditions. Another issue is that currently available therapeutics need to be 
injected. Potential combination therapies of GLP-1 mimetics and DPP-IV inhibitors such as 





Adapted from Flatt, Green 2006, Kim, Kim 2012. GIP and GLP-1 are cleaved by DPP-IV at alanine 
residues which are at position 2 of the active peptides. 
 
1.3.3: Peptide YY (PYY) 
PYY was first described in 1980 as a 36 amino acid peptide that was present in the brain and 
intestine of pigs (Tatemoto, Mutt 1980). PYY is present in the L-cells of the small intestine along 
with GLP-1 and it is more concentrated towards the distal end, with the highest concentrations being 
found in the ileum (Adrian et al. 1985). The full length peptide can bind to various Y receptor 
subtypes such as Y1, Y2 and Y5 (Batterham, Bloom 2003). Similarly to GLP-1, PYY is cleaved by 
DPP-IV to form the 34 amino acid long PYY(3-36) which activates the Y2 receptor (Medeiros, 
Turner 1994). Both PYY(1-36) and PYY(3-36) are the main forms of PYY which circulate around 
the body in the blood (Grandt et al. 1994). PYY is released in response to the intake of nutrients 
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(Adrian et al. 1985) with the maximal levels of PYY being seen 90 minutes postprandially 
(Batterham, Bloom 2003). Administration of PYY(3-36) has been shown to reduce appetite and 
weight gain as well as increase insulin sensitivity (Batterham et al. 2002, Vrang et al. 2006) and 
these effects on appetite appear to be through Y2 receptor activation in the brain (Batterham, Bloom 
2003). PYY can also reduce gastric emptying (Savage et al. 1987) and the effects of PYY make it 
and the receptors it activates attractive targets in the treatment of metabolic disorders such as obesity 
and Type 2 Diabetes. 
PYY is also present in the endocrine cells of the pancreas and as seen in the small intestine it is co-
localised with the proglucagon protein (Ali-Rachedi et al. 1984) as well as being observed in the 
PP secreting cells (Bottcher et al. 1993). It appears that PYY activation of the Y1 receptor is 
essential for the storage of various intestinal and pancreatic hormones which interestingly include 
insulin despite PYY not being present in the β-cells of the pancreas (Sam et al. 2012). Further 
evidence for this includes the inhibition of glucose and carbachol stimulated insulin secretion by 
PYY(1-36) and PYY knockout leading to hyperinsulinaemia (Persaud, Bewick 2014). The 
shortened form of the protein, PYY(3-36), has been shown to have no effect on insulin secretion 
(Chandarana et al. 2013) despite showing the ability to inhibit insulin secretion in vitro (Khan et al. 
2016). Both the full length and shortened forms of PYY increased β-cell proliferation and as a result 
increased pancreatic β-cell mass which is one of the major complications seen in diabetes (Khan et 
al. 2016). 
 
1.3.4: Cholecystokinin (CCK) 
CCK is present in both the duodenum and jejunum of the small intestine (Buffa, Solcia & Go 1976) 
where it is secreted from the I cells (Buchan et al. 1978). The gene that codes for the CCK precursor 
protein is located on chromosome 3 in humans (Lund et al. 1986) and codes for a 115 amino acid 
long protein (Takahashi et al. 1985). This protein is post translationally processed into various forms 
of CCK with the most abundant in humans being CCK-33 closely followed by CCK-22 (Rehfeld et 
al. 2001). CCK is released from the small intestine in response to a wide variety of stimuli including 
glucose, amino acids and fatty acids (Liddle et al. 1985). CCK receptors are found throughout the 
body with the CCK1 receptor being predominantly found in the gastrointestinal tract and CCK2 
receptor being more predominant in the brain (Wank 1995). Therefore CCK has a variety of 
functions including gallbladder contraction, decreased appetite and amino acid directed insulin 
secretion (Liddle et al. 1985, Rushakoff et al. 1987a, Gibbs, Young & Smith 1997) all of which can 





The pancreas is an organ found in the upper abdomen in humans. It is separated into different 
regions such as the head, neck, body and tail with the head of the pancreas being attached to the 
duodenum of the small intestine by the ampulla of Vater (Slack 1995). These regions of the pancreas 
are well defined in humans with the head being located at the proximal end and the tail located at 
the distal end of the pancreas, however in rodents this is less defined. The pancreas is made up of 
exocrine glands which are acinar in shape (Pictet et al. 1972) and secrete enzymes into the small 
intestine which help with the absorption of nutrients from food (Slack 1995) as well as endocrine 
glands. The endocrine glands are arranged into islets of Langerhans which were first described in 
1869 (Langerhans, Paul,, Friedrich-Wilhelms-Universität Berlin.,Medizinische Fakultät., 1869). In 
humans, pancreatic islets consist of β, α, δ, ε and PP-cells which are scattered about the islet with 
no particular order (Brissova et al. 2005, Cabrera et al. 2006) and make up 1-2% of the pancreas 
(Pour, Standop & Batra 2002). This same conformation is seen in monkeys while in mice and pigs 
a more structured conformation is observed. These cells were found to be closely related to the 
vascular system in humans with 48 to 59% of the pancreas being made up of β-cells. 33 to 46% α-
cells and 8 to 12% δ-cells (Cabrera et al. 2006). However, the section of the pancreas can affect the 
composition of the islet, with the islets found in the head of the pancreas being shown to be rich in 
PP-cells while the rest of the pancreas was rich in α-cells (Orci et al. 1978, Malaisse-Lagae et al. 
1979, Stefan et al. 1982). This appears to be conserved in mammalian species as rat pancreas has 
been shown to have the same PP-rich regions in the uncinate process of the head of the pancreas 
(Elayat, el-Naggar & Tahir 1995). Despite the differences in the composition between human and 
rat islets, and despite the fact that a human pancreas is larger with many more islets than a rat 
pancreas, the overall islet size appears to be conserved between species which suggests that there is 
an optimal size at which they work (Henderson 1969). Pancreatic islets are also essential in the 
development of a pancreas as well as the duodenum of the small intestine during embryogenesis as 
the mutagenesis of insulin-promoter-factor 1 (also known as PDX1) has led to the absence of this 
organ completely (Jonsson et al. 1994, Offield et al. 1996). 
 
1.4.1: Insulin 
Insulin was first discovered in 1922 by both Frederick Banting and Charles Best who demonstrated 
extracts from dog pancreatic islets had a powerful anti-diabetic effect (Banting et al. 1922). The 
first clinical trials using insulin commenced in 1922 with Frederick Banting and John McLeod 
(Banting, Best & Macleod 1922), who provided the laboratory for the work to be undertaken and 
supervised the research, both receiving the Nobel Prize in Physiology or Medicine in 1923 for the 
discovery (Raju 1998). Following the discovery of insulin, monomeric insulin was isolated using 
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X-ray crystallography (Abel 1926) with the B chain of 30 amino acids being described in 1951 and 
the A chain of 21 amino acids being sequenced in 1953 (Sanger, Tuppy 1951a, Sanger, Tuppy 
1951b, Sanger, Thompson 1953a, Sanger, Thompson 1953b) while the hexamer conformation in 
which insulin is stored being elucidated at a later date (Blundell et al. 1972, Crowfoot 1935). The 
sequencing work carried out by Frederick Sanger was the first time a protein sequence had been 
described. Despite this, due to difficulties in isolated the insulin receptor, the binding between 
insulin and the insulin-receptor was not visualised until 2013 (Menting et al. 2013). The gene coding 
the insulin protein is found on chromosome 11p15.5 (Owerbach et al. 1980, Owerbach et al. 1981). 
The main physiological role of insulin is the regulation of hepatic glucose output while it also 
facilitates the entry of glucose into peripheral tissues via the GLUT4 receptor (Sonksen, Sonksen 
2000). The mechanism through which insulin regulates hepatic glucose production is via FoxO6 
inhibition (Kim et al. 2011). Insulin has been proven to regulate free fatty acid release alongside 
hepatic glucose production in humans (Hall, Saunders & Sönksen 1979). It is stored in its inactive 
hexamer configuration (Sudmeier et al. 1981) in storage vesicles which are rich in zinc and calcium 
ions inside the β-cells of the pancreas (Dunn 2005). Insulin is released from these vesicles whenever 
the threshold potential of approximately -50mV is reached (Ashcroft, Rorsman 1989) and this 
potential is proportional to blood glucose levels with levels below 3mM leading to a resting potential 
around -70mV and no insulin secretion while concentrations of 7mM and above will induce the 
threshold potential. The main stimulus for insulin secretion is glucose which activates the 
respiratory chain (Soejima et al. 1996). The ATP molecules generated by the mitochondrial action 
causes depolarisation of the membrane due to the closure of ATP sensitive KATP channels and the 
opening of Ca2+ channels which allow calcium ions into the cell and thus leads to insulin exocytosis 
(Komatsu et al. 2013). The other main stimuli for insulin secretion include the incretin hormones, 
GLP-1 and GIP, short-term free fatty acid exposure (Komatsu, Sharp 1998) and parasympathetic 
nervous system activation (Ahren 2000). 
 
1.4.2: Glucagon 
Following on from the discovery of insulin in pancreatic extracts in 1922, glucagon was first 
described the following year in 1923 (Kimball, Murlin 1923) with the amino acid sequence of the 
29 amino acid long peptide being elucidated in 1957 (Bromer, Sinn & Behrens 1957). A role for 
glucagon in glucose homeostasis was first described in 1969 when it was shown that glucagon 
secretion was blocked by induced hyperglycaemia in dogs (Ohneda et al. 1969). This discovery 
lead to increased interest in the role of glucagon in diabetes and it was shown that glucagon levels 
were increased in those who underwent diabetic ketoacidosis (Gerich et al. 1975). The framework 
of the vasculature in the pancreas provides evidence of the role of glucagon, as capillaries are first 
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directed towards the β-cells of the pancreas before reaching the glucagon secreting α-cells 
(Taborsky 2010). These capillaries then run into the hepatic portal vein. Therefore this provides 
evidence that secretion from β-cells will affect the secretion from alpha cells and that the main effect 
of glucagon and insulin will be seen in the liver. Stimulation of the sympathetic nervous system 
leads to increased glucagon secretion (Marliss et al. 1973, Ahren, Veith & Taborsky 1987) which 
can be activated by hypoglycaemia (Havel, Mundinger & Taborsky 1996). Parasympathetic nerve 
stimulation was also shown to increase glucagon secretion, however the response to stimulation was 
less than that seen for insulin as well as sympathetic nerve effects on glucagon (Ahren, Taborsky 
1986). The effect seen by parasympathetic nervous system activation appears to be reduced in 
diabetes, however this activity can recover through carbachol treatment (Patel 1984). The gene 
which codes for glucagon contains six exons and codes for a variety of proteins (Heinrich, Gros & 
Habener 1984). The tissue that the proglucagon gene is expressed in regulates which of these 
proteins are cleaved from the precursor protein through post translational processing (Mojsov et al. 
1986). In α-cells the active glucagon protein along with a major proglucagon fragment consisting 
of GLP-1 and GLP-2 which are joined by IP2 are expressed while in the brain and small intestine 
active forms of GLP-1 and GLP-2 are released along with oxyntomodulin and glicentin, both of 
which include the whole glucagon molecule (Taborsky 2010). Differences in proglucagon gene 
processing between tissues can be explained through the enzyme which regulates the post 
translational modification of the precursor protein. In the pancreas this is carried out by PC2 
(Rouille et al. 1994) while in the intestine it is regulated by PC1/3 (Tucker, Dhanvantari & Brubaker 
1996). The main physiological effect of glucagon can be seen in the liver (Herold, Jaspan 1986) 
where it helps in hepatic glucose production and output (Liljenquist et al. 1977). The secretion of 
glucagon from α-cells is regulated by the secretion from β-cells (Franklin et al. 2005, Weir et al. 















Tissue dependent post-translational processing of the proglucagon gene. The peptide precursor of 
the proglucagon protein, preproglucagon, undergoes cleavage resulting in the removal of the signal 
peptide present at the N-terminus. The remaining proglucagon gene undergoes post-translational 
modifications which are dependent on the tissue that the proglugacon protein are expressed in. In 
the α-cells of pancreatic islets, the proglucagon protein is processed by PC2 resulting in the 
production of glucagon. In the intestine, PC1/3 processes the proglucagon protein post-
translationally resulting in the production of GLP-1 and GLP-2. 
 
1.4.3: Somatostatin 
Somatostatin is a hormone which inhibits insulin, growth hormone and glucagon secretion (Koerker 
et al. 1974, Brazeau et al. 1974, Gerich, Lovinger & Grodsky 1975). The somatostatin protein was 
initially thought to consist of 14 amino acids (Brazeau et al. 1973) however identification of the 
somatostatin coding gene (Shen, Rutter 1984, Shen, Pictet & Rutter 1982) lead to the discovery of 
several forms of somatostatin (Schally et al. 1976) with the larger 28 amino acid isoform being up 
to 5 times more potent at inhibiting insulin secretion than the 14 amino acid long peptide (Hadjidakis 
et al. 1986). When Asn5 is deleted the inhibitory effect on glucagon secretion is lost while D-Cys14-
somatostatin was unable to inhibit insulin release (Luft, Efendić & Hökfelt 1978). The presence of 
somatostatin secreting δ-cells was first confirmed in humans in 1975 (Dubois et al. 1975). Acute 
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administration of somatostatin results in hypoglycaemia while long term administration leads to 
hyperglycaemia (Lins, Efendic 1976). Five different somatostatin receptors have been described 
(Rossowski, Coy 1994) with glucagon inhibition primarily being mediated through the SSTR2 
receptor while SST5R is the main regulator of insulin inhibition (Strowski et al. 2000). Like both α 
and β-cells of the pancreatic islets, secretion of somatostatin from δ-cells is regulated by Ca2+ 
signalling and KATP channel depolarisation and thus blood glucose concentrations (Berts et al. 
1996). As described above, pancreatic islets are closely related to the vascular system with β-cells 
being the first point of contact with the capillaries followed by α-cells. Further research into this 
architecture has shown that following on from the α-cells, the vascular system is directed towards 
the δ-cells thus suggesting that δ-cells have a paracrine effect on the secretion from β and α-cells 
(Stagner, Samols & Bonner-Weir 1988, Stagner, Samols 1992). This also allows the β-cells to signal 
to δ-cells, inhibiting somatostatin secretion through Urocortin3 (van der Meulen et al. 2015). 
 
1.4.4: Pancreatic polypeptide (PP) 
Pancreatic polypeptide (PP) was first described in 1975 as a 36 amino acid peptide with a molecular 
weight of 4240Da (Kimmel, Hayden & Pollock 1975). The gene sequence for the precursor protein 
from which PP is cleaved consists of a 95 amino acid peptide with PP being situated in the middle 
of this sequence (Leiter, Keutmann & Goodman 1984). The gene encoding PP is found on 
chromosome 17q21.1 and is 10kb apart from the peptide YY gene which is another closely related 
peptide (Hort et al. 1995). It appears that peptide YY arose from a duplication event of NPY while 
a second duplication of peptide YY resulted in PP. This is confirmed as peptide YY and PP have 
70 and 55% sequence homology with NPY in humans (Hort et al. 1995). PP is mainly found in the 
pancreas and levels remain high for a longer duration than insulin postprandially (Adrian et al. 
1976) and is secreted in response to ingestion of nutrients (Adrian et al. 1977). Obesity leads to 
lower PP levels (Glaser et al. 1988) and injection of PP in mice lead to reduced food intake 
(Asakawa et al. 1999).  
 
1.4.5: Amylin 
Amylin is another hormone which is secreted from the β-cells of the pancreas (Schmitz, Brock & 
Rungby 2004). It consists of a 67 amino acid propeptide which is co-localised with insulin in the 
secretory granules of β-cells and insulin production may regulate the production of amylin (Higham 
et al. 2000). Like insulin, amylin can reduce glucagon secretion while also reducing gastric 
emptying thus improving appetite control (Schmitz, Brock & Rungby 2004). The amylin peptide 
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itself is 37 amino acid long and is found to be aggregated in the pancreas of Type 2 Diabetes 
sufferers (Cooper et al. 1987). 
 
1.5: G-protein coupled receptors (GPCRs) 
GPCRs are the largest family of membrane bound proteins and are characterised by their 7 domains 
which span the membrane with the N-terminus being located extracellularly while the C-terminus 
extends into the cytoplasm (Horn et al. 2002, Isberg et al. 2015). There are roughly 800 GPCRs in 
the human genome (Isberg et al. 2015). The role of GPCRs is to allow the extracellular environment 
of the cell affect the processes and downstream signalling events intracellularly and the importance 
of this was recognised when Lefkowitz and Kobilka were awarded the Nobel Prize in Chemistry in 
2012 for their discovery (Bockaert 2012). Intracellular signalling is carried out by an intact G-
protein which is attached to inactive receptors on the cytosolic side of the cell membrane. The intact 
G-protein consists of 3 different subunits (α, β and γ) which are further split into different classes. 
The best characterised subunit is the α-subunit which has 4 different classes identified (Gαs, Gαi, 
Gαq, and Gα12/13). The less well defined β-subunit has 5 classes while the γ-subunit has 12 different 
classes. The purpose of various different subunits is that there are a number of combinations of 
subunits and this can then be used to define the function of receptor activation (Layden, Durai & 
Lowe Jr. 2010).  
 
1.5.1: GPCR signalling cascades 
The intact G-protein on the intracellular side of a GPCR is described as a heterotrimeric G-protein 
due to the composition of subunits from which it is made (Tuteja 2009). Upon ligand binding, the 
heterotrimeric G-protein undergoes a conformational change where the α-subunit dissociates from 
the β and γ-subunits leading to intracellular signalling (Layden, Durai & Lowe Jr. 2010). 
Dissociation of these subunits occurs when the C-terminal tail of the α-subunit catalyses the 
replacement of GDP, which is attached to the α-subunit in the resting heterotrimeric state, for GTP 
(Moran, Flatt & McKillop 2016). After this dissociation, both the α and βγ-subunits have an effect 
on ion channels, phospholipases and adenylyl cyclases resulting in a biological effect due to the 
activation or inhibition of effectors by secondary messengers such as intracellular Ca2+, cAMP, 
DAG and phosphoinositides (Lattin et al. 2007). Gαq and Gαi subunit signalling is controlled by 
regulators of G-protein signalling with GTPase activity (Tilley 2011). Gαs signalling results in 
increased cAMP and protein kinase A (PKA) as a result (Tilley 2011, Moran, Flatt & McKillop 
2016). Contrary to this, Gαi inhibits the production of cAMP and as a result there are increased in 
protein kinase C (PKC) (Moran, Flatt & McKillop 2016). Gα12/13 signalling has not been as 
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extensively studied however activation of this subunit leads to guanine nucleotide exchange factors 
(GEFs) known as RhoGEFs to be activated and ultimately the GTPase RhoA leading to a number 
of downstream signalling processes (Tilley 2011). The Gβγ-subunit is able to mediate a range of 
effectors such as PLC and adenylyl cyclase however these subunits need to be more extensively 
studied (Patel 2004). 
 




Adapted from Layden, Durai & Lowe Jr. 2010. 
A. In the receptors inactive form, a G-protein intact with all subunits present is attached to the 
receptor on the cystolic side of the membrane. The G-protein is intact when the α-subunit is bound 
to the βγ-subunits and GDP. 
B. Upon receptor activation through ligand binding, the GDP bound to the G-protein is exchanged 
for GTP which forms a complex with the α-subunit. 
C. The α-subunit GTP complex dissociates from the βγ-subunit. This triggers signalling processes 




Upon extracellular ligand binding to the receptor, the intact intracellular G-protein attached on the 
intracellular side of the membrane undergoes a conformational change. GDP, which is attached to 
the Gα-subunit, is replaced by GTP. This causes the Gα-subunit to become dissociated from the 
Gβγ-subunit and leads to intracellular signalling. Due to the number of different combinations of 
subunits, there are a number of different signals which can be sent. The receptors themselves are 
split into 5 different families – rhodopsin, secretin, glutamate, adhesion and Frizzled/Taste2 
(Layden, Durai & Lowe Jr. 2010). The largest GPCR family is the rhodopsin family with estimates 
that 80% of human GPCRs are classed as belonging to this group (Lagerstrom, Schioth 2008).  
  
1.5.3: GPCRs as drug targets 
There are a wide number of reviews discussing GPCRs as therapeutic drug targets with some 
estimates suggesting approximately 50% of all marketed drugs target a GPCR (Davies et al. 2008). 
In a 2006 analysis, over 20000 FDA approved drugs were grouped depending on the classification 
of their target (Overington, Al-Lazikani & Hopkins 2006). A total of 324 target families were 
identified with 26.8% of targets being classified as rhodopsin-like GPCRs. In a more recent study 
(Rask-Andersen, Almen & Schioth 2011) this was increased to approximately 36% of all FDA 
approved drugs (Figure 1.7). A particular area of interest for GPCRs is as therapeutic targets in 
Type 2 Diabetes. In the pancreas there are 293 GPCRs expressed in islets (Amisten et al. 2013). 
Many of these receptors are likely to be present in the gastrointestinal tract as large intestine, small 
intestine, pancreas and stomach were clustered together based on the expression of GPCRs (Regard, 
Sato & Coughlin 2008). The islet receptors have various roles in the pancreas however at there were 
107 drugs found which increased insulin secretion while 184 drugs inhibited insulin secretion 
(Amisten et al. 2013). However the role of many of these GPCRs on pancreatic hormone secretion 













From (Amisten et al. 2013). A range of pancreatic GPCRs are targeted for the treatment of Type 2 
diabetes. The graph above details the expression level of these receptors and their effects on insulin, 
glucagon and somatostatin secretion. The effects of many of the targeted GPCRs on hormonal 


















From 193 proteins, 82 were GPCRs (42.5%). From the overall data set 36% of drugs targeted class 
A GPCRs. Over 21000 active agents were analysed with 1357 unique drugs being identified. (Rask-
Andersen, Almen & Schioth 2011) 
 
1.5.4: Monoatomic ion and macromolecule binding GPCRs 
The monoatomic ions Ca2+, H+, Mg2+ and Zn2+ are expressed ubiquitously throughout the body. Six 
different receptors which can be activated by these ions and macromolecules have been identified 
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as being expressed in human pancreatic islets (Amisten et al. 2013). Ca2+ and H+ can activate the 
calcium-sensing receptor (CaSR) and the ovarian cancer gene receptor 1 (OGR1) respectively (Wei 
et al. 2015). Ca2+ has also been shown to activate the GABAB receptor (Wise et al. 1999) and the 
mGluR receptors (Kubo, Miyashita & Murata 1998) however the activation of mGluR by Ca2+ 
receptors has been questioned (Nash et al. 2001). Mg2+ also appears to activate the CasR and this 
receptor is expressed in a range of tissues throughout the body including the intestine, placenta, 
cartilage-forming cells and a range of cells in the bone (Brown, MacLeod 2001). Zn2+ has been 
shown to activate the zinc-sensing receptor ZnR which is also known as GPR39 (Cohen et al. 2012), 
toll-like receptor 4 (TLR4) (Liang, Dempski & Burdette 2016), the SLC30 and SLC39 families of 
zinc transporters (Jeong, Eide 2013) as well as the P2X4 and P2X2 receptors, the second of which 
is also activated by CuCl2 (Xiong et al. 1999). H+ has also been shown to activate GPR4, GPR68 
and GPR132 in the pancreas (Amisten et al. 2013) 
 
1.5.5: G-protein coupled receptor 39 (GPR39) 
As stated above, GPR39 is also called ZnR and it is the zinc-sensing receptor that has been 
researched the most. Both GPR39 and Zn2+ have been shown to be present in the islets of the 
pancreas (Amisten et al. 2013) while other tissues that express GPR39 include the liver, kidney, 
intestines and white adipose tissue (Egerod et al. 2007b). Previous work looking at GPR39 has 
shown that activation of this receptor results in insulin secretion both in vitro and in vivo (Moran et 
al. 2016a). This confirmed earlier work which demonstrated the insulinotropic effect of GPR39 in 
both age-dependent and diet-induced insulin resistant mice by knocking out GPR39 (Tremblay et 
al. 2009, Holst et al. 2009b). A number of different Gα subunits attach to GPR39 and as a result it 
affects a number of different signalling pathways as it has demonstrated an ability to increase 
intracellular calcium, cAMP (Moran et al. 2016a) as well as IP3 turnover (Holst et al. 2007a). 
GPR39 was originally thought to be stimulated by obestatin (Zhang et al. 2005a), however further 
studies have concluded that this is not the case (Holst et al. 2007a). Two forms of the GPR39 
receptor have been identified, the active GPR39-1a form and an inactive truncated form which is 
known as GPR39-1b and is a 5 transmembrane domain truncated form of the protein (Egerod et al. 
2007b, Yasuda, Ishida 2014). 
 
1.5.6: Cannabinoid receptors 
The first cannabinoid receptor to be recognised was the CB1 receptor (Matsuda et al. 1990). This 
was followed by the identification of the CB2 receptor (Munro, Thomas & Abu-Shaar 1993). Both 
CB1 and CB2 are attached to a Gαi subunit on the cystolic side of the membrane (Howlett 2002), 
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however CB1 can also attach to Gαs and Gαq proteins (Howlett et al. 2002). CB1 is highly expressed 
in the brain, with lower expression levels found throughout the body in tissues such as the liver, 
pancreas and muscle while CB2 is expressed in neurons and immune cells (Mackie 2008). Other 
putative cannabinoid receptors have been suggested such as vanilloid type 1 receptor (TRPV1) and 
GPR55 (Aizpurua-Olaizola et al. 2017). CB1 activation by rimonabant has positive effects on 
weight loss in obese people, however due to the detrimental side effects on people with mental 
disorders this drug was removed as a therapeutic aid (Moreira, Crippa 2009). CB2 activation has 
been linked with reduced inflammation however it might also be a trigger for increased tissue 
damage (Pacher, Mechoulam 2011).  
 
1.5.7: G-protein coupled receptor 55 (GPR55) 
GPR55 is a putative cannabinoid receptor which is expressed in a range of tissues such as pancreatic 
islets (Amisten et al. 2013), gastrointestinal tract, brain (Ryberg et al. 2007) and white adipose 
tissue (Beltowski 2012). Lysophosphatidylinositol (LPI) was the first compound to be identified as 
a GPR55 agonist (Oka et al. 2007), however this compound was later shown to stimulate ovarian 
cancer cell growth (Goldsmith et al. 2011). Whilst there is less known about GPR55, the 
insulinotropic effects of GPR55 have previously been demonstrated (Romero-Zerbo et al. 2011, 
McKillop et al. 2013, McKillop et al. 2016) and GPR55 has been shown to be activated by a range 
of synthetic and endogenous fatty acids (McKillop et al. 2013).  
 
1.5.8: G-protein coupled receptor 119 (GPR119) 
GPR119 is a class A rhodopsin-like GPCR (Fredriksson et al. 2003c). GPR119 is expressed in both 
the L-cells of the small intestine and pancreatic islets and it has been described as the most expressed 
cannabinoid receptor in the β-cells of the pancreas (Kebede et al. 2009, Amisten et al. 2013). 
Activation of GPR119 present in the β-cells of the pancreas has resulted in increased glucose-
stimulated insulin release (Moran et al. 2014a) and it has also been shown to increase PYY and 
incretin hormone secretion from the intestine (Chu et al. 2008). The endogenous ligand OEA was 
the first GPR119 agonist to be identified (Overton et al. 2006) however this ligand has also been 
shown to activate GPR55 (McKillop et al. 2013). GPR119 activation increases cAMP and is bound 
to the Gαs subunit (Chu et al. 2007b, McKillop et al. 2013). Insulin secretion mediated by GPR119 





1.5.9: Free Fatty Acid Receptors (FFAR) 
Of the 293 identified GPCRs in the human islet, 99 receptors were activated by 87 small organic 
molecules (Amisten et al. 2013). Small organic molecules were defined as lipids, free fatty acids, 
nucleotides, steroids, eicosanoids and amino acids. The number of activating molecules is less than 
the number of receptors activated as 35 small organic molecules were able to activate 2 or more 
receptors. The highest expressed receptor which is activated by fatty acids is GPR40. GPR40 
expression levels were over 100 times higher than those seen for GPR41 and GPR43. These 
receptors are activated by various fatty acids but are dependent on the triglyceride chain length with 
short chain fatty acids having six or less carbons, medium chain fatty acids having 6 to 12 carbons 
and long chain fatty acids being longer than medium chain fatty acids (Miyamoto et al. 2016). Fatty 
acid receptors are essential as some of the essential fatty acids which cannot be synthesised in the 
human body signal through these receptors. 
 
1.5.10: G-protein coupled receptor 40 (GPR40) 
As stated above, GPR40 is the most abundant free fatty acid receptor in pancreatic islets and it is 
activated by both medium and long chain fatty acids (Briscoe et al. 2003). The sequence of this 
receptor is conserved across various species (Itoh et al. 2003a) and it has been shown to signal 
through both the Gαq and Gαs pathways (Briscoe et al. 2003, Welters et al. 2006). Both DHA and 
EPA are the most potent agonists for GPR40 however these agonists can also activate GPR120 
(Moran et al. 2014b, Miyamoto et al. 2016). GPR40 is expressed in the intestine tastes buds and 
central nervous system (Ma et al. 2007, Edfalk, Steneberg & Edlund 2008, Cartoni et al. 2010, 
Sykaras et al. 2012a). Activation of GPR40 increases both incretin and insulin secretion and is a 
potential therapeutic target in Type 2 Diabetes (Itoh et al. 2003a, Edfalk, Steneberg & Edlund 2008). 
In fact a selective GPR40 agonist made it to stage 3 clinical trials for the treatment of Type 2 
Diabetes however this was stopped at this stage due to concerns over liver toxicity (Kaku et al. 
2015). 
 
1.5.11: G-protein coupled receptor 41 (GPR41) 
GPR41 is activated by short chain fatty acids such as formate, propionate, butyrate, and 
pentanoate with pentanoate being the most potent out of these agonists (Brown et al. 2003). It has 
been shown to increase IP3 and intracellular calcium and is attached to a Gαi subunit (Le Poul et al. 
2003). Activation of GPR41 has been shown to increase leptin levels and knockout of this receptor 
has been linked to a variety of inflammatory disorders such as obesity and asthma (Ang, Ding 2016). 
The ligands for GPR41 are produced endogenously in the intestine through the fermentation of fibre 
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which has been ingested (Tazoe et al. 2008). GPR41 is expressed in adipose tissue, pancreas, spleen, 
lymph nodes, bone marrow, and peripheral blood mononuclear cells (Ang, Ding 2016). Due to the 
different tissue GPR41 is expressed in, it can be hard to determine the function of this receptor. 
However knockout of GPR41 leads to hypoglycaemia and increased insulin secretion (Veprik et al. 
2016, Tang et al. 2015). Interestingly GPR41 agonists have been shown to increase the secretion of 
the incretin hormone GLP-1 which is in contrast to knockout models looking at GPR41 effects on 
glucose homeostasis (Tolhurst et al. 2011b). 
 
1.5.12: G-protein coupled receptor 43 (GPR43) 
 Like GPR41, GPR43 is activated by short chain fatty acid agonists (Brown et al. 2003, Le Poul et 
al. 2003). It is found in the intestine and activation of this receptor has been shown to increase PYY 
secretion from the L cells of the small intestine (Karaki et al. 2006). GPR43 can bind to both Gαi 
and Gαq subunits and as a result there is some confusion over the role that this receptor plays in 
various biological processes. For instance, one study found that GPR43 activation can both enhance 
and inhibit glucose stimulated insulin secretion (Priyadarshini et al. 2015). Although the sequence 
of GPR43 is highly conserved between the human and mouse genomes (Nilsson et al. 2003), 
different GPR43 agonists have shown to have differing responses in each species (Priyadarshini et 
al. 2015). Therefore there may be limitations in using murine models when assessing the 
effectiveness of GPR43 as a therapy for Type 2 Diabetes. 
  
1.5.13: G-protein coupled receptor 84 (GPR84) 
GPR84 is another receptor which is activated by fatty acid ligands. In particular, GPR84 is activated 
by medium chain fatty acids with a triglyceride chain length of 9-14 carbons (Wang et al. 2006). 
GPR84 was first described in 2001 and the gene which codes for this receptor is located on 
chromosome 12q13.13 in humans (Wittenberger, Schaller & Hellebrand 2001). The GPR84 protein 
is 396 amino acids long and was also known as EX33 which was identified as being expressed in 
bone marrow, lung and peripheral blood leukocytes (Yousefi et al. 2001). The first study to identify 
GPR84 agonists identified decanoic acid (10 carbon chain), undecanoic acid (11 carbon chain) and 
lauric acid (12 carbon chain) as potent stimuli of GPR84 (Wang et al. 2006) however new agonists 






1.5.14: G-protein coupled receptor 120 (GPR120) 
GPR120 is a class A rhodopsin-like GPCR (Fredriksson et al. 2003c) that is also classified as a free 
fatty acid receptor (Amisten et al. 2013). Like GPR43, GPR120 is activated by both medium and 
long chain fatty acids despite having only 10% sequence homology (Miyamoto et al. 2016). The 
receptor appears to signal through the Gαq pathway, however further research is required to 
elucidate which other pathways GPR120 activates (Miyamoto et al. 2016). Activation of GPR120 
by fatty acid agonists increases glucose stimulated insulin secretion from the pancreas (Moran et al. 
2014b) and GLP-1 and CCK secretion from the intestine (Hirasawa et al. 2005a, Sidhu et al. 2000). 
This suggests that GPR120 plays an important role in glucose homeostasis and is an attractive 
therapeutical target for the treatment of Type 2 Diabetes. This is confirmed by the expression of 
GPR120 in a range of tissues which are affected in metabolic disorders such as the intestine, 
pancreas, adipocytes and immune cells (Miyamoto et al. 2016).   
 
1.5.15: GPCRs activated by peptides 
Of the 293 receptors present in the islet, 110 were identified as being activated by a peptide with 
178 peptides being agonists for islet GPCRs and 80 peptides activating 2 or more receptors (Amisten 
et al. 2013). Advances in crystallisation techniques means that this under targeted area of GPCR 
may become thoroughly researched using structural based screens for ligands (Ranganathan et al. 
2017). 
 
1.5.16: GLP-1 receptor (GLP1R) 
In humans the GLP1R is a 463 amino acid receptor which activates multiple signalling pathways 
(Dillon et al. 1993). It is expressed in both the pancreas and the brain (Dillon et al. 1993, Cork et 
al. 2015). GLP1R activation increases both insulin and somatostatin release from the pancreas 
(Heller, Aponte 1995) while reducing glucagon secretion (Hare et al. 2009). The GLP1R agonist 
exenatide has been used as a therapy in Type 2 Diabetes since 2005 and has been shown to have 
positive effects on glucose homeostasis and weight loss (Kendall et al. 2005, Buse et al. 2010). 
Another GLP1R agonist, Liraglutide, is also clinically available and has the same positive effects 
as exenatide (Shyangdan et al. 2011). GLP-1 mimetics are desirable GLP1R agonists as they have 
a longer half-life than GLP-1 (Agerso et al. 2002). Activation of this receptor may lead to acute 
pancreatitis (Anderson, Trujillo 2010) or the formation against the drug itself, which is more likely 




1.5.17: GIP receptor (GIPR) 
The gene that codes for the GIPR is found on chromosome 19q13.2-q13.3 (Stoffel et al. 1995) and 
is expressed in the gut, adipose tissue, heart, pituitary gland and brain (Usdin et al. 1993). The GIPR 
is a 455 amino acid long protein with 44% sequence homology with the glucagon receptor 
(Brubaker, Drucker 2002). GIPR expression has been shown to be reduced in the islets of diabetic 
rats (Lynn et al. 2001). GIPR activation leads to increases in both cAMP and insulin secretion in 
pancreatic β-cells (Szecowka et al. 1982) while in normal glucose concentrations GIPR activation 
results in increased glucagon secretion (Meier et al. 2003).  
 
1.5.18: Glucagon receptor (GCGR) 
The human GCGR gene can be found on chromosome 17q25 and with a coding region of over 5.5kb 
pairs and encodes a 477 amino acid long protein (Lok et al. 1994, Menzel et al. 1994). GCGR is a 
class B GPCR which is expressed in various tissues within the body including the pancreas, liver, 
brain, heart and kidney (Brubaker, Drucker 2002, Siu et al. 2013). A mutation in the GCGR gene 
has been implicated in Type 2 Diabetes in people of European descent, however this mutation was 
not found in diabetic individuals from Japan (Hager et al. 1995, Fujisawa et al. 1995). An 
extracellular missense mutation in GCGR resulted in reduced glucagon affinity for GCGR, 
hyperglucagonemia and α-cell hyperplasia (Zhou et al. 2009). When the body is in a fasting state, 
glucagon binds to the GCGR and this leads to hepatic glucose release (Siu et al. 2013). The GCGR 
is bound to both the Gαq and Gαi subunits through which it increases intracellular calcium through 
the PLC pathway (Xu, Xie 2009). Interestingly, despite the cAMP pathway inhibition shown by the 
Gαi subunit, the GCGR has also been shown to increase cAMP through Gαs binding (Iyengar et al. 
1988).  
 
1.5.19: G-protein coupled receptor 75 (GPR75) 
The first recognised GPR75 agonist was the proinflammatory chemokine CCL5/RANTES (Ignatov 
et al. 2006). Recently a second agonist has been identified, which is known as 20-HETE (Garcia et 
al. 2017). It is suspected that GPR75 is attached to a Gαq subunit intracellularly as GPR75 activation 
leads to increased IP3 and calcium levels intracellularly (Ignatov et al. 2006, Garcia et al. 2017). 
GPR75 is widely expressed throughout the body with high levels of expression seen in the brain, 
endocrine glands and reproductive organs (Garcia et al. 2017). GPR75 has also been shown to be 
present in the islets of the pancreas and its activation by CCL5 has increased insulin secretion and 
glucose tolerance (Liu et al. 2013). 
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1.5.20: Neuropeptide receptors 
The human islet has various neuropeptide sensing receptors present which includes Y1, Y4, Y5 and 
GPR83 which are activated by neuropeptide Y (NPY), pancreatic polypeptide (PP) and PYY 
(Amisten et al. 2013). These receptors are expressed throughout the body including the brain and 
spinal chord (Brothers, Wahlestedt 2010, Muller et al. 2013). NPY has been shown to inhibit insulin 
secretion while there is some confusion over its role on glucagon secretion as it increases secretion 
in healthy rats but supresses it in diabetic rats (Ponery, Adeghate 2000, Schwetz, Ustione & Piston 
2013). PYY binds to all of the above receptors except Y5 but also binds to the Y2 receptor (Sah et 
al. 2007). PP binds to the Y1, Y2, Y4 and Y5 receptors and has been shown to inhibit insulin 
secretion in rats (Amisten et al. 2013, Murphy et al. 1981). 
 
1.6: Aims and objectives 
The effects of GPCR agonists such as GLP-1 on the pancreas have been extensively studied. It is 
thought that lipid, protein and carbohydrate sensing GPCRs are present in the small intestine in 
order to signal the presence of nutrients. The localisation and function of GPCRs in the small 
intestine is not as well established as those present in the pancreas. Fatty acid sensing GPCRs such 
as GPR40, GPR41 and GPR43 have been of particular interest in this research area. There are 
currently limited studies which have assessed the ability of both endogenous and synthetic agonists 
of other GPCRs to control glucose homeostasis through the regulation of gastrointestinal hormone 
secretion. There are also limited studies investigating the effects of GPCR agonists as a combination 
therapy with DPP-IV inhibitors. 
 
The main aims of the research project are as follows: 
 Evaluate the ability of agonists of a range of GPCRs (GPR39, GPR55, GPR75, GPR119 and 
GPR120) to increase GLP-1, GIP and insulin secretion from intestinal (GLUTag and pGIPneo STC-
1) and pancreatic (BRIN-BD11) cell lines as well as lean and diabetic mouse models 
 Determine the expression and localisation of GPCRs and gastrointestinal hormones (GLP-1, GIP 
and PYY) in a range of intestinal cell lines as well as lean and diabetic mouse models using qPCR 
and immunohistochemistry  
 Examine the acute effects of GPCR agonist and DPP-IV inhibitor combination therapy on glucose 
homeostasis in lean mouse models 
 Investigate the long term effects of GPR55 agonist Abn-CBD and GPR119 agonist AS1269574 




The hypothesis of this thesis is that the GPCRs investigated are present in the enteroendocrine cells 
of the intestine and can be targeted to increase incretin hormone and insulin secretion and improve 



















































2.1: Tissue culture 
 
2.1.1: Materials 
RPMI 1640 medium, 1x Dulbecco’s modified Eagle’s medium (DMEM), 4.5x DMEM and foetal 
bovine serum (FBS), penicillin/streptomycin (100U/ml; 0.1mg/ml), 10x trypsin/EDTA and Hanks 
Buffered Saline Solution (HBSS) were all purchased from Gibco Life Technologies (Paisley, 
Strathclyde, UK). HEPES, sodium chloride (NaCl), potassium chloride (KCl), calcium chloride 
dihydrate (CaCl2.2H2O), sodium hydroxide (NaOH), dimethylsulphoxide (DMSO), geneticin 
(G418), bovine serum albumin (BSA) and hydrogen peroxide (H2O2) were sourced from Sigma-
Aldrich (Poole, Dorset, UK). Sterile, flat bottom, 96-well tissue culture plates were obtained from 
Nunclon (Roskilde, Denmark). 
 
2.1.2: Culture of clonal BRIN-BD11 cells 
The effects of GPCR agonists on insulin secretion and cell viability were investigated using the 
insulin secreting BRIN-BD11 cell line. In order establish the insulin secreting pancreatic BRIN-
BD11 cell line, RINm5F cells were fused with New England Deaconess Hospital (NEDH) rat 
pancreatic beta cells via electroporation (McClenaghan et al. 1996). Cells (passages 15-45) were 
maintained in RPMI-1640 media with 1% antibiotics (v/v), 10% FBS (v/v) and a glucose 
concentration of 11.1mM. Cells were grown in 20ml of media in 75cm3 vented sterile tissue culture 
flasks at 37˚C in 5% CO2 and 95% air inside a LEEC incubator (Laboratory Technical Engineering, 
Nottingham, UK). Cell stocks, containing 1 million BRIN-BD11 cells, were cryopreserved in 1ml 
of freezing medium containing 80% FBS (v/v), 10% RPMI-1640 (v/v), 10% DMSO (v/v) and stored 
in 1.5ml cryovials (Sterilin, Houslow, UK). Cryovials containing stocks were stored at -20˚C for 4 
hr before transfer to -80˚C until long-term storage in liquid nitrogen.  
Confluent cells (75-90%) were harvested by washing in 10ml of HBSS and incubated with pre-
warmed 0.025% (w/v) trypsin/EDTA at 37˚C for 5 min. Confirmation of detachment was performed 
by visual inspection using a phase contrast microscope (Zeiss, Germany). Cells were resuspended 
in 5ml of RPMI-1640 media, transferred to a 20ml sterilin tube (Sterilin, Houslow, UK) and 
centrifuged at 900rpm for 5 mins using a bench centrifuge (MSE Mistral 200, RHYS International, 
Manchester, UK). Supernatant was decanted and the cell pellet resuspended in a known volume of 
media. An aliquot of cell suspension (100μl) was stained by adding to trypan blue (100μl, 1:2 
dilution), mixed thoroughly and added to a Neubauer haemocytometer (Scientific Supplies Co, 
Middlesex, UK) for counting. 
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2.1.3: Culture of GLUTag cells 
GLUTag cells (a gift courtesy of Professor D. J. Drucker, University of Toronto, Canada) were 
developed from nude transgenic mice producing a glucagon expressing neuroendocrine carcinoma 
due to the presence of a glucagon gene simian virus-40 large T-antigen (GLUTag) fusion gene as 
described previously (Drucker et al. 1992). This cell line was utilised to test the effect of GPCR 
activation on GLP-1 secretion and cell viability in vitro. Cells were cultured in DMEM containing 
5.5mM glucose, 2mM L-glutamine, 10% (v/v) FBS and antibiotics (penicillin (100U/ml), 
streptomycin (0.1mg/l)). Cell stocks, containing 1 million cells, were cryopreserved in 1ml of 
freezing medium containing 80% FBS (v/v), 10% DMEM (v/v), 10% DMSO (v/v) and stored in 
1.5ml cryovials (Sterilin, Houslow, UK). Cryovials containing stocks were stored at -20˚C for 4 hr 
before transfer to -80˚C until long-term storage in liquid nitrogen. 
Confluent cells (70-90%) were harvested by washing in 10ml of HBSS and incubated with pre-
warmed 0.025% (w/v) trypsin/EDTA at 37˚C for 5 min. Confirmation of detachment was performed 
by visual inspection using a phase contrast microscope (Zeiss, Germany). Cells were resuspended 
in 5ml of DMEM medium, transferred to a 20ml sterilin tube (Sterilin, Houslow, UK) and mixed 
up and down vigorously by pipetting. For counting, cells were pelleted by centrifugation at 900rpm 
for 5 mins using a bench centrifuge (MSE Mistral 200, RHYS International, Manchester, UK). 
Supernatant was decanted and the cell pellet resuspended in a known volume of media. An aliquot 
of cell suspension (100μl) was stained by adding to trypan blue (100μl, 1:2 dilution), mixed 
thoroughly and added to a Neubauer haemocytometer (Scientific Supplies Co, Middlesex, UK). 
 
2.1.4: Culture of pGIPneo STC-1 cells 
pGIPneo STC-1 cells were a kind gift from Dr. Burton Wice (Washington University in St. Louis, 
USA) with permission from Professor Douglas Hanahan (École Polytechnique Fédérale de 
Lausanne, CH). These cells were developed via the transfection of native STC-1 cells with a plasmid 
(pGIPneo) which encoded for neomycin phosphotransferase and selected cells containing the GIP 
promoter. Due to the increased number of cells containing the GIP promoter, pGIPneo STC-1 cells 
were used to examine the in vitro effects of GPCR activation on GIP secretion and cell viability. 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 25mM glucose, 
2mM L-glutamine, 10% (v/v) FBS and antibiotics (penicillin (100U/ml), streptomycin (0.1mg/l) 
and geneticin (400 μg/mL)). Cell stocks, containing 1 million cells, were cryopreserved in 1ml of 
freezing medium containing 80% FBS (v/v), 10% DMEM (v/v), 10% DMSO (v/v) and stored in 
1.5ml cryovials (Sterilin, Houslow, UK). Cryovials containing stocks were stored at -20˚C for 4 hr 
before transfer to -80˚C until long-term storage in liquid nitrogen. Confluent cells (70-90%) were 
harvested and cells were counted as described in section 2.1.4. 
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2.1.5: Culture of STC-1 cells 
STC-1 cells were a kind gift from Dr. Burton Wice (Washington University in St. Louis, USA) with 
permission from Professor Douglas Hanahan (École Polytechnique Fédérale de Lausanne, CH). 
STC-1 cells were developed from a RIP1Tag2/RIP2PyST1 mouse which developed intestinal 
neuroendocrine tumours (Grant et al. 1991). STC-1 cells were used to investigate the localisation 
of GPCRs in PYY immunoreactive cells. STC-1 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 25mM glucose, 2mM L-glutamine, 17.5% (v/v) FBS and antibiotics 
(penicillin (100U/ml) and streptomycin (0.1mg/l)). Cell stocks, containing 1 million cells, were 
cryopreserved in 1ml of freezing medium containing 80% FBS (v/v), 10% DMEM (v/v), 10% 
DMSO (v/v) and stored in 1.5ml cryovials (Sterilin, Houslow, UK). Cryovials containing stocks 
were stored at -20˚C for 4 hr before transfer to -80˚C until long-term storage in liquid nitrogen. 
Confluent cells (70-90%) were harvested and cells were counted as described in section 2.1.4. 
 
2.1.6: Acute insulin secretory tests in BRIN-BD11 cells 
Confluent BRIN-BD11 (70-90%) cells were cultured and harvested as described in section 2.1.2. 
Cells were subsequently seeded into 24 well plates (Nunclon, Roskilde, DK) with each well 
containing 150,000 cells and 1ml RPMI-1640 media. Upon seeding cells were incubated at 37˚C in 
5% CO2 and 95% air overnight to allow for the development of monolayers. Before test solutions 
were added, media was decanted and cells were initially incubated with 1ml of 1.1mM glucose in 
Krebs Ringer Bicarbonate Buffer (KRBB, 4.7mM KCl, 115mM NaCl, 1.28mM CaCl2.2H2O, 
25mM NaHCO3, 0.1% BSA (w/v), 1.2mM KH2PO4, 1.2mM MgSO4.7H2O, 20mM HEPES (pH 
7.4)) for 40 mins at 37˚C in 5% CO2 and 95% air. Following this incubation, 1.1mM glucose was 
decanted and cells were incubated with varying concentrations (10-12 to 10-4M) of GPCR agonists 
in both 5.6mM and 16.7mM glucose in KRBB for 20 mins at 37˚C in 5% CO2 and 95% air. 
Supernatant (950μl) of test solutions were collected subsequent to this incubation and stored at -
20˚C until insulin measurement by radioimmunoassy or LDH assay.   
 
2.1.7: Acute incretin secretory tests in GLUTag and pGIPneo STC-1 cells 
Confluent cells (70-90%) were cultured and harvested as described in sections 2.1.3 and 2.1.4. Cells 
were subsequently seeded into 24 well plates with each well containing 150,000 cells and 1ml of 
culture media. Cells were mixed vigorously up and down via pipetting before seeding to allow for 
the development of monolayers and incubated at 37˚C in 5% CO2 and 95% air for 48 hrs. Before 
test solutions were added, media was decanted and cells were initially incubated with 1ml of 1.1mM 
glucose in KRBB for 1 hr at 37˚C in 5% CO2 and 95% air. Following this incubation, 1.1mM 
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glucose was decanted and cells were incubated with varying concentrations (10-12 to 10-4M) of 
GPCR agonists in 2mM glucose in KRBB for 2 hrs at 37˚C in 5% CO2 and 95% air. Supernatant 
(950μl) of test solutions were collected subsequent to this incubation and stored at -20˚C until 
hormone measurement by ELISA.     
 
2.1.8: Alamar Blue Assay 
BRIN-BD11 cells were harvested as described above (section 2.1.2) and seeded into 96-well plates 
(Nunclon, Roskilde, DK) at a density of 40000 cells per well. Cells were incubated overnight at 
37˚C in 5% CO2 and 95% air. After overnight incubation, media was decanted and test solutions 
consisting of varying concentrations (10-12 to 10-4M) of GPCR agonists were added in both 5.6mM 
and 16.7mM glucose in KRBB and incubated for 20 mins at 37˚C in 5% CO2 and 95% air. Test 
solutions were subsequently decanted and 10µl of FluoroFire-Blue ProViaTox (Molecutools, 
Dublin, IRL) was added and cells were incubated at 37°C, 5% CO2 and 95% air for 5 hrs. 
Fluorescence excitation and emission were measured using using the FlexStation 3 (Molecular 
Devices, CA, USA) at 560nm and 590nm respectively.  
 
2.1.9: 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) Assay 
BRIN-BD11, GLUTag and pGIPneo STC-1 cells were harvested as described above (sections 2.1.2, 
2.1.3 and 2.14) and seeded into 96-well plates (Nunclon, Roskilde, DK) at a density of 40000 cells 
per well. BRIN-BD11 cells were incubated overnight at 37˚C in 5% CO2 and 95% air. After 
overnight incubation, media was decanted and test solutions consisting of varying concentrations 
(10-12 to 10-4M) of GPCR agonists were added in both 5.6mM and 16.7mM glucose in KRBB and 
incubated for 20 mins at 37˚C in 5% CO2 and 95% air. GLUTag and pGIPneo STC-1 cells were 
incubated for 48 hrs at 37˚C in 5% CO2 and 95% air. Subsequent to this incubation, media was 
decanted and test solutions consisting of varying concentrations (10-12 to 10-4M) of GPCR agonists 
were added in 2mM glucose for 2 hrs at 37˚C in 5% CO2 and 95% air. Following incubation, test 
solutions were decanted and 0.5mg/ml MTT in culture media was added for 2 hrs and cells were 
incubated at 37˚C in 5% CO2 and 95% air. MTT was decanted and DMSO and cells were incubated 
for 5 mins on a horizontal orbital microplate shaker (Titramax 1000, Heidolph Instruments, 
Schwabach, DE). Fluorescence excitation and emission were measured using using the FlexStation 





2.2: Insulin Radioimmunoassay (RIA) 
 
2.2.1: Materials  
Thimerosal, iodogen (1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril), BSA, activated charcoal, 
sequencing grade TFA, dextran T-70 and bovine insulin were purchased from Sigma-Aldrich 
(Poole, Dorset, UK). Dichloromethane (CH2Cl2) and HPLC grade acetonitrile were sourced from 
Rathburn (Walkersburn, UK). Radiolabelled sodium iodide (Na125I) was supplied by Amersham 
Pharmacia Biotech (Buchinghamshire, UK). Rat insulin standards were purchased from Novo 
Industria (Copenhagen, Denmark). All other chemicals used were obtained from BHD chemicals 
(Poole, Dorset, UK).  
 
2.2.2: Preparation of iodinated bovine insulin  
In order to coat microcentrifuge tubes (Sarstedt, DE) with a layer of iodegen, dichloromethane 
(100μg/ml) was used to dissolve iodegen. Dissolved iodegen was then added to tubes in 100μl 
aliquots before evaporation using a gentle stream of helium to ensure the iodegen layer was uniform. 
Coated iodegen reaction tubes were then used and iodination was carried out in a designated 
controlled area with both lead and Perspex shielding. A 20μl solution of bovine insulin (125μg/ml 
in 500mM sodium phosphate buffer, pH 7.4) and 5μl of Na125I (100mCi/ml) were added to the 
coated iodegen tubes and tubes were agitated 3-4 times per min while being cooled on ice between 
agitations. This continued for 15 mins. In order to stop the reaction, the mixture was transferred 
from the reaction tube into a fresh microcentrifuge tube, with the reaction tube being washed with 
500μl of 50mM sodium phosphate buffer. This buffer was also transferred to the new 
microcentrifuge tube. The iodination mixture was kept cool on ice until reverse-phase high 
performance liquid chromatography (RP-HPLC) separation of bound and unbound fractions.  
A Spectra Series P200 TSP HPLC gradient pump system (CA, USA) with a Vydac C-8 analytical 
column (4.6 x 250mm, Phenomenex, Macclesfield, UK) was used to separate fractions using RP-
HPLC. Column equilibrium was achieved using 0.12% (v/v) TFA/H2O and eluted with 0.1% (v/v) 
TFA in 70% acetonitrile/H2O from 0-40% over 10 mins, from 40-80% over 40 mins and 80-100% 
over 10 mins. Fractions were collected using a LKB2112 Redirac fraction collector (Bromma, S) in 
72 x 12mm polypropylene tubes (Sarstedt, DE). From each 1ml fraction, 5μl aliquots were 
transferred to plastic LP3 tubes (Sarstedt, DE) and counts per min (CPM) measured using a gamma 
counter (1470 Wizard multigamma counter, PerkinElmer, USA). Fractions with the highest CPM 
underwent an antibody binding test. Fractions with similar binding were subsequently pooled and 
double diluted using 40mM sodium phosphate buffer (pH 7.4) containing 1% BSA (w/v), 1.2mg/ml 
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thiomersal and stored at 4˚C. A typical RP-HPLC elution profile of the iodination reaction with 
CPM/μl versus time (min) is displayed in Fig. 2.1. 
 
2.2.3: Determination of insulin by RIA  
The determination of insulin content of both in vitro and in vivo samples was achieved using a 
modified dextran-coated charcoal RIA as previously described (Flatt, Bailey 1981). Stock assay 
buffer was prepared using 40mM disodium hydrogen orthophosphate with 0.3% NaCl (w/v) and 
0.02% thimersol (w/v). This buffer was titrated with 40mM sodium dihydrogen orthophosphate 
until pH 7.4 was observed. Working assay buffer consisted of stock assay buffer supplemented with 
0.5% BSA (w/v) and was used to dilute guinea-pig anti-porcine insulin antibody (1:35000 to 
1:55000 depending on the binding test), rat insulin standards and bovine insulin labelled with I125. 
A standard curve (0.039-20ng/ml) for rat insulin standards was prepared by serial dilution and each 
standard was assayed in triplicate. Diluted antibody (100μl) was added to each standard or unknown 
sample. Total and non-specific binding tubes received no antibody. Samples were incubated for 24 
hrs before bovine insulin labelled with I125, which was diluted in working assay buffer to achieve 
10,000 CPM/100μl, was added to all tubes including total and non-specific binding. Samples were 
incubated for a further 24 hrs at 4˚C. Working assay buffer was used to dilute dextran T-70 coated 
charcoal 1:5 and 1ml of this was added to all tubes except the total tubes for 20 mins at 4˚C. 
Following this 20 min incubation, tubes were centrifuged for 20 mins at 2,500rpm and 4˚C using a 
Model J-6B Centrifuge (Beckman Instruments, UK). Following centrifugation, the supernatant was 
decanted with unbound I125 labelled insulin fraction remaining as a black pellet. The CPM of this 
pellet was measured using the gamma counter. There was an inverse correlation between counts 
bound to the antibody (total CPM minus CPM bound to charcoal) to the concentration of insulin in 
standards or unknown samples. The rat insulin standard curve was constructed with spline curve 
fitting algorithm with unknown samples being interpolated from the curve. The rat insulin standard 
stock of 1 ng/ml insulin is equal to 173 pM and conversion from ng/ml to pM was performed by 
multiplication by a factor of 173. A typical rat insulin standard curve is shown with CPM versus 








2.3: Enzyme-linked immunosorbent assay (ELISA) 
 
2.3.1: Materials 
Multi species GLP-1 total ELISA and rat/mouse GIP total ELISA kits were purchased from Merck 
Millipore (Watford, UK). 
 
2.3.2: Measurement of GLP-1 
Multi species GLP-1 total ELISA kits were used to quantify the GLP-1 content of both plasma and 
cell culture supernatant samples. This is a sandwich based ELISA which measures both the 7-36 
and 9-36 forms of GLP-1. For cell supernatant samples, 50μl of supernatant collected in section 2.1 
was used. For plasma samples, 20μl of plasma was diluted in 30μl of assay buffer. Each kit 
contained one 96 well plate. 
Components of the ELISA were pre-warmed to room temperature before commencing the assay as 
per manufacturer’s protocol. A 1000pM GLP-1 standard underwent a series of dilutions in order to 
obtain a standard curve ranging from 4.1 to 1000pM. Quality control 1 and quality control 2 were 
reconstituted in μQ H2O with excess kept at -20°C. Blank, standard and quality control wells of the 
96 well plate received 50μl of matrix solution. Blank and unknown sample wells received 50μl of 
assay buffer. Following plate and sample preparation, 50μl of standards, quality controls and 
unknown samples were added to the appropriate wells. Blank, standard and quality control wells 
were tested in duplicate while unknown samples were assayed in triplicate. The plate was 
subsequently incubated at room temperature for 1.5 hrs on a horizontal orbital microplate shaker at 
450rpm. Following this incubation, solution from all wells was decanted and wells were washed 3 
times with wash buffer (300μl). Detection antibody (100μl) was added subsequent to washing and 
the plate was incubated for 1 hr on a horizontal orbital microplate shaker at room temperature at 
450rpm. Detection antibody was decanted and wells were again washed 3 times with 300μl of wash 
buffer before the addition of 100μl of enzyme solution and incubation for 30 mins on a horizontal 
orbital microplate shaker at 450rpm. Enzyme solution was decanted, wells were washed 3 times 
with wash buffer (300μl) and 100μl of substrate solution was added. The plate was incubated on a 
horizontal orbital microplate shaker at 450rpm until a blue colour was formed in all wells with 
increasing intensity in the standards according to the amount of GLP-1 present in the well. Stop 
solution (100μl) was subsequently added and the plate was shook gently by hand before absorbance 
was read at 450nm and 590nm using a FlexStation 3. A typical GLP-1 standard curve is shown with 
absorbance versus log GLP-1 concentrations in Fig. 2.3. 
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2.3.3: Measurement of GIP 
Rat/mouse GIP total ELISA kits were used to quantify the GIP content of both plasma and cell 
culture supernatant samples. This is a sandwich based ELISA which measures both the 1-42 and 3-
42 forms of GIP. For cell supernatant samples, 10μl of supernatant collected in section 2.1 was used 
while 10μl of plasma was used for plasma samples. Each kit contained one 96 well plate. 
Components of the ELISA were pre-warmed to room temperature before commencing the assay as 
per manufacturer’s protocol. A 2000pM GIP standard underwent a series of dilutions in order to 
obtain a standard curve ranging from 8.2 to 2000pM. Quality control 1 and quality control 2 were 
reconstituted in μQ H2O with excess kept at -20°C. Before addition of any samples to the plate, 
each well was incubated for 5 mins in 300μl of wash buffer. Following this incubation, wash buffer 
was decanted and standard and quality control wells received 80μl of assay buffer and 10μl of matrix 
solution. Blank wells received 90μl of assay buffer and 10μl of matrix solution. Unknown sample 
wells received 90μl of assay buffer. Blank, standard and quality control wells were tested in 
duplicate while unknown samples were assayed in triplicate. Following plate preparation, 10μl of 
standards, quality controls and unknown samples were added to the appropriate wells. The plate 
was subsequently incubated at room temperature for 1.5 hrs on a horizontal orbital microplate 
shaker at 450rpm. Following this incubation, solution from all wells was decanted and wells were 
washed 3 times with wash buffer (300μl). Detection antibody (100μl) was added subsequent to 
washing and the plate was incubated for 1 hr on a horizontal orbital microplate shaker at room 
temperature at 450rpm. Detection antibody was decanted and wells were again washed 3 times with 
300μl of wash buffer before the addition of 100μl of enzyme solution and incubation for 30 mins 
on a horizontal orbital microplate shaker at 450rpm. Enzyme solution was decanted, wells were 
washed 3 times with wash buffer (300μl) and 100μl of substrate solution was added. The plate was 
incubated on a horizontal orbital microplate shaker at 450rpm until a blue colour was formed in all 
wells with increasing intensity in the standards according to the amount of GIP present in the well. 
Stop solution (100μl) was subsequently added and the plate was shook gently by hand before 
absorbance was read at 450nm and 590nm using a FlexStation 3. A typical GIP standard curve is 
shown with absorbance versus log GIP concentrations in Fig. 2.4. 
 
2.4: Lactate dehydrogenase (LDH) assay  
 
2.4.1: Materials  
CytoTox96 non-radioactive cytotoxicity assay kits were purchased from Promega (Madison, USA). 
Phosphate buffered saline (PBS) tablets were sourced from Analab (Dublin, Ireland). 
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2.4.2: Measurement of LDH activity  
Cell supernatants were collected as outlined in section 2.1 for the measurement of LDH. Cellular 
release of LDH was used as an indicator of membrane integrity following the addition of test 
solutions to cells. This assay is based on the principle that the breakdown of the cell membrane will 
result in the presence of LDH. The presence of LDH will convert the tetrazolium salt (INT) into a 
red formazan product with the amount of colour produced being directly proportional to the amount 
of LDH present. The assay was performed as per manufacturer’s instructions. All reagents were 
thawed and incubated at room temperature. Substrate mix was reconstituted using 12ml of assay 
buffer. The cell supernatant (50μl) and substrate reagent (50μl) were added to each well of a 96 well 
plate. The plate was covered and protected from light for 30 mins at room temperature. To stop the 
reaction, 50 μl of stop solution was added to all wells. Absorbance was measured at 490 nm using 
a Flexstation 3. Cellular LDH release (% of control) was quantified using the following equation:  
 
Cellular LDH release = 100 x Experimental LDH release (OD, 490nm) 
            Control LDH release (OD, 490nm) 
 
2.5: Pancreatic islet isolation  
 
2.5.1: Materials  
Collagenase-P derived from Clostridium histolyticum was obtained from Sigma-Aldrich (Poole, 
Dorset, UK). All other chemicals used were obtained from BHD chemicals as outlined previously. 
 
2.5.2: Isolation of mouse pancreatic islets  
KRBB isolation solution was prepared as described in section 2.1.6 except for CaCl2.2H2O, 
NaHCO3 and HEPES which were used at concentrations of 2.56mM, 20mM and 16mM 
respectively. Isolation solution (5ml) without KRBB was used to prepare collagenase (1.4mg/ml) 
which was kept on ice. Mouse pancreatic islets were isolated from lean and HFF Swiss TO mice 
(Envigo, Huntingdon, UK) by enzymatic collagenase digestion (Moskalewski 1969). Mice were 
culled using cervical dislocation after being anaesthetised by isoflurane. Pancreases were extracted 
and placed in a universal tube containing collagenase solution and placed on ice. This process was 
repeated for each pancreas which were then incubated at 37°C in a preheated shaking water bath 
for 5 mins at high speed (300 cycles/ min). After this incubation, samples were vigorously shaken 
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manually for 10 secs until the solution was homogenous. In order to ensure the breakdown of large 
sections of pancreas, tissues were further minced using scissors for 1 min. The pancreases then 
underwent another 5 min incubation at 37˚C and were again shaken vigorously for 10 secs. To stop 
islet over digestion, ice cold isolation buffer was added to all tubes prior to centrifugation at 
1,200rpm for 2 mins using a Beckman microcentrifuge (Beckman Instruments, UK). Following this 
step, the supernatant was discarded and the remaining pellet resuspended in 10ml of isolation 
solution. To remove any undigested pancreatic tissue the resuspended islet solution was poured 
through a tea strainer. The remaining solution centrifuged at 1,200rpm for 2 mins and the 
supernatant discarded. The subsequent pellet was resuspended in 25ml of RPMI-1640 and 
transferred to tissue culture dishes. Isolated islets were incubated at 37˚C, 5% CO2 and 95% air for 
48 hrs to allow for the detachment of exocrine tissue. 
 
2.5.3: Acute insulin secretion tests  
Glucose solutions (1.1mM, 5.6mM and 16.7mM) were prepared in KRBB as described in section 
2.1.6. Test solutions were prepared in 5.6mM and 16.7mM glucose in KRBB. Isolated islets were 
visualised using a phase contrast microscope (Zeiss, Germany) and transferred to a microcentrifuge 
tube (10 islets per tube) using a micropipette. All tubes were centrifuged at 900rpm for 5 mins using 
a Beckman microcentrifuge (Beckman Instruments, UK) and excess media discarded. Islets were 
subsequently incubated for 1 hr with 1.1mM glucose in KRBB (1ml) at 37˚C, 5% CO2 and 95% air 
before another centrifugation at 900rpm for 5 mins after which the supernatant was decanted. Each 
tube received 1ml of test solution as appropriate. Tubes were again incubated for 1hr at 37˚C, 5% 
CO2 and 95% air and centrifuged at 900rpm for 5 mins following this incubation. Supernatants 
(980μl) from all tubes were collected and transferred to labelled LP3 tubes (Sarstedt, Germany) 
before insulin measurement via RIA. The remaining pellets were treated with 1ml ice cold acid 
ethanol (1.5% HCl (v/v), 75% ethanol (v/v) and 23.5% H2O (v/v)). Tubes underwent another 
centrifugation step at 900rpm for 5 mins before transfer to LP3 tubes for measurement of insulin 
content via RIA. From the 1ml of collected supernatant for insulin content, 20μl was diluted with 
180μl of working RIA assay buffer for insulin RIA with. Insulin secretion from islets was measured 
using 200μl of islet supernatant. Insulin release (% of total pancreatic insulin content) was 
calculated using the following equation:  
 
Insulin Release (% of content) = 100 x        Insulin release__________                     




2.6: Histology   
 
2.6.1: Materials  
Paraformaldehyde (PFA), 4’ 6-diamidino-2-phenylindole (DAPI) nuclear stain, p-
Phenylenediamine (antifade) and ethanol were purchased from Sigma-Aldrich (Poole, Dorset, UK). 
Xylene was obtained from VWR (Dublin, Ireland). All other chemicals used were obtained as 
described previously. Suppliers of all primary and secondary antibodies used for 
immunohistological staining are shown in Table 2.1.  
 
2.6.2: Immunofluorescence staining of GLUTag, pGIPneo STC-1 and STC-1 cells  
GLUTag, pGIPneo STC-1 and STC-1 cells were harvested as described in section 2.1. Cells were 
seeded for 48 hrs at a density of 40,000 cells per drop on polylysine-coated slides (25 x 75 x 1mm, 
VWR) with 3 drops per slide. Cells were incubated at 37˚C, 5% CO2 and 95% air and in tissue 
culture dishes with 15ml of DMEM culture media. Following incubation, slides were washed twice 
in PBS for 5 mins before cells fixation in 4% PFA/PBS (v/v) for 20 mins at room temperature. Fixed 
slides were washed in PBS 3 times for 5 mins. Antigen retrieval was performed by incubation in 
50mM sodium citrate (pH 6.0) at 95˚C for 30 mins. Prior to addition of the primary antibody, slides 
were blocked with 2% BSA (w/v) for 1 hr to prevent non-specific binding. Primary antibodies 
(200μl per slide) were diluted in blocking solution and added at appropriate concentrations as shown 
in Table 2.1, and slides were incubated overnight at 4˚C or 1 hr at 37˚C. Subsequent to primary 
antibody incubation, slides were washed in PBS 3 times for 5 minutes with appropriate secondary 
antibodies (200μl per slide) being diluted in blocking solution and added for 45 mins at 37˚C, 
protected from light. Following secondary antibody incubation, slides were washed 3 times in PBS 
for 5 mins and DAPI (0.1μg/ml, 200μl per slide) was added to slides which were incubated at 37˚C 
for 30 mins. Finally slides were washed twice in PBS for 5 mins and mounted with antifade before 
fixation with clear nail varnish. Slides were analysed under the 350nm filter (DAPI), fluorescein 
isothiocyante (FITC) filter (488nm) and tetramethylrhodamine isothiocyanate filter (TRITC) filter 
(594nm) using a fluorescent microscope (Olympus BX51 microscope, South-on-Sea, UK) and 
images acquired using the DP70 camera.       
  
2.6.3: Tissue processing and immunofluorescence staining of tissue  
Non-fasted mice were culled by cervical dislocation after anesthetisation by isoflurane. Pancreases 
were extracted and cut in half from head to tail while small intestinal tissue was arranged into the 
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“Swiss Roll” technique as described previously (Moolenbeek, Ruitenberg 1981). Extracted tissue 
was placed into labelled cassettes before fixation in 4% PFA (w/v) for at least 48 hr at 4˚C. Samples 
were embedded in paraffin wax using an automated Leica TP1020 automated tissue processor 
(Leica Bio systems, Germany) as per manufacturer’s guidelines. Briefly, tissues in labelled cassettes 
were placed into the tissue basket and attached placed into the tissue basket holder. The tissue basket 
holder revolved around the instrument transferring cassettes between 4% PFA (w/v), increasing 
concentrations of ethanol, xylene and molten paraffin wax as follows: 70%, 80%, 96% ethanol (v/v) 
for 2 hr each, 100% ethanol 2 changes for 2 hr, xylene 2 changes for 1 hr 30 mins and 2 changes in 
paraffin wax for 4 hr. Subsequent to this processing, tissues were placed into plastic moulds, 
appropriately orientated, covered in molten paraffin wax and labelled cassettes attached to the top. 
Molten paraffin wax blocks were allowed to set for 24 hrs at room temperature, after which blocks 
were removed from the moulds and stored at 4°C.  
A microtome (RM2035, Leica, Germany) was used to cut 8μm tissue sections, which were 
subsequently floated on a 37˚C water bath and lifted onto polylysine-coated slide (25 x 75 x 1mm, 
VWR). To ensure no bias in tissue selection, a random number generator was used to select which 
tissue sections were collected. Slides were dried on a hot plate at 37˚C overnight. Slides with 
paraffin embedded tissue were dewaxed twice in xylene for 10 mins. Tissue was rehydrated using 
decreasing concentrations of ethanol as follows: 100% ethanol twice for 5 mins, 95% ethanol (v/v) 
for 5 mins, 80% ethanol (v/v) for 5 mins and distilled water for 5 mins. Antigen retrieval, blocking, 
staining procedure, mounting and visualisation of slides was performed as outlined above (Section 
2.6.2). 
 
2.7: Animal models  
All animal experiments were performed in accordance with the UK Animal (Scientific Procedures) 
Act 1986 and the ARRIVE guidelines for experiments involving animals (Kilkenny et al. 2012). 
All mice were housed in an air-conditioned room maintained at 22 ± 2˚C with a 12 hr dark: 12 hr 
light cycle (08:00-20:00).  
 
2.7.1: Swiss TO mice  
Male Swiss TO mice (8 wk) were purchased from Envigo (Huntingdon, UK) derived from a colony 
originally sourced from Statens Serum Institute (Copenhagen, DK). Mice were housed in single 
cages and supplied drinking water and standard rodent maintenance diet (60% carbohydrate, 30% 
protein, 10% fat (12.99 kJ/g), Trouw Nutrition, Cheshire, UK) ad libitum. Swiss TO mice on a 
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standard rodent maintenance diet exhibited normal glycaemic levels, no weight gain and had normal 
glucose tolerance.     
 
2.7.2: Diet induced diabetic mice  
Male NIH Swiss mice (8-10 wks) were obtained from Harlan (Blackthorne, UK) and derived from 
a colony originally sourced from the National Institute of Health (Maryland, USA). Mice were 
individually housed and supplied with drinking water and high fat diet (35% carbohydrate, 20% 
protein, 45% fat (26.15 kJ/g), Special Diet Service, Essex, UK) ad libitum for 5 months to induce 
obesity-diabetes. High fat fed (HFF) mice had increased body weight and hyperglycaemia and also 
exhibited impaired glucose tolerance when compared to NIH Swiss mice on the standard rodent 
maintenance diet as described previously (Bailey et al. 1986). This model of diet-induced diabetes 
in mice simulates a high fat western diet and induces several important clinical features identified 
in human obesity. 
 
2.7.3: Multiple low dose streptozotocin induced-diabetic mice 
Age-matched (26 wks), male Swiss TO mice were sourced from Envigo (Huntingdon, UK). Mice 
were housed in single cages and were supplied drinking water and standard rodent maintenance diet 
(60% carbohydrate, 30% protein, 10% fat (12.99 kJ/g), Trouw Nutrition, Cheshire, UK) ad libitum. 
Streptozotocin is a glucose analogue which is cytotoxic to the insulin secreting β-cells of the 
pancreas (Szkudelski 2001). Due to the similarities in structure with glucose, streptozotocin is able 
to enter β-cells through the GLUT2 receptor and induce diabetes through β-cell toxicity and a T-
cell mediated immune response against β-cells in the pancreas (Wang, Gleichmann 1998, 
Szkudelski 2001). The alkylating properties of streptozotozin mean that free radicals are added to 
DNA present in β-cells and destroying the cell and preventing it from metabolising glucose due to 
the breakdown of mitochondrial DNA (Szkudelski 2001). The effects of multiple low dose 
streptozotocin induced diabetes on rats has previously shown to result in mild hyperglycaemia, 
hypoinsulinaemia, hyperphagia and polydipsia with no adverse effects on weight gain (Kobayashi, 
Olefsky 1979). Diabetes was chemically induced in 4 hr fasted Swiss TO mice through 4 
intraperitoneal injections of streptozotocin (40mg/kg body weight, 0.1M sodium citrate, pH 4.5) 
which were received on alternate days. Diabetes was confirmed through an oral glucose tolerance 
test (OGTT) which was performed 14 days after the first injection of streptozotocin injection (day 




2.7.4: Acute food intake in 3 hr trained mice 
Age matched male Swiss TO mice (20-24 wk) were sourced from Envigo (Huntingdon, UK). Mice 
were housed in single cages and were supplied drinking water ad libitum and standard rodent 
maintenance diet (60% carbohydrate, 30% protein, 10% fat (12.99 kJ/g), Trouw Nutrition, Cheshire, 
UK). Mice were habituated to feeding for 3 hr per day as described previously (O'Harte et al. 
1998a). Briefly, mice were initially supplied standard rodent diet ad libitum. After 7 days this was 
reduced to 12 hrs for another 7 days. There was a further reduction to 6 hr access to diet for 7 days 
before a final reduction to 3 hrs. Mice continued on 3 hr access to standard rodent maintenance diet 
for 7 days before experimentation. All GPCR agonists were administered in 0.9% saline (n=8). 
  
2.8: Acute in-vivo glucose tolerance tests  
 
2.8.1: Materials  
Fluoride/ heparin coated microcentrifuge tubes tubes were purchased from Sarstedt (DE). D-glucose 
and NaCl were obtained from BDH Chemicals (Poole, Dorset, UK). Bayer Contour Next glucose 
meter and strips were sourced from Williams Medical Supplies (Rhymney, UK).   
 
2.8.2: Glucose tolerance tests  
Acute oral glucose tolerance tests were carried out in Swiss TO mice on standard rodent 
maintenance diet. Mice were fasted for 18 hrs prior to testing. Groups of mice (n=6) were 
maintained as described in section 2.7.1 with food withheld for the duration of the experiment. 
Blood samples were collected via tail vein bleeding of conscious mice prior to the commencement 
of testing (0 mins). GPCR agonists were administered orally in combination with glucose 
(18mmol/kg BW) or in combination with glucose and the DDP IV inhibitor Sitagliptin Phosphate 
(50mg/kg BW). Blood was collected at 15, 30, 60, 90 and 120 mins post administration. Collected 
blood was centrifuged at 13,000rpm for 5 mins at 4˚C using a Beckman microcentrifuge (Beckman 
Instruments, UK). Plasma was aliquoted into microcentrifuge tubes and stored at -20˚C prior to 
glucose, insulin, GLP-1 and GIP measurement. 
 
2.8.3: Biochemical analysis  
Blood glucose determination was performed using a Bayer Contour Next meter (Leverkusen, DE). 
This is an automated glucose analyser that can read glucose concentrations up to 35mM. Plasma 
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insulin was quantified using insulin RIA as previously described in section 2.2. Plasma (20μl) was 
diluted (1:10) in working assay buffer and results multiplied accordingly. Plasma GLP-1 and GIP 
were measured using ELISA as described in section 2.3. For GLP-1 samples, plasma was diluted 
1:2.5 and all results were multiplied accordingly. 
 
2.9: Chronic biological effects of GPCR agonist administration both as a monotherapy and 
combination therapy in multiple-low streptozotocin induced-diabetic mice   
 
2.9.1: Materials  
Abn-CBD and AS-1269594 were purchased from Tocris Bioscience (Bristol, UK). Sitagliptin 
Phosphate was sourced from Apex Bioscience (Durham, North Carolina, USA). Multi species GLP-
1 total and rat/mouse GIP total ELISA kits were supplied by Merck Millipore (Watford, UK). 
Streptozotocin and bovine insulin were purchased from Sigma-Aldrich (Poole, Dorset, UK). D-
glucose and NaCl were obtained from BDH Chemicals (Poole, Dorset, UK). Materials for 
triglyceride assay were purchased from Instrumentation Laboratory (Warrington, UK) while kits 
for total cholesterol and HDL were purchased from Randox (Co Antrim, UK). 
 
2.9.2: Treatment procedure and parameters assessed  
The long term effects of oral Abn-CBD and AS-1265974 (0.1µmol/kg BW) or saline (0.9% w/v 
NaCl) in multiple low dose streptozotocin-induced diabetic Swiss TO mice (n=6) (section 2.7.3) 
was assessed over a period of 21 days. Hyperglycaemia was confirmed in diabetic mice through an 
oral glucose tolerance test which was performed 14 days after the first streptozotocin injection (day 
0) on 18 hr fasted NIH Swiss mice as previously described (section 2.8.2). Fluid intake, food intake, 
body weight, non-fasted blood glucose, insulin, GLP-1 and GIP concentrations were monitored 
every 3 days. Blood was collected via tail vein bleeding of conscious mice and was collected and 
analysed for blood glucose, insulin, GLP-1 and GIP as described in section 2.8.4. After the testing 
period, glucose tolerance tests (18mmol/kg body weight) were carried out to assess glucose 
tolerance on 18 hr fasted streptozotocin treated mice and Swiss TO mice on standard rodent 






2.9.3: Insulin sensitivity   
Prior to the injection of insulin, blood glucose was measure in non-fasted Swiss TO mice via tail 
vein bleeding using the Bayer Contour glucose meter. Bovine insulin (25U/kg) in 0.9% saline was 
administered using intraperitoneal injection of bovine insulin (25U/kg) and blood glucose was 
monitored at 30 and 60 mins post injection.   
 
2.9.4: Dual energy X-ray absorption (DEXA)  
Non-fasted Swiss TO mice were culled by cervical dislocation after being anesthetised using 
isoflurane, and subsequently arranged on the specimen tray to ensure both limbs and tail were 
extended away from the body. In order to ensure calibration and quality control, 25 measures of the 
aluminium/lucite phantom (0.069g/cm2, 12.0% fat) were taken using a Lunar PIXImus Dual energy 
X-ray absorption (DEXA) system (software version 1.4x) before any specimens were measured. 
DEXA scanning was performed on all carcasses as per manufacturer’s guidelines. The Lunar 
PIXImus DEXA system measures percentage body fat as well as bone mineral density (BDM, 
g/cm3) and bone mineral content (BMC, g) using a fully integrated densitometer. A representative 
DEXA scan of a lean Swiss TO mouse and a multiple low dose streptozotocin-induced diabetic 
mouse are shown in Fig. 2.5.  
 
2.9.5: Measurement of plasma hormones 
Blood was collected via tail vein bleed on conscious mice every 3 days for biochemical analysis on 
a variety of hormones. Blood glucose determination was performed using a Bayer Contour Next 
meter (Leverkusen, DE) every 3 days. Plasma insulin was quantified using insulin RIA as 
previously described in section 2.2. Rat/mouse GIP total ELISA kit (Millipore, Watford, UK) was 
used to measure total GIP concentrations in mouse plasma following chronic treatment. Multi 
species GLP-1 total ELISA was used to measure total GLP-1 content of mouse plasma. These 
sandwich based ELISAs are described in detail in section 2.3. 
 
2.9.6: Assessment of plasma lipid profiles  
Plasma triglyceride and HDL cholesterol concentrations were measured using an I-lab 650 clinical 




2.10: Determination of mRNA expression in BRIN-BD11, GLUTag and STC-1 cells and NIH 
Swiss mouse pancreas and small intestine 
 
2.10.1: Materials  
TRIzol reagent, propan-2-ol and chloroform was supplied by Sigma (Poole, Dorset, UK). 
Superscript II reverse transcriptase RNase H kit was supplied by Invitrogen (Paisley, UK). 
Eppendorf real-time PCR tube strips & masterclear cap strips were sourced from Bio-Rad 
Laboratories (Herrtfordshire, UK). LightCycler® 480 SYBR Green I Master was obtained from 
Roche (Basel, CH).  
 
2.10.2: mRNA extraction and conversion to cDNA  
mRNA was extracted from all cell lines and tissue using the phenol chloroform method as described 
previously (Chomczynski, Sacchi 1987). Briefly, cells and tissue were harvested as previously 
mentioned (Sections 2.1. and 2.6.3). Tissue was homogenised lysed in an LP3 tube with 1ml of 
TRIzol reagent. Cells were seeded in 6-well plates, treated with test solutions for the appropriate 
time and lysed using TRIzol on ice for 10 mins. Cells were agitated with gentle stirring. Tissue and 
cells were transferred to a fresh microcentrifuge tube and 200μl of chloroform was added. This 
suspension was agitated and incubated at room temperature for 10 mins before undergoing 
centrifugation at 12000g for 15 mins at 4°C (MIKRO 200R, Hettich Zentrifugen, Germany). The 
clear upper aqueous phase containing mRNA was transferred to a new microcentrifuge tube 
subsequent to centrifugation and 0.5ml of propan-2-ol was added. The interphase and organic phase 
was discarded. The mixture was agitated and incubated at room temperature for 10 mins before 
centrifugation at 12000g for 10 mins at 4°C. The supernatant was discarded and 70 % ethanol was 
used to wash the pellet of mRNA off the side of the microcentrifuge tube and centrifuged at 12000g 
for 10 mins at 4°C. This was repeated for a total of 3 times. Subsequent to 3 washes of 70% ethanol, 
the supernatant was discarded and pellets air dried at room temperature for 10 mins. Following air 
drying, the pellet was suspended in 30μl of RNase free water and boiled at 70°C for 5 mins before 
determination of the mRNA yield using a nanophotometer (Implen, version 2.0). The quality of 
mRNA was determined by 260/280 ratios with ratios between 1.9 and 2.1 being deemed acceptable. 
The 260/230 ratios were also measured with the requirement that this value was higher than the 
260/280 ratio and greater than 2. From this mRNA, 1-5 μg was converted to cDNA using the 
superscript II reverse transcriptase – Rnase H kit as per suppliers’ instructions. mRNA samples were 




2.10.3: Quantitative real-time PCR (qPCR) 
qPCR was performed using LightCycler® 480 SYBR Green I Master. Reactions were performed 
using 4.5μl of 2x concentrated SYBR green, 1μl of forward and reverse primers (primer sequences 
are listed in Table 2.2), 1μl of cDNA and 3μl of RNase free water (n=3). All reactions included a 
negative template control with RNase free water added instead of cDNA (n=3). The reactions were 
carried out in 8-well real-time PCR Tube Strips and Masterclear™ Cap Strips (Eppendorf, HAM, 
DE). Amplification conditions were 5 mins initial denaturation at 95°C, followed by 40 cycles of 
30 secs denaturation at 95°C, 30 secs annealing at 58°C and 30 secs extension at 72°C and a final 
elongation step for 5 mins at 72°C. Reactions included melting curve analysis with temperature 
range of 60 °C to 90 °C. All reactions were carried out using the MiniOpticon two colour real time 
PCR detection system (BioRad, UK). Analysis of results was performed using the Livak method 
and the mRNA levels of all genes were normalised using the housekeeping gene GAPDH. Primer 
sequences for qPCR are listed in Table 2.2 
 
2.11: Statistics  
Data are expressed as the mean ± the standard error of the mean (SEM). Results were compared 
using the Student’s t-test on Prism graph pad version 5.0. Incremental area under the curve (AUC) 
with baseline subtraction, were calculated using Prism graph pad. Differences in data were 


















Bovine insulin labelled with Na125I was prepared using the iodogen method described in section 
2.2.2. Separation of bound and unbound fractions was achieved by RP-HPLC using a Vydac C-8 
column. Elution of the iodination reaction mixture occurred using 70% acetonitrile/H2O (v/v) 
increased to 40% after 10 min, to 80% over 40 mins and 80- 100% over 10 min. Unbound Na125I 
was initially eluted between 3-6 mins while bovine insulin labelled with Na125I was eluted between 
24-30 mins as indicated by the black arrows on the graph. Fractions with the highest CPM 
underwent antibody binding testing and fractions with similar binding were pooled and stored at 









Figure 2.2: Typical standard curve obtained for insulin RIA from rat insulin standards 
 
A rat insulin standard curve ranging from 0.039-20ng/ml by serial dilutions of the stock standard 
(R2 = 0.96). Unknown values were interpolated from the standard curve and insulin concentrations 















Figure 2.3: Typical standard curve obtained for multi species GLP-1 total ELISA 
 




























A GLP-1 standard curve with standard concentrations of 4.1-1000pM by serial dilution of a 1000pM 
stock (R2 = 0.9990). Absorbance of unknown values was used to interpolate their concentration 
from the standard curve to quantify GLP-1 concentration. Quality control samples (QC1, QC2) 
which both fell within the recommended range were provided by the supplier and used to validate 













Figure 2.4: Typical standard curve obtained for rat/mouse GIP total ELISA 
 




























A GIP standard curve with standard concentrations of 8.2-2000pM by serial dilution of a 2000pM 
stock (R2 = 0.9990). Absorbance of unknown values was used to interpolate their concentration 
from the standard curve to quantify GIP concentration. Quality control samples (QC1, QC2) which 
both fell within the recommended range were provided by the supplier and used to validate the 













Figure 2.5: Representative Dual energy X-ray absorption (DEXA) images of (A) a lean Swiss 





Mice were analysed after prior calibration and quality control with the aluminium/lucite phantom 














1:500 Abcam (Cambridge, UK) 
Glucagon Mouse 1:100 Abcam (Cambridge, UK) 
GLP-1 Goat 1:40 
Santa Cruz Biotechnology 
(CA, USA) 
GIP Goat 1:40 
Santa Cruz Biotechnology 
(CA, USA) 
PYY Goat 1:40 
Santa Cruz Biotechnology 
(CA, USA) 
GPR39 Rabbit 1:1000 Abcam (Cambridge, UK) 
GPR55 Rabbit 1:150 
Cayman Chemical 
(Michigan, USA) 
GPR75 Rabbit 1:50 
Santa Cruz Biotechnology 
(CA, USA) 
GPR119 Rabbit 1:50 
Santa Cruz Biotechnology 
(CA, USA) 
GPR120 Rabbit 1:50 






alexa fluor 488nm 
Mouse 1:400 
Molecular probes, Life 




Molecular probes, Life 
Technologies (Paisley, UK) 
Anti-goat alexa fluor 
488nm 
Donkey 1:400 
Molecular probes, Life 




Molecular probes, Life 
Technologies (Paisley, UK) 
 
Primary and secondary antibodies used for immunocytochemistry and immunohistochemistry 












































































Activation of GPR75 increases insulin and 
















3.1: Overview of results 
GPR75 is a G-protein coupled receptor which was originally found in the human eye. CCL5 is a 
proinflammatory chemokine that has been shown to activate GPR75 leading to increased insulin 
secretion from the pancreas. There are currently no studies which have studied the role of GPR75 
activation on intestinal hormones and there is currently only one previously published study which 
identifies a role for GPR75 in glucose homeostasis. The current study aims to determine the role of 
the novel GPCR, GPR75, activation by CCL5 on intestinal and pancreatic function and glucose 
homeostasis. The cytotoxicity of CCL5 to β-cells was determined by MTT assay. 
Immunohistochemistry and qPCR was used to determine the expression of GPR75 in both lean and 
HFF NIH Swiss mouse pancreas and small intestine. Secretory studies were performed using the 
pancreatic BRIN-BD11 cell line. Immunocytochemistry was performed using BRIN-BD11, 
αTC1.9, STC-1 and GLUTag cells. The acute in vivo effects of CCL5 (25nmol/kg BW) were 
examined orally and via IP injection in fasted male Swiss TO mice (n=6). CCL5 (25nmol/kg BW) 
delivered orally was tested as a lone treatment and in combination therapy with Sitagliptin (50mg/kg 
BW, n=6).  
In 5.6mM glucose CCL5 increased insulin secretion 1.3 to 1.8 fold (p0.05 to p<0.001) while in 
hyperglycaemic conditions (16.7mM glucose) insulin secretion was augmented 1.1 to 1.8-fold 
(p<0.01 to p<0.001). At both glucose conditions, CCL5 had no cytotoxic effects. qPCR was used 
to determine the expression of GPR75 in lean and HFF mouse pancreas and small intestine and this 
was confirmed with immunohistochemistry. A HFF diet led to a 36.7% (p<0.01) increase in 
pancreatic GPR75 expression (n=6) with GPR75 being co-localised with the β-cells of the pancreas 
but not α-cells. BRIN-BD11 cells treated for 20 mins with CCL5 resulted in increased insulin 
expression (p<0.001) with this being exhausted after 4hr treatment (p<0.05-p<0.01) in 5.6 and 
16.7mM glucose when compared to vehicle control as determined by immunohistochemistry. 
GPR75 expression was increased after both 20 min (p<0.001) and 4hr treatment (p<0.05-p<0.01) 
in both 5.6 and 16.7mM glucose when compared to vehicle control.  
In the intestine a 46.4% (p<0.05) reduction in GPR75 expression was observed in HFF mice 
compared to lean (n=6). The expression of GPR75 in the L and K-cells of the intestine was 
determined using double immunohistochemistry. GPR75 was confirmed in both the L and K-cells 
of the intestine as it was found to be co-localised of with GLP-1, GIP and PYY being observed. In 
GLUTag cells treated with CCL5 for 2 hrs both proglucagon (3.0-fold, p<0.001) and PC1 (2.3-fold, 
p<0.001) gene expression were increased compared to vehicle control. 
IP injection of CCL5 (25nmol/kg BW) in fasted male Swiss TO mice (n=6) increased insulin 
secretion 1.4-fold (p<0.001) and resulted in a 1.3-fold reduction in blood glucose (p<0.001). When 
administered orally, CCL5 alone had the greatest reduction in blood glucose with a 1.9-fold 
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decrease being observed (p<0.001). Insulin secretion was increased 1.4-fold (p<0.001). While 
combination of CCL5 and Sitagliptin also reduced blood glucose, this was less than with CCL5 
treatment alone as a 1.7-fold decrease resulting from this treatment (p<0.001). The increase in 
insulin secretion was also lower than CCL5 administration alone with a 1.3-fold increase being 
observed (p<0.001). 
This study demonstrates that GPR75 is readily expressed in both the pancreas and intestine. This 
result suggests a role for GPR75 activation in both the pancreas and intestine can be utilised to help 
regulate glucose homeostasis. Therefore CCL5 activation of GPR75, and other future novel 
agonists, may be a potential therapy for Type 2 Diabetes. The identification of new GPR75 agonists 
and future research of GPR75 activation on intestinal endocrine cell function will help to elucidate 
the mechanisms through which this can be achieved. The in vivo results in this study show that 
CCL5 activates receptors found in the endocrine cells of the intestine. 
 
3.2: Introduction 
The human form of GPR75 was first identified in 1999, which found that a gene on chromosome 
2p16 encoded a 543 amino acid long protein with a molecular weight of 59.4kDa (Tarttelin et al. 
1999). GPR75 was originally only found to be present in the brain, eye, blood and spinal cord of 
humans, however as the mouse gene had yet to be cloned, the expression pattern of GPR75 in mice 
was not ascertained. Later research confirmed the presence of GPR75 in the mouse genome and 
showed it had 87% homology with human GPR75 (Visel, Thaller & Eichele 2004, Ignatov et al. 
2006). Unlike human GPR75, mouse GPR75 is found on chromosome 11a4 (Ignatov et al. 2006). 
The receptor was most closely related to rat galanin receptor type 3 (25% homology), C. elegans 
neuropeptide Y receptor (24% homology) and porcine growth hormone secretagogue receptor type 
1bAs (23% homology). As GPR75 was first identified to be present in the eye, research was carried 
out to try and identify mutations in GPR75 which may have an effect in age related macular 
degeneration (Sauer et al. 2001). A cohort of 535 patients affected by AMD discovered 6 pathogenic 
variants of GPR75 however no functional studies were carried out and further research is required 
to see if any of these may be a possible cause of AMD. Earlier research found no mutations in 
GPR75 in a screen of patient’s who suffered from Doyne’s honeycomb retinal dystrophy (Tarttelin 
et al. 1999) and further work into the effects of GPR75 on disorders in the eye need to be carried 
out. 
The first identified GPR75 agonist was Chemokine (C-C motif) ligand 5 (CCL5, also known as 
RANTES or regulated on activation, normal T cell expressed and secreted) which was shown to 
increase intracellular calcium, inositol trisphosphate and stimulation of the luciferase assay in cells 
which had been transfected with GPR75 (Ignatov et al. 2006). Gαq has previously been identified as 
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the G-protein α subunit which activates phospholipase C (PLC) activity (Maurice et al. 1993) and 
the presence of U73122, a PLC inhibitor, prevented CCL5 increasing intracellular calcium thus 
demonstrating that GPR75 signals through the Gαq pathway. Another cytokine, MIP1α, was shown 
to stimulate luciferase gene expression, however no effect on intracellular calcium was observed 
and further work needs to be carried out to elucidate whether MIP1α is an agonist for GPR75. CCL5 
is produced endogenously by fibroblasts, platelets, macrophages, CD8+ T cells, endometrial cells 
and epithelial cells (Appay, Rowland-Jones 2001, Levy 2009) and has previously been shown to 
reduce HIV infection as it competes with HIV to bind to C-C chemokine receptor type 5 (CCR5), 
while having an effect in experimental autoimmune uveitis (Crane et al. 2001) as well as having 
proinflammatory effects (Alkhatib et al. 1996, Benamar, Geller & Adler 2008). These 
proinflammatory effects include the recruitment of T cells, monocytes, eosinophils, natural killer 
cells, basophils, mast cells and dendritic cells to sites of inflammation (Schall 1991, Appay, 
Rowland-Jones 2001). Only recently has a second GPR75 agonist been identified. 20-
Hydroxyeicosatetraenoic acid (20-HETE) was found to bind to GPR75 in human cells with the same 
increase in inositol trisphosphate as seen with CCL5 treatment (Garcia et al. 2017) thus confirming 
the signalling of GPR75 through Gαq. As of yet no antagonists for GPR75 have been identified. 
The search for further GPR75 agonists and antagonists is important for several reasons. Firstly, 
CCL5 is able to signal through several receptors such as CCR1 (Neote et al. 1993), CCR3 
(Daugherty et al. 1996), CCR4 (Power et al. 1995) and CCR5 (Samson et al. 1996), all of which 
are also GPCRs like GPR75 with which they have 12-16% sequence homology (Liu et al. 2013). 
Therefore it is important to determine the selectivity of CCL5 for the receptor being studied. This 
becomes less challenging when one CCL5 binding receptor is highly expressed while the others are 
seen at low levels, with such an expression pattern being demonstrated in the pancreas (Liu et al. 
2013). Secondly, the activation of these chemokine receptors has been linked to a variety of 
syndromes (D'Ambrosio, Panina-Bordignon & Sinigaglia 2003) making it harder to elucidate the 
effects of GPR75 activation. CCL5 activity can be reduced through wartmannin which inhibits PI 
3-kinase activity (Turner, Ward & Westwick 1995) although this effect has yet to be seen for 
GPR75. 
The ability of GPR75 to increase PLC and thus intracellular calcium through the Gαq pathway led 
to an interest in the effects of GPR75 activation on insulin secretion (Liu et al. 2013). This research 
confirmed the presence of both CCL5 and GPR75 in both mouse and human pancreatic islets using 
immunohistochemistry and PCR. Immunohistochemistry and qPCR showed that the cytokine 
receptors GPR75 agonist CCL5 activate, namely CCR1, CCR3 and CCR5, were either massively 
downregulated or not present in both human and mouse pancreatic islets. Downregulation of GPR75 
using siRNA in MIN6 cells demonstrated the specificity of CCL5 for GPR75 in the β cells of the 
pancreas while also confirming the activation of the Gαq pathway which was shown to be activated 
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in earlier research (Ignatov et al. 2006). The insulinotropic effect demonstrated in MIN6 cells was 
further shown in isolated mouse and human islets. CCL5 activation of GPR75 also resulted in 
increased insulin secretion in vivo. These results demonstrate a role for GPR75 in glucose 
homeostasis and it may be a potential therapy in the treatment of Type 2 Diabetes. There are high 
expression levels of CCR5 on T and B cells which can be activated by CCL5. NOD mice treated 
with a neutralising anti-CCR5 antibody had reduced β-cell destruction thus demonstrating a role for 
CCL5 in the autoimmune destruction of β-cells which is seen in Type 1 Diabetes. Therefore further 
research will need to be carried out to further determine the suitability of GPR75 activation for 
individuals with Type 1 Diabetes. 
Previous work demonstrating the effect of GPR75 activation on insulin secretion (Liu et al. 2013) 
was carried out in pancreatic cells while the method of drug delivery in vivo bypassed the intestine. 
Interestingly CCL5 is cleaved by DPP-IV in the intestine (Proost et al. 1998). This study will 
elucidate the effects of GPR75 agonist CCL5 on the intestine in vivo as well as determine the 
expression pattern of GPR75 in a range of intestinal and pancreatic cell lines. The effects of 
activation of GPR75 on intestinal and pancreatic hormone secretion in vivo will also be determined.     
 
3.3: Materials and methods 
 
3.3.1: Materials 
CCL5 was purchased from SynPeptide (SHA, CN). All other materials were sourced as described 
in Chapter 2. 
 
3.3.2: Acute insulin secretion from pancreatic BRIN-BD11 cells 
Cells were seeded in 24-well plates with 150000 BRIN-BD11 cells per well and incubated overnight 
in 1ml of RPMI 1640 media at 37°C and 5% CO2. Following this incubation, cells were 
preincubated with 1.1mM glucose for 40 mins with subsequent acute incubations being carried out 
at 37°C 5% CO2 for 20 mins in 5.6mM and 16.7mM glucose in KRBB buffer supplemented with 
10-12M to 10-5M concentrations of CCL5 with 10mM alanine as a positive control (n=8). After 






3.3.3: Acute effects of CCL5 on cell toxicity 
Cells were seeded in 96-well plates with 40000 cells per well of BRIN-BD11 cells and incubated 
overnight in cell culture media (as described in Chapter 2, section 2.1.2) in an atmosphere of 5% 
CO2 at 37°C. After 20hrs, cells were preincubated with 1.1mM glucose for 40 mins with subsequent 
acute incubations being carried out at 37°C 5% CO2 for 20 mins in 5.6mM and 16.7mM glucose in 
KRBB buffer supplemented with 10-12M to 10-5M concentrations of CCL5 with 1mM H2O2 as a 
cytotoxic control (n=3). After incubation, supernatant was decanted, cells were washed with HBSS 
and 0.5mg/ml MTT was added for 2hrs. Following MTT incubation, supernatant was discarded and 
DMSO was added to solubilise crystals. Optical density was subsequently measured at 570nm and 
630nm using the Flexstation 3 (Molecular Devices, CA, USA). 
  
3.3.4: Acute insulin secretion from isolated islets  
Pancreatic islets were isolated from both lean and HFF Swiss TO mice by enzymatic collagenase 
digestion as outlined in Chapter 2, section 2.5.2. CCL5 and alanine (10mM) were added to KRBB 
buffer in 11.1mM glucose and acute insulin secretion assessed in isolated islets as previously 
described in Chapter 2, section 2.5.3. 
 
3.3.5: Immunofluorescence staining in GLUTag, STC-1 cells and lean and HFF NIH Swiss mouse 
small intestine 
GLUTag, pGIPneo STC-1 and STC-1 cells were seeded at a density of 40000 cells on to polylysine 
coated slides overnight at 37°C in an atmosphere of 95% air and 5% CO2 as described in Chapter 2, 
section 2.1. Swiss TO mice were anesthetised by isoflurane and killed by cervical dislocation. 
Pancreas and intestine was excised as described in Chapter 2, section 2.6.3. Immunohistochemistry 
was carried out by incubating with rabbit polyclonal anti-GPR75 and guinea pig polyclonal anti-
insulin, mouse polyclonal anti-glucagon, goat polyclonal anti-GLP-1, goat polyclonal anti-GIP or 
goat polyclonal anti-PYY with the dilutions outlined in Chapter 2, Table 2.2. 
 
3.3.6: Quantitative real-time PCR (qPCR) 
qPCR was performed using LightCycler® 480 SYBR Green I Master. Reactions were performed 
using 4.5μl of 2x concentrated SYBR green, 1μl of forward and reverse primers (primer sequences 
are listed in Chapter 2, Table 2.2), 1μl of cDNA and 3μl of RNase free water (n=3). All reactions 
included a negative template control with RNase free water added instead of cDNA (n=3). The 
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reactions were carried out in 8-well real-time PCR Tube Strips and Masterclear™ Cap Strips 
(Eppendorf, HAM, DE). Amplification conditions were 5 mins initial denaturation at 95°C, 
followed by 40 cycles of 30 secs denaturation at 95°C, 30 secs annealing at 58°C and 30 secs 
extension at 72°C and a final elongation step for 5 mins at 72°C. Reactions included melting curve 
analysis with temperature range of 60 °C to 90 °C. All reactions were carried out using the 
MiniOpticon two colour real time PCR detection system (BioRad, UK). Analysis of results was 
performed using the Livak method and the mRNA levels of all genes were normalised using the 
housekeeping gene GAPDH. 
   
3.3.7: Acute in vivo glucose tolerance tests 
Male Swiss TO mice were housed as described in Chapter 2, section 2.7. The effects GPR75 agonist 
CCL5 (25nmol/kg BW), as well as in combination with Sitagliptin Phosphate (50mg/kg BW) in 
lean male Swiss TO mice (n=6) were investigated. Before test compounds were administered, mice 
were fasted for 18 hrs and blood subsequently collected (t=0). Test compounds were administered 
orally and via intraperitoneal injection in glucose (18mmol/kg BW), and blood was collected at 15, 
30, 60, 90 and 120 mins along with blood glucose measurements. Collected blood was centrifuged 
at 10000gfor 5 mins at 4°C using a Beckman centrifuge (Beckman Instruments, UK). Plasma was 




3.4.1: Effects of CCL5 on insulin secretion from pancreatic BRIN-BD11 cells 
The effects of CCL5 on insulin secretion from pancreatic BRIN-BD11 cells were tested in both 
5.6mM and 16.7mM glucose (Figures 3.1 and 3.2). At 5.6mM glucose, CCL5 increased insulin 
secretion 1.3 to 1.8 fold (10-9-10-5M, p<0.05-p<0.001), Figure 3.1A). In hyperglycaemic conditions 
(Figure 3.2A), CCL5 increased insulin secretion 1.1 to 1.8-fold (10-8-10-5M, p<0.01-p<0.001). At 
both glucose conditions tested, CCL5 had no cytotoxic effects (Figures 3.1B and 3.2B). 
 
3.4.2: Effects of CCL5 on insulin secretion from isolated islets 
In mouse islets isolated from both lean and HFF Swiss TO mice, CCL5 increased insulin secretion 
from 10-10 to 10-6M (p<0.05 - p<0.001). In lean islets, CCL5 increased secretion maximally at 10-
6M 3.3-fold compared to basal control (p<0.001, Figure 3.3A). This effect was demonstrated until 
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10-10M (p<0.05) which augmented insulin secretion 1.3-fold. In HFF mouse islets, insulin secretion 
was increased 1.8-fold by CCL5 at 10-6M (p<0.001, Figure 3.3B). Again this insulinotropic effect 
was maintained until 10-10M, which increased insulin secretion 1.3-fold compared to glucose alone 
(p<0.05). 
 
3.4.3: Distribution of GPR75 and insulin in BRIN-BD11 cells and lean and HFF NIH Swiss mouse 
pancreas 
In order to determine the cellular localisation of GPR75 and insulin, double immunohistochemistry 
was carried out in BRIN-BD11 cells and lean and HFF mouse pancreas (Figure 3.4). GPR75 and 
insulin were found to be co-localised in pancreatic BRIN-BD11 cells (Figure 3.4D). The co-
localisation of GPR75 and insulin was confirmed in lean and HFF mouse pancreas (Figure 3.4H 
and 3.4L). The effects of a high fat diet on NIH Swiss mice was calculated with a 36.9% increase 
(p<0.01) in GPR75 expression being observed in the pancreas of animals who received a high fat 
diet (Figure 3.5). 
 
3.4.4: Distribution of GPR75 and glucagon in αTC1.9 cells and lean and HFF NIH Swiss mouse 
pancreas 
As with BRIN-BD11 cells, the co-localisation of GPR75 with glucagon was investigated in αTC1.9 
cells and lean and HFF NIH Swiss mouse pancreas. It was found that GPR75 and glucagon were 
not co-localised in lean or HFF mouse small intestine (Figures 3.6H and 3.6L), however it was 
found to be present in αTC1.9 cells with glucagon (Figure 3.6D). 
 
3.4.5: Distribution of GPR75 and GLP-1, GIP and PYY in intestinal cell lines and lean and HFF 
NIH Swiss mouse small intestine 
The expression of GPR75 in the intestinal GLUTag and STC-1 cell lines as well as lean and HFF 
small intestine was examined using immunohistochemistry. Both GLP-1 and GPR75 were found 
throughout GLUTag cells (Figure 3.7D) and found to be co-localised in the intestinal cells of lean 
and HFF NIH Swiss mouse (Figures 3.7H and 3.7L).  
GPR75 and GIP were found to be co-localised in the intestine, however not all GPR75 expressing 
cells were shown to be secreting GIP (Figures 3.9D and 3.9H). This was also seen for GPR75 and 
PYY which were found to be co-localised in both lean and HFF small intestinal tissue (Figures 
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3.10H and 3.10L). PYY and GPR75 were also found to be expressed throughout STC-1 cells (Figure 
3.10D).  
The effects of a high fat diet on GPR75 expression in the small intestine of NIH Swiss mice was 
determined using qPCR. Mice fed a high fat diet had a 46.37% reduction in GPR75 expression 
(Figure 3.8, p<0.05). 
 
3.4.6: Effects of CCL5 on GPR75 and insulin expression in BRIN-BD11 cells 
In order to examine the effects of CCL5 treatment on GPR75 and insulin expression both qPCR and 
immunohistochemistry was carried out on BRIN-BD11 cells which had been treated for 20 mins 
and 4 hrs respectively. BRIN-BD11 cells treated with 5.6mM glucose demonstrated no change in 
insulin protein expression compared to media (Figures 3.11A and 3.11B). Treatment with CCL5 
(10-6M) in 5.6mM glucose resulted in a 69.1% increase in expression when compared to media 
(p<0.01). Compared to 5.6mM glucose vehicle a 195.0% increase was observed (p<0.001). 
Treatment with 16.7mM glucose resulted in a downregulation of insulin expression with a 60.1% 
reduction observed when compared to media (p<0.001). BRIN cells treated with CCL5 (10-6M) in 
16.7mM glucose resulted in no change in insulin expression when compared to cells treated with 
media. When compared to 16.7mM glucose vehicle, CCL5 treatment resulted in a 292.0% increase 
in insulin protein expression (p<0.001). 
When BRIN-cells were treated for 4 hrs, all treatments downregulated insulin gene expression, with 
CCL5 treatment resulting in the largest downregulation at both 5.6 and 16.7mM glucose (Figures 
3.12A and 3.12B). Treatment with 5.6 and 16.7mM glucose resulted in downregulation of 87.1% 
and 91.3% when compared to untreated cells respectively (p<0.001). Treatment with CCL5 in both 
concentrations resulted in downregulation of 94.0% in 5.6mM glucose while a downregulation of 
95.8% was observed in 16.7mM glucose compared to media (p<0.001). When compared to the 
vehicle controls, there was a 53.7% reduction in insulin protein expression from cells treated with 
CCL5 in 5.6mM glucose (p<0.01), while a 51.5% reduction was observed in cells treated with CCL5 
in 16.7mM glucose (p<0.05). 
Treatment of BRIN-BD11 cells for 20 mins resulted in downregulated GPR75 expression in all but 
one condition when compared to untreated cells (Figures 3.14A and 3.14B). Cells treated with 10-
6M CCL5 in 5.6mM glucose were upregulated 43.1% (p<0.001). When compared to the vehicle 
control, this upregulation was increased to 222.0% (p<0.001) as treatment of BRIN-BD11 cells with 
5.6mM glucose resulted in a 55.6% reduction when compared to cells which were treated with 
media (p<0.001). Treatment with 16.7mM glucose reduced GPR75 expression 71.9% (p<0.001), 
however the presence of CCL5 in this glucose concentration increased GPR75 expression 86.0% 
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(p<0.001). When GPR75 expression levels of BRIN-BD11 cell treatment with CCL5 in 
hyperglycaemic conditions was compared to untreated cells, a 47.0% reduction was observed 
(p<0.001). 
BRIN-BD11 cells treated for 4 hrs resulted in reduced GPR75 expression in all conditions tested 
(Figures 3.15A and 3.15B). Both 5.6mM and 16.7mM glucose had lower expression levels than 
those demonstrated when cells were also supplemented with CCL5. In normoglycaemic conditions, 
a 85.6% downregulation was observed while a reduction of 85.8% was seen in 16.7mM glucose 
when compared to untreated cells (p<0.001). BRIN-BD11 levels treated with CCL5 in 5.6mM 
glucose demonstrated a downregulation of 77.1% compared to the expression level seen in cells 
treated with media (p<0.001). This was a 1.6-fold increase in GPR75 expression when compared to 
the vehicle control (p<0.05). Meanwhile treatment of cells with CCL5 in 16.7mM glucose resulted 
in a 78.7% reduction in GPR75 expression (p<0.001) which was a 1.5-fold increase when compared 
to the 16.7mM glucose treatment alone (p<0.01). 
qPCR on cells treated for 4 hrs demonstrated reduced insulin expression (Figure 3.13). Treatment 
of BRIN-BD11 cells resulted in greater insulin gene expression downregulation when compared 
with the vehicle control. Both 5.6mM and 16.7mM glucose reduced insulin gene expression 46.0% 
(p<0.05) and 40.0% (p<0.05), compared to untreated cells. Treatment with CCL5 in 5.6mM glucose 
resulted in downregulation of 41.3% (p<0.05) when compared to vehicle control. Treatment with 
CCL5 at 16.7mM glucose had no effect. 
 
3.4.7: Effects of CCL5 on proglucagon and PC1 gene expression in intestinal GLUTag cells 
In order to assess the effects of CCL5 treatment on GLP-1 expression, GLUTag cells were treated 
with CCL5 (10-6M, Figure 3.16A and 3.16B). Cells treated with 2mM glucose were upregulated 14-
fold while those treated with CCL5 were upregulated 41-fold when compared to untreated cells 
(p<0.001) (Figure 3.16A). When compared to cells treated with glucose, CCL5 increased 
proglucagon gene expression 2-fold (p<0.05). The proglucagon gene is processed by PC1/3 in the 
small intestine and treatment of GLUTag cells with CCL5 resulted in a 1.8-fold increase compared 
to untreated cells (Figure 3.16B, p<0.05). Compared to the 2mM glucose vehicle control PC1 
expression is upregulated 2.3-fold (p<0.05) (Figure 3.16B). 
 
3.4.8: Acute effects of GPR39 agonists on blood glucose and insulin in fasted male Swiss TO mice 
In order to test the effects of GPR75 activation in vivo, CCL5 was administered both orally and via 
IP injection to male fasted Swiss TO mice. CCL5 was also administered orally with the DPP-IV 
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inhibitor Sitagliptin Phosphate. IP administration of 25nmol/kg BW CCL5 resulted in reduced 
blood glucose from 30 to 60 mins post administration (Figure 3.17A, p<0.001). A 1.5-fold reduction 
in blood glucose was observed after 30 mins and this was sustained after 60 mins. The AUC (Figure 
3.17B) confirmed an overall reduction of 1.3–fold (p<0.001). Insulin secretion was enhanced by 
41.6% (Figure 3.18A, p<0.001) 15 mins post administration. This effect was sustained 30 mins post 
injection with an increase of 41.7% being observed. Overall, CCL5 increased insulin secretion in 
lean mice by 40.1% as measured by AUC (Figure 3.18B, p<0.001). 
Oral administration of 25nmol/kg BW CCL5 (Figure 3.19A) resulted in a reduction in blood glucose 
from 15-120 mins (p<0.01-p<0.001). The greatest reduction in blood glucose was seen 90 mins post 
administration with a 49.8% reduction being observed (Figure 3.19A). Blood glucose was reduced 
by 39.8%, 47.1%, 39.3% and 47.4% at 15, 30, 60 and 120 mins, respectively post administration. 
Like CCL5 administration alone, Sitagliptin in combination with CCL5 reduced blood glucose over 
the course of the testing period with reductions of 39.8%, 43.2%, 30.6%, 41.6% and 31.0% (Figure 
3.19A, p<0.05-p<0.001). However compared to CCL5 treatment alone there was an overall increase 
in blood glucose of 7.5% (Figure 3.19B). Overall there was a 41.9% reduction in blood glucose as 
determined by the AUC (p<0.001). Administration of Sitagliptin alone reduced blood glucose over 
the course of the study. Blood glucose was reduced 20.0%, 34.1%, 27.1%, 37.1% and 34.4% at 15, 
30, 60, 90 and 120 mins respectively (Figure 3.19A). Compared to Sitagliptin and CCL5 there was 
a 24.8% increase in blood glucose 15 mins post administration (p<0.05) and this effect was seen 
overall in the AUC (p<0.001).  
The largest increase in insulin secretion was observed in mice treated with CCL5 alone (Figure 
3.20A). Insulin secretion was increased 2.2-fold (p<0.001) 30 minutes post administration when 
compared to glucose administration alone, while this effect was sustained until 60 mins with a 1.6-
fold increase being observed (p<0.05). CCL5 administered alongside Sitagliptin also increased 
insulin secretion (1.9-fold increase) 30 mins post administration (p<0.001). Sitagliptin 
administration alone resulted in a 1.3-fold increase in insulin secretion after 15 mins, compared to 
glucose administration. Both CCL5 and CCL5 in combination with Sitagliptin outperformed 
Sitagliptin treatment alone with 1.8 and 1.5-fold increases in secretion being observed after 30 mins 
(p<0.001).  
 
3.5: Discussion  
GPR75 was first identified in the human genome in the eye (Tarttelin et al. 1999) and so to date 
much research has explored the effects of GPR75 activation on eye disorders (Tarttelin et al. 1999, 
Sauer et al. 2001). The first identified GPR75 agonist was CCL5 (Ignatov et al. 2006), a 
proinflammatory cytokine (Keane, Strieter 2000) that had previously been identified as playing a 
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role in experimental autoimmune uveitis (Crane et al. 2001) as well as the recruitment of immune 
cells to β-cells of the pancreas in Type 1 Diabetes (Carvalho-Pinto et al. 2004). Interestingly, CCL5 
is degraded by DPP-IV (Oravecz et al. 1997) and the degraded form of CCL5 reduces the ability of 
HIV to infect the body (Schols et al. 1998). A second GPR75 agonist has been identified recently 
(Garcia et al. 2017). 
Previous research has shown that GPR75 activation can play a role in glucose homeostasis (Liu et 
al. 2013). This study investigated the in vitro and in vivo effects of GPR75 activation by CCL5 on 
insulin secretion as well as the effects on gastrointestinal hormone expression. A dose dependent 
increase in insulin secretion was observed in BRIN-BD11 cells and isolated islets from lean and 
HFF mice treated with CCL5. This confirms the insulin secretory effects described previously (Liu 
et al. 2013). The insulinotropic effect of CCL5 was greater in lean islets than those from HFF mice. 
Previous studies have shown that HFF mice have reduced glucose induced insulin secretion and 
while the insulin level is reduced when compared to total pancreas size, there was no significant 
difference between the insulin content of lean and HFF mice (Capito et al. 1992). Interestingly there 
were no cytotoxic effects observed in BRIN-BD11 cells as CCL5 has been shown to play a role in 
the destruction of β-cells in Type 1 Diabetes (Carvalho-Pinto et al. 2004) however it appears that 
this only occurs when an immune response to the body’s β-cells is triggered.  
Both GPR75 and CCL5 have been found to be co-localised with insulin and glucagon in the 
pancreas (Liu et al. 2013). In this study we confirmed the co-localisation of insulin and GPR75 in 
both lean and HFF pancreas as well as BRIN-BD11 cells showing that CCL5 activation of GPR75 
is an autocrine effect. However, we were unable to find any co-localisation of GPR75 and glucagon 
in the α-cells of the intestine. Feeding mice a high fat diet led to increased GPR75 gene expression 
making it a promising target in the treatment of Type 2 Diabetes which is closely linked with obesity 
(Kahn, Hull & Utzschneider 2006). Treatment of BRIN-BD11 cells with CCL5 resulted in 
upregulation of insulin and GPR75 protein expression. However, qPCR studies found that insulin 
expression was downregulated while GPR75 expression was still upregulated at both 5.6mM and 
16.7mM glucose. There may be a number of factors involved, however it appears that the increased 
insulin secretory effect of CCL5 treatment causes the initial upregulation of insulin but cells are not 
able to maintain the production of insulin and existing stocks become exhausted. The initial 
downregulation of insulin by both 5.6 and 16.7mM glucose provides further evidence of this as 
initially insulin production is reduced. The protein expression studies using immunocytochemistry 
were confirmed using qPCR. Meanwhile GPR75 production will still be increased after 4 hours as 
the receptor protein will not be secreted. Rather the receptor will become internalised, repackaged 
and transported back to the membrane.  
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There is currently limited information on the presence of GPR75 in the intestine. Intestinal 
endocrine cells make up 1% of the small intestine (Mace, Tehan & Marshall 2015) and there is 
currently no published research showing the presence of GPR75. Using immunohistochemistry and 
qPCR, the presence of GPR75 in the K and L cells of the intestine were identified. qPCR 
demonstrated the presence of GPR75 in the small intestine, with downregulation when mice were 
fed a high fat diet. Both GLP-1 and PYY were co-localised with GPR75 in the L-cells of the 
intestine while GIP was co-localised with GPR75 in the K-cells of the intestine. Staining in both 
GLUTag and STC-1 cells confirmed the co-localisation seen ex vivo. Treatment of GLUTag cells 
with CCL5 also resulted in upregulation of the proglucagon gene along with the PC1 gene which 
processes the proglucagon gene into GLP-1 in the small intestine. This suggests that CCL5 
treatment will increase GLP-1 secretion from L-cells of the intestine however this would need 
explored. 
To further confirm the in vitro findings, fasted male Swiss TO mice were administered 25nmol/kg 
body weight CCL5 both orally and via IP injection. This concentration of CCL5 was selected as it 
is the concentration used in our lab previously for peptides used in vivo studies (Moffett et al. 2015). 
As DPP-IV, an enzyme that degrades GLP-1 and GIP (Hansen et al. 1999, Deacon 2004), also 
degrades CCL5 (Oravecz et al. 1997), oral administration of the agonist was also carried out in 
combination with the DPP-IV inhibitor Sitagliptin Phosphate. Sitagliptin has previously been used 
in combination studies in such as with Metformin (Shannon et. al. 2009), pioglitazone (Alba et. al. 
2009 and Bailey et. al. 2010) and glimepiride (Ishii et. al. 2014). Previously CCL5 has shown to 
have glucose lowering and insulinotropic effects in vivo (Liu et al. 2013). This study confirms the 
previous effects seen in vivo with IP administration reducing blood glucose and increasing insulin 
secretion from the pancreas. Interestingly CCL5 had glucose reducing and insulinotropic actions 
when administered orally both alone and in combination with Sitagliptin. The evidence presented 
in this study suggests that CCL5 is present in the enteroendocrine cells of the intestine and this 
opens this area for further investigation. Sitagliptin administration with CCL5 also performed better 
than Sitagliptin treatment alone. There is precedent for the cleaved form of CCL5 performing better 
than the intact form as cleaved CCL5 has been shown to be better at protecting from HIV protection 
(Proost et al. 1998). Further work using the cleaved form of CCL5 needs to be carried out to 
elucidate whether this is the case including in vitro studies. As CCL5 recruits T cells to places of 
inflammation including to the pancreas (Carvalho-Pinto et al. 2004) the long term effects of CCL5 
treatment on peripheral tissues will need to be investigated further. Furthermore the conflicting 
evidence on CCL5 binding to GPR75 mean further studies including GPR75 knockodown and 
GPR75 knockout will need to be carried out to further elucidate the effects of CCL5 on this receptor. 
In conclusion, this study has determined that CCL5 increases insulin secretion in vitro and in vivo. 
This confirmed previous research in this area (Liu et al. 2013). GPR75 was also found to be present 
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in the endocrine cells of the intestine, namely the L and K –cells. Treatment of GLUTag cells with 
CCL5 leads to increased proglucagon and PC1 expression suggesting GPR75 activation has a role 
in the regulation of incretin hormone secretion. Oral administration of CCL5 reduced blood glucose 
however when used in combination with Sitagliptin this effect was reduced, suggesting that DPP-
IV cleavage of CCL5 may increase its effectiveness as an antidiabetic therapy. These results indicate 
that GPR75 may play a role in incretin and insulin secretion and may be a possible therapy in the 
























Figure 3.1: Effects of GPR75 agonist CCL5 on insulin secretion and cell viability in pancreatic 
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Effect of CCL5 (10-12 to 10-5M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using MTT Assay. Results are mean ± SEM (n=8) 
for insulin secretion and (n=3) for cell viability. *p<0.05 and ***p<0.001, compared to basal 




Figure 3.2: Effects of GPR75 agonist CCL5 on insulin secretion and cell viability in pancreatic 

























































Effect of CCL5 (10-12 to 10-5M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose 
in BRIN-BD11 cells. Cell viability was measured using MTT Assay. Results are mean ± SEM (n=8) 
for insulin secretion and (n=3) for cell viability. **p<0.01 and ***p<0.001 compared to basal 
glucose control for insulin secretion and 1mM H2O2 toxic control for cell viability. 
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Figure 3.3: Effect of GPR75 agonist CCL5 on insulin secretion from isolated islets from lean 



























































































Effect of CCL5 on insulin secretion from isolated islets from lean (A) and HFF (B) Swiss TO mice 
in 11.1mM glucose. Results are the mean ± SEM (n=4). *p<0.05, **p<0.01 and ***p<0.001, 




Figure 3.4: Double immunofluorescence staining of GPR75 and insulin in BRIN-BD11 cells 
and lean and HFF NIH Swiss mouse pancreas 
 
Distribution of DAPI (A, E, I), insulin (B, F, J), GPR75 (C, G, K) and double immunofluorescence 
(D, H, L) of insulin and GPR75 in BRIN-BD11 cells (A-D), lean (E-H) and HFF (I-L) NIH Swiss 
mouse tissue. Images are taken at x200 magnification and examples of positive staining are 























































Effect of HFF diet on GPR75 gene expression in male NIH Swiss Mouse Pancreas (n=6). ** p<0.01, 















Figure 3.6: Double immunofluorescence staining of GPR75 and glucagon in αTC1.9 cells and 
lean and HFF NIH Swiss mouse pancreas 
 
Distribution of DAPI (A, E, I), glucagon (B, F, J), GPR75 (C, G, K) and double 
immunofluorescence (D, H, L) of glucagon and GPR75 in αTC1.9 cells (A-D), lean (E-H) and HFF 
(I-L) NIH Swiss mouse tissue. Images are taken at x200 magnification and examples of positive 






Figure 3.7: Double immunofluorescence staining of GLP-1 and GPR75 in GLUTag cells and 
lean and HFF NIH Swiss mouse small Intestine 
 
Distribution of DAPI (A, E, I), GLP-1 (B, F, J), GPR75 (C, G, K) and double immunofluorescence 
(D, H, L) of GLP-1 and GPR75 in GLUTag cells (A-D), lean (E-H) and HFF (I-L) NIH Swiss 
mouse tissue. Images are taken at x200 magnification and examples of positive staining are 





























































Effect of HFF diet on GPR75 gene expression in male NIH Swiss mouse small intestine (n=6). * 














Figure 3.9: Double immunofluorescence staining of GIP and GPR75 in pGIPneo STC-1 cells 
and lean and HFF NIH Swiss mouse small intestine 
 
Distribution of DAPI (A and E), GIP (B and F), GPR75 (C and G) and double immunofluorescence 
(D and H) of GIP and GPR75 in lean (A-D) and HFF (E-H) NIH Swiss mouse small intestinal 


















Figure 3.10: Double immunofluorescence staining of PYY and GPR75 in STC-1 cells and lean 
and HFF NIH Swiss mouse small intestine 
 
Distribution of DAPI (A, E, I), PYY (B, F, J), GPR75 (C, G, K) and double immunofluorescence 
(D, H, L) of PYY and GPR75 in STC-1 cells (A-D), lean (E-H) and HFF (I-L) NIH Swiss mouse 


















































































Effects of CCL5 on insulin protein expression after 20 min treatment in pancreatic BRIN-BD11 
cells in 5.6mM and 16.7mM glucose (n=3). A – media; B – 5.6mM glucose; C – 5.6mM glucose + 
CCL5; D – 16.7mM glucose; E. 16.7mM glucose + CCL5; F – negative control without primary 
antibody. Intensity values for negative control without primary antibody were subtracted from the 
fluorescence intensity values obtained for test conditions. ** p<0.01 and *** p<0.001 compared to 














































































Effects of CCL5 on Insulin gene expression after 4 hr treatment in pancreatic BRIN-BD11 cells in 
5.6mM and 16.7mM glucose (n=3). A – media; B – 5.6mM glucose; C – 5.6mM glucose + CCL5; 
D – 16.7mM glucose; E. 16.7mM glucose + CCL5; F – negative control without primary antibody. 
Intensity values for negative control without primary antibody were subtracted from the 
fluorescence intensity values obtained for test conditions. *** p<0.001 compared to untreated cells. 





Figure 3.13: Effect of 4 hr CCL5 treatment on insulin expression in BRIN-BD11 Cells 
























Treatment in 5.6mM Glucose






























Effects of CCL5 on Insulin gene expression after 4 hour treatment in pancreatic BRIN-BD11 cells 
in 5.6mM and 16.7mM glucose (n=3). * p<0.05 compared to untreated cells. + p<0.05 and ++ 




























































































Effects of CCL5 on GPR75 protein expression after 20 min treatment in pancreatic BRIN-BD11 
cells in 5.6mM and 16.7mM glucose (n=3).. A – media; B – 5.6mM glucose; C – 5.6mM glucose + 
CCL5; D – 16.7mM glucose; E. 16.7mM glucose + CCL5; F – negative control with no primary 
antibody. Intensity values for negative control without primary antibody were subtracted from the 
fluorescence intensity values obtained for test conditions. *** p<0.001 compared to untreated cells. 























































Treatment in 5.6mM Glucose























Effects of CCL5 on GPR75 protein expression after 4 hour treatment in pancreatic BRIN-BD11 
cells in 5.6mM and 16.7mM glucose (n=3). A – media; B – 5.6mM glucose; C – 5.6mM glucose + 
CCL5; D – 16.7mM glucose; E. 16.7mM glucose + CCL5; F – negative control with no primary 
antibody. Intensity values for negative control without primary antibody were subtracted from the 
fluorescence intensity values obtained for test conditions. *** p<0.001 compared to untreated cells. 
















































Effects of CCL5 treatment on GCG gene expression in intestinal GLUTag cells at 2mM glucose. * 










































Effects of CCL5 treatment on PC1 gene expression in intestinal GLUTag cells at 2mM glucose. * 









































Figure 3.17: Acute effects of IP administration of CCL5 on blood glucose in male Swiss TO 
mice 
A.   









































Glucose (18mmol/kg BW) or glucose in combination with CCL5 (25nmol/kg BW) were 
administered via IP injection to male Swiss TO mice (n=6). (A) Blood glucose (B) AUC of A. *** 










































Figure 3.18: Acute effects of IP administration of CCL5 on plasma insulin in male Swiss TO 
mice 






































Glucose (18mmol/kg BW) or glucose in combination with CCL5 (25nmol/kg BW) were 
administered via IP injection to male Swiss TO mice (n=6). (A) Plasma insulin (B) AUC of A. * 










Glucose + 50mg/kg Sitagliptin
25 nmol/kg BW CCL5































Figure 3.19: Acute effects of oral administration of CCL5 on blood glucose in male Swiss TO 
mice 
A.        








Glucose + 50mg/kg Sitagliptin
25nmol/kg BW CCL5











































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with CCL5 (25nmol/kg BW) or glucose in combination with CCL5 and 
Sitagliptin Phosphate were all administered orally to male Swiss TO mice (n=6). (A) Blood glucose 
(B) AUC of A. * p<0.05, ** p<0.01 and *** p<0.001 compared to glucose treatment alone. + 










































































































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with CCL5 (25nmol/kg BW) or glucose in combination with CCL5 and 
Sitagliptin Phosphate were all administered orally to male Swiss TO mice (n=6). (A) Plasma insulin 
(B) AUC of A. * p<0.05, ** p<0.01 and *** p<0.001 compared to glucose treatment alone. + 











Examining the role of trace metal ions on 
GPR39 activation and incretin hormone 
















4.1: Overview of results 
Originally thought to be the obestatin receptor, the rhodopsin like GPR39 can be activated by trace 
metals. While originally found in the brain, the presence of GPR39 has been confirmed in a range 
of peripheral tissues such as throughout the gastrointestinal tract and the pancreas. Previous work 
has shown that GPR39 activation through trace metals can increase insulin secretion while some of 
these trace metals increase insulin secretion through other pathways as well. There are very few 
studies looking at the activation of GPR39 on incretin and PYY hormone secretion, however one 
bioavailable GPR39 agonist has been developed. The current study has identified the effects of 
GPR39 activation by trace metals CuCl2, NiSO4 and ZnCl2 on hormone secretion from GLUTag, 
pGIPneo STC-1 and BRIN-BD11 cells. Cytotoxicity was determined by Alamar Blue and MTT 
assay while membrane integrity was ascertained by LDH assay. Immunohistochemistry, qPCR 
determined the expression profile of GPR39 in the cell lines tested as well as in ex vivo intestinal 
tissue. This was further confirmed using qPCR. In vivo effects of ZnCl2 and CuCl2 (50μmol/kg BW) 
were determined in fasted male Swiss TO mice (n=6) both alone and in combination with Sitagliptin 
(50mg/kg BW). 
In GLP-1 secreting GLUTag cells, CuCl2 (31.25 to 500μM) resulted in a 2.4 to 2.9-fold increase in 
GLP-1 secretion (p<0.05) in 2mM glucose while ZnCl2 and NiSO4 (125μM) reduced the expression 
of GPR39 3.1 and 1.3-fold respectively (p<0.01). CuCl2 (125μM) treatment resulted in a 1.4-fold 
increase in GIP secretion from pGIPneo STC-1 cells (p<0.01) while NiSO4 demonstrated a 1.3-fold 
increase (125μM, p<0.01). ZnCl2 (125μM) also demonstrated the ability to increase GIP secretion 
in vitro with a 1.3-fold increase being observed (p<0.01). 
Gene expression studies using qPCR demonstrated a 1.3-fold decrease in GPR39 expression in the 
small intestine, of HFF mice (p<0.05). Double immunohistochemistry confirmed the presence of 
the GPR39 receptor in both L and K-cells with co-localisation found between GPR39 and GIP as 
well as PYY. No GLP-1 secreting L-cells were found to have GPR39 present. Oral administration 
of GPR39 agonists in fasted male Swiss TO mice resulted in a reduction of blood glucose and 
increased insulin secretion. CuCl2 demonstrated an overall ability to decrease blood glucose 25.3% 
(p<0.05) while ZnCl2 decreased blood glucose 36.5% (p<0.001). These agonists increased insulin 
secretion 49.1% (p<0.001) and 86.4% (p<0.001). The DPP-IV inhibitor Sitagliptin decreased blood 
glucose 13.0% while combination of GPR39 agonists with Sitagliptin resulted in further reductions 
of blood glucose as well as further increases in insulin secretion. CuCl2 in combination with 
Sitagliptin reduced blood glucose 46.3% (p<0.001) with a further reduction of 36.2% (p<0.001) 
compared to Sitagliptin alone while insulin secretion was increased 63.5% (p<0.001). ZnCl2 
administration in combination with Sitagliptin reduced blood glucose 48.5% (p<0.001) while this 
reduction was 39.6% (p<0.001). ZnCl2 in combination increased insulin secretion 85.3% (p<0.001). 
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GPR39 agonists had no effect on feeding although CuCl2 in combination resulted in a 15% decrease 
in appetite after 3 hrs. 
This study demonstrates a role for GPR39 in the regulation of intestinal enteroendocrine cells and 
suggests that the activation of GPR39 by trace metals may be used as a potential therapy for Type 
2 Diabetes in the future. 
 
4.2: Introduction 
GPR39 was first identified along with GPR38 as a ghrelin family receptor with 52% amino acid 
sequence homology to the human ghrelin receptor GHS-R1a (McKee et al. 1997). The 230kb 
GPR39 gene encodes a 453 amino acid protein. Using FISH, the authors of this work were able to 
map the GPR39 coding gene to chromosome 2q21-q22 in humans. GPR39 was found to be 
expressed in the brain as well as other peripheral tissues such as the intestine, stomach and pancreas. 
Like GPR38 (Feighner et al. 1999) and GHS-R (Howard et al. 1996), GPR39 has two variants with 
the full length seven transmembrane domain GPR39-1a and the shorter five transmembrane domain 
GPR39-1b (Egerod et al. 2007a). This work identified that GPR39 has a 200kb intron in a similar 
position to both GPR38 and GHS-R which separates the last 2 transmembrane domains from the 
first 5. It was also discovered that the antisense gene for GPR39 also coded for Ly-6/PLAUR 
domain containing 1 (LYPD) gene which is transcribed along with the truncated form of the GPR39 
gene.   
Like other receptors in the ghrelin family, GPR39 has high levels of activity without being activated 
by an agonist (Popovics, Stewart 2011) but the first identified agonist of GPR39 was obestatin 
(Zhang et al. 2005b). This study identified a new hormone which was post-translationally processed 
from the preproghrelin protein and named it obestatin. This name was due to the appetite reducing 
effects identified in rats treated with obestatin. Radiolabelled obestatin was found to bind to an 
orphan GPCR. Transfection of Chinese Hamster ovary cells with various cDNAs of orphan GPCRs 
were used to test which GPCR obestatin binds to. It was found that GPR39 bound the radiolabelled 
obestatin suggesting it is the obestatin receptor. This work was further supported by work in GPR39 
knockout mice which had quicker gastric emptying, increased body weight, increased body fat 
composition and increased cholesterol (Moechars et al. 2006).  
However, the identification of GPR39 as the obestatin receptor and the appetite reducing effects of 
obestatin remain controversial. A response to the original research into GPR39 and obestatin 
disputed the authors’ findings (Chartrel et al. 2007) and the authors were unable to reproduce their 
initial in vitro results (Zhang et al. 2007). Further studies using GPR39 knockout mice found no 
difference in body weight and food intake when compared to wild type mice regardless of gender 
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(Tremblay et al. 2007). There was also no significant effect on plasma insulin or blood glucose 
levels in 24-week old mice. Injection of obestatin into the mice produced no effect on feeding over 
24 hrs. Treatment of cells transfected with a cDNA clone for GPR39 with human or mouse obestatin 
had no effect on transcriptional activity of cells transfected with the clone suggesting that obestatin 
does not activate GPR39. This was further supported by work which showed that obestatin treatment 
of cells transfected with GPR39 cDNA did not increase cAMP or intracellular calcium (Lauwers et 
al. 2006). 
As the search for endogenous GPR39 agonists continued, the receptors’ expression in the stomach 
and the small intestine suggested that meal ions may be potential agonists. This lead to the 
identification of ZnCl2 as a GPR39 agonist (Holst et al. 2004). Further work also looking at 
obestatin, identified an increase in downstream signalling events upon treatment with Zn2+ while 
this effect was not seen with obestatin (Holst et al. 2007b). Radiolabelled obestatin also did not bind 
to GPR39 expressing cells. This was supported by later work that identified that treatment of cells 
transfected with a clone of human GPR39 cDNA with Zn2+ resulted in increased intracellular 
calcium (Lauwers et al. 2006). Phospholipase C (PLC) inhibitor stopped the agonistic effects of 
Zn2+ demonstrating that GPR39 can work through the Gαq pathway (Yasuda et al. 2007). The 
receptor has also been shown to increase serum response element (SRE)-mediated transcription 
which suggests that GPR39 can also work through Gα12/13 (Holst et al. 2004). 
GPR39 null mice have been shown to have increase anxiety and demonstrate depression-like 
behaviour and GPR39 has been identified as a possible target in the treatment of depression 
(Młyniec et. al. 2015). GPR39 was also found to be present in the pancreatic β-cells but not in the 
glucagon releasing α-cells, the somatostatin producing δ-cells or the pancreatic polypeptide PP cells 
(Holst et al. 2009a). Interestingly the same study looked at plasma glucagon levels in wild type 
versus GPR39 knockout mice and found glucagon levels were decreased in knockout mice, 
suggesting a role for GPR39 in glucagon secretion. Blood glucose was increased in GPR39 null 
female mice and an increase in insulin was also observed. GPR39 expression was high in fat from 
pregnant females (Fontenot, DeVente & Seidel 2007) and is found to be upregulated in adipose 
tissue in both fasting and streptozotocin induced diabetic rats (Egerod et al. 2007a) and GPR39 may 
play a protective role for β-cells in mice (Egerod et al. 2011). In humans, the expression of GPR39 
has been found to be down regulated in the adipose tissue of obese patients with Type 2 Diabetes 
(Catalan et al. 2007). All of this research supports the concept that GPR39 may play an important 
role in glucose homeostasis.  
One such study used an obesity induced diabetic mice model where mice fed a high fat diet had 
decreased GPR39 expression in adipose tissue. (Verhulst et al. 2011). However the majority of 
these studies have explored the knocking out of the GPR39 receptor and have not induced its 
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activation by an agonist. The effects of various trace metals on GPR39 activation and its role in 
glucose homeostasis was therefore investigated previously by our research group (Moran et al. 
2016b). Trace metals Zn2+, Cu2+, Ni2+ and Co2+ were all found to increase insulin secretion in vitro. 
Both intracellular calcium and cAMP were increased and oral administration of GPR39 agonists 
resulted in reduced blood glucose and increased insulin secretion with the exception of Co2+. 
It is known that GPR39 is expressed throughout the gastrointestinal tract and may play a role in its 
regulation. In fact zinc tablets are currently a treatment for diarrhoea (Nasrin et al. 2005) thus giving 
this idea credence. However the majority of these studies have looked into obestatin and have not 
looked into the activation of GPR39 by trace metal agonists. One study has developed the first 
bioavailable oral GPR39 agonist which increased GLP-1 secretion in the mouse enteroendocrine 
STC-1 cell line (Peukert et al. 2014). As our previous work has determined that oral administration 
of GPR39 agonists in vivo reduces blood glucose and increases insulin secretion, we propose that 
this is through increased gastrointestinal hormone secretion. The effects of transition metals Cu2+, 
Ni2+ and Zn2+ were tested in the GLP-1 secreting GLUTag cell line, GIP secreting pGIPneo STC-1 
cells and PYY secreting STC-1 cells. The effects of these agonists on receptor and hormone 
expression was also investigated along with their effects on cell viability. Both Zn2+ and Cu2+ were 
then tested in vivo in male Swiss TO mice. 
 
4.3: Materials and methods 
 
4.3.1: Materials 
Copper chloride (CuCl2), nickel sulphate (NiSO4) and zinc chloride (ZnCl2), were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). Multi species GLP-1 total and rat/mouse GIP total ELISA were 
purchased from Merck Millipore (Watford, UK). 
 
4.3.2: Acute hormone secretion from intestinal cell lines 
GLUTag or pGIPneo STC-1 cells were seeded into 24-well plates with 150000 cells per well which 
were incubated overnight in 1ml of culture medium (as described previously) at 37°C and 5% CO2. 
To ensure that cells grew in monolayers, they were pipetted up and down vigorously to ensure 
proper mixing before seeding. After overnight incubation and preincubation with 1.1mM glucose 
for 40 mins, acute incubations were carried out at 37°C 5% CO2 for 2 hrs in 2mM glucose in KRBB 
buffer supplemented with 1.95μM to 500μM concentrations of CuCl2, NiSO4 and ZnCl2. After 
incubations, supernatants (950μl) were collected and frozen at -20°C until ELISA was carried out. 
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4.3.3: Acute insulin secretion from pancreatic BRIN-BD11 cells 
Cells were seeded in 24-well with 150000 BRIN-BD11 cells per well and incubated overnight in 
1ml of RPMI 1640 media at 37°C and 5% CO2. Following this incubation, cells were preincubated 
with 1.1mM glucose for 40 mins with subsequent acute incubations being carried out at 37°C 5% 
CO2 for 20 mins in 5.6mM and 16.7mM glucose in KRBB buffer supplemented with 1.95μM to 
500μM concentrations of CuCl2, NiSO4 and ZnCl2 with 10mM alanine as a positive control. After 
incubations, supernatants (950μl) were collected and frozen at -20°C until radioimmunoassay was 
carried out. 
 
4.3.4: Immunofluorescence staining in GLUTag, pGIPneo STC-1, STC-1 cells and lean and HFF 
NIH Swiss mouse small intestine 
GLUTag, pGIPneo STC-1 and STC-1 cells were seeded at a density of 40000 cells on to polylysine 
coated slides overnight at 37°C in an atmosphere of 95% air and 5% CO2 as described in Chapter 2, 
section 2.1. Swiss TO mice were anesthetised by isoflurane and killed by cervical dislocation. 
Pancreas and intestine was excised as described in Chapter 2, section 2.6.3. Immunohistochemistry 
was carried out by incubating with rabbit polyclonal anti-GPR39 and goat polyclonal anti-GLP-1, 
goat polyclonal anti-GIP or goat polyclonal anti-PYY with the dilutions outlined in Chapter 2, Table 
2.1. 
 
4.3.5: Acute effects of CuCl2, NiSO4 and ZnCl2 on cell toxicity 
Cells were seeded in 96-well plates with 40000 cells per well of BRIN-BD11, GLUTag or pGIPneo 
STC-1 cells and incubated overnight in cell culture media (as described in Chapter 2, section 2.1) 
in an atmosphere of 5% CO2 at 37°C. After 20hrs, BRIN-BD11 cells were preincubated with 1.1mM 
glucose for 40 mins with subsequent acute incubations being carried out at 37°C 5% CO2 for 20 
mins in 5.6mM and 16.7mM glucose in KRBB buffer supplemented with 1.95μM to 500μM 
concentrations of GPR39 agonist with 1mM H2O2 as a cytotoxic control (n=3). After 48hrs, 
GLUTag and pGIPneo STC-1 cells were preincubated with 1.1mM glucose for 40 mins with 
subsequent acute incubations being carried out at 37°C 5% CO2 for 2 hrs in 2mM in KRBB buffer 
supplemented with 1.95μM to 500μM concentrations of GPR39 agonists with 1mM H2O2 as a 
cytotoxic control (n=3). After incubation, supernatant was decanted, cells were washed with HBSS 
and 0.5mg/ml MTT was added for 2 hrs. Following MTT incubation, supernatant was discarded 
and DMSO was added to solubilise crystals. Optical density was subsequently measured at 570nm 
and 630nm using the Flexstation 3 (Molecular Devices, CA, USA). LDH assay was carried out as 
described previously in Chapter 2, section 2.4.2. 
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4.3.6: Quantitative real-time PCR (qPCR) 
qPCR was performed using LightCycler® 480 SYBR Green I Master. Reactions were performed 
using 4.5μl of 2x concentrated SYBR green, 1μl of forward and reverse primers (primer sequences 
are listed in Chapter 2, Table 2.2), 1μl of cDNA and 3μl of RNase free water (n=3). All reactions 
included a negative template control with RNase free water added instead of cDNA (n=3). The 
reactions were carried out in 8-well real-time PCR Tube Strips and Masterclear™ Cap Strips 
(Eppendorf, HAM, DE). Amplification conditions were 5 mins initial denaturation at 95°C, 
followed by 40 cycles of 30 secs denaturation at 95°C, 30 secs annealing at 58°C and 30 secs 
extension at 72°C and a final elongation step for 5 mins at 72°C. Reactions included melting curve 
analysis with temperature range of 60 °C to 90 °C. All reactions were carried out using the 
MiniOpticon two colour real time PCR detection system (BioRad, UK). Analysis of results was 
performed using the Livak method and the mRNA levels of all genes were normalised using the 
housekeeping gene GAPDH. 
 
4.3.7: Acute in vivo glucose tolerance tests 
Male Swiss TO mice were housed as described in Chapter 2, section 2.7. The effects of GPR39 
agonists CuCl2 and ZnCl2 (50μmol/kg BW), as well as in combination with Sitagliptin Phosphate 
(50mg/kg BW) in lean male Swiss TO mice were investigated. Before test compounds were 
administered mice were fasted for 18 hrs and blood subsequently collected (t=0). Test compounds 
were administered orally in glucose (18mmol/kg BW), and blood was collected at 15, 30, 60, 90 
and 120 mins along with blood glucose measurements. Collected blood was centrifuged at 
13200rpm for 5 mins at 4°C using a Beckman centrifuge (Beckman Instruments, UK). Plasma was 
stored at -20°C until hormone measurements by RIA or ELISA as described in Chapter 2, section 




4.4.1: Effects of GPR39 agonists on GLP-1 secretion from intestinal GLUTag cells 
GLUTag cells were treated for 2 hrs with GPR39 agonists (31.25-125μM) in 2mM glucose. 
Treatment of GLUTag cells with CuCl2 (31.3 to 125μM) resulted in a 2.4 to 2.9-fold increase in 
GLP-1 secretion (p<0.05) in 2 mM glucose (Figure 4.1A). Treatment of GLUTag cells with NiSO4 




4.4.2: Effects of GPR39 agonists on GIP secretion from intestinal pGIPneo STC-1 cells 
The effects of GPR39 agonist treatment on pGIPneo STC-1 cells were investigated by measuring 
GIP secretion via ELISA. All agonists tested demonstrated an increase in GIP secretion CuCl2 
(31.3-125μM) had the greatest effect on GIP secretion with a 1.3 to 1.4-fold increase (p<0.05-
p<0.01) in secretion (Figure 4.4A). NiSO4 (31.3-125μM) increased GIP 1.21 to 1.33-fold (p<0.05-
p<0.01) compared to basal control (Figure 4.5A). ZnCl2 (31.3-125μM) increased GIP secretion 1.2 
to 1.3-fold from pGIPneo STC-1 cells, compared to basal levels (p<0.01) (Figure 4.6A). 
 
4.4.3: Effects of GPR39 agonists on insulin secretion from pancreatic BRIN-BD11 cells 
The effects of transition metal GPR39 agonists CuCl2, NiSO4 and ZnCl2 on insulin secretion from 
pancreatic BRIN-BD11 cells were tested in both 5.6mM and 16.7mM glucose (Figures 4.7-4.12). 
In normoglycaemic conditions, CuCl2 demonstrated the best insulinotropic ability followed by 
ZnCl2 then NiSO4. Treatment of BRIN-BD11 cells with CuCl2 resulted in a 1.2 to 2.8-fold increase 
in insulin secretion (15.6-500μM, p<0.001) when compared to secretion levels from cells treated 
with 5.6mM glucose (Figure 4.7A). BRIN-BD11 cells treated with GPR39 agonist ZnCl2 exhibited 
a 1.2 to 2.4-fold increase (15.6-500μM, p<0.01-p<0.001) in insulin secretion compared to basal 
secretion levels (Figure 4.11A). NiSO4 treatment of BRIN-BD11 cells produced a 1.4 to 2.4-fold 
increase (31.25-500μM, p<0.001) in insulin secretion (Figure 4.9A). 
ZnCl2 was the GPR39 agonist which demonstrated the greatest insulinotropic effect of acute 
treatment of BRIN-BD11 cells in hyperglycaemic conditions (Figure 4.12A). Insulin secretion was 
increased 1.2 to 2.2-fold (15.6-500μM, p<0.001), compared to 16.7mM glucose. CuCl2 had a 
slightly lower insulinotropic effect than ZnCl2 while NiSO4 provided the lowest effect on insulin 
secretion as demonstrated in 5.6mM glucose. CuCl2 (Figure 4.8A) increased insulin secretion 1.2 
to 2.2-fold (15.6-500μΜ, p<0.01-p<0.001) while NiSO4 (Figure 4.10A) exhibited a 1.4 to 2.0-fold 
increase (31.3-500μM, p<0.05-p<0.001) in insulin secretion, compared to basal levels. 
In normoglycaemic conditions, CuCl2, was also the most potent agonist tested with an EC50 value 
of 66.3 ± 0.9μM. Despite being the worst performing agonist in relation to insulin secretion, NiSO4 
was more potent than ZnCl2 with EC50 values of 104.5 ± 1μM and 142.2 ± 1μM respectively (Figure 
4.13A). 
In hyperglycaemic conditions, NiSO4, was determined to be the most potent with an EC50 value of 





4.4.4: Effects of GPR39 activation on cell viability in BRIN BD11, GLUTag and pGIPneo STC-1 
cells 
MTT assay was used to assess the effects of GPR39 agonists on GLUTag cells. CuCl2 (2-500μM) 
had no effect on GLUTag cell viability (Figure 4.1B), however NiSO4 (Figure 4.2B) reduced cell 
viability 1.5-fold at the highest concentration tested (500μΜ, p<0.05). Due to the reduced cell 
viability of GLUTag cells treated with NiSO4 at the highest concentration tested, a membrane 
integrity assay was carried out using LDH assay. This assay showed that NiSO4 (250, 125 and 
7.8μM, p<0.05-p<0.001) and ZnCl2 (250, 62.5, 31.25 and 3.9μΜ, p<0.05-p<0.001) increased 
membrane integrity in GLUTag cells (Figures 4.2C and 4.3C). 
Treatment of pGIPneo STC-1 cells with CuCl2 resulted in a 1.2 to 1.3-fold increase (Figure 4.4B) 
in cell viability (1.95-125μM, p<0.05-p<0.01). Unlike in GLUTag cells were viability was reduced, 
treatment of pGIPneo STC-1 cells with NiSO4 resulted in a 1.1 to 1.2-fold increase (Figure 4.5B) 
in cell viability (7.8, 31.3 and 500μM, p<0.05). ZnCl2 reduced cell viability 1.7-fold (Figure 4.6B) 
at the highest concentration tested (500μM, p<0.01). 
The effects of GPR39 agonists on the cell viability of BRIN-BD11 cells was tested using Alamar 
Blue assay. All agonists (2-500μM) had no toxic effects on BRIN-BD11 cells (Figures 4.7B, 4.8B, 
4.9B, 4.10B, 4.11B and 4.12B). In order to assess the relevancy of MTT assay for GPR39 agonists, 
an MTT assay was carried out for NiSO4 and ZnCl2 in BRIN BD11 cells Figures 4.9C, 4.10C, 4.11C 
and 4.12C). As seen with Alamar Blue assay, MTT assay determined that GPR39 agonists have no 
cytotoxic effects in BRIN BD11 cells.  
 
4.4.5: Distribution of GPR39, GLP-1, GIP and PYY in intestinal cell lines and lean and HFF NIH 
Swiss mouse small intestine 
In order to determine the effects of GPR39 both in vitro and in vivo, suitable models must be 
selected. The expression of GPR39 in the endocrine cells of the intestine was determined through 
double immunohistochemistry in both lean and HFF diet mice as well as GLUTag, pGIPneo STC-
1 and STC-1 cells.  
In GLUTag cells, GPR39 and GLP-1 demonstrated areas of co-localisation (Figure 4.14D). 
However in lean and HFF small intestine from NIH Swiss mice, no GLP-1 secreting L cells were 
found to have GPR39 present (Figure 4.15C and 4.16C). 
Double immunohistochemistry determined that both GIP and GPR39 were present in pGIPneo 
STC-1 cells (Figure 4.18). The presence of GPR39 in GIP secreting intestinal K-cells was confirmed 
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in both lean (Figure 4.19C) and HFF (Figure 4.20C) mouse small intestine as areas of co-localisation 
between GIP and GPR39 were observed (Figures 4.19D and 4.20D). 
The expression of GPR39 along with PYY was investigated in STC-1 cells (Figure 4.21). Double 
immunohistochemistry confirmed the presence of GPR39 in PYY secreting L cells as co-
localisation was demonstrated (Figure 4.21D). The presence of GPR39 in PYY secreting L cells 
was also confirmed in lean and HFF mouse small intestine (Figure 4.22D and 4.23D) with areas of 
co-localisation between GPR39 and PYY being observed.  
The differences in GPR39 gene expression in lean and HFF NIH Swiss mouse small intestine were 
determined using qPCR (Figure 4.17). NIH Swiss mice fed a diet rich in a HFF diet results in a 1.3-
fold reduction (p<0.05) in intestinal GPR39 gene expression.  
 
4.4.6: Effects of GPR39 agonists on proglucagon gene expression in intestinal GLUTag cells 
In order to determine the effects of GPR39 agonists on proglucagon gene expression in intestinal L 
cells, GLUTag cells were treated with GPR39 agonists at a concentration of 125μΜ (Figure 4.24). 
Treatment with GPR39 agonists NiSO4 and ZnCl2 reduced GPR39 gene expression 1.3 and 3.1-fold 
respectively compared to untreated cells (p<0.01). When compared to 2mM glucose, there was a 
2.9-fold decrease in proglucagon expression in GLUTag cells treated with ZnCl2 (p<0.05).  
 
4.4.7: Acute effects of GPR39 agonists on incretin hormones in male Swiss TO mice 
Male Swiss TO mice were administered GPR39 agonists orally so that the effect of these agonists 
on the secretion of incretin hormones could be assessed. Administration of CuCl2 (Figure 4.25A) 
increased GLP-1 secretion 2.0 (p<0.001) and 3.3-fold (p<0.001) 15 and 30 mins post administration 
respectively. ZnCl2 (Figure 4.25A) increased GLP-1 secretion 2.9-fold (p<0.001) 30 mins post 
administration. Overall CuCl2 increased GLP-1 secretion 106.7% (p<0.001) while ZnCl2 increased 
GLP-1 secretion 96.5% (p<0.001) as measured by AUC (Figure 4.25B). 
Both CuCl2 and ZnCl2 (Figure 4.26A) increased GIP secretion with CuCl2 increasing secretion 2.6-
fold (p<0.001) 15 mins post administration. ZnCl2 increased GIP secretion 2.2 (p<0.01) and 4.1-
fold (p<0.001) 15and 30 mins post administration respectively. ZnCl2 had an overall increase of 
165.1% (p<0.001) while CuCl2 increased GIP secretion 72.0% (p<0.001) as measured by AUC 
(Figure 4.26B). ZnCl2 also increased GIP secretion compared to CuCl2 with an increase of 54.1% 




4.4.8: Acute effects of GPR39 agonists on blood glucose and insulin in male Swiss TO mice 
Oral administration of GPR39 agonist CuCl2 (50μmol/kg BW) in Swiss TO mice reduced blood 
glucose 41.2% 30 mins after dosage (p<0.01) and this effect persisted until 60 mins with a 26.8% 
decrease observed (p<0.05, Figure 4.27A). Sitagliptin alone resulted in a reduction of 26.6% 
(p<0.01) 60 mins post administration (Figure 4.27A). Sitagliptin significantly reduced blood 
glucose from 15 to 30 mins post administration with reductions of 22.3% (p<0.05) and 23.7% 
(p<0.01).  
Combination of CuCl2 and Sitagliptin had the greatest effect on blood glucose with a reduction seen 
from 15 to 60 mins (Figure 4.27A). After 15 mins, blood glucose was reduced 45.0% (p<0.001) 
compared to glucose while there was a 35.1% reduction compared to CuCl2 alone (p<0.001) and a 
29.2% decrease compared to Sitagliptin (p<0.05). After 30 mins the reduction compared to glucose 
had increased to 55.2% (p<0.001) and was 34.9% after 60 mins (p<0.001). 
The glucose lowering effects of combination treatment persisted for the duration of the test when 
compared to Sitagliptin alone. After 30 and 60 mins, blood glucose was reduced 41.2% (p<0.001) 
and 34.8% a (p<0.001) respectively with reductions of 25.9% (p<0.05) and 30.2% (p<0.05) 
observed after 90 and 120 mins respectively. These reductions were confirmed with the AUC for 
each treatment (Figure 4.27B).  
Overall Sitagliptin had the lowest effect on glycaemic excursion with a 13.0% reduction (p<0.05). 
CuCl2 treatment alone resulted in a 25.3% overall reduction (p<0.05). Compared to Sitagliptin, 
CuCl2 had a 14.1% reduction in reducing glycaemic excursion (p<0.05). Combination of both CuCl2 
and Sitagliptin had the greatest overall reducing effect on blood glucose with an overall reduction 
of 46.3% (p<0.01) compared to glucose being observed. Compared to Sitagliptin alone, this 
reduction was 38.3% (p<0.001) while compared to CuCl2 alone it was 28.1% (p<0.05). 
In terms of insulin secretion, oral administration of CuCl2 increased secretion 4.3-fold 15 mins post 
administration (Figure 4.28A, p<0.001) compared to glucose administration. The insulinotropic 
effect of CuCl2 was sustained 30 mins post administration with 2.0-fold increase being observed 
(p<0.05). The insulinotropic effect of CuCl2 was delayed when administered in combination with 
Sitagliptin. Insulin secretion was increased 3.04-fold (p<0.001) 30 mins post administration. 
Sitagliptin treatment alone lead to an increase of 2.08-fold when compared to glucose alone 
(p<0.01). Overall there were no significant differences observed between Sitagliptin treatment alone 
and Sitagliptin in combination with CuCl2 (Figure 4.28B). 
Oral administration of ZnCl2 reduced glycaemic excursion (Figure 4.27C) throughout the duration 
of the GTT with a reduction of 37.21% initially observed (p<0.001) followed by reductions of 
41.7%, 30.9%, 57.6% and 49.7% at 30, 60, 90 and 120 mins respectively (p<0.01-p<0.001). 
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Combination of ZnCl2 also reduced blood glucose with reductions of 53.8%, 60.0%, 44.6%, 36.4% 
and 34.0% being observed from 15 to 120 mins (p<0.01-p<0.001). Compared to Sitagliptin alone, 
ZnCl2 reduced blood glucose 38.5%, 24.1%, 46.5% and 37.4% at 15, 30, 90 and 120 mins 
respectively (p<0.01-p<0.001). ZnCl2 in combination with Sitagliptin also lowered blood glucose 
compared to Sitagliptin alone with reductions of 54.8%, 47.9% and 33.9% at 15, 30 and 60 mins 
(p<0.001). Comparing combination treatment with ZnCl2 alone resulted in reductions of 26.5% and 
31.3% after 15 and 30 mins (p<0.05-p<0.01) although blood glucose was increased 33.4% at 90 
mins. The AUC for this (Figure 27D) showed that combination treatment had a greater overall effect 
than ZnCl2 alone with a reduction of 19.0% observed (p<0.05). Compared to glucose combination 
treatment reduced glycaemic excursion 48.6% (p<0.001) while ZnCl2 lowered glucose 36.5% 
(p<0.001). Compared to Sitagliptin this effect was 39.6% and 25.4% for combination treatment and 
ZnCl2 alone respectively (p<0.001, p<0.05).  
Oral Administration of ZnCl2 lead to a 2.9-fold increase in insulin secretion 30 mins after 
administration (Figure 4.28C, p<0.001). ZnCl2 in combination with Sitagliptin also demonstrated 
an insulinotropic response with increases of 1.8 and 2.6-fold being observed 15 and 30 mins after 
administration respectively (p<0.01-p<0.001). Overall, ZnCl2 had no significant difference between 
ZnCl2 in combination with Sitagliptin or Sitagliptin treatment alone (Figure 4.28D). 
 
4.4.9: Acute effects of GPR39 agonists on feeding 
In order to assess the acute effects of GPR39 agonists on feeding, male Swiss TO mice were trained 
to eat for 3 hrs daily (Figure 4.29). Treatment with CuCl2 had no effect on feeding while CuCl2 in 
combination with Sitagliptin Phosphate reduced feeding 14.4% (p<0.05) after 3 hrs (Figure 4.29A). 
ZnCl2 had an initial reduction in feeding of 38.6% after 30 mins (p<0.01), however this effect was 
not sustained and there was no further appetite reducing effect observed (Figure 4.29B). ZnCl2 in 
combination with Sitagliptin also had an initial appetite lowering effect with a reduction of 41.2% 
being observed after 30 mins (p<0.01). After 60 mins appetite was increased by 35.2% (p<0.01) 
when compared to ZnCl2 treatment alone however this effect was also not sustained and no further 
changes in appetite were observed. 
 
4.5 Discussion  
There has been considerable interest into the activation of GPR39 by obestatin (Zhang et al. 2005b, 
Tremblay et al. 2007, Chartrel et al. 2007, Zhang et al. 2007, Holst et al. 2007b). This research has 
cast doubt not only on the activation of GPR39 by obestatin but also the appetite reducing effects 
of obestatin. Further work has identified zinc as a possible GPR39 agonist (Holst et al. 2004, 
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Lauwers et al. 2006, Holst et al. 2009a) and further work has implicated a role for GPR39 in the 
treatment of depression (Młyniec et. al. 2015) and diabetes (Egerod et al. 2007a, Moran et al. 
2016b). GPR39 has previously been shown to be present throughout the gastrointestinal tract 
(McKee et al. 1997) and has been shown to be present in the enteroendocrine cells in vitro (Peukert 
et al. 2014).  
The present study assessed the in vitro effects of GPR39 agonists by transition metals on GLP-1, 
GIP and insulin secretion in vitro. The presence of GPR39 in the enteroendocrine cells of the small 
intestine has previously been confirmed (Peukert et al. 2014). In the GLP-1 secreting GLUTag cell 
line, both ZnCl2 and NiSO4 had no effect on GLP-1 secretion while CuCl2 caused an increase in 
secreted GLP-1. Previously only one bioavailable GPR39 agonist has been developed that increases 
GLP-1 secretion (Peukert et al. 2014). It is therefore not a surprising finding that both Zn2+ and Ni2+ 
do not increase GLP-1 secretion while Cu2+ is the second GPR39 agonist which has been identified 
to increase GLP-1. There are currently no published studies which have looked at the effects of 
GPR39 activation on GIP secretion and this study determined that all 3 trace metals tested caused 
an increase in GIP secretion in vitro. This confirms previous in vivo work in our lab which was 
carried out in GLP-1 and GIP knockout mice which showed the incretin effect persisted in GLP-1 
knockout mice but not GIP knockout mice (unpublished). In the insulin secreting BRIN BD11 cell 
line, CuCl2 had the greatest insulin secretory effect followed by ZnCl2 then NiSO4 in 
normoglycaemic conditions. In hyperglycaemic conditions, ZnCl2 provided the greatest 
insulinotropic effect followed by CuCl2 then NiSO4. This confirms the previous research showing 
that Zn2+ can increase insulin secretion  (Lauwers et al. 2006, Holst et al. 2007b, Moran et al. 2016b) 
and the transition metals Cu2+ and Ni2+ increase insulin secretion in vitro (Moran et al. 2016b). 
The localisation of GPR39 in the intestinal cell lines as well as lean and HFF mouse small intestine 
was confirmed using immunohistochemistry and qPCR. GPR39 has previously been shown to be 
present the intestinal STC-1 cell line (Peukert et al. 2014) as well as throughout the gastrointestinal 
tract (McKee et al. 1997). The presence in STC-1 cells was confirmed in this study as well as the 
presence of GPR39 in GLUTag cells and pGIPneo STC-1 cells. GPR39 was also found to be present 
in PYY secreting L-cells but no co-localisation was found with GLP-1 secreting cells. Very few 
GPR39 agonists have been found to increase GLP-1 secretion and it may be due to the GPR39-1b 
isoform being present in GLP-1 secreting L-cells rather than the active GPR39-1a form although 
further work would need to be carried out to determine this. Feeding mice a high fat diet led to 
decreased expression in the small intestine which is an effect also seen in the adipose tissue of obese 
humans with Type 2 Diabetes (Catalan et al. 2007). 
The treatment of intestinal cell lines with trace metal GPR39 agonists had some surprising results. 
Both NiSO4 and ZnCl2 reduced the cell viability of GLUTag cells at 500μM while this effect was 
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also seen for ZnCl2 in pGIPneo STC-1 cells at the same concentration. It must be recognised that 
this is a high concentration. Many studies have shown that Zn2+ can be toxic to a range of cell lines 
(Toussaint, Nederbragt 1993, Walther et al. 2000, Daniels et al. 2004, Bozym et al. 2010) and some 
of these cells have shown toxicity at lower levels of zinc than used in this current study. Likewise 
Ni2+ has also shown to be toxic in mammalian cells (Skreb, Fischer 1984) and this may be due to 
the displacement of Fe2+ leading to a hypoxic response (Permenter, Lewis & Jackson 2011). 
Interestingly neither NiSO4 nor ZnCl2 break down the cell membrane as shown by LDH assay so 
the toxic effects seen appear to have a direct effect on cell metabolism. 
Treatment of GLUTag cells with a non-toxic (125μM) dose of trace metal GPR39 may explain the 
secretory results. Treatment with both NiSO4 and ZnCl2 leads to significant down regulation of 
GPR39 while ZnCl2 significantly downregulates GPR39 The agonist which increases GLP-1 
secretion, CuCl2, has no effect on GPR39 expression in GLUTag cells when compared to untreated 
cells or vehicle control. This suggests that the agonists which have no effect on secretion 
downregulate the receptor to prevent it from becoming activated leading to an increase in secretion. 
It may also lead to an increase in the expression of the GPR39-1b isoform although further work is 
needed to elucidate this. 
In order to validate the in vitro findings discussed above, male Swiss TO mice were orally 
administered with either CuCl2 or ZnCl2 (50μmol/kg BW). Previous work in our lab has determined 
that IP administration of GPR39 trace metal agonists had no effect on blood glucose, however oral 
administration did reduce glucose in non-fasted mice (Moran et al. 2016b). The agonists were also 
administered as a combination treatment with Sitagliptin Phosphate (50 mg/kg BW) at a 
concentration used previously by our group (Gault, Lennox & Flatt 2015). Sitagliptin has been 
studied in combination with Metformin (Miller, St Onge & Accardi 2009) as well as other anti-
diabetic drugs such as pioglitazone (Alba et al. 2009, Bailey, Green & Flatt 2010) and glimepiride 
(Ishii et al. 2014) and possible triple combination therapies have been postulated (Hirao et al. 2012). 
The glucose lowering effects previously seen in male non-fasted mice were confirmed in this study 
in fasted mice with both ZnCl2 and CuCl2 reducing blood glucose while also increasing insulin 
secretion thus confirming previous research which determined that Zn2+ had glucose lowering 
effects in obesity induced diabetic mice (Adachi et al. 2006). Combination of GPR39 agonists with 
Sitagliptin had further glucose lowering effects and this was significant compared to either agonist 
or Sitagliptin alone. However, the insulinotropic effects of this treatment did not show significant 
increases overall compared to GPR39 agonists or Sitagliptin treatment alone. CuCl2 treatment alone 
did have a more rapid response in terms of insulin secretion than ZnCl2, while the insulinotropic 
effect of ZnCl2 was quicker and more sustained in combination with Sitagliptin than ZnCl2 treatment 
alone. Previous work in our lab using incretin receptor knockout mice determined that GPR39 
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increases GIP secretion and it is likely that this decreased blood glucose was caused by an increase 
in GIP secretion along with delayed DPP-IV activity due to Sitagliptin treatment. 
The acute effects of CuCl2 and ZnCl2 on GIP and GLP-1 secretion were also assessed. Previous 
work has shown that GPR39 agonists are likely to increase GIP secretion (Moran et al. 2016b). 
Both GPR39 agonists tested in this study demonstrated the ability to increase GIP secretion. 
Interestingly despite ZnCl2 not showing an ability to increase GLP-1 secretion in GLUTag cells, 
both agonists were also able to increase GLP-1 secretion in male Swiss TO mice. Only one 
bioavailable GPR39 agonist has been shown to increase GLP-1 previously (Peukert et al. 2014) and 
this is the first study to directly show that GPR39 activation in the intestinal K cells can increase 
GIP secretion. 
Male Swiss TO mice were trained to eat for 3 hrs daily. This protocol has found that trained mice 
complete the majority of their daily feeding within the first 2 hrs but need the third hr of eating to 
sustain their body weight (O'Harte et al. 1998b). GPR39 had previously been implicated in appetite 
reduction through obestatin (Zhang et al. 2005b) however this work could not be replicated in vitro 
and has been largely discredited. Administration of GPR39 agonists had no effect over the course 
of feeding in this model which backs up other studies have shown that GPR39 has no effect on 
appetite (Tremblay et al. 2007). CuCl2 in combination with Sitagliptin did have a reducing effect 
on appetite and this may be due to it being the only GPR39 agonist tested that increased both GLP-
1 secretion and GIP. Studies have shown that GLP-1 can decrease appetite with GIP having no 
effect (Turton et al. 1996, Tang-Christensen et al. 1996, Larsen et al. 2001, Chelikani, Haver & 
Reidelberger 2005, Edholm et al. 2010a).  
In conclusion, this study has determined that GPR39 agonists increase GLP-1, GIP and insulin 
secretion both in vitro and in vivo. GPR39 was found to be present in all of the intestinal cell lines 
tested, namely GlP-1 secreting cells (GLUTag), GIP secreting cells (pGIPneo STC-1) and PYY 
secreting cells (STC-1cells). Oral administration of GPR39 agonists reduces blood glucose and 
increases plasma insulin, GIP and GLP-1 in male Swiss TO mice but has no acute effects on 
appetite. GPR39 agonists work better in combination with Sitagliptin, a drug which has previously 
been used in combination therapies. These results implicate GPR39 in glucose homeostasis through 








Figure 4.1: Effects of GPR39 agonist CuCl2 on GLP-1 secretion and cell viability in intestinal 







































































































Effect of GPR39 agonist CuCl2 (1.95-500μM) on GLP-1 secretion (A) and cell viability (B) in 2mM 
glucose in GLUTag cells. Cell viability was compared to untreated cells in culture growth medium. 
GLP-1 secretion was measured using ELISA while cell viability was measured using MTT assay. 
Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. * p<0.05, ** p<0.01 and *** 
p<0.001 compared to basal glucose control for GLP-1 secretion and media non-toxic control for 




Figure 4.2: Effects of GPR39 agonist NiSO4 on GLP-1 secretion and cell viability in intestinal 
GLUTag cells in 2mM glucose 
A.       B.       



































































Effect of GPR39 agonist NiSO4 (1.95-500μM) on GLP-1 secretion (A) and cell viability (B and C) 
in 2mM glucose in GLUTag cells. Cell viability was compared to untreated cells in culture growth 
medium. GLP-1 secretion was measured using ELISA and cell viability was measured using MTT 
and (C) LDH assay. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. * p<0.05, 
**p<0.01 and *** p<0.001 compared to basal glucose control for GLP-1 secretion and media non-







































































































Figure 4.3: Effects of GPR39 agonist ZnCl2 on GLP-1 secretion and cell viability in intestinal 
GLUTag cells in 2mM glucose 



































































Effect of GPR39 agonist ZnCl2 (1.95-500μM) on GLP-1 secretion (A) and cell viability (B and C) 
at 2mM glucose in GLUTag cells. Cell viability was compared to untreated cells in culture growth 
medium. GLP-1 secretion was measured using ELISA and cell viability was measured using MTT 
and LDH assay. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. *p<0.05, ** 
p<0.01 and *** p<0.001 compared to basal glucose control for GLP-1 secretion and media non-

















































































































































Figure 4.4: Effects of GPR39 agonist CuCl2 on GIP secretion and cell viability in intestinal 


























































Effect of GPR39 agonist CuCl2 (1.95-500μM) on GIP secretion (A) and cell viability (B) at 2mM 
glucose in pGIPneo STC-1 cells. GIP secretion was measured using ELISA and cell viability was 
measured using MTT assay. Results are mean ± SEM (n=3) for GIP secretion and cell viability. 
*p<0.05, **p<0.01 and *** p<0.001 compared to basal glucose control for GIP secretion and media 




Figure 4.5: Effects of GPR39 agonist NiSO4 on GIP secretion and cell viability in intestinal 
































































































Effect of GPR39 agonist NiSO4 (1.95-500M) on GIP secretion (A) and cell viability (B) at 2mM 
glucose in pGIPneo STC-1 cells. Cell viability was measured using MTT. Results are mean ± SEM 
(n=3) for GIP secretion and cell viability. *** p<0.001 compared to basal glucose control for GIP 




Figure 4.6: Effects of GPR39 agonist ZnCl2 on GIP secretion and cell viability in intestinal 


































































































Effect of GPR39 agonist ZnCl2 (1.95-500μM) on GIP secretion (A) and cell viability (10-12-10-4M) 
(B) at 2mM glucose in pGIPneo STC-1 cells. GIP secretion was measured using ELISA and cell 
viability was measured using MTT assay. Results are mean ± SEM (n=3) for GIP secretion and cell 
viability. ** p<0.01 and *** p<0.001 compared to basal glucose control for GIP secretion and media 
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Figure 4.7: Effects of GPR39 agonist CuCl2 on insulin secretion and cell viability in pancreatic 
BRIN-BD11 cells in 5.6mM glucose 
A.      






































Effect of CuCl2 (1.95-500μM) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. *** p<0.001 compared to basal glucose 
































Figure 4.8: Effects of GPR39 agonist CuCl2 on insulin secretion and cell viability in pancreatic 
BRIN-BD11 cells in 16.7mM glucose 



















Effect of CuCl2 (1.95-500μM) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. ** p<0.01 and *** p<0.001 compared to 
basal glucose control for insulin secretion and GLP-1 (10-7M) non-toxic control for cell viability. 
 
























Figure 4.9: Effects of GPR39 agonist NiSO4 on insulin secretion and cell viability in pancreatic 




















Effect of NiSO4 (1.95-500μM) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue and MTT Assay. Results are 
mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. ** p<0.01 and *** p<0.001 
compared to basal glucose control for insulin secretion, GLP-1 (10-7M) non-toxic control for 
Alamar Blue assay and 5.6mM glucose vehicle control for MTT assay. 
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Figure 4.10: Effects of GPR39 agonist NiSO4 on insulin secretion and cell viability in 














































16.7mM Glucose + NiSO4








































NiSO4 + 16.7mM Glucose
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Effect of ZnCl2 (1.95-500μM) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue and MTT Assay. Results are 
mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** 
p<0.001 compared to basal glucose control for insulin secretion, GLP-1 (10-7M) non-toxic control 
for Alamar Blue assay and 16.7m glucose vehicle control for MTT assay. 




























Figure 4.11: Effects of GPR39 agonist ZnCl2 on insulin secretion and cell viability in 










































5.6mM Glucose + ZnCl2
5.6mM Glucose












Effect of ZnCl2 (1.95-500μM) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue and MTT Assay. Results are 
mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. ** p<0.01 and *** p<0.001 
compared to basal glucose control for insulin secretion, GLP-1 (10-7M) non-toxic control for 
Alamar Blue assay and 5.6mM glucose vehicle control for MTT assay. 
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Figure 4.12: Effects of GPR39 agonist ZnCl2 on insulin secretion and cell viability in 











































ZnCl2 + 16.7mM glucose
16.7mM Glucose












Effect of ZnCl2 (1.95-500μM) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue and MTT Assay. Results are 
mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. *** p<0.001 compared to basal 
glucose control for insulin secretion, GLP-1 (10-7M) non-toxic control for Alamar Blue assay and 
16.7mM glucose vehicle control for MTT assay. 




























































































NiSO4           EC50 104.5M  0.96M
ZnCl2 EC50 142.2M  1M
CuCl2 EC50 66.3M  0.88M




































NiSO4            EC50 47.36M  1M
CuCl2 EC50 51.94M  1.2M
ZnCl2 EC50 235.2M  1.1M
EC50 GPR39 Agonists 16.7mM Glucose





























EC50 values for GPR39 agonists CuCl2, NiSO4 and ZnCl2 in BRIN-BD11 cells in 5.6mM glucose 








Figure 4.14: Double immunofluorescence staining of GLP-1 and GPR39 in intestinal GLUTag 
cells 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR39 and (D) combined fluorescence of GLP-1 and 
GPR39 in GLUTag cells. Images are taken at x200 magnification and examples of positive staining 











Figure 4.15: Double immunofluorescence staining of GLP-1 and GPR39 in lean NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR39 and (D) combined fluorescence of GLP-1 and 
GPR39 in lean NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification 













Figure 4.16: Double immunofluorescence staining of GLP-1 and GPR39 in HFF NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR39 and (D) combined fluorescence of GLP-1 and 
GPR39 in HFF NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification 












































































Effect of HFF diet on GPR39 gene expression in male NIH Swiss mouse small intestine in NIH 















Figure 4.18: Double immunofluorescence staining of GIP and GPR39 in pGIPneo STC-1 cells 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR39 and (D) combined fluorescence of GIP and GPR39 
in pGIPneo STC-1 cells. Images are taken at x200 magnification and examples of positive staining 











Figure 4.19: Double immunofluorescence staining of GIP and GPR39 in lean NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR39 and (D) combined fluorescence of GIP and GPR39 
in lean NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification and 














Figure 4.20: Double immunofluorescence staining of GIP and GPR39 in HFF NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR39 and (D) combined fluorescence of GIP and GPR39 
in HFF NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification and 














Figure 4.21: Double immunofluorescence staining of PYY and GPR39 in STC-1 cells 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR39 and (D) combined fluorescence of PYY and GPR39 
in lean NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification and 












Figure 4.22: Double immunofluorescence staining of PYY and GPR39 in lean NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR39 and (D) combined fluorescence of PYY and GPR39 
in lean NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification and 
















Figure 4.23: Double immunofluorescence staining of PYY and GPR39 in HFF NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR39 and (D) combined fluorescence of PYY and GPR39 
in HFF NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification and 




















































































Effects of GPR39 agonists on GPR39 gene expression in intestinal GLUTag cells at 2mM glucose. 



















































































Glucose (18mmol/kg BW) or glucose in combination with a GPR39 agonist (0.1μmol/kg BW) were 
administered orally to male Swiss TO mice (n=6). (A) Plasma GLP-1 of mice treated with CuCl2 













































































Glucose (18mmol/kg BW) or glucose in combination with a GPR39 agonist (0.1μmol/kg BW) were 
administered orally to male Swiss TO mice (n=6). (A) Plasma GIP of mice treated with CuCl2 and 

































































50mol/kg BW Copper Chloride





































Figure 4.27: Acute effects of oral administration of GPR39 agonists on blood glucose in male 
Swiss TO mice 















Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with a GPR39 agonist (50μmol/kg BW), glucose in combination with a 
GPR39 agonist and Sitagliptin Phosphate or saline (0.9% NaCl (w/v)) in combination with a GPR39 
agonist were all administered orally to male Swiss TO mice (n=6). (A) Blood glucose of mice 
treated with CuCl2 (B) AUC of A (C) Blood glucose of mice treated with ZnCl2 (D) AUC of C. * 
p<0.05, ** p<0.01 and *** p<0.001 compared to glucose treatment alone. Δ p<0.05, ΔΔ p<0.01 
and ΔΔΔ p<0.001 compared to agonist treatment alone. + p<0.05, ++ p<0.01 and +++ p<0.001 











Glucose + 50mg/kg Sitagliptin
50mol/kg Zinc Chloride
50mol/kg Zinc Chloride and 50mg/kg Sitagliptin














































Glucose + 50mg/kg Sitagliptin
50mol/kg Copper Chloride
50mol/kg Copper Chloride + 50mg/kg Sitagliptin













































































Glucose + 50mg/kg Sitagliptin
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Figure 4.28: Effects of oral administration of GPR39 agonists and GPR39 agonists in 
combination with Sitagliptin on plasma insulin in male Swiss TO mice  

















Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with a GPR39 agonist (50μmol/kg BW) or glucose in combination with a 
GPR39 agonist and Sitagliptin Phosphate were administered orally to fasted Swiss TO mice (n=6). 
(A) Plasma insulin of mice treated with CuCl2 (B) AUC of A (C) Plasma insulin of mice treated 
with ZnCl2 (D) AUC of C. * p<0.05, ** p<0.01 and *** p<0.001 compared to glucose treatment 
alone. Δ p<0.05, ΔΔ p<0.01 and ΔΔΔ p<0.001 compared to agonist treatment alone. + p<0.05, ++ 

















































































































0.1mol/kg BW Copper Chloride




































Figure 4.29: Effects of GPR39 agonists on feeding in trained male Swiss TO mice 
A. 













0.9% NaCl + 50mol/kg BW CuCl2
0.9% NaCl + 50mg/kg BW Sitagliptin + 50mol/kg BW CuCl2
*


























0.9% NaCl + 50mol/kg BW ZnCl2
0.9% NaCl + 50mg/kg BW Sitagliptin + 50mol/kg BW ZnCl2
** **















Saline (0.9%) or saline and a GPR39 agonist (50μmol/kg BW) were administered orally to Swiss 
TO mice which had been trained to eat for 3 hrs daily (n=8). * p<0.05 and **p<0.01 compared to 













Investigating the effects of GPR120 
activation by fatty acids on insulin and 
















5.1: Overview of results 
GPR120 is a GPCR that is expressed throughout the body in organs such as the lungs and brain as 
well as the gastrointestinal tract and was first found to be expressed in the stomach. There had been 
some contention over the presence of GPR120 in the pancreas, however recent studies have 
identified GPR120 as having a role in insulin, glucagon and somatostatin secretion. The current 
study investigates the role of GPR120 in intestinal hormone secretion from a range of cell lines as 
well as its role in insulin secretion from BRIN-BD11 cells. The effects of treating GLUTag, 
pGIPneo STC-1 and BRIN-BD11 cell lines with the GPR120 agonists ALA, DHA and GW9508 at 
concentrations between 10-12 and 10-4M was examined. Cytotoxicity was assessed in in GLUTag 
and pGIPneo STC-1 cells using an MTT assay while in BRIN-BD11 cells this was measured using 
the Alamar blue assay. Expression of GPR120, GIP, GLP-1 and PYY were determined using double 
immunohistochemistry of intestinal cells in vivo and in vitro and confirmed using qPCR. The 
metabolic in vivo effects of agonists DHA and GW9508 were determined at 0.1μmol/kg BW both 
alone and in combination with Sitagliptin (50mg/kg BW) in male Swiss TO mice (n=6). 
The omega 3 fatty acid DHA increased GLP-1 secretion 113% (p<0.001) at 10-6M compared to 
basal glucose concentrations in GLUTag cells. ALA increased GLP-1 secretion 75.2% (p<0.01) at 
a concentration of 10-6M while GW9508 increased GLP-1 secretion 43.8% (p<0.001) at 10-6M in 
2mm glucose. GW9508 was the only GPR120 agonist stimulate GIP secretion in pGIPneo STC-1 
cells as it demonstrated a 98.5% increase (p<0.05) at 10-6M. Compared to the GPR120 agonist 
AH7614, GW9508 increased GIP secretion 85.3% (p<0.05). ALA and DHA demonstrated no effect 
on GIP secretion at all concentrations tested (10-10 to 10-6M).  
In BRIN-BD11 cells, all GPR120 agonists tested demonstrated an insulinotropic effect. The 
endogenous agonist DHA demonstrated a 1.2 to 2.1-fold increase in insulin secretion (p<0.01 to 
p<0.001) at concentrations of 10-9-10-4M in 5.6mM glucose while ALA increased insulin secretion 
1.2-1.5-fold increase (p<0.05-p<0.001) at concentrations of 10-8-10-4M. The synthetic GPR120 
agonist GW9508 increased insulin secretion 1.2 to 1.7-fold (p<0.05-p<0.001) at concentrations of 
10-10-10-4M in 5.6mM glucose. The EC50 values showed that DHA was the least potent agonist with 
an EC50 value of 3.87x10-6M while the most potent agonist tested in 5.6mM glucose was ALA (EC50 
= 2.04x10-8M) followed by GW9508 (EC50 = 5.16x10-8M). 
In 16.7mM glucose, BRIN-BD11 cells treated with ALA had a 1.3 to 1.9-fold (p<0.05-p<0.001) 
insulin in secretion at concentrations of 10-8-10-4M, DHA increased insulin secretion 1.3 to 1.8-fold 
(p<0.05-p<0.001) at concentrations of 10-9-10-4M and GW9508 demonstrated a 1.3 to 1.8-fold 
(p<0.05-p<0.001) increase in insulin secretion at 10-9-10-4M. GW9508 was the most potent agonist 
in 16.7mM glucose (EC50 = 8.26x10-10M) followed by DHA (EC50 = 7.34x10-9M) and ALA (EC50 
= 6.18x10-8M). No GPR120 agonist had detrimental effects on cell viability. 
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qPCR confirmed the expression of GPR120 in the small intestine while double 
immunohistochemistry confirmed the co-localisation of GPR120 with GLP-1, GIP and PYY. HFF 
NIH Swiss mice demonstrated a 29.1% (p<0.05) downregulation of GPR120 in the small intestine 
when compared to lean mice. Treatment of GLUTag cells with GPR120 demonstrated an 
upregulation compared to untreated cells. ALA increased GPR120 expression 4.6-fold (p<0.01) 
compared to untreated cells while GW9508 increased proglucagon expression 4.7-fold (p<0.01). 
There was no difference between these agonists and basal control. DHA increased GPR120 gene 
expression 2.6-fold compared to untreated GLUTag cells however this was a 52.7% downregulation 
compared to 2mM glucose (p<0.01). 
Proglucagon gene expression was increased in GLUTag cells treated by ALA and DHA compared 
to vehicle control. DHA treatment resulted in a 29.5% (p<0.05) upregulation when compared to 
untreated cells which increased to a 2.4-fold (p<0.01) increase compared to vehicle control. ALA 
increased proglucagon gene expression 2.0-fold (p<0.01) compared to 2mM glucose with no 
difference to untreated cells. GW9508 had no effect on proglucagon gene expression in GLUTag 
cells compared to 2mM glucose, however a 42.7% (p<0.05) downregulation was observed 
compared to untreated cells. 
As the proglucagon gene is cleaved by PC1/3 to release GLP-1, the expression of this gene was also 
investigated. Interestingly treatment of agonists completely ablated PC1/3 gene expression 
(p<0.001). 
Acute oral administration of GPR120 agonists both alone and in combination with Sitagliptin in 
lean Swiss TO mice (n=6) reduced blood glucose and increased insulin secretion. Oral 
administration of DHA caused a 22.2% (p<0.05) in blood glucose. When DHA was administered 
alongside the GPR120 antagonist AH7614, there was a 20.3% (p<0.05) increase in blood glucose 
compared to DHA administration alone. DHA administration in combination with Sitagliptin 
reduced blood glucose 52.1% overall (p<0.001). Administration of GW9508 decreased blood 
glucose 31.3% (p<0.05) while combining GW9508 with Sitagliptin resulted in a 34.0% (p<0.01) 
overall decrease. 
Oral administration of DHA increased insulin secretion from male Swiss TO mice 1.9-fold 
(p<0.001) while a combination of DHA and Sitagliptin resulted in a 1.7-fold (p<0.001) increase. 
When DHA administration is compared to DHA combined with AH7614, DHA administration 
causes a 1.6-fold (p<0.001) increase in insulin secretion. GW9508 administration increases insulin 
secretion 1.8-fold (p<0.001) and in combination with Sitagliptin a 1.9-fold (p<0.001) increase is 
observed. GW9508 also increases insulin secretion 1.5-fold (p<0.05) compared to GW9508 in 
combination with Sitagliptin.  
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Oral administration of GPR120 agonists also increased incretin hormone secretion in male Swiss 
TO mice. DHA increased GLP-1 secretion 2.7-fold (p<0.001) 30 mins post administration while 
this was a 3.3-fold (P<0.001) increase in mice treated with GW9508. Both agonists also increased 
GIP secretion with increases of 2.6-fold (p<0.001) and 2.7-fold (p<0.001) observed 15 mins post 
administration for DHA and GW9508 respectively. Further to this both agonists in combination 
with Sitagliptin reduced appetite with decreases of 16.9% (p<0.05) and 19.8% (p<0.05) observed 
respectively in Swiss TO mice trained to eat for 3 hrs (n=8).  
The results of this study further establish a role for GPR120 activation in incretin and 
gastrointestinal hormone secretion and may be an important therapeutic target for in the treatment 
of Type 2 Diabetes and metabolic disorders.  
 
5.2: Introduction 
GPR120 is a 377-amino acid long rhodopsin-like GPCR that was first recognised as being present 
on chromosome 10 in 2003 using bioinformatical analysis of the human genome (Fredriksson et al. 
2003a). This study found the human GPR120 gene which was expressed in the stomach and had 4 
coding exons. The sequence for the GPR120 gene was highly conserved in mice with 86% 
similarity, however the mouse protein is 16 amino acid residues shorter at 361 amino acids and 
present on chromosome 19 (Fredriksson et al. 2003a). As no ortholog was found within fish it was 
determined that, along with GPR141, GPR120 must have evolved into the mammalian genome at a 
stage after it had diverged from the common mammalian ancestor with fish (Fredriksson et al. 
2003a). It was later found that human GPR120 has both the long isoform reported above and a 
shorter isoform consisting of 361 amino acids (Strausberg et al. 2002). 
As an orphan receptor, GPR120 was of interest to researchers looking for novel treatments for a 
range of diseases. One of the first disorders which was of interest to researchers was Type 2 Diabetes 
(Hirasawa et al. 2005a). Using qPCR, it was found that GPR120 was expressed in both human and 
mouse small intestine as well as the intestinal STC-1 cell line which is also derived from mice. 
Interestingly this study did not find GPR120 to be present in a range of other cell lines including 
the pancreatic MIN6 cell line (Hirasawa et al. 2005a). It was discovered that a range of long chain 
fatty acids such as palmitoleic, alpha-linoleic (ALA) and docosahexaenoic acid (DHA) all 
stimulated GPR120 (Hirasawa et al. 2005a). Saturated fatty acids stimulated GPR120 in shorter 
chains (C14 to C18) than unsaturated fatty acids (C16 to C22). As the free form of fatty acids had 
previously been shown to increase both CCK (Guimbaud et al. 1997) and GLP-1 in humans (Holst, 
Orskov 2001), the research then focused on the effects of these fatty acids on GLP-1 secretion from 
STC-1 cells through GPR120. Using siRNAs, the researchers were able to determine that the fatty 
acids used were able to stimulate GLP-1 secretion through GPR120 but not GPR40 (Hirasawa et 
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al. 2005a). GPR40 was also targeted in this research as it is also a free fatty acid receptor that is 
activated by long chain fatty acids (Watson, Brown & Holliday 2012). Despite both receptors being 
activated by long chain fatty acids, they share only 10% sequence homology (Hirasawa et al. 2008). 
However due to the similarity in their agonists, they are classified as free fatty acid receptors 
alongside GPR41 and GPR43 (Hirasawa et al. 2008, Stoddart, Smith & Milligan 2008). 
While long chain fatty acids activate GPR120, some can bind to the receptor and prevent ligand 
binding, resulting in an antagonistic effect. AH7614 is a GPR120 specific antagonist which can be 
used to block the activation of the receptor (Sparks et al. 2014). AH7614 is able to antagonise 
GPR120 as it is a negative allosteric modulator that decreases the affinity of GPR120 agonists for 
the receptor (Watterson et al. 2017). Another possible GPR120 antagonist known as TUG-1837 
may be able to exert the same effects as AH7614 via the same mechanism (Watterson et al. 2017). 
The second hormone linked with metabolic disorders to be investigated was CCK (Tanaka et al. 
2008b). This in vivo study determined that the GPR120 agonists ALA, palmitoleic and octanoic 
acid all increased CCK secretion from intestinal L-cells in a GPR120 specific manner. In order to 
confirm the specificity of these agonists for GPR120, shRNAs were used to block the action of 
either GPR120 or GPR40. GPR40 was targeted in both studies as it is also activated by medium to 
short chain fatty acids (Itoh et al. 2003a).  
As CCK has previously been shown to increase insulin secretion (Rushakoff et al. 1987b) and GLP-
1 has a well defined incretin effect on insulin secretion, further research focused on the presence of 
GPR120 and effects of GPR120 agonists on insulin secretion from the pancreas. Contrary to the 
earlier studies (Hirasawa et al. 2005a), GPR120 was found to be present in both pancreatic BRIN-
BD11 and INS1 cell lines (Dhayal, Welters & Morgan 2008) as well as the MIN6 cell line which it 
was previously reported to be absent from as well as isolated mouse islets (Kebede et. al. 2009). 
The presence of GPR120 was confirmed in the BRIN-BD11 cell line as well as isolated islets in a 
study which investigated both the in vitro and in vivo effects of GPR120 agonists (Moran et. al. 
2014). This study identified that activation of GPR120 agonists increased insulin secretion from 
BRIN-BD11 cells while having glucose lowering effects in vivo in lean mice. It was suggested that 
this was through both the Ca2+ and cAMP pathway, however this needs further study as previous 
research did not find any cAMP pathway activation upon GPR120 stimulation, rather it was found 
that GPR120 increased intracellular calcium and activated the ERK signalling cascade (Hara et. al. 
2011). This research suggests that GPR120 binds to the Gαq family, however further investigation 
in our lab has confirmed that GPR120 agonists have an effect on cAMP signalling (unpublished 
data). This further work has also examined the effects of GPR120 activation on glucagon secretion 
as it has been suggested that GPR120 agonists have a role to play in glucagon secretion in the 
pancreatic islet (Suckow et. al. 2014). Another pancreatic hormone of interest is somatostatin which 
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was studied using knock-in mice. The authors of this study demonstrated the co-localisation of 
GPR120 with somatostatin in the delta cells of the islet as well as the loss of response in δ-cells of 
GPR120 knockout mice (Stone et. al. 2014). 
The most recent hormone which has been studied in relation to the effect of GPR120 on diabetes is 
GIP (Iwasaki et. al. 2015). This research used GFP knock-in mice to try and identify the K cells of 
the intestine whilst also looking at the expression of fatty acid receptors. The presence of GPR120 
in GFP positive K cells was identified and confirmed using GPR120 knockout mice. It was found 
that GPR120 knockout reduced GIP secretion and increased blood glucose. 
Further research into the role of GPR120 focused on obesity, which is closely linked to Type 2 
Diabetes, as well as a range of other disorders. In humans of European descent, a mutation 
(p.R270H) was identified in the GPR120 gene of obese subjects that inhibited GPR120 signalling 
(Ichimura et. al. 2012). Furthermore, mice without GPR120 which were fed a high fat diet 
developed obesity, fatty livers and glucose intolerance (Ichimura et al. 2012). GPR120 has also 
been implicated in reducing inflammation (Oh et. al. 2010) which is one of the many 
pathophysiological effects of Type 2 Diabetes.  
All of the above research implicates GPR120 in an anti-diabetic role. More research is necessary to 
understand the role of GPR120 activation in intestinal hormone secretion and glucose homeostasis. 
The effects of GPR120 activation on GLP-1 and GIP were investigated in GLUTag and pGIPneo 
STC-1 cell lines, while the insulinotropic actions of GPR120 agonists ALA, DHA and GW9508 
were studied in pancreatic BRIN-BD11 and intestinal. Gene and protein expression of GPR120 was 
investigated using qPCR and histological analysis. The acute biological effects of GPR120 agonists, 
DHA and GW9508, were assessed in male Swiss TO mice.  
 
5.3: Materials and methods 
  
5.3.1: Materials 
ALA (L2376-500MG) was purchased from Sigma-Aldrich (Poole, Dorset, UK) whilst DHA 
(ab145212), GW9508 (ab144444) and AH7614 (ab146181) were purchased from Abcam 
(Cambridge, UK). Multi species GLP-1 total and rat/mouse GIP total ELISA kits were purchased 





5.3.2: Acute insulin secretion from pancreatic BRIN-BD11 cells 
Cells were seeded in 24-well plates with 150000 BRIN-BD11 cells per well and incubated overnight 
in 1ml of RPMI 1640 media at 37°C and 5% CO2. Following this incubation, cells were 
preincubated with 1.1mM glucose for 40 mins with subsequent acute incubations being carried out 
at 37°C 5% CO2 for 20 mins in 5.6mM and 16.7mM glucose in KRBB buffer supplemented with 
10-12 to 10-4M concentrations of ALA, DHA and GW9508 with 10mM alanine as a positive control. 
After incubations, supernatants (950μl) were collected and frozen at -20°C until radioimmunoassay 
could be carried out as described in Chapter 2, section 2.2. 
 
5.3.3: Acute hormone secretion from intestinal cell lines 
GLUTag or pGIPneo STC-1 cells were seeded into 24-well plates with 150000 cells per well which 
were incubated overnight in 1ml of culture medium (as described previously) at 37°C and 5% CO2. 
To ensure that cells grew in monolayers, they were pipetted up and down vigorously to ensure 
proper mixing before seeding. After overnight incubation and preincubation with 1.1mM glucose 
for 40 mins, acute incubations were carried out at 37°C 5% CO2 for 2 hrs in 2mM glucose in KRBB 
buffer supplemented with 10-10 to 10-4M concentrations of ALA, DHA and GW9508. Test solutions 
were added both alone and in combination with the GPR120 antagonist AH7614 at a concentration 
of 10-5M. After incubations, supernatants (950μl) were collected and frozen at -20°C until ELISA 
could be carried out as described in Chapter 2, section 2.3. 
 
5.3.4: Acute effects of ALA, DHA and GW9508 on cell toxicity 
Cells were seeded in 96-well plates with 40000 cells per well of BRIN-BD11, GLUTag or pGIPneo 
STC-1 cells and incubated overnight in cell culture media (as described in Chapter 2, section 2.1) 
in an atmosphere of 5% CO2 at 37°C. After 20hrs, BRIN-BD11 cells were preincubated with 1.1mM 
glucose for 40 mins with subsequent acute incubations being carried out at 37°C 5% CO2 for 20 
mins in 5.6mM and 16.7mM glucose in KRBB buffer supplemented with 10-12M to 10-4M 
concentrations of GPR120 agonist with 1mM H2O2 as a cytotoxic control (n=3). After 48hrs, 
GLUTag and pGIPneo STC-1 cells were preincubated with 1.1mM glucose for 40 mins with 
subsequent acute incubations being carried out at 37°C 5% CO2 for 2 hrs in 2mM in KRBB buffer 
supplemented with 10-12M to 10-4M concentrations of ALA, DHA and GW9508 with 1mM H2O2 
as a cytotoxic control (n=3). After incubation, supernatant was decanted, cells were washed with 
HBSS and 0.5mg/ml MTT was added for 2 hrs. Following MTT incubation, supernatant was 
discarded and DMSO was added to solubilise crystals. Optical density was subsequently measured 
at 570nm and 630nm using the Flexstation 3 (Molecular Devices, CA, USA).  
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5.3.5: Immunofluorescence staining in GLUTag, pGIPneo STC-1, STC-1 cells and lean and HFF 
NIH Swiss mouse small intestine 
GLUTag, pGIPneo STC-1 and STC-1 cells were seeded at a density of 40000 cells on to polylysine 
coated slides overnight at 37°C in an atmosphere of 95% air and 5% CO2 as described in Chapter 2, 
section 2.1. Swiss TO mice were anesthetised by isoflurane and killed by cervical dislocation. 
Pancreas and intestine was excised as described in Chapter 2, section 2.6.3. Immunohistochemistry 
was carried out by incubating with rabbit polyclonal anti-GPR120 and goat polyclonal anti-GLP-1, 
goat polyclonal anti-GIP or goat polyclonal anti-PYY with the dilutions outlined in Chapter 2, Table 
2.1.   
 
5.3.6: Quantitative real-time PCR (qPCR) 
qPCR was performed using LightCycler® 480 SYBR Green I Master. Reactions were performed 
using 4.5μl of 2x concentrated SYBR green, 1μl of forward and reverse primers (primer sequences 
are listed in Chapter 2, Table 2.2), 1μl of cDNA and 3μl of RNase free water (n=3). All reactions 
included a negative template control with RNase free water added instead of cDNA (n=3). The 
reactions were carried out in 8-well real-time PCR Tube Strips and Masterclear™ Cap Strips 
(Eppendorf, HAM, DE). Amplification conditions were 5 mins initial denaturation at 95°C, 
followed by 40 cycles of 30 secs denaturation at 95°C, 30 secs annealing at 58°C and 30 secs 
extension at 72°C and a final elongation step for 5 mins at 72°C. Reactions included melting curve 
analysis with temperature range of 60 °C to 90 °C. All reactions were carried out using the 
MiniOpticon two colour real time PCR detection system (BioRad, UK). Analysis of results was 
performed using the Livak method and the mRNA levels of all genes were normalised using the 
housekeeping gene GAPDH. 
 
5.3.7: Acute in vivo glucose tolerance tests 
Male Swiss TO mice were housed as described in Chapter 2, section 2.7. The effects GPR120 
agonists DHA and GW9508 (0.1μmol/kg BW), as well as in combination with Sitagliptin Phosphate 
(50mg/kg BW) in lean male Swiss TO mice were investigated. Before test compounds were 
administered mice were fasted for 18 hrs and blood subsequently collected (t=0). Test compounds 
were administered orally in glucose (18mmol/kg BW), and blood was collected at 15, 30, 60, 90 
and 120 mins along with blood glucose measurements. Collected blood was centrifuged at 
13200rpm for 5 mins at 4°C using a Beckman centrifuge (Beckman Instruments, UK). Plasma was 
stored at -20°C until hormone measurements by RIA or ELISA as described in Chapter 2, sections 





5.4.1: Effects of GPR120 agonists and antagonist AH7614 on GLP-1 secretion from intestinal 
GLUTag cells 
The effects of endogenous GPR120 agonists ALA and DHA and synthetic agonist GW9508 along 
with GPR120 antagonist AH7614 on GLP-1 secretion from GLUTag cells in 2mM glucose was 
examined. The endogenous GPR120 agonist DHA (Figure 5.2A) had the greatest increase in GLP-
1 secretion as it demonstrated a 1.6 to 2.7-fold (p<0.01 to p<0.001) increase compared to basal 
levels at 10-8 to 10-6M. This was followed by the endogenous agonist ALA (Figure 5.1A) which 
exhibited a 1.5 to 1.8-fold increase (p<0.01) from 10-8-10-6M and the synthetic agonist GW9508 
(Figure 5.3A) which increased GLP-1 secretion 1.8-fold (p<0.001) from GLUTag cells at 10-6M in 
2mM glucose.  
When GLUTag cells were treated with both a GPR120 agonist and the antagonist AH7614 (10-5M) 
all agonists tested demonstrated selectivity for the GPR120 receptor as AH7614 reduced the 
agonistic action on GLP-1 secretion (p<0.05-p<0.01). In the presence of AH7614, ALA secretory 
action was reduced from 1.3 to 1.5-fold (10-8M to 10-6M, p<0.05-p<0.01) while DHA action was 
reduced 1.7 to 2.4-fold (10-10M to 10-6M, p<0.01). The secretory ability of synthetic GPR120 agonist 
GW9508 was reduced 1.5 to 1.7-fold (10-8M to 10-6M, p<0.01). All agonists tested demonstrated 
no adverse effects on cell viability or cell proliferation as observed through measurement of MTT 
(Figures 5.1B, 5.2B and 5.3B). 
 
5.4.2: Effects of GPR120 agonists and antagonist AH7614 on GIP secretion from intestinal 
pGIPneo STC-1 cells 
The effects of GPR120 agonists on GIP secretion was investigated through treatment of intestinal 
pGIPneo STC-1 cells. The endogenous agonists tested (ALA and DHA) had no significant effect 
on GIP secretion compared to vehicle control (2mM glucose) (Figures 5.4A and 5.5A). Synthetic 
GPR120 agonist GW9508 (Figure 5.6A) demonstrated a 2.0-fold (p<0.05) increase in GIP secretion 
from pGIPneo STC-1 cells at 10-4M. Treatment of pGIPneo STC-1 cells with both GPR120 agonist 
GW9508 (10-4M) and antagonist AH7614 (10-5M) reduced GIP secretion to basal levels (1.9-fold 
decrease) demonstrating the selectivity of GW9508 for GPR120. All agonists tested demonstrated 





5.4.3: Effects of GPR120 agonists on insulin secretion from pancreatic BRIN-BD11 cells 
The effects of both endogenous (ALA and DHA) and synthetic (GW9508) fatty acid GPR120 
agonists on insulin secretion were investigated in the clonal BRIN BD11 cell line in both normal 
and hyperglycaemic conditions (Figures 5.7-5.12). The endogenous agonist DHA (Figure 5.9A) 
demonstrated a 1.2 to 2.1-fold increase in insulin secretion (p<0.01-p<0.001) at concentrations of 
10-9-10-4M in 5.6mM glucose. ALA (Figure 5.7A) increased insulin secretion 1.2 to 1.5-fold 
(p<0.05-p<0.001) at concentrations of 10-8-10-4M in 5.6mM glucose while the synthetic GPR120 
agonist GW9508 (Figure 5.11A) increased insulin secretion 1.2 to 1.7-fold (p<0.05-p<0.001) at 
concentrations of 10-1 to 10-4M at the same concentration of glucose. DHA was the least potent 
agonist examined in 5.6mM glucose (Figure 5.13A) with an EC50 value of 3.87x10-6M. The most 
potent agonist tested in normal conditions was ALA which had an EC50 value of 2.04x10-8M which 
was closely followed by GW9508 (5.16x10-8M). 
When examining the insulinotropic effects of GPR120 agonists in hyperglycaemic conditions, all 
agonists demonstrated similar effects. ALA (Figure 5.8A) increased insulin secretion 1.3 to 1.9-fold 
(p<0.05-p<0.001) at concentrations of 10-8-10-4M. The endogenous agonist DHA (Figure 5.10A) 
demonstrated a 1.3 to 1.8-fold (p<0.05-p<0.001) increase in insulin secretion at 10-9-10-4M. The 
synthetic agonist GW9508 (Figure 5.12A) exhibited a 1.3 to 1.8-fold (p<0.05-p<0.001) 
insulinotropic effect in 16.7mM glucose at concentrations of 10-9 to 10-4M. The most potent agonist 
tested in hyperglycaemic conditions was GW9508 (EC50 8.26x10-10M). This was followed by DHA 
(EC50 7.34x10-9M) with ALA (EC50 6.18x10-8M) being the least potent agonist (Figure 5.13B). 
There were no adverse effects on cell viability or proliferation (Figures 5.7B-5.12B) at either normal 
or hyperglycaemic conditions for all GPR120 agonists tested. 
 
5.4.4: Distribution of GPR120, GLP-1, GIP and PYY in intestinal cell lines and lean and HFF NIH 
Swiss mouse small intestine 
The presence or absence of GPR120 in the L and K cells of the intestine was determined through 
double immunohistochemistry in both lean and HFF diet mice as well as GLUTag, pGIPneo STC-
1 and STC-1 cells. Both GPR120 and GLP-1 were expressed throughout GLUTag cells (Figure 
5.14). Immunohistochemistry in both lean and HFF small intestine confirmed the co-localisation of 
GPR120 and GLP-1 in intestinal L-cells (Figure 5.15D and 5.16D). PYY, also secreted from the L-
cells of the small intestine, was found to be co-localised with GPR120 in both STC-1 cells (Figure 
5.21) and lean and HFF mouse small intestine (Figure 5.22D and 5.23D) thus confirming the 
presence of GPR120 in L-cells. GIP, secreted from intestinal K-cells, was observed to be co-
localised with GPR120 in lean (Figure 5.19D) and HFF (Figure 5.20D) diet mouse small intestine 
as well as pGIPneo STC-1 cells (Figure 5.18D). qPCR was carried out on whole lean and HFF diet 
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mouse small intestine (Figure 5.17) to determine how diet affects GPR120 expression. It was 
determined that mice fed a HFF diet have a 1.4-fold reduction in intestinal GPR120 expression 
(p<0.05). However this result confirmed that seen in GPR120 staining with GPR120 being present 
in both lean and HFF mouse small intestinal tissue. 
 
5.4.5: Effects of GPR120 agonists on proglucagon, PC1 and GPR120 gene expression in intestinal 
GLUTag cells 
The effects of GPR120 agonists in 2mM glucose on GPR120 gene expression was determined using 
qPCR (Figure 5.24A). Treatment of GLUTag cells with DHA demonstrated a 2.1-fold decrease in 
GPR120 gene expression compared to vehicle control (p<0.01). GPR120 agonists ALA and 
GW9508 had no significant effect on expression compared to 2mM glucose vehicle control (Figure 
5.24A). 
DHA was the GPR120 agonist with the greatest increase on proglucagon gene expression in 
GLUTag cells (Figure 5.24B) with a 2.4-fold (p<0.01) increase compared to vehicle control. 
Compared to the vehicle control, ALA exhibited a 2.0-fold increase (p<0.01) in proglucagon gene 
expression. GW9508 had no effect compared to vehicle control. 
As the proglucagon gene is cleaved by PC1/3 to release GLP-1, the expression of this gene was also 
investigated. Interestingly treatment of agonists completely ablated PC1/3 gene expression 
(p<0.001, Figure 5.24C). 
 
5.4.6: Acute effects of GPR120 agonists on incretin hormones in male Swiss TO mice 
The effects of oral administration of GPR120 agonists on the incretin hormones GLP-1 and GIP 
was also investigated in this study. Both DHA and GW9508 increased the secretion of these 
hormones. DHA (Figure 5.25A) increased GLP-1 secretion 2.7-fold (p<0.001) 30 mins post 
administration when compared to glucose administration. GW9508 (Figure 5.25A) had a more 
sustained effect, with increases of 2.1 and 3.2-fold (p<0.001) being observed 15 and 30 mins post 
administration respectively. 
As seen with GLP-1, both agonists tested demonstrated increases in GIP secretion (Figure 5.26A). 
DHA exhibited a 2.6-fold (p<0.001) increase in GIP secretion whilst GW9508 demonstrated a 2.7-





5.4.7: Acute effects of GPR120 agonists on blood glucose and insulin in male Swiss TO mice 
Oral administration of GPR120 agonists DHA (Figure 5.27B) and GW9508 (Figure 5.28B) at 
concentrations of 0.1μmol/kg body weight in fasted Swiss TO mice reduced blood glucose 22% 
(p<0.05) and 31% (p<0.05) over 120 mins with synthetic GPR120 agonist GW9508 demonstrating 
the most potent properties.  
GW9508 had reduced blood glucose 25% (p<0.05) 15 mins post administration with this effect 
continuing 30 mins post administration with a 36% (p<0.001) reduction in blood glucose (Figure 
5.28A). Administration of GW9508 with GPR120 antagonist AH7614 confirmed the selectivity of 
GW9508 for GPR120 with reductions in blood glucose of 37% (p<0.01), 32% (p<0.05) and 29% 
(p<0.01) after 30, 60 and 90 mins post administration respectively. 
DHA (Figure 5.27A) reduced blood glucose 27% (p<0.001) and 30% (p<0.001) after 15 and 30 
mins post administration. As observed with GW9508, administration of DHA with GPR120 
antagonist AH7614 confirmed it’s selectivity for GPR120 with DHA administration alone 
decreasing blood sugar 26% (p<0.001) and 18% (p<0.05) after 15 and 30 mins, respectively.  
Administration of DHA with DPP-IV inhibitor Sitagliptin Phosphate (Figure 5.27A) demonstrated 
a marked reduction in blood glucose compared to both vehicle control and DHA itself. Compared 
to glucose, blood glucose was reduced 51% (p<0.001), 63% (p<0.001), 54% (p<0.001), 51% 
(p<0.001) and 52% (p<0.001) at 15, 30, 60, 90 and 120 mins post administration respectively. 
Compared to DHA itself, DHA in combination with Sitagliptin reduced blood glucose 33% 
(p<0.001), 49% (p<0.001), 43% p<0.001), 36% (p<0.01) and 34% (p<0.05) at 15, 30, 60, 90 and 
120 mins post administration. When GW9508 was administered in conjunction with Sitagliptin 
(Figure 5.28A), blood glucose was decreased 34% (p<0.001) and 41% (p<0.001) after 15 and 
30mins. There was no significant difference between GW9508 combination treatment and GW9508 
alone. 
Oral administration of GPR120 agonists also lead to increased insulin secretion. DHA treatment 
alone (Figure 5.29A) lead to a 3.4-fold increase 30 mins post administration compared to glucose 
control (p<0.001). The same effect was seen when DHA was administered in combination with 
Sitagliptin with a 3.09-fold increase being observed at this time point (p<0.001). Sitagliptin 
treatment alone lead to a 2.1-fold increase in insulin secretion 15 mins post administration 
(p<0.001), however this effect was not sustained after this. The insulinotropic effect of DHA was 
reduced 2.2-fold when administered in the presence of GPR120 antagonist AH7614 (0.1μmol/kg 
body weight, p<0.001). 
Administration of GW9508 (Figure 5.30A) led to a 2.6-fold increase in insulin secretion (p<0.001). 
Like DHA this effect was seen 30 mins post administration. GW9508 in combination with 
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Sitagliptin had a greater insulinotropic effect than GW9508 treatment alone with an increase of 2.8-
fold being observed 30 mins post administration (p<0.001). AH7614 also reduced the insulinotropic 
effects of GW9508 with a decrease of 1.6-fold being exhibited. 
 
5.4.8: Acute effects of GPR120 agonists on feeding 
The acute effects of oral administration of GPR120 agonists on male Swiss TO mice trained to eat 
for 3 hrs only was investigated. DHA (Figure 5.31A) had an initial effect on appetite with feeding 
being reduced 33% (p<0.01) and 22% (p<0.05) after 30 mins and 1 hr respectively. However this 
effect was not sustained and there was no difference in total feeding over 3 hrs when compared to 
saline control. When DHA was administered in combination with Sitagliptin, appetite was reduced 
after 150 and 180 mins by 18% (p<0.01) and 17% (p<0.05) respectively.  
Oral administration of GW9508 (Figure 5.31B) also resulted in an initial reduction in appetite as 
this was reduced for the first 90 mins with reductions of 65% (p<0.001), 49% (p<0.001), 38% 
(p<0.001), 25% (p<0.05) and 21% (p<0.05). Like DHA, this effect was not sustained and after 3 
hrs of feeding there was no effect. However, administration of a combination of GW9508 and 
Sitagliptin did result in an overall reduction in appetite with an appetite reduction of 20% (p<0.05) 
after 3hrs. 
 
5.5: Discussion  
GPR120 has previously been shown to play a role in incretin (Hirasawa et. al. 2004, Iwasaki et. al. 
2015) and other gastrointestinal hormone (Tanaka et. al. 2008) secretion. GPR120 is activated by 
long chain omega 3 fatty acids (Hirasawa et. al. 2004) and a mutation in GPR120 has shown 
increased levels of obesity in humans of European descent (Ichimura et. al. 2012). This has led to 
interest into how GPR120 activation can be used as a therapeutic treatment in metabolic disorders 
such as Type 2 Diabetes (Moran et. al. 2014). 
This study investigated the effects of both endogenous and synthetic GPR120 agonists on intestinal 
hormone and insulin secretion. ALA, DHA and GW9508 effects on GLP-1 secretion were assessed 
in GLUTag cells. The agonist which caused the greatest increase in GLP-1 secretion was DHA 
followed by GW9508 then ALA. Both DHA and ALA have previously been shown to increase 
GLP-1 secretion from STC-1 cells (Hirasawa et al. 2005a). GLP-1 secretion was increased in a dose 
dependent manner with agonist specificity being confirmed through AH7614 antagonism. When 
assessing GIP secretion from pGIPneo STC-1 cells, only the synthetic agonist GW9508 caused an 
increase. The omega 3 fatty acids ALA and DHA had no effect on GIP secretion. These results 
157 
 
confirm previous research (Hirasawa et. al. 2004, Iwasaki et. al. 2015) which suggested that 
GPR120 may play a role in incretin hormone secretion. All agonists tested did not cause any 
cytotoxicity in the cell lines tested. The effects of GPR120 agonists on insulin secretion were 
investigated in BRIN-BD11 cells. In normoglycaemic conditions ALA performed most efficiently 
followed by GW9508 and DHA. In hyperglycaemic conditions GW9508 was the most efficient 
agonist followed by DHA then ALA. These results are similar to those previously reported (Moran 
et. al. 2014).  
Previous research has indicated the presence of GPR120 in both the L-cells (Hirasawa et. al. 2004) 
and K-cells (Iwasaki et. al. 2015) of the intestine. In order to confirm these findings, the expression 
of GPR120 in the small intestine was determined via qPCR and double immunohistochemistry. As 
qPCR was carried out in whole intestine extract, the double immunohistochemistry was used to 
confirm the cell types which GPR120 is present in. GIP is secreted from K cells of the intestine and 
staining of both pGIPneo STC-1 cells and lean and HFF small intestine confirmed the presence of 
GPR120 in GIP secreting K cells. Both PYY and GLP-1 are secreted from the L cells of the intestine 
and double immunohistochemistry in lean and HFF mouse small intestine as well as GLUTag cells 
for GLP-1 and STC-1 cells for PYY confirmed the presence of GPR120 in the L cells of the 
intestine. Mice fed a high fat diet had reduced GPR120 expression which is in keeping with recent 
research which found various changes in GPR120 expression in the gastrointestinal tract when mice 
were fed a high fat diet (Widmayer et. al. 2015). GPR120 was upregulated in GLUTag cells when 
cells were treated with 2mM glucose however neither ALA nor GW9508 had any effect. DHA 
downregulated GPR120 expression yet upregulated proglucagon gene expression suggesting that 
GPR120 was being internalised and the downstream signalling events occurring due to receptor 
internalisation are increasing proglucagon production. This has previously been seen for GPR120 
when activated by GW9508 in human eosinophils (Konno et al. 2015). ALA also upregulated 
proglucagon gene expression suggesting that the production of GLP-1 was being increased. PC1/3 
expression would be expected to increase in tandem with proglucagon gene expression, however as 
these agonists increase GLP-1 secretion the cellular stores of proglucagon may need replenished 
and PC1/3 production halts. However further research is needed to confirm this.   
As DHA and GW9508 increased GLP-1 to a greater degree than that demonstrated by ALA and 
that GW9508 was the only agonist to increase GIP secretion, both DHA and GW9508 were selected 
for further investigation. Furthermore ALA has also been previously shown to have no effect on 
GLP-1 secretion (Paulsen et. al. 2014) and DHA provided the greatest increase in GLP-1 secretion 
and may have increased GIP secretion in a GPR120 specific manner at hugher concentrations in 
vitro. ALA demonstrated no trend compared to GPR120 antagonism and was not selected for further 
study for these reasons. In order to determine the effects of these agonists on gastrointestinal 
hormone secretion, they were administered by oral gavage rather than intraperitoneal injection. Both 
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agonists increased insulin secretion and reduced blood glucose. This has been demonstrated 
previously via IP injection (Moran et al. 2014b, Shimura et al. 1997) or intracolonically (Shida et 
al. 2013). Oral administration of DHA has shown to improve arthritis in the knee (Torres-Guzman 
et al. 2014) thus suggesting that it may also have anti-inflammatory effects. The oral effects of 
GW9508 have not yet been investigated. Both agonists were administered alongside the DPP-IV 
inhibitor Sitagliptin and demonstrated an additive effect in the reduction of blood glucose.  
Intracolonic administration of DHA has previously shown that DHA administration can increase 
GLP-1 secretion (Emery et al. 2014), however this is the first study to determine an increase through 
oral administration. GW9508 also demonstrated the ability to increase GLP-1 and this effect was 
demonstrated for a longer time period than DHA. There is currently no published research 
determining the effects of DHA and GW9508 on GIP secretion. In this study both GIP and DHA 
increased GIP secretion when administered orally in vivo. Both agonists demonstrated similar 
effects with a prompt increase in GIP after 15 mins and returning to basal levels by 30 min. GLP-1 
has demonstrated an ability to slow gastric emptying (Shah, Vella 2014), while the effects of GIP 
on satiety appear to be minimal (Edholm et al. 2010b). Despite an initial reduction in appetite, 
agonist treatment alone did not reduce appetite. However in combination with Sitagliptin the satiety 
effect was prolonged and appetite was reduced.  
In conclusion, this study is the first study to identify the GIP GLP-1 secreting effects of DHA and 
GW9508 in vitro and orally in vivo. Administration in combination with Sitagliptin also reduced 
appetite in vivo. GPR120 expression was confirmed in a range of intestinal cell lines as well as lean 
and HFF mouse small intestine. As well as increasing GLP-1 and GIP, oral administration of DHA 
and GW9508 reduces blood glucose and increase plasma insulin. The results presented in this study 
demonstrate a role for GPR120 agonists in glucose homeostasis through intestinal hormone 











Figure 5.1: Effects of endogenous GPR120 agonist ALA on GLP-1 secretion and cell viability 
in intestinal GLUTag cells in 2mM glucose 














































ALA + 2mM Glucose













Effect of GPR120 agonist ALA (10-8-10-4M) and GPR120 antagonist AH7614 (10-5M) on GLP-1 
secretion (A) and cell viability (C) at 2mM glucose in GLUTag cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. * p<0.05, ** 
p<0.01 and *** p<0.001 compared to basal glucose control for GLP-1 secretion and media non-
toxic control for cell viability. ∆ p<0.05 and ΔΔ p<0.01 compared to antagonist treatment at same 




Figure 5.2: Effects of DHA on GLP-1 secretion and cell viability in intestinal GLUTag cells in 
2mM glucose 
















































DHA + 2mM Glucose













Effect of GPR120 agonist DHA (10-10-10-6M) and antagonist AH7614 (10-5M) on GLP-1 secretion 
(A) and cell viability (B) at 2mM glucose in GLUTag cells. Cell viability was measured using MTT. 
Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. * p<0.05 and *** p<0.001 
compared to basal glucose control for GLP-1 secretion and media non-toxic control for cell 




Figure 5.3: Effects of GW9508 on GLP-1 secretion and cell viability in intestinal GLUTag 















































GW9508 + 2mM Glucose













Effect of GPR120 agonist GW9508 (10-10-10-6M) and antagonist AH7614 (10-5M) on GLP-1 
secretion (A) and cell viability (B) at 2mM glucose in GLUTag cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. ** p<0.01 and 
*** p<0.001 compared to basal glucose control for GLP-1 secretion and media non-toxic control 




Figure 5.4: Effects of endogenous GPR120 agonist ALA on GIP secretion and cell viability in 



















ALA + 2mM Glucose













Effect of GPR120 agonist ALA (10-8-10-4M) and antagonist AH7614 on GIP secretion (A) and cell 
viability (10-12-10-4M) (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GIP secretion and cell viability. *** p<0.001 
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Figure 5.5: Effects of endogenous GPR120 agonist DHA on GIP secretion and cell viability in 
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Effect of GPR120 agonist DHA (10-8-10-4M) and antagonist AH7614 on GIP secretion (A) and cell 
viability (10-12-10-4M) (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GIP secretion and cell viability. *** p<0.001 
compared to basal glucose control for GIP secretion and media non-toxic control for cell viability. 
164 
 
Figure 5.6: Effects of synthetic GPR120 agonist GW9508 on GIP secretion and cell viability 









































GW9508 + 2mM Glucose













Effect of GPR120 agonist GW9508 (10-8-10-4M) and antagonist AH7614 on GIP secretion (A) and 
cell viability (10-12-10-4M) (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GIP secretion and cell viability. * p<0.05 and *** 
p<0.001 compared to basal glucose control for GIP secretion and media non-toxic control for cell 




Figure 5.7: Effects of endogenous GPR120 agonist ALA on insulin secretion and cell viability 












































5.6mM Glucose + ALA
STZ GLP-1 10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4













Effect of ALA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 





Figure 5.8: Effects of endogenous GPR120 agonist ALA on insulin secretion and cell viability 















































16.7mM Glucose + ALA
STZ GLP-1 10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4












Effect of ALA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05 and *** p<0.001 compared to basal 






Figure 5.9: Effects of endogenous GPR120 agonist DHA on insulin secretion and cell viability 












































5.6mM Glucose + DHA
STZ GLP-1 10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4












Effect of DHA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. ** p<0.01 and *** p<0.001 compared to 








Figure 5.10: Effects of endogenous agonist DHA on insulin secretion and cell viability in 














16.7mM glucose + DHA





























16.7mM Glucose + DHA
STZ GLP-1 10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4












Effect of DHA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 







Figure 5.11: Effects of synthetic GPR120 agonist GW9508 on insulin secretion and cell 













































5.6mM Glucose + GW9508
STZ GLP-1 10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4












Effect of GW9508 (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 








Figure 5.12: Effects of synthetic GPR120 agonist GW9508 on insulin secretion and cell 













































16.7mM Glucose + GW9508
STZ GLP-1 10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4












Effect of GW9508 (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose 
in BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± 
SEM (n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 









Figure 5.13: EC50 of GPR120 agonists ALA, DHA and GW9508 in BRIN-BD11 cells 
A. 







-9  1.0 M
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ALA            EC50 6.18x10
-8  1.3 M
GW9508     EC50 8.26x10
-10  1.2 M
DHA    EC50 7.34x10
-9  1.3 M





























EC50 values for GPR120 agonists ALA, DHA and GW9508 in BRIN-BD11 cells in 5.6mM glucose 
(A) and 16.7mM glucose (B). 
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Figure 5.14: Double immunofluorescence staining of GLP-1 and GPR120 in intestinal 
GLUTag cells 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR120 and (D) combined fluorescence of GLP-1 and 
GPR120 in GLUTag cells. Images are taken at x200 magnification and examples of positive staining 










Figure 5.15: Double immunofluorescence staining of GLP-1 and GPR120 in lean NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR120 and (D) combined fluorescence of GLP-1 and 
GPR120 in lean NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 













Figure 5.16: Double immunofluorescence staining of GLP-1 and GPR120 in HFF NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR120 and (D) combined fluorescence of GLP-1 and 
GPR120 in HFF NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 
































































Effect of HFF diet on GPR120 gene expression in male NIH Swiss mouse small intestine. Results 














Figure 5.18: Double immunofluorescence staining of GIP and GPR120 in pGIPneo STC-1 
cells 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR120 and (D) combined fluorescence of GIP and 
GPR120 in pGIPneo STC-1 cells. Images are taken at x200 magnification and examples of positive 











Figure 5.19: Double immunofluorescence staining of GIP and GPR120 in lean NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR120 and (D) combined fluorescence of GIP and 
GPR120 in lean NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 











Figure 5.20: Double immunofluorescence staining of GIP and GPR120 in HFF NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR120 and (D) combined fluorescence of GIP and 
GPR120 in HFF NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 














Figure 5.21: Double immunofluorescence staining of PYY and GPR120 in STC-1 cells 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR120 and (D) combined fluorescence of PYY and 
GPR120 in STC-1 cells. Images are taken at x200 magnification and examples of positive staining 














Figure 5.22: Double immunofluorescence staining of PYY and GPR120 in lean NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR120 and (D) combined fluorescence of PYY and 
GPR120 in lean NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 
















Figure 5.23: Double immunofluorescence staining of PYY and GPR120 in HFF NIH Swiss 
mouse small intestine 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR120 and (D) combined fluorescence of PYY and 
GPR120 in HFF NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 













Figure 5.24: Effect of GPR120 Agonists on GPR120, proglucagon and PC1 gene expression in 
GLUTag cells 































































Effects of GPR120 agonists on GPR120 (A) proglucagon (B) and PC1 (C) gene expression in 
intestinal GLUTag cells at 2mM glucose. Results are ± SEM (n=3). *p<0.05, ** p<0.01 and 













































































































































































Glucose (18mmol/kg BW) or glucose in combination with a GPR120 agonist (0.1μmol/kg BW) 
were administered orally to male Swiss TO mice (n=6). (A) Plasma GLP-1 of mice treated with 













































































Glucose (18mmol/kg BW) or glucose in combination with a GPR120 agonist (0.1μmol/kg BW) 
were administered orally to male Swiss TO mice (n=6). (A) Plasma GIP of mice treated with DHA 







Figure 5.27: Acute effects of oral administration of GPR120 agonist DHA on blood glucose in 
male Swiss TO mice 
A. 







Glucose + 50mg/kg Sitagliptin
0.1mol/kg DHA
0.1mol/kg DHA + 50mg/kg Sitagliptin
































































































Glucose + 50mg/kg Sitagliptin
0.1mol/kg DHA
0.1mol/kg DHA + 50mg/kg Sitagliptin




































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with DHA (0.1μmol/kg BW), glucose in combination with DHA and the 
GPR120 antagonist AH7614 (0.1μmol/kg BW), glucose in combination with DHA and Sitagliptin 
Phosphate or saline (0.9% NaCl (w/v)) in combination with a DHA were all administered orally to 
male Swiss TO mice (n=6). (A) Blood glucose of mice treated with DHA (B) AUC of A. * p<0.05, 
** p<0.01 and *** p<0.001 compared to glucose alone. + p<0.05 and +++ p<0.001 compared to 




Figure 5.28: Acute effects of oral administration of GPR120 agonist GW9508 on blood glucose 
in male Swiss TO mice 
A. 







Glucose + 50mg/kg Sitagliptin
0.1mol/kg GW9508
0.1mol/kg GW9508 + 50mg/kg Sitagliptin



















































































Glucose + 50mg/kg Sitagliptin
0.1mol/kg GW9508
0.1mol/kg GW9508 + 50mg/kg Sitagliptin
0.1mol/kg GW9508 + 0.1mol/kg AH7614
***
**

































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with GW9508 (0.1μmol/kg BW), glucose in combination with GW9508 
and the GPR120 antagonist AH7614 (0.1μmol/kg BW), glucose in combination with GW9508 and 
Sitagliptin Phosphate or saline (0.9% NaCl (w/v)) in combination with GW9508 were all 
administered orally to male Swiss TO mice. (A) Blood glucose of mice treated with GW9508 (B) 
AUC of A. * p<0.05, ** p<0.01 and *** p<0.001 compared to glucose alone. + p<0.05 and ++ 

















































































































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with DHA (0.1μmol/kg BW), glucose in combination with DHA and the 
GPR120 antagonist AH7614 (0.1μmol/kg BW), glucose in combination with DHA and Sitagliptin 
Phosphate or saline (0.9% NaCl (w/v)) in combination with DHA were all administered orally to 
male Swiss TO mice (n=6). (A) Plasma insulin of mice treated with DHA (B) AUC of A. * p<0.05 
and *** p<0.001 compared to glucose treatment alone. + p<0.05 and ++ p<0.01 compared to agonist 
in combination with antagonist. ΔΔ P<0.01 and ΔΔΔ p<0.001 compared to glucose and Sitagliptin. 
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Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with GW9508 (0.1μmol/kg BW), glucose in combination with GW9508 
and the GPR120 antagonist AH7614 (0.1μmol/kg BW), glucose in combination with GW9508 and 
Sitagliptin Phosphate or saline (0.9% NaCl (w/v)) in combination with GW9508 were all 
administered orally to male Swiss TO mice (n=6). (A) Plasma insulin of mice treated with GW9508 
(B) AUC of A. * p<0.05, ** p<0.01 and *** p<0.001 compared to glucose treatment alone. + p<0.05 
compared to agonist treatment in combination with the GPR120 antagonist AH7614. Δ p<0.05 




Figure 5.31: Effects of GPR120 agonists on feeding in trained male Swiss TO mice 
A.  
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0.9% NaCl + 0.1mol/kg BW GW9508






















 Saline (0.9%) or saline and a GPR120 agonist (0.1μmol/kg BW) were administered orally to Swiss 
TO mice which had been trained to eat for 3 hrs daily (n=8). * p<0.05, **p<0.01 and *** p<0.001 












Investigating the acute and long term 
effects of GPR55 activation on incretin 










6.1: Overview of results 
Novel cannabinoid receptor GPR55 is expressed throughout the body and may regulate a variety of 
physiological processes. Activation of GPR55 by fatty acids has been shown to have an 
insulinotropic effect both in vitro and in vivo as well as after acute and long term administration. 
Recently research has been published demonstrating the effect of GPR55 activation by LPI on GLP-
1 secretion. The effects of GPR55 activation on GIP and PYY have yet to be elucidated, however 
administration of Abn-CBD in GIP receptor knockout mice has shown that GPR55 agonists may 
play a role in GIP secretion. The current study investigates the effects of GPR55 agonists on 
intestinal hormone secretion in various cell lines in vitro while also examining these effects in vivo. 
In order to confirm that GPR55 agonists are non-toxic, cytotoxicity was determined by Alamar Blue 
and MTT assay. The expression of GPR55 in vitro and ex vivo was determined using 
immunofluorescence and qPCR. The in vivo effects of Abn-CBD and AM251 (0.1μM/kg BW) were 
determined in fasted male Swiss TO mice (n=6) both alone and each in combination with Sitagliptin 
(50mg/kg BW). The biological effects of chronic treatment of GPR55 agonist Abn-CBD both as a 
monotherapy and a combination therapy with Sitagliptin were examined in straptozotocin induced 
diabetic Swiss TO mice (n=6). 
Treatment of GLUTag cells with GPR55 agonists in 2mM glucose increased GLP-1 secretion in 
vitro. Abn-CBD increased GLP-1 secretion 1.7 to 2.4-fold (10-8-10-4M, p<0.05) and this was 
decreased 1.4 to 1.7-fold (10-8-10-4M, p<0.05). AM251, increased GLP-1 secretion 1.4 to 1.7-fold 
(10-8M to 10-6M, p<0.01-p<0.001) compared to 2mM glucose and this was reduced 1.7to 2.1-fold 
(10-10 to 10-6M, p<0.01) in the presence of 10-5M CBD. PEA increased GLP-1 secretion from 
GLUTag cells 1.3 to 2.5-fold (10-8M to 10-4M, p<0.01 to p<0.001) compared to basal control with 
the addition of 10-5M CBD reducing the effect of PEA agonism by 1.6, 1.4 and 1.9-fold (10-8 to 10-
4M, p<0.05 to p<0.001). OEA (10-6 to 10-4M) promoted GLP-1 secretion 1.8 to 2.0-fold (p<0.001) 
compared to 2mM glucose. In the presence of 10-5M CBD, GLP-1 secretion decreased 1.4-fold at 
10-6M and 10-4M respectively (p<0.05). AM251 was the most potent agonist tested with an EC50 
value of 5.9 x 10-9M followed by Abn-CBD (EC50 = 2.4 x10-6M), OEA (EC50 = 2.1 x 10-6M) and 
PEA (EC50 = 1.21x10-6M).  
In pGIPneo STC-1 cells treated with GPR55 agonists, GIP secretion was not affected by either Abn-
CBD or AM251 when compared to 2mM glucose. The endogenous agonists OEA and PEA 
increased GIP secretion 1.1 and 1.7-fold (10-6 to 10-4M, p<0.05 to p<0.01) and 1.1 to 1.8-fold (10-
8M to 10-6M, p<0.05) respectively. The effect of OEA (10-6M) was reduced 41.1% (p<0.01) by 10-
5M CBD, while the effect seen by PEA (10-6M) was reduced by 31.0% (p<0.05). 
All agonists tested demonstrated the ability to increase insulin secretion from pancreatic BRIN-
BD11 cells. Synthetic GPR55 agonists Abn-CBD and AM251 increased insulin secretion 1.2 to 2.4-
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fold from 10-9 to 10-4M (p<0.05-p<0.001) and 1.4 to 1.7-fold (10-8-10-4M, p<0.01-p<0.001) 
respectively in 5.6mM glucose. The endogenous GPR119 agonists OEA and PEA increased insulin 
secretion in BRIN-BD11 cells from 1.4 to 2.2 fold (10-8-10-4M, p<0.05-p<0.001) and 1.1 to 1.5-fold 
from 10-8 to 10-4M (p<0.05-p<0.001) in 5.6mM glucose. In 5.6mM glucose, the most potent agonist 
tested as determined by EC50 was AM251 (5.27x10-9M) followed by Abn-CBD (5.53x10-8M), OEA 
(2.83x10-7M) and PEA (1.6x10-7M). 
Abn-CBD demonstrated a 1.4 to 2.4-fold (p<0.05-p<0.001) increase in insulin secretion while 
AM251 exhibited a 1.4 to 2.2-fold (10-7-10-4M, p<0.05-p<0.001) insulinotropic effect in 16.7mM 
glucose. OEA increased insulin secretion 1.1 to 1.7-fold (10-10-10-4M, p<0.05-p<0.001) while PEA 
demonstrated a 1.2 to 1.7-fold increase (10-8-10-4M, p<0.05-p<0.001) compared to 16.7mM 
glucose. PEA (7.7x10-8M) was the most potent agonist in 16.7mM glucose followed by Abn-CBD 
(7.83x10-7M) and OEA (1.3x10-7M). AM251 (1.35x10-6M) was the least potent agonist tested in 
16.7mM glucose.  
GPR55 was found to be co-localised with GLP-1 and PYY in the L cells of the intestine and GIP in 
the K cells of the intestine as determined by double immunofluorescent staining. Treatment with 
GPR55 agonists increased GPR55 gene expression in GLUTag cells. AM251 (10-4M) increased 
GPR55 expression 1.3-fold (p<0.01) while Abn-CBD (10-4M) and OEA (10-4M) demonstrated a 
1.2-fold (p<0.05 to p<0.01) increase compared to vehicle control. In male NIH Swiss mouse small 
intestine, GPR55 expression was reduced 58.9% (p<0.05).  
GPR55 agonists Abn-CBD and AM251 (0.1μmol/kg body weight) were administered orally to 
fasted male Swiss TO mice and increased insulin secretion and lowered blood glucose. Abn-CBD 
reduced blood glucose 22% (p<0.001) and 36.3% (p<0.001) after 15 and 30 mins post 
administration. Administration of Abn-CBD along with GPR55 antagonist CBD confirmed the 
selectivity of Abn-CBD for GPR55 as insulin secretion was increased 25.2% (p<0.05) in the 
presence of CBD. AM251 reduced blood glucose 34.6% (p<0.001) 30 mins post administration 
compared to glucose. Sitagliptin reduced glycaemic excursion by 24% after 30 mins when 
administered with glucose. Abn-CBD in combination with Sitagliptin reduced blood glucose 
reductions of 53.5%, 65.2%, 49.1%, 44.9% and 48.5% (p<0.001) 15, 30, 60, 90 and 120 mins post 
administration. AM251 with Sitagliptin reduced blood glucose 32.0% (p<0.001) and 43.9% 
(p<0.001) 15 and 30 mins post administration respectively. 
Both Abn-CBD and AM251 increased GLP-1 secretion 15 and 30 mins post administration with 
increases of 2.1 and 3.2-fold (p<0.001) being observed 15 and 30 mins post administration for Abn-
CBD and 1.6 and 2.5-fold (p<0.001) increases in GLP-1 secretion being observed for AM251. 
Overall Abn-CBD displayed a 2.2-fold increase in GLP-1 secretion (p<0.001) while AM251 
increased GLP-1 secretion 1.6-fold (p<0.001). Abn-CBD increased GIP secretion 2.5-fold 
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(p<0.001) 15 mins post administration while AM251 had no effect. Abn-CBD reduced appetite 23% 
(p<0.05) while AM251 in combination with Sitagliptin reduced appetite 15% (p<0.05) Sitagliptin 
alone had no effect on appetite. 
Insulin secretion increased 1.5-fold (p<0.05) and 2.6-fold (p<0.001) 15 and 30 mins in Swiss TO 
mice post Abn-CBD administration. Abn-CBD with Sitagliptin increased insulin 2.9-fold increase 
30 mins post administration (p<0.001). Overall Abn-CBD increased insulin secretion 1.7-fold 
(p<0.001) while Abn-CBD in combination with Sitagliptin increased insulin secretion 1.5-fold 
(p<0.001). AM251 administration increased insulin secretion 1.8-fold (p<0.01) and 2.6-fold 
(p<0.001) after 15 and 30 mins respectively while AM251 with Sitagliptin augmented insulin 
secretion 1.3-fold 30 mins post gavage (p<0.001). Overall AM251 increased insulin secretion 3.0-
fold (p<0.001) while AM251 in combination with Sitagliptin increased insulin secretion 2.6-fold 
(p<0.001). 
Streptozotocin induced diabetic Swiss TO mice exhibited hyperglycaemia as the demonstrated a 
1.7-fold (p<0.01) increase in blood glucose after 18 hrs of fasting and a 2.2-fold (p<0.001) increase 
in non-fasting blood glucose. Higher blood glucose levels were exhibited in streptozotocin induced 
diabetic mice compared to lean mice during an oral glucose tolerance test with increases of 1.3, 1.6, 
1.6, 1.8 and 1.9-fold at 15, 30, 60, 90 and 120 mins post administration respectively (p<0.05-
p<0.001). The overall increase in blood glucose of streptozotocin induced diabetic mice was 1.6-
fold (p<0.001) as determined by AUC. Streptozotocin treatment resulted in a 1.1-fold (p<0.001) 
reduction in body weight while lean mice exhibited no reduction. 
Streptozotocin induced diabetic mice treated with saline had in increased blood glucose for the 
duration of the study (p<0.001). Daily treatment with Abn-CBD reduced blood glucose 1.4-fold 
overall (p<0.01) while Abn-CBD and Sitagliptin combination therapy resulted in a 1.1-fold 
reduction (p<0.05) in blood glucose. Abn-CBD treatment increased insulin secretion 2.4-fold 
(p<0.001) over the course of the study while Abn-CBD and Sitagliptin combination therapy in a 
2.1-fold increase (p<0.001). Abn-CBD and Abn-CBD in combination with Sitagliptin increased 
circulating incretin hormones with overall increases of 1.5 (p<0.01) and 1.4-fold (p<0.01) being 
observed for respectively GLP-1. Circulating GIP was increased 1.2-fold (p<0.001) in Abn-CBD 
treated mice while Abn-CBD in combination with Sitagliptin augmented circulating GIP levels 1.3-
fold increase (p<0.001). 
When challenged with glucose, Abn-CBD monotherapy and Abn-CBD combination therapy with 
Sitagliptin reduced blood glucose 1.4 (p<0.01) and 1.5-fold (p<0.001) when compared to 
streptozotocin mice dosed with saline over the course of the study. These treatments also increased 
insulin secretion over the course of this glucose tolerance test with 1.4-fold (p<0.001) increases 
being observed overall.  
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Streptozotocin induced diabetic mice had a 1.1-fold increase in body weight compared to lean mice 
(p<0.05). Abn-CBD administration reduced body weight 1.1-fold (p<0.01) compared to diabetic 
mice. Abn-CBD monotherapy or Abn-CBD with Sitagliptin reduced fat mass compared to diabetic 
mice (p<0.05) as well as lean (p<0.01). This correlated into a 1.3-fold and a 1.6-fold decrease in 
body fat percentage compared to lean mice (p<0.05).  
The research outlined in this study demonstrates that activation of GPR55 plays an important role 
in glucose homeostasis, β-cell function and incretin hormone regulation. Targeting this receptor 
with small molecules such as specific FFA agonists that increase enteroendocrine and pancreatic 
hormone secretion may be a novel therapy for Type 2 Diabetes. 
 
6.2: Introduction 
GPR55 is part of the purin receptor cluster of the γ-group of Class A rhodopsin-like GPCRs 
(Fredriksson et al. 2003b). GPR55 was first described in 1999 after its identification from the 
expressed sequence tags database (Sawzdargo et al. 1999). This research described how the GPR55 
gene, which is present on chromosome 2q36.3, encodes a receptor consisting of 319 amino acids. 
It is most closely related to GPR35, GPR23 and purinoceptor P2Y5. Despite having low sequence 
homology with the cannabinoid receptors CB1 and CB2 and the lack of the cannabinoid receptor 
pocket (Petitet, Donlan & Michel 2006), GPR55 is still described as a putative cannabinoid receptor 
due to its ability to bind atypical cannabinoids (Yang, Zhou & Lehmann 2016). Low sequence 
identity is common for GPCRs within the purin receptor cluster however GPR55 does share higher 
sequence homology with a range of GPCRs in this group (Fredriksson et al. 2003b). The expression 
of GPR55 is widespread throughout the body including the brain, dorsal root ganglion neurons, 
adrenal glands, gastrointestinal tract and pancreas (Sawzdargo et al. 1999, Lauckner et al. 2008, 
Ryberg et al. 2007, McKillop et al. 2013). 
GPR55 was recognised as an orphan receptor until the identification of its endogenous ligand 
lysophosphatidylinositol (LPI) (Oka et al. 2007). However the ability of LPI to stimulate the growth 
of cancer cells in ovarian cancer means its use as a therapeutic aid is limited and other ligands are 
sought after (Hofmann et al. 2015). Three of the first ligands to be identified were Abn-CBD, O1602 
and CP55940 (Johns et al. 2007, Ryberg et al. 2007) closely followed by AM251 and SR141716A 
(Kapur et al. 2009). The search for new ligands has focused on cannabinoids however researchers 
are now looking further afield with promising results (Heynen-Genel et al. 2010). Searching 
through cannabinoids identified a GPR55 antagonist, CBD, which is highly selective for GPR55 
(Sylantyev et al. 2013). 
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GPR55 binds to several different G-proteins as it has been shown to bind to Gα12 or Gαq (Lauckner 
et al. 2008) as well as Gα13 (Henstridge et al. 2009). This results in GPR55 being able to affect 
several different signalling cascades as it can activate a number of different downstream signalling 
events such as PLC, RhoA, ROCK, ERK, p38 mitogen activated protein kinase, and Ca2+ release 
(Shore, Reggio 2015). These signalling cascades are thought to be agonist dependent. 
As GPR55 is expressed throughout the body it is involved in a wide range of physiological 
processes. In the intestine GPR55 has been implicated in gut motility (Lin et al. 2011), inflammatory 
bowel diseases (Schicho et al. 2010, Wlodarczyk et al. 2017) and hormone secretion (Harada et al. 
2017). Knockout of GPR55 leads to increased bone mass and GPR55 antagonism reduced bone 
resorption thus demonstrating a role for GPR55 in bone formation and thus confirming GPR55 as 
a receptor for CBD (Whyte et al. 2009). Activation of GPR55 by O-1602 lead to reduced colitis 
and neutrophil recruitment (Schicho et al. 2010) while other research has shown GPR55 helps CB2 
to recruit neutrophils to sites of inflammation whilst reducing the proinflammatory response 
mediated by ROS production due to CB2 activation (Balenga et al. 2011). GPR55 knockout mice, 
which had no obvious phenotypic differences from their GPR55+/+ littermates, had increased 
cytokines and reduced response to pain compared to mice with GPR55 (Staton et al. 2008). This 
research demonstrates that GPR55 may play a role in inflammation and also demonstrates a need 
for further research into the mechanisms behind cannabinoid receptor signalling. Due to the receptor 
independent effects of cannabinoids on vasculature (White, Hiley 1998) it was suggested that these 
effects were through another cannabinoid receptor. However it has since been proven that GPR55 
has no effect on vasodilation whilst activated by cannabinoids (Johns et al. 2007). GPR55 was found 
to be highly expressed in the MDA-MB-231 breast cancer cell line, with activation by LPI resulting 
in increased cell motility with this effect being prevented when GPR55 was targeted with siRNA 
(Ford et al. 2010). It has also been shown to contribute to an autocrine loop driving the proliferation 
of cells in prostate and ovarian cancer cell lines (Pineiro, Maffucci & Falasca 2011) as well as being 
upregulated in skin cancers (Perez-Gomez et al. 2013). Therefore, GPR55 agonists may be novel 
cancer biomarkers while targeting GPR55 may disrupt the migration and invasiveness of tumours.  
Chronic Type 2 Diabetes may lead to increased inflammation and further complications such as 
nephropathy, neuropathy and retinopathy. GPR55 has previously been shown to have a beneficial 
effect on inflammation (Staton et al. 2008) as well as insulin secretion (McKillop et al. 2013, 
McKillop et al. 2016). This has led to the discovery of increased GPR55 expression in disorders 
such as Crohn’s disease or ulcerative colitis (Wlodarczyk et al. 2017). Previous work carried out in 
our lab has indicated that activation of GPR55 by Abn-CBD increase incretin hormone secretion 
and may play a role in glucose homeostasis through both direct and indirect actions on the pancreas 
(McKillop et al. 2016). Antagonism of the cannabinoid receptor CB1 has also previously been 
shown to be a successful strategy for the reduction of food intake (Reimann, Tolhurst & Gribble 
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2012) however, due to the serious side effects of rimonobant, other therapeutic targets are sought. 
As another cannabinoid receptor, GPR55 is therefore an attractive target in metabolic disorders such 
as Type 2 Diabetes and obesity. 
While previous work has focused on the effect of GPR55 on glucose homeostasis through direct 
action on the pancreas, there are no studies currently published on the effects of GPR55 activation 
on incretin and intestinal hormone regulation. The effects of GPR55 activation by synthetic (Abn-
CBD and AM251) and endogenous agonists (OEA and PEA) on GLP-1 and GIP secretion in both 
GLUTag and pGIPneo STC-1 cells, respectively, was determined. Agonists were administered in 
combination with the GPR55 antagonist CBD (10-5M) to assess agonist specificity. The effects of 
GPR55 agonists on GPR55, proglucagon, GIP and PC1/3 gene expression was also determined in 
GLUTag cells. The biological effects of Abn-CBD and AM251 alone and in combination with the 
DPP-IV inhibitor Sitagliptin on pancreatic and intestinal hormone secretion were ascertained in lean 
and streptozoticin induced diabetic mice, complemented by receptor expression studies. 
 
6.3: Materials and methods 
 
6.3.1: Materials 
Abn-CBD (CAY10429, ab144464), OEA (ab141141), PEA (ab120345) and CBD (ab120448) were 
purchased from Abcam (Cambridge, UK). Multi species GLP-1 total and rat/mouse GIP total 
ELISA kits were purchased from Merck Millipore (Watford, UK). 
 
6.3.2: Acute hormone secretion from intestinal cell lines 
GLUTag or pGIPneo STC-1 cells were seeded into 24-well plates with 150000 cells per well which 
were incubated overnight in 1ml of culture medium (as described previously in Chapter 2, section 
2.1) at 37°C and 5% CO2. To ensure that cells grew in monolayers, they were pipetted up and down 
vigorously to ensure proper mixing before seeding. After overnight incubation and preincubation 
with 1.1mM glucose for 40 mins, acute incubations were carried out at 37°C 5% CO2 for 2 hrs in 
2mM glucose in KRBB buffer supplemented with 10-12 to 10-4M concentrations of Abn-CBD, 
AM251, OEA and PEA. After incubations, supernatants (950μl) were collected and frozen at -20°C 





6.3.3: Acute insulin secretion from pancreatic BRIN-BD11 cells 
Cells were seeded in 24-well plates with 150000 BRIN-BD11 cells per well and incubated overnight 
in 1ml of RPMI 1640 media at 37°C and 5% CO2. Following this incubation, cells were 
preincubated with 1.1mM glucose for 40 mins with subsequent acute incubations being carried out 
at 37°C 5% CO2 for 20 mins in 5.6mM and 16.7mM glucose in KRBB buffer supplemented with 
10-12 to 10-4M concentrations of Abn-CBD, AM251, OEA and PEA with 10mM alanine as a positive 
control. After incubations, supernatants (950μl) were collected and frozen at -20°C until 
radioimmunoassay could be carried out as described in Chapter 2, section 2.2. 
 
6.3.4: Acute effects of GPR55 on cell toxicity 
Cells were seeded in 96-well plates with 40000 cells per well of GLUTag, pGIPneo STC-1 or BRIN-
BD11 cells and incubated overnight in cell culture media (as described in Chapter 2, section 2.1) in 
an atmosphere of 5% CO2 at 37°C. After 20hrs, BRIN-BD11 cells were preincubated with 1.1mM 
glucose for 40 mins with subsequent acute incubations being carried out at 37°C 5% CO2 for 20 
mins in 5.6mM and 16.7mM glucose in KRBB buffer supplemented with 10-12M to 10-4M 
concentrations of GPR55 agonist with 1mM H2O2 as a cytotoxic control (n=3). After 48hrs, 
GLUTag and pGIPneo STC-1 cells were preincubated with 1.1mM glucose for 40 mins with 
subsequent acute incubations being carried out at 37°C 5% CO2 for 2 hrs in 2mM in KRBB buffer 
supplemented with 10-12M to 10-4M concentrations of GPR55 agonists with 1mM H2O2 as a 
cytotoxic control (n=3). After incubation, supernatant was decanted, cells were washed with HBSS 
and 0.5mg/ml MTT was added for 2 hrs. Following MTT incubation, supernatant was discarded 
and DMSO was added to solubilise crystals. Optical density was subsequently measured at 570nm 
and 630nm using the Flexstation 3 (Molecular Devices, CA, USA).  
 
6.3.5: Immunofluorescence staining in GLUTag, pGIPneo STC-1, STC-1 cells and lean and HFF 
NIH Swiss mouse small intestine 
GLUTag, pGIPneo STC-1 and STC-1 cells were seeded at a density of 40000 cells on to polylysine 
coated slides overnight at 37°C in an atmosphere of 95% air and 5% CO2 as described in Chapter 2, 
section 2.1. Swiss TO mice were anesthetised by isoflurane and killed by cervical dislocation. 
Pancreas and intestine was excised as described in Chapter 2, section 2.6.3. Immunohistochemistry 
was carried out by incubating with rabbit polyclonal anti-GPR55 and goat polyclonal anti-GLP-1, 




6.3.6: Quantitative real-time PCR (qPCR) 
qPCR was performed using LightCycler® 480 SYBR Green I Master. Reactions were performed 
using 4.5μl of 2x concentrated SYBR green, 1μl of forward and reverse primers (primer sequences 
are listed in Chapter 2, Table 2.2), 1μl of cDNA and 3μl of RNase free water (n=3). All reactions 
included a negative template control with RNase free water added instead of cDNA (n=3). The 
reactions were carried out in 8-well real-time PCR Tube Strips and Masterclear™ Cap Strips 
(Eppendorf, HAM, DE). Amplification conditions were 5 mins initial denaturation at 95°C, 
followed by 40 cycles of 30 secs denaturation at 95°C, 30 secs annealing at 58°C and 30 secs 
extension at 72°C and a final elongation step for 5 mins at 72°C. Reactions included melting curve 
analysis with temperature range of 60 °C to 90 °C. All reactions were carried out using the 
MiniOpticon two colour real time PCR detection system (BioRad, UK). Analysis of results was 
performed using the Livak method and the mRNA levels of all genes were normalised using the 
housekeeping gene GAPDH. 
 
6.3.7: Acute in vivo oral glucose tolerance tests 
Male Swiss TO mice were housed as described in Chapter 2, section 2.7. The effects GPR55 
agonists Abn-CBD and AM251 (0.1μmol/kg BW), as well as in combination with Sitagliptin 
phosphate (50mg/kg BW) or CBD (0.1μmol/kg BW) in lean male Swiss TO mice were investigated. 
Before test compounds were administered mice were fasted for 18 hrs and blood subsequently 
collected (t=0). Test compounds were administered orally in glucose (18mmol/kg BW), and blood 
was collected at 15, 30, 60, 90 and 120 mins along with blood glucose measurements. Collected 
blood was centrifuged at 13200rpm for 5 mins at 4°C using a Beckman centrifuge (Beckman 
Instruments, UK). Plasma was stored at -20°C until hormone measurements by RIA or ELISA as 
described in Chapter 2, section 2.3. 
 
6.3.8: Multiple low dose streptozotocin induced-diabetic mice 
Age-matched (26 wks), male Swiss TO mice were sourced from Envigo (Huntingdon, UK). Mice 
were housed in single cages and were supplied drinking water and standard rodent maintenance diet 
(60% carbohydrate, 30% protein, 10% fat (12.99 kJ/g), Trouw Nutrition, Cheshire, UK) ad libitum. 
Diabetes was chemically induced in 4 hr fasted Swiss TO mice through 4 intraperitoneal injections 
of streptozotocin (40mg/kg body weight, 0.1M sodium citrate, pH 4.5) which were received on 
alternate days. Diabetes was confirmed through an oral glucose tolerance test (OGTT) which was 
performed 14 days after the first injection of streptozotocin injection (day 0) on 18 hr fasted Swiss 
TO mice.  
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6.3.9: Treatment procedure and parameters assessed  
The long term effects of oral Abn-CBD (0.1µmol/kg BW) or saline (0.9% w/v NaCl) in multiple 
low dose streptozotocin-induced diabetic Swiss TO mice (n=6) was assessed over a period of 21 
days. Hyperglycaemia was confirmed in diabetic mice through an oral glucose tolerance test which 
was performed 14 days after the first streptozotocin injection (day 0) on 18 hr fasted NIH Swiss 
mice as previously described (Chapter 2, section 2.8.2). Fluid intake, food intake, body weight, non-
fasted blood glucose, insulin, GLP-1 and GIP concentrations were monitored every 3 days. Blood 
was collected via tail vein bleeding of conscious mice and was collected and analysed for blood 
glucose, insulin, GLP-1 and GIP as described in Chapter 2, section 2.8.4. After the testing period, 
glucose tolerance tests (18mmol/kg body weight) were carried out to assess glucose tolerance on 
18 hr fasted streptozotocin treated mice and Swiss TO mice on standard rodent maintenance diet as 
outlined in Chapter 2, Section 2.8.2. 
 
6.3.10: Measurement of plasma hormones 
Blood was collected via tail vein bleed on conscious mice every 3 days for biochemical analysis on 
a variety of hormones. Blood glucose determination was performed using a Bayer Contour Next 
meter (Leverkusen, DE) every 3 days. Plasma insulin was quantified using insulin RIA as 
previously described in Chapter 2, section 2.2. Rat/mouse GIP total ELISA kit (Millipore, Watford, 
UK) was used to measure total GIP concentrations in mouse plasma following chronic treatment. 
Multi species GLP-1 total ELISA was used to measure total GLP-1 content of mouse plasma. These 
sandwich based ELISAs are described in detail in Chapter 2, section 2.3. 
 
6.3.11: Insulin sensitivity   
Prior to the injection of insulin, blood glucose was measure in non-fasted Swiss TO mice via tail 
vein bleeding using the Bayer Contour glucose meter. Bovine insulin (25U/kg) in 0.9% saline was 
administered using intraperitoneal injection of bovine insulin (25U/kg) and blood glucose was 
monitored at 30 and 60 mins post injection.   
 
6.3.12: Dual energy X-ray absorption (DEXA)  
Non-fasted Swiss TO mice were culled by cervical dislocation after being anesthetised using 
isoflurane, and subsequently arranged on the specimen tray to ensure both limbs and tail were 
extended away from the body. In order to ensure calibration and quality control, 25 measures of the 
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aluminium/lucite phantom (0.069g/cm2, 12.0% fat) were taken using a Lunar PIXImus Dual energy 
X-ray absorption (DEXA) system (software version 1.4x) before any specimens were measured. 
DEXA scanning was performed on all carcasses as per manufacturer’s guidelines. The Lunar 
PIXImus DEXA system measures percentage body fat as well as bone mineral density (BDM, 
g/cm3) and bone mineral content (BMC, g) using a fully integrated densitometer.  
 
6.3.13: Assessment of plasma lipid profiles  
Plasma triglyceride and HDL cholesterol concentrations were measured using an I-lab 650 clinical 




6.4.1: Effects of GPR55 agonists and antagonist CBD on GLP-1 secretion from intestinal GLUTag 
cells 
The effects of endogenous GPR55 agonists OEA and PEA and synthetic agonists Abn-CBD and 
AM251 along with GPR55 antagonist CBD on GLP-1 secretion from GLUTag cells was 
investigated in 2mM glucose. Synthetic agonist Abn-CBD demonstrated a 1.7 to 2.4-fold (10-8-10-
4M, p<0.05) increase in GLP-1 secretion from GLUTag cells compared to 2mM glucose basal 
control (Figure 6.1A). When tested in combination with the GPR55 agonist CBD (10-5M), GLP-1 
secretion was reduced to basal levels with a 1.4 to 1.7-fold (10-8-10-4M, p<0.05) decrease in 
secretion being observed.  
The other synthetic GPR55 agonist, AM251, increased GLP-1 secretion 1.4 to 1.7-fold (10-8M to 
10-6M, p<0.01-p<0.001) compared to basal control (Figure 6.2A). The addition of 10-5M CBD 
decreased GLP-1 secretion at all concentrations tested. The largest decrease in GLP-1 secretion was 
demonstrated at 10-6M and 10-8M AM251, where a 2.1-fold decrease in secretory ability was 
detected (p<0.01 to p<0.001). At the lowest concentration of AM251 tested (10-10M), there was a 
1.7-fold decrease in GLP-1 secretion compared to the absence of CBD (p<0.01). 
PEA (Figure 6.4A) was the most potent endogenous GPR55 agonist in augmenting GLP-1 
secretion. GLP-1 secretion from GLUTag cells was increased 1.3 to 2.5-fold compared to basal 
control (10-8M to 10-4M, p<0.01 to p<0.001), with the addition of 10-5M CBD reducing the effect 
of PEA agonism by 1.6, 1.4 and 1.9-fold (p<0.05 to p<0.001)  
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The other endogenous GPR55 agonist tested, OEA (10-6 to 10-4M), promoted GLP-1 secretion 1.8 
to 2.0-fold (p<0.001) compared to 2mM glucose (Figure 6.3A). In the presence of 10-5M CBD, 
GLP-1 secretion decreased 1.4-fold compared to OEA treatment alone at 10-6M and 10-4M 
respectively (p<0.05).  
AM251 was the most potent agonist tested with an EC50 value of 5.9 x 10-9M. The other synthetic 
agonist, Abn-CBD (EC50 = 2.4 x10-6M), was more potent than the endogenous agonists tested. The 
most potent endogenous agonist was OEA (EC50 = 2.1 x 10-6M) with PEA the least potent of all 
agonists (EC50 = 1.21x10-6M). All agonists tested showed no adverse effect on cell viability as 
measured by MTT assay (Figures 6.1B-6.4B). 
 
6.4.2: Effects of GPR55 agonists and antagonist CBD on GIP secretion from intestinal pGIPneo 
STC-1 cells 
Intestinal pGIPneo STC-1 cells were treated with both synthetic, Abn-CBD (Figure 6.5A) and 
AM251 (Figure 6.6A), and endogenous, OEA (Figure 6.7A) and PEA (Figure 6.8A), GPR55 
agonists to assess the effect of GPR55 activation on GIP secretion from the K cells of the intestine. 
Both synthetic agonists tested demonstrated no ability to increase GIP secretion compared to the 
vehicle control (2mM glucose). The endogenous agonist OEA (Figure 6.7A) increased GIP 
secretion 1.1 and 1.7-fold (10-6 to 10-8M, p<0.05 to p<0.01). In the presence of 10-5M CBD, this 
effect was reduced 41.1% (p<0.01). PEA promoted the secretion of GIP from pGIPneo STC-1 cells 
as a 1.1 to 1.8-fold increase was observed (10-6M to 10-4M, p<0.05). In the presence of GPR55 
antagonist 10-5M CBD, the effect of PEA (10-4M) on GIP secretion was reduced by 31.0% (p<0.05) 
(Figure 6.8A). All agonists tested demonstrated no cytotoxic effects as measured by MTT assay 
(Figures 6.5B-6.8B). Interestingly, both Abn-CBD (10-6M to 10-4M, Figure 6.5B) and AM251 (10-
8M to 10-4M, Figure 6.6B) demonstrated an increased K-cell viability (p<0.05). 
 
6.4.3: Effects of GPR55 agonists on insulin secretion from pancreatic BRIN-BD11 cells 
The insulinotropic ability of the synthetic GPR55 agonists Abn-CBD and AM251, as well as 
endogenous agonists OEA and PEA were tested at both 5.6 and 16.7mM glucose in pancreatic 
BRIN-BD11 cells (Figures 6.9A-6.16A). In normoglycaemic conditions synthetic agonist, Abn-
CBD (Figure 6.9A), increased insulin secretion 1.2 to 2.4-fold from 10-9 to 10-4M (p<0.05-p<0.001). 
The other synthetic GPR55 agonist, AM251 (Figure 6.11A), increased insulin secretion 1.4 to 1.7-
fold (10-8-10-4M, p<0.01-p<0.001). Endogenous agonist OEA (Figure 6.13A) increased insulin 
secretion from 1.4 to 2.2 fold in a dose dependent manner (10-8-10-4M, p<0.05-p<0.001). PEA 
(Figure 6.15A) increased insulin secretion 1.1 to 1.5-fold from 10-8 to 10-4M (p<0.05-p<0.001).  
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In hyperglycaemic conditions Abn-CBD (Figure 6.10A) increased secretion of insulin 1.4 to 2.4-
fold (p<0.05-p<0.001) while AM251 (Figure 6.12A) exhibited a 1.4 to 2.2-fold (10-7-10-4M, p<0.05-
p<0.001) insulinotropic effect. OEA (Figure 6.14A) increased insulin secretion 1.1 to 1.7-fold (10-
10-10-4M, p<0.05-p<0.001) compared to 16.7mM glucose, while PEA (Figure 6.16A) demonstrated 
a 1.2 to 1.7-fold increase (10-8-10-4M, p<0.05-p<0.001).  
The potency of all agonists tested was determined by calculation of the EC50 value (Figure 6.17A 
and 6.17B). The most potent agonist tested in 5.6mM glucose was AM251 (5.27x10-9M), closely 
followed by another synthetic agonist, Abn-CBD (5.53x10-8M). The endogenous agonists tested 
had very similar potencies for GPR55 in normal glucose conditions with OEA (2.83x10-7M) being 
more potent than PEA (1.6x10-7M). In hyperglycaemic conditions PEA demonstrated the highest 
potency (7.7x10-8M) while AM251 was the least potent agonist tested (1.35x10-6M). Abn-CBD 
(7.83x10-7M) was again more potent than OEA (1.3x10-7M). Apart from PEA, all agonists tested 
had lower potency in hyperglycaemic conditions compared to 5.6mM glucose. All agonists tested 
also demonstrated no significant effects on cell viability or proliferation (Figures 6.9B-6.16B) at 
both concentrations of glucose tested. 
 
6.4.4: Distribution of GPR55 and GLP-1 in intestinal GLUTag cells and lean and HFF NIH Swiss 
mouse small intestine 
The localisation of GPR55 in the L-cells of the intestine was examined through 
immunohistochemistry in both the intestinal GLUTag cell line and in NIH Swiss mice which have 
been fed either a lean or HFF diet. GLP-1 was expressed throughout GLUTag cells (Figure 6.18B) 
and was also present in the L-cells of the small intestine of both lean and HFF NIH Swiss mice 
(Figure 6.19B and 6.20B). The presence of GPR55 in GLUTag cells and lean and HFF NIH Swiss 
mice was also confirmed (Figure 6.18C, Figure 6.19C and Figure 6.20C). The combined 
fluorescence of both GLP-1 and GPR55 demonstrated the co-localisation of GPR55 and GLP-1 in 
intestinal L-cells (Figure 6.18D, Figure 6.19D and Figure 6.20D). qPCR confirmed the presence of 
GPR55 in both lean and HFF mouse small intestinal tissue (Figure 6.21), with a 2.5-fold decrease 
in GPR55 gene expression observed in mice on a HFF diet (p<0.05). 
 
6.4.5: Distribution of GPR55 and GIP in intestinal pGIPneo STC-1 cells and lean and HFF NIH 
Swiss mouse small intestine 
The cellular localisation of GPR55 and GIP in the K cells of the intestine was investigated through 
the immunohistochemical staining of pGIPneo STC-1 cells (Figure 6.22) and lean and HFF NIH 
Swiss mice (Figures 6.23 and 6.24). GPR55 was found to be present in the pGIPneo STC-1 cells 
203 
 
(Figure 6.22C). GIP was found to be present in both lean and HFF NIH Swiss mouse small intestine 
(Figures 6.23B and 6.24B), as was GPR55 (Figures 6.23C and 6.24C). A merge of both GPR55 and 
GIP confirmed the presence of both entities in the same K-cell (Figure 6.23D and 6.24D).  
 
6.4.6: Distribution of GPR55 and PYY in intestinal STC-1 and lean and HFF NIH Swiss mouse 
small intestine 
The presence of PYY and GPR55 in STC-1 cells (Figure 6.25) was determined through 
immunohistochemistry. PYY (Figure 6.25B) and GPR55 (Figure 6.25C) were found throughout 
STC-1 cells and combining the fluorescences of both images showed large areas of co-localisation 
of GPR55 and PYY (Figure 6.25D). GPR55 and PYY were also co-localised in both lean and HFF 
small intestine from NIH Swiss mice (Figures 6.26D and 6.27D).  
 
6.4.7: Effects of GPR55 agonists on GPR55 gene expression in intestinal GLUTag cells 
The effects of 2mM glucose and GPR55 agonists on GPR55 gene expression were examined using 
qPCR. (Figure 6.28A). AM251 (10-4M) increased GPR55 expression 1.3-fold (p<0.01) while 
AM251 and OEA up-regulated GPR55 gene expression 1.2-fold (p<0.05 to p<0.01) compared to 
2mM glucose vehicle control. 
 
6.4.8: Acute effects of GPR55 agonists on incretin hormones in male Swiss TO mice 
Mice were orally gavaged in this study in order to study the effects of GPR55 agonists on both GLP-
1 and GIP secretion. Both Abn-CBD and AM251 increased GLP-1 secretion 15 and 30 mins post 
administration (Figure 6.29A). Abn-CBD activation of the GPR55 receptor generated the highest 
effect on GLP-1 secretion, with a 2.1 and 3.2-fold increase 15 and 30 mins post administration 
respectively (p<0.001). AM251 increased GLP-1 secretion 1.6 and 2.5-fold at 15 and 30 mins post 
administration (p<0.001). Overall Abn-CBD displayed a greater effect on GLP-1 secretion as 
determined by AUC (Figure 6.29B) with a 2.2-fold increase being observed (p<0.001) while 
AM251 increased GLP-1 secretion 1.6-fold overall (p<0.001). 
Of both GPR55 agonists tested, only Abn-CBD increased GIP secretion (Figure 6.30A). At 15 mins 
post administration GIP secretion was increased 2.45-fold (p<0.001) before returning to basal levels 
30 mins post administration. AM251 provided no significant effect on GIP secretion. Overall Abn-




6.4.9: Acute effects of GPR55 agonists on blood glucose and insulin in male Swiss TO mice 
Abn-CBD and AM251 were administered to fasted male Swiss TO mice via oral gavage at 
concentrations of 0.1μmol/kg body weight. Abn-CBD (Figure 6.31A) displayed a greater effect on 
reducing blood glucose in vivo compared to AM251 (Figure 6.32A). Blood glucose was reduced by 
22% at 15 mins after Abn-CBD administration (p<0.05) and 36.3% after 30 mins (p<0.001). 
Administration of Abn-CBD along with GPR55 antagonist CBD (0.1μmol/kg BW) increased blood 
glucose 25.2% 15 mins post administration (p<0.05). AM251 (Figure 6.32A) reduced blood glucose 
34.6% (p<0.001) 30 mins post administration compared to glucose. 
The DPP-IV inhibitor Sitagliptin reduced glycaemic excursion by 24% after 30 mins when 
administered with glucose. When Abn-CBD and Sitagliptin were administered in combination 
(Figure 6.31A), blood glucose was markedly reduced at 15, 30, 60, 90 and 120 mins post 
administration with reductions of 53.5%, 65.2%, 49.1%, 44.9% and 48.5% (p<0.001). AM251 in 
combination with Sitagliptin (Figure 6.32A) reduced blood glucose 32.0% (p<0.001) and 43.9% 
(p<0.001) 15 and 30 mins post administration respectively. 
Abn-CBD administration alone increased insulin secretion 1.5-fold (p<0.05) 15 mins post 
administration (Figure 6.33A) with this effect sustained 30 mins post gavage with an increase of 
2.6-fold (p<0.001) being observed. Abn-CBD in combination with Sitagliptin resulted in a 2.9-fold 
increase on insulin secretion 30 mins post administration (p<0.001). Overall Abn-CBD increased 
insulin secretion 1.7-fold (p<0.001) while Abn-CBD in combination with Sitagliptin increased 
insulin secretion 1.5-fold (p<0.001) as determined by AUC (Figure 6.33B). 
Oral administration of AM251 (Figure 6.34A) reduced blood glucose 34.6% 30 mins post 
administration (p<0.01). When administered in combination with Sitagliptin, blood glucose was 
reduced by 30% after 15 mins (p<0.01). This effect was continued after 30 mins when blood glucose 
was reduced 44% (p<0.001). The effects on blood glucose were reduced when AM251 was 
administered alongside the GPR55 antagonist CBD (0.1μmol/kg BW). Insulin secretion increased 
1.78-fold (p<0.01) and 2.6-fold (p<0.001) 15 and 30 mins post administration respectively (Figure 
6.34A) in mice administered AM251. When AM251 was administered in combination with 
Sitagliptin, insulin was increased 1.3-fold 30 mins post gavage (p<0.001) compared to glucose 
administration alone. Overall AM251 increased insulin secretion 3.0-fold (p<0.001) while AM251 
in combination with Sitagliptin increased insulin secretion 2.6-fold (p<0.001) as determined by 






6.4.10: Acute effects of GPR55 agonists on feeding 
Male Swiss TO mice were trained to eat for 3 hrs daily and the effects of oral administration of 
GPR55 agonists and Sitagliptin on these mice was tested. Abn-CBD (0.1μmol/kg BW) reduced 
appetite by 23% (p<0.05) when administered alone (Figure 6.35A). Sitagliptin alone had no effect 
on appetite. Oral administration of AM251 (0.1μmol/kg BW) in combination with Sitagliptin was 
able to reduce appetite 15% (p<0.05) after 3 hrs (Figure 6.35B). The administration of AM251 alone 
produced no significant effect.  
 
6.4.11: Effects of multiple low dose streptozotocin on blood glucose and plasma insulin in male 
Swiss TO mice 
The blood glucose of lean and multiple low dose streptozotocin treated mice was observed for 14 
days after initial injection of streptozotocin (Figure 6.36).  
Lean mice underwent no changes in blood glucose for the duration of saline injections. However 
streptozotocin caused an initial 38% decrease in blood glucose 2 days after the first streptozotocin 
injection (p<0.001). By the last streptozotocin injection mice had increased blood glucose compared 
to lean mice at the same time point (p<0.01) however there was no increase compared to day 1 
blood glucose levels. Four days after the last injection blood glucose had increased in streptozotocin 
treated mice 1.5-fold (p<0.001) compared to initial levels. 
Both lean mice and mice treated with multiple low dose streptozotocin were fasted for 18 hrs and 
underwent an oral glucose tolerance test 15 days after initial injection of streptozotocin (Figure 
6.36A). After 18 hrs of fasting streptozotocin induced diabetic mice had increased blood glucose 
with an increase of 1.7-fold being observed (p<0.01). Oral administration of 18mmol/kg BW 
glucose lead to increased blood glucose in both lean and streptozotocin induced mice. Throughout 
the course of the test streptozotocin treated mice had higher blood glucose levels than lean mice 
with increases of 1.3, 1.6, 1.6, 1.8 and 1.9-fold at 15, 30, 60, 90 and 120 mins post administration 
respectively (p<0.05-p<0.001). The overall increase in blood glucose of streptozotocin induced 
diabetic mice was 1.6-fold (p<0.001) as determined by AUC (Figure 6.35B). 
Streptozotocin induced diabetic mice also had increased non-fasting blood glucose compared to 
lean mice with a 2.2-fold (p<0.001) increase in being demonstrated (Figure 6.37A). Before 
treatment, streptozotocin treated mice were split into groups with no significant difference in blood 
glucose levels (Figure 6.37B). 
Streptozotocin treatment resulted in a reduction in body weight (Figure 6.39A) with a 1.1-fold 
decrease being observed on the last day of streptozotocin injection (p<0.01) and a 1.1-fold decrease 
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being observed 14 days after the first injection (p<0.001). Lean mice had no reduction in body 
weight (Figure 6.39B) while the reduction in body weight in streptozotocin treated mice did not 
result in significant body weight differences with lean mice before grouping (Figure 6.40A). After 
grouping, streptozotocin induced diabetic mice had no significant difference in body weight (Figure 
6.40B). 
 
6.4.12: Effects of Abn-CBD on non-fasting GIP and GLP-1 levels 
Daily oral administration of Abn-CBD or Abn-CBD in combination with Sitagliptin resulted in 
increased circulating incretin hormones. Abn-CBD demonstrated an earlier effect on GLP-1 than 
Abn-CBD and with a 1.6-fold increase being observed after 12 days of treatment (Figure 6.44A, 
p<0.001). After 21 days Abn-CBD in combination with Sitagliptin had increased circulating GLP-
1 levels 2.0-fold (p<0.001) while Abn-CBD administration had increased GLP-1 levels 2.1-fold. 
Overall Abn-CBD and Sitagliptin had the greatest effect as determined by AUC with an overall 
increase in GLP-1 levels of 1.5-fold (Figure 6.44B, p<0.01) while Abn-CBD demonstrated an 
increase of 1.4-fold (p<0.01). 
As seen with GLP-1 levels, Abn-CBD combined with Sitagliptin increased GIP levels earlier than 
Abn-CBD treatment alone (Figure 6.45A). After 12 days of administration, Abn-CBD and 
Sitagliptin had increased GIP levels 1.8-fold (p<0.01). After 21 days of administration Abn-CBD 
in combination with Sitagliptin produced an increase of 2.0-fold compared to diabetic mice 
(p<0.001) while Abn-CBD administration resulted in a 1.7-fold increase (p<0.001). The overall 
increase demonstrated by Abn-CBD and Sitagliptin was 1.3-fold compared to streptozotocin 
induced diabetic mice (p<0.05). Abn-CBD treatment alone resulted in a 1.2-fold increase (p<0.01). 
Interestingly streptozotocin induced diabetic mice had a 1.3-fold increase in GIP levels compared 
to lean mice. 
 
6.4.13: Effects of GPR55 agonist Abn-CBD on body weight, fluid intake, non-fasting blood glucose 
and plasma insulin 
Chronic administration of Abn-CBD monotherapy and Abn-CBD combination therapy with 
Sitagliptin had no effect on body weight throughout the study (Figure 6.41A). Abn-CBD 
monotherapy reduced appetite after 18 days of treatment with a 27.7% (p<0.001) reduction being 
observed at this stage compared to diabetic mice treated with saline (Figure 6.42B). This effect was 
continued until the end of the study where Abn-CBD treated mice exhibited a 29.0% reduction 
(p<0.001) in appetite. Abn-CBD combination therapy with Sitagliptin also reduced appetite after 
18 days of treatment. This therapy produced reductions of 28.8% and 32.2% (p<0.001) after 18 and 
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21 days of treatment respectively compared to streptozotocin induced diabetic mice. Abn-CBD 
combination therapy was the only treatment that reduced fluid intake (Figure 6.43) compared to 
streptozotocin induced diabetic mice as it exhibited a reduction of 46.3% (p<0.05). 
Compared to lean mice, streptozotocin resulted in increased blood glucose for the duration of the 
study (Figure 6.46A, p<0.001). Daily treatment with Abn-CBD reduced blood glucose 1.4-fold 
overall (Figure 6.46B, p<0.01) while treatment with Abn-CBD and Sitagliptin resulted in a 1.12-
fold reduction (p<0.05). These results were confirmed as both Abn-CBD and Abn-CBD in 
combination increased insulin secretion from streptozotocin induced diabetic mice (Figure 6.47A). 
Overall Abn-CBD treatment increased insulin secretion 2.4-fold (p<0.001) while Abn-CBD in 
combination with Sitagliptin resulted in a 2.1-fold increase (Figure 6.47B, p<0.001). 
 
6.4.14: Effects of Abn-CBD on glucose tolerance and insulin sensitivity 
Daily oral administration of Abn-CBD or Abn-CBD in combination with Sitagliptin resulted in 
positive effects on glucose tolerance (Figure 6.48A). When administered glucose orally, mice who 
were treated with Abn-CBD had an overall reduction of 1.4-fold when compared to streptozotocin 
mice dosed with saline over the course of the study (Figure 6.48B, p<0.01). Like Abn-CBD 
treatment alone, Abn-CBD in combination also had a reducing effect on hyperglycaemia with a 
decrease in blood glucose of 1.5-fold being observed overall during the glucose tolerance test 
(p<0.001).  
Both Abn-CBD and Abn-CBD in combination with Sitagliptin increased insulin secretion when 
compared to streptozotocin mice over the course of the glucose tolerance test. Abn-CBD 
demonstrated a 1.6-fold increase in insulin secretion 15 mins after glucose had been administered 
(Figure 6.49A, p<0.001) and the same effect was observed with Abn-CBD and Sitagliptin which 
demonstrated a 1.6-fold increase in insulin secretion at the same time point (p<0.001). Lean mice 
demonstrated increased insulin secretion compared to streptozotocin induced diabetic mice treated 
with saline at all time points except for 60 mins post administration (p<0.01 to p<0.001). Overall 
both Abn-CBD (p<0.001) and Abn-CBD combined with Sitagliptin (p<0.01) increased insulin 
secretion 1.4-fold compared to streptozotocin treated mice (Figure 6.49B). When injected with 
insulin both Abn-CBD and Abn-CBD in combination with Sitagliptin reduced blood glucose 






6.4.15: Effects of Abn-CBD as measured by DEXA 
Of all the groups analysed, mice with streptozotocin induced diabetes had the highest body weight 
and this was the only group which was increased 1.1-fold compared to lean mice (Figure 6.52A, 
p<0.05). Daily oral administration of Abn-CBD resulted in a 1.1-fold reduction in body weight 
(p<0.01) compared to diabetic mice treated with saline, however this effect was not maintained 
when administered in combination with Sitagliptin. No significant effects were observed in lean 
mass (Figure 6.52B) however both groups of mice treated with Abn-CBD or Abn-CBD with 
Sitagliptin had reduced fat mass (Figure 6.53A, p<0.05) compared to diabetic mice as well as lean 
(p<0.01). This correlated into a 1.3-fold and a 1.6-fold decrease in body fat percentage compared 
to lean mice (Figure 6.53B, p<0.05)  
 
6.4.16: Effects of chronic Abn-CBD treatment on lipid profiles 
Streptozotocin treated mice had reduced triglycerides compared to lean mice (Figure 6.56A). 
Diabetic mice treated with saline exhibited a 2.9-fold (p<0.001) decrease in triglycerides compared 
to lean mice with decreases of 2.3-fold (p<0.001) and 1.7-fold (p<0.001) being observed in mice 
treated with Abn-CBD monotherapy and combination therapy respectively. Streptozotocin induced 
diabetes had no effect on total cholesterol nor had Abn-CBD monotherapy or in combination with 
Sitagliptin (Figure 6.56B). HDL cholesterol was also not affected (Figure 6.57B). Induction of 
diabetes with streptozotocin reduced LDL levels with saline treated mice having a 1.6-fold (p<0.05) 
reduction compared to lean mice (Figure 6.57A). Diabetic mice treated with Abn-CBD combination 
therapy exhibited a 1.9-fold (p<0.05) reduction in LDL compared to lean mice. Abn-CBD 
monotherapy reduced LDL levels 2.92-fold (p<0.001) compared to lean mice and this was 
significantly lower than the LDL levels observed in streptozotocin induced diabetic mice treated 
with saline with a reduction of 45.1% being observed (p<0.05) 
 
6.5: Discussion  
GPR55 is a novel cannabinoid receptor which has previously been shown to increase intracellular 
calcium through Gα12 and Gαq and it has also been shown to be coupled to Gα13 (Ryberg et al. 2007). 
Due to its widespread expression throughout the body, GPR55 has been proposed to play a role in 
various physiological processes and has been proposed as a new novel anticancer target (Leyva-
Illades, DeMorrow 2013). This receptor has also demonstrated insulinotropic activity both in vitro 
(McKillop et al. 2013) and in vivo (McKillop et al. 2016) and it may play a regulatory role on 
glucagon secretion (Liu et al. 2016). Therefore the effects of GPR55 activation on glucose 
homeostasis make it an interesting target for the treatment of Type 2 Diabetes.  
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This study investigated the effects of GPR55 agonists on insulin, GLP-1, GIP and PYY secretion. 
In BRIN-BD11 cells, all agonists tested demonstrated a dose dependent insulinotropic effect in both 
normal and hyperglycaemic conditions. The most potent agonist tested in normal conditions was 
AM251 followed by Abn-CBD then the endogenous agonists OEA and PEA as per the EC50 value 
for each agonist. In hyperglycaemic conditions PEA became the most potent agonist whilst AM251 
was the least potent. Abn-CBD was again more potent than OEA but less potent than PEA. Abn-
CBD demonstrated the greatest insulinotropic effect followed by OEA, AM251 and PEA in normal 
conditions. In hyperglycaemic conditions, Abn-CBD again had the greatest insulinotropic effect 
followed by AM251, OEA and PEA. This confirms the previous results which have demonstrated 
that activation of GPR55 can regulate glucose homeostasis through insulin secretion (McKillop et 
al. 2016, McKillop et al. 2013, Liu et al. 2016). 
GPR55 agonist LPI has previously demonstrated that activation of GPR55 increases GLP-1 
secretion from GLUTag cells (Liu et al. 2016). In this study, immunohistochemistry confirmed the 
co-localisation of GPR55 and GLP-1 in GLUTag cells confirming earlier work showing the 
presence of GPR55 in GLUTag cells (Liu et al. 2016). Abn-CBD has also previously been shown 
to increase GLP-1 secretion after long term administration to mice with streptozotocin induced 
diabetes (McKillop et al. 2016) and it demonstrated the greatest effect on GLP-1 release from 
GLUTag cells while being more potent than both OEA and PEA based on EC50 values. While 
displaying greater potency than Abn-CBD, AM251 demonstrated a smaller increase in GLP-1 
secretion. Of the endogenous agonists tested, OEA demonstrated the greatest effect on GLP-1 
secretion as well as having the highest potency. PEA had no effect on GLP-1 secretion. GPR55 
antagonist CBD was used to determine selectivity of the tested agonists for GPR55. All agonists 
tested demonstrated selectivity for GPR55. Abn-CBD and AM251 demonstrated selectivity at all 
concentrations tested, while OEA demonstrated selectivity for GPR55 at concentrations which 
increased GLP-1 secretion. PEA only demonstrated selectivity at the lowest concentration which 
was investigated.  
The determination of proglucagon gene expression from GLUTag cells helps to confirm/validate 
these findings. Both Abn-CBD and AM251 as well as OEA increase proglucagon gene expression 
while PEA demonstrates no effect. In order for more GLP-1 to be secreted at the protein level, more 
GLP-1 needs to be expressed during mRNA synthesis. These results suggest that GPR55 plays a 
regulatory role in GLP-1 secretion.  
The effects of GPR55 agonists on GIP secretion from pGIPneo STC-1 cells was studied and 
demonstrated that both Abn-CBD and AM251 had no effect on the release of GIP. 
Immunohistochemistry in primary tissue confirmed the co-localisation of both GIP and GPR55 ex 
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vivo. Both OEA and PEA increased GIP secretion although these agonists have the ability to work 
through other receptors that may be present in these cells (Moran et al. 2014a).  
As the agonists tested had demonstrated an ability to increase intestinal hormone secretion, their 
effects in vivo was tested orally in lean Swiss TO mice. Abn-CBD demonstrated the greatest effects 
on hyperglycaemia. When administered in combination with Sitagliptin, a DPP-IV inhibitor which 
is also administered orally, both agonists reduced hyperglycaemia. This confirmed previous results 
demonstrating that oral administration of Abn-CBD played a role in glucose homeostasis (McKillop 
et al. 2016). Previous work has demonstrated that cannabinoid receptors may help to potentiate 
GLP-1 receptor activation (Radziszewska, Bojanowska 2012) and using knock out mice models it 
has been shown that the effects of Abn-CBD on glucose homeostasis are diminished in the absence 
of incretin hormone receptors (McKillop et al. 2016). The work carried out in this study 
demonstrates that both Abn-CBD and AM251 can increase both GLP-1 and GIP secretion acutely 
and long term. It also confirms the previous work which has shown that GPR55 agonists can 
regulate glucose homeostasis (McKillop et al. 2016, McKillop et al. 2013). 
The CB1 cannabinoid receptors has been shown to increase appetite while antagonism of this 
receptors can lead to reduced appetite (Wiley et al. 2005) whereas activation of CB2 can reduce 
appetite in mice (Verty et al. 2015). In order to test the effects of GPR55 activation on appetite, 
mice were trained to eat for 3 hrs and orally administered with a GPR55 agonist before eating. Abn-
CBD administration reduced appetite, however this effect was lost in the presence of Sitagliptin, 
suggesting that Abn-CBD may have an effect on PYY secretion. Contrary to this, AM251 only 
reduced appetite when administered in combination with Sitagliptin. This suggests that AM251 
increases GLP-1 and GIP secretion as the inhibitor will allow both hormones to circulate for longer 
thus having a greater effect. Sitagliptin treatment alone did not reduce appetite as it is likely that 
GLP-1 secretion was not increased as significantly as when AM251 was present.  
In order to observe the long term effects of Abn-CBD in this study, a multiple low dose 
streptozotocin model of diabetes was utilised as has been used previously (McKillop et al. 2016). 
Streptozotocin is a glucose analogue which is cytotoxic to the insulin secreting β-cells of the 
pancreas (Szkudelski 2001). Due to the similarities in structure with glucose, streptozotocin is able 
to enter β-cells through the GLUT2 receptor and induce diabetes through β-cell toxicity and a T-
cell mediated immune response against β-cells in the pancreas (Wang, Gleichmann 1998, 
Szkudelski 2001). The alkylating properties of streptozotozin mean that free radicals are added to 
DNA present in β-cells and destroying the cell and preventing it from metabolising glucose due to 
the breakdown of mitochondrial DNA (Szkudelski 2001). The effects of multiple low dose 
streptozotocin induced diabetes on rats has previously shown to result in mild hyperglycaemia, 
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hypoinsulinaemia, hyperphagia and polydipsia with no adverse effects on weight gain (Kobayashi, 
Olefsky 1979).  
Treatment of mice with streptozotocin led to increased non-fasting hyperglycaemia, food intake, 
fluid intake and GIP secretion while plasma insulin and the ability to control glycaemia after glucose 
intake was reduced due to reduced insulin sensitivity and lower insulin secretion in response to 
glucose. Treatment of streptozotocin induced diabetic mice with Abn-CBD reduced LDL 
cholestetrol, non-fasting hyperglycaemia, body fat, hyperglycaemia after glucose challenge, fluid 
intake and food intake. Daily oral Abn-CBD treatment increased incretin hormone and insulin 
secretion, insulin response to glucose, insulin sensitivity and bone mineral density in the femur. 
Abn-CBD combined with Sitagliptin reduced body fat, non-fasting hyperglycaemia, 
hyperglycaemia in response to glucose challenge, food intake and fluid intake. Plasma insulin, 
insulin secretion in response to glucose, incretin hormone secretion and insulin sensitivity were all 
increased. Previous work has shown that Abn-CBD administration improved glucose homeostasis 
(McKillop et al. 2016), however this is the first study to show the long term effects of this agonist 
on incretin hormone secretion and is the first study to demonstrate improved glycaemic control in 
combination with Sitagliptin. In order to better elucidate the effects seen in this study, further studies 
in GPR55 knockout and other diabetic animal models are required. 
This study differed from previous work as it looked at the direct action of GPR55 activation on 
incretin hormones as well as being the first study to use Abn-CBD in combination with the DPP-IV 
inhibitor Sitagliptin. Daily oral administration of both Abn-CBD and Abn-CBD in combination 
with Sitagliptin increased insulin secretion in non-fasted mice while also increasing circulating 
incretin hormone levels. These factors all lead to reduced blood glucose in both treatment groups. 
There is currently only one published study demonstrating that GPR55 activation can increase GLP-
1 secretion directly (Harada et al. 2017) and this was done using LPI. Therefore this is the first 
study to show direct action of Abn-CBD and AM251 can increase incretin hormone secretion to 
better help regulate glucose homeostasis. 
In conclusion, the research described in this study confirms the insulinotropic effect of GPR55 
agonists in β-cells of the pancreas both in vitro and in vivo. GPR55 agonists also demonstrated an 
ability to increase GLP-1 secretion in vitro while only those agonists which work through other 
GPCRs were able to increase GIP secretion. The effects of these agonists on GLP-1 secretion were 
confirmed with qPCR demonstrating that GPR55 agonists increase proglucagon gene expression. 
Oral administration of GPR55 agonist Abn-CBD and AM251 resulted in a significant glucose 
lowering and insulinotropic effect in vivo and when administered in combination with a DPP-IV 







































Figure 6.1: Effects of Abn-CBD on GLP-1 secretion and cell viability in intestinal GLUTag 





















































Effect of GPR55 agonist Abn-CBD (10-12-10-4M) and GPR55 antagonist CBD (10-5M) on GLP-1 
secretion (A) and cell viability (B) at 2mM glucose in GLUTag cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. * p<0.05 and 
*** p<0.001 compared to basal glucose control for GLP-1 secretion and media non-toxic control 
















































































Figure 6.2: Effects of AM251 on GLP-1 secretion and cell viability in intestinal GLUTag cells 





















Effect of GPR55 agonist AM251 (10-12-10-4M) and GPR55 antagonist CBD (10-5M) on GLP-1 
secretion (A) and cell viability (B) at 2mM glucose in GLUTag cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. ** p<0.01 and 
*** p<0.001 compared to basal glucose control for GLP-1 secretion and media non-toxic control 




























































































Effect of GPR55 agonist OEA (10-12-10-4M) on GLP-1 secretion (A) and cell viability (B) at 2mM 
glucose in GLUTag cells. Cell viability was measured using MTT. Results are mean ± SEM (n=3) 
for GLP-1 secretion and cell viability. * p<0.05, ** p<0.01 and *** p<0.001 compared to basal 
glucose control for GLP-1 secretion and media non-toxic control for cell viability. ∆ p<0.05 






























































Effect of GPR55 agonist PEA (10-12-10-4M) and GPR55 antagonist CBD (10-5M) on GLP-1 
secretion (A) and cell viability (B) at 2mM glucose in GLUTag cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. * p<0.05, ** 
p<0.01 and *** p<0.001 compared to basal glucose control for GLP-1 secretion and media non-




















































10M Fsk + 1mM IBMX





























































Figure 6.5: Effects of Abn-CBD on GIP secretion and cell viability in intestinal pGIPneo STC-





















Effect of GPR55 agonist Abn-CBD (10-12-10-4M) and GPR55 antagonist CBD on GIP secretion (A) 
and cell viability (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was measured using 
MTT. Results are mean ± SEM (n=3) for GIP secretion and cell viability. * p<0.05, and *** p<0.001 
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Figure 6.6: Effects of AM251 on GIP secretion and cell viability in intestinal pGIPneo STC-1 





















Effect of GPR55 agonist AM251 (10-12-10-4M) and GPR55 antagonist CBD on GIP secretion (A) 
and cell viability (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was measured using 
MTT. Results are mean ± SEM (n=3) for GIP secretion and cell viability. * p<0.05 and *** p<0.001 
compared to basal glucose control for GIP secretion and media non-toxic control for cell viability. 
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Figure 6.7: Effects of OEA on GIP secretion and cell viability in intestinal pGIPneo STC-1 





























































































Effect of GPR55 agonist OEA (10-12-10-4M) and GPR55 antagonist CBD on GIP secretion (A) and 
cell viability (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was measured using MTT. 
Results are mean ± SEM (n=3) for GIP secretion and cell viability. * p<0.05, ** p<0.01 and *** 













































Figure 6.8: Effects of PEA on GIP secretion and cell viability in intestinal pGIPneo STC-1 





















Effect of GPR55 agonist PEA (10-12-10-4M) and GPR55 antagonist CBD on GIP secretion (A) and 
cell viability (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was measured using MTT. 
Results are mean ± SEM (n=3) for GIP secretion and cell viability. * p<0.05, ** p<0.01 and *** 

































































































Figure 6.9: Effects of Abn-CBD on insulin secretion and cell viability in pancreatic BRIN-




















































5.6mM Glucose + Abn-CBD












Effect of Abn-CBD (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose 
in BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± 
SEM (n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 






















































Figure 6.10: Effects of Abn-CBD on insulin secretion and cell viability in pancreatic BRIN-




















































16.7mM Glucose + Abn-CBD














Effect of Abn-CBD (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose 
in BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± 
SEM (n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, **p<0.01 and *** p<0.001 














































5.6mM Glucose + AM-251











Figure 6.11: Effects of AM251 on insulin secretion and cell viability in pancreatic BRIN-BD11 














































Effect of AM251 (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability.* p<0.05, ** p<0.01 and *** p<0.001 


























































































16.7mM Glucose + AM-251











Figure 6.12: Effects of AM251 on insulin secretion and cell viability in pancreatic BRIN-BD11 





















Effect of AM251 (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 




Figure 6.13: Effects of OEA on insulin secretion and cell viability in pancreatic BRIN-BD11 






























































































5.6mM Glucose + OEA













Effect of OEA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 






















































Figure 6.14: Effects of OEA on insulin secretion and cell viability in pancreatic BRIN-BD11 




















































16.7mM Glucose + OEA













Effect of OEA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 




















































Figure 6.15: Effects of PEA on insulin secretion and cell viability in pancreatic BRIN-BD11 




















































5.6mM Glucose + PEA













Effect of PEA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 





















































Figure 6.16: Effects of PEA on insulin secretion and cell viability in pancreatic BRIN-BD11 


















































16.7mM Glucose + PEA












Effect of PEA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, **p<0.01 and *** p<0.001 








Figure 6.17: EC50 of GPR44 agonists Abn-CBD, AM251, OEA and PEA in BRIN-BD11 cells 
A. 
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EC50 values for GPR55 agonists Abn-CBD, AM251, OEA and PEA in BRIN-BD11 cells in 5.6mM 






Figure 6.18: Immunofluorescence staining of GLP-1 and GPR55 in intestinal GLUTag cells 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR55 and (D) combined fluorescence of GLP-1 and 
GPR55 in GLUTag cells. Images are taken at x200 magnification and examples of positive staining 
















Figure 6.19: Immunofluorescence staining of GLP-1 and GPR55 in lean NIH Swiss mouse 
small intestine 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR55 and (D) combined fluorescence of GLP-1 and 
GPR55 in lean NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification 
















Figure 6.20: Immunofluorescence staining of GLP-1 and GPR55 in HFF NIH Swiss mouse 
small intestine 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR55 and (D) combined fluorescence of GLP-1 and 
GPR55 in HFF NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification 








































































Effect of HFF diet on GPR55 gene expression in male NIH Swiss mouse small intestine. * p<0.05 


















Figure 6.22: Immunofluorescence staining of GIP and GPR55 in pGIPneo STC-1 cells 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR55 and (D) combined fluorescence of GIP and GPR55 
in pGIPneo STC-1 cells. Images are taken at x200 magnification and examples of positive staining 










Figure 6.23: Immunofluorescence staining of GIP and GPR55 in lean NIH Swiss mouse small 
intestine 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR55 and (D) combined fluorescence of GIP and GPR55 
in lean NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification and 














Figure 6.24: Immunofluorescence staining of GIP and GPR55 in HFF NIH Swiss mouse small 
intestine 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR55 and (D) combined fluorescence of GIP and GPR55 
in HFF NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification and 














Figure 6.25: Immunofluorescence staining of PYY and GPR55 in STC-1 cells 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR55 and (D) combined fluorescence of PYY and GPR55 
in STC-1 cells. Images are taken at x200 magnification and examples of positive staining are 
















Figure 6.26: Immunofluorescence staining of PYY and GPR55 in lean NIH Swiss mouse small 
intestine 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR55 and (D) combined fluorescence of PYY and GPR55 
in lean NIH Swiss Mouse Small Intestinal tissue. Images are taken at x200 magnification and 














Figure 6.27: Immunofluorescence staining of PYY and GPR55 in HFF NIH Swiss mouse small 
intestine 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR55 and (D) combined fluorescence of PYY and GPR55 
in HFF NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification and 










































































Effects of GPR55 agonists on the expression of the GPR55 gene in intestinal GLUTag cells at 2mM 
glucose.* p<0.05 and ** p<0.01 compared to untreated media control. ∆ p<0.05 and ∆∆ p<0.01 


























































































Glucose (18mmol/kg BW) or glucose in combination with a GPR55 agonist (0.1μmol/kg BW) were 
administered orally to male Swiss TO mice (n=6). (A) Plasma GLP-1 of mice treated with GPR55 
agonists (B) AUC of A. **p<0.01 and ***p<0.001 compared to glucose treatment alone. ΔΔ p<0.01 








































































Glucose (18mmol/kg BW) or glucose in combination with a GPR55 agonist (0.1μmol/kg BW) were 
administered orally to male Swiss TO mice (n=6). (A) Plasma GIP of mice treated with GPR55 







Figure 6.31: Effects of GPR55 agonist Abn-CBD on blood glucose in male Swiss TO mice 
A. 







Glucose + 50mg/kg Sitagliptin
0.1mol/kg Abn-CBD
0.1mol/kg Abn-CBD + 50mg/kg Sitagliptin






























































































Glucose + 50mg/kg Sitagliptin
0.1mol/kg Abn-CBD
0.1mol/kg Abn-CBD + 50mg/kgSitagliptin



































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with Abn-CBD (0.1μmol/kg BW), glucose in combination with Abn-CBD 
and the GPR55 antagonist CBD (0.1μmol/kg BW), glucose in combination with Abn-CBD and 
Sitagliptin Phosphate or saline (0.9% NaCl (w/v)) in combination with Abn-CBD were all 
administered orally to male Swiss TO mice. (A) Blood glucose of mice treated with Abn-CBD (B) 






Figure 6.32: Effects of GPR55 agonist AM251 on blood glucose in male Swiss TO mice 
A. 








18mmol/ kg BW Glucose + 50mg/kg Sitagliptin
0.1mol/kg AM251
0.1mol/kg AM251 + 50mg/kg Sitagliptin





































Glucose + 50mg/kg Sitagliptin
0.1mol/kg AM251
0.1mol/kg AM251 + 50mg/kg Sitagliptin










































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with AM251 (0.1μmol/kg BW), glucose in combination with AM251 and 
the GPR55 antagonist CBD (0.1μmol/kg BW), glucose in combination with AM251 and Sitagliptin 
Phosphate or saline (0.9% NaCl (w/v)) in combination with a AM251 were all administered orally 





















































































































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with Abn-CBD (0.1μmol/kg BW), and glucose in combination with Abn-
CBD and Sitagliptin Phosphate were all administered orally to male Swiss TO mice (n=6). (A) 
Plasma insulin of mice treated with Abn-CBD (B) AUC of A. * p<0.05, ** p<0.01 and *** p<0.001 
compared to glucose.  
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Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with AM251 (0.1μmol/kg BW), and glucose in combination with AM251 
and Sitagliptin Phosphate were all administered orally to male Swiss TO mice (n=6). (A) Plasma 
insulin of mice treated with AM251 (B) AUC of A. * p<0.05, ** p<0.01 and *** p<0.001 compared 
to glucose. +++ p<0.001 compared to agonist in combination with CBD. ΔΔ p<0.01 and ΔΔΔ 










0.9% NaCl + 0.1mol/kg BW Abn-CBD
0.9% NaCl + 50mg/kg BW Sitagliptin + 0.1mol/kg BW Abn-CBD
*
0
30 60 120 150 160 180
50mg/kg BW Sitagliptin
*





















0.9% NaCl + 0.1mol/kg BW AM251
0.9% NaCl + 50mg/kg BW Sitagliptin + 0.1mol/kg BW AM251
**
0



















Saline (0.9%), saline and Abn-CBD (A) or AM251 (B) (0.1μmol/kg BW), saline with a GPR55 
agonist and Sitagliptin (50mg/kg BW) or saline and Sitagliptin were administered orally to Swiss 







Figure 6.36: Effect of multiple low dose streptozotocin on blood glucose in male Swiss TO 
mice 
A. 




































































In order to induce diabetes, 4 hr fasted male Swiss TO mice were administered streptozotocin 
(40mg/kg BW, 0.1M sodium citrate, pH 4.5) via intraperitoneal injection. Reduced glucose 
tolerance was confirmed 14 days after the initial injection of streptozotocin (day 1) via oral glucose 
tolerance test. Glucose (18mmol/kg body weight) was administered orally to either lean or 
streptozotocin treated Swiss TO mice (n=6 for lean mice, n=12 for streptozotocin treated mice). (A) 




Figure 6.37: Effect of multiple low dose streptozotocin on non-fasting blood glucose in male 























































25 Blood glucose of Group Treated with Abn-CBD



















In order to induce diabetes, 4 hr fasted male Swiss TO mice were administered streptozotocin 
(40mg/kg BW, 0.1M sodium citrate, pH 4.5) via intraperitoneal injection. Non-fasting blood 
glucose was measured 14 days after initial injection (n=6 for lean and n=12 for streptozotocin 
induced diabetic mice) (A) Non fasting blood glucose of mice 14 days after initial treatment (B) 
Non-fasting blood glucose levels between treatment groups of streptozotocin treated mice when 
separated 14 days after initial treatment. Mice were separated to ensure no significant differences 
between groups before treatment commenced.  
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Figure 6.38: Effects of multiple low dose streptozotocin on blood glucose in 4 hr fasted male 





































Male Swiss TO mice were fasted for 4 hrs prior to streptozotocin treatment to induce diabetes 

































































































Body weights of both streptozotocin treated (A) and lean male Swiss TO mice (B) was monitored 
prior to injection (n=32 for streptozotocin treated mice, n=6 for lean mice). Lean mice received 





Figure 6.40: Differences in body weight between treatment groups of streptozotocin induced 
















































Body Weight of Group Treated with Abn-CBD













Body weight was compared between lean and streptozotocin treated mice 14 days after initial 
injection (A) and body weights were checked prior to initial agonist treatment (B).  
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Figure 6.41: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on body 
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Effect of daily oral administration of saline (0.9%), Abn-CBD monotherapy (0.1μmol/kg body 
weight) and Abn-CBD (0.1μmol/kg body weight) combination therapy with Sitagliptin (50mg/kg 
body weight) on body weight. (A) Body weight (B) AUC of A. Parameters obtained before and 




Figure 6.42: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on food 







0 3 6 9 12 15 18 21-6 -3

























































































Effect of daily oral administration of saline (0.9%), Abn-CBD monotherapy (0.1μmol/kg body 
weight) and Abn-CBD (0.1μmol/kg body weight) combination therapy with Sitagliptin (50mg/kg 
bodyweight) on food intake. (A) Food intake (B) AUC of A. Parameters obtained before and during 
the 21 days treatment period (indicated by the horizontal black bar). Values are mean ± SEM (n=6). 
* p<0.05, ** p<0.01 and *** p<0.001 compared to lean mice. ΔΔ p<0.01 and ΔΔΔ p<0.001 
compared to streptozotocin induced diabetic mice. 
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Figure 6.43: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on fluid 
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Effect of daily oral administration of saline (0.9%), Abn-CBD monotherapy (0.1μmol/kg body 
weight) and Abn-CBD (0.1μmol/kg body weight) combination therapy with Sitagliptin (50mg/kg 
body weight) on fluid intake. (A) Fluid intake (B) AUC of A. Parameters obtained before and during 
the 21 days treatment period (indicated by the horizontal black bar). Values are mean ± SEM (n=6). 
* p<0.05 and *** p<0.001 compared to lean mice. Δ p<0.05, ΔΔ p<0.01 and ΔΔΔ p<0.001 
compared to the streptozotocin group. 
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Figure 6.44: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on plasma 























































































Effect of daily oral administration of saline (0.9%), Abn-CBD (0.1μmol/kg body weight) or Abn-
CBD (0.1μmol/kg body weight) in combination with Sitagliptin (50mg/kg body weight) on (A) 
Plasma GLP-1 (B) AUC of A. ** p<0.01 and *** p<0.001 compared to lean mice. ΔΔ p<0.01 and 
ΔΔΔ p<0.001 compared to streptozotocin group. 
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Figure 6.45: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on plasma 















































































Effect of daily oral administration of saline (0.9%), Abn-CBD (0.1μmol/kg body weight) or Abn-
CBD (0.1μmol/kg body weight)  in combination with Sitagliptin (50mg/kg body weight) on (A) 
Plasma GIP of mice treated with GPR55 agonists (D) AUC of C. ** p<0.01 and *** p<0.001 
compared to lean mice. Δ p<0.05, ΔΔ p<0.01 and ΔΔΔ p<0.001 compared to streptozotocin group. 
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Figure 6.46: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on blood 
glucose in multiple low dose streptozotocin mice 
A. 

















































































































Effect of daily oral administration of saline (0.9%), Abn-CBD (0.1μmol/kg BW) or Abn-CBD 
(0.1μmol/kg BW) in combination with Sitagliptin (50mg/kg BW) on non-fasting blood glucose. (A) 
Non-fasting blood glucose (B) AUC of A. Parameters obtained before and during the 21 day 
treatment period (indicated by the horizontal black bar). Values are mean ± SEM (n=6). * p<0.05, 
** p<0.01, *** p<0.001 compared to the lean group. Δ p<0.05, ΔΔ p<0.01 and ΔΔΔ p<0.001 




Figure 6.47: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on plasma 










































































































Effect of daily oral administration of saline (0.9%), Abn-CBD (0.1μmol/kg BW) or Abn-CBD 
(0.1μmol/kg BW) in combination with Sitagliptin (50mg/kg BW) on non-fasting plasma insulin (A) 
Non-fasting plasma insulin. Parameters obtained before and during the 21 day treatment period 
(indicated by the horizontal black bar). Values are mean ± SEM (n=6). * p<0.05, ** p<0.01, *** 




Figure 6.48: Effects of long term oral treatment of GPR55 agonist Abn-CBD on glucose 
tolerance in multiple low dose streptozotocin mice 
A. 






















































































































Oral glucose tolerance test (18mmol/kg body weight) was performed 21 days after treatment with 
saline (0.9%), Abn-CBD (0.1μmol/kg body weight) or Abn-CBD (0.1μmol/kg BW) in combination 
with Sitagliptin (50mg/kg BW) to 18 hr fasted Swiss TO mice. (A) Blood glucose (B) AUC of A. 
Results are the mean ± SEM (n=6). ** p<0.01 and *** p<0.001 compared to glucose alone. ΔΔ 




Figure 6.49: Effects of long term oral treatment of GPR55 agonist Abn-CBD on acute insulin 
secretion in multiple low dose streptozotocin mice 
A. 
































































































Oral glucose tolerance test (18mmol/kg body weight) was performed 21 days after treatment with 
saline (0.9%), Abn-CBD (0.1μmol/kg body weight) or Abn-CBD (0.1μmol/kg BW) in combination 
with Sitagliptin (50mg/kg BW) to 18 hr fasted Swiss TO mice. (A) Plasma insulin (B) AUC of A. 
Results are the mean ± SEM (n=6). ** p<0.01 and *** p<0.001 compared to lean mice. Δ p<0.05, 





Figure 6.50: Effects of long term daily oral treatment GPR55 agonist Abn-CBD on insulin 

































































































Insulin sensitivity (25 U/kg body weight, I. P. injection dissolved in 0.9% NaCl) was performed 21 
days after treatment with saline, Abn-CBD monotherapy (0.1μmol/kg body weight) or Abn-CBD 
(0.1μmol/kg body weight) combination therapy with Sitagliptin (50mg/kg body weight) in non-
fasted Swiss TO mice (n=6). (A) Blood glucose, (B) AUC of blood glucose. Results are the mean 





Figure 6.51: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on insulin 



























































































Insulin sensitivity (25 U/kg body weight, I. P. injection dissolved in 0.9% NaCl) was performed 21 
days after treatment with saline, Abn-CBD monotherapy (0.1μmol/kg body weight) or Abn-CBD 
(0.1μmol/kg BW) combination therapy with Sitagliptin (50mg/kg body weight) in non-fasted Swiss 
TO mice (n=6). (A) Blood glucose (% change) (B) AUC of blood glucose (% change) are shown. 




Figure 6.52: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on body 
















































































Effect of daily oral administration of saline, Abn-CBD (0.1μmol/kg body weight) or Abn-CBD 
(0.1μmol/kg BW) in combination with Sitagliptin (50mg/kg body weight) on (A) body weight and 
(B) lean mass as measured by DEXA scanning following 21 day treatment period in streptozotocin-
induced diabetic mice. Values are mean ± SEM (n=6). * p<0.05 compared to the lean group. ΔΔ 




Figure 6.53: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on fat mass 

















































































Effect of daily oral administration of saline (0.9%), Abn-CBD (0.1μmol/kg body weight) or Abn-
CBD (0.1μmol/kg BW) in combination with Sitagliptin (50mg/kg body weight) on (A) fat mass and 
(B) fat (% of bodyweight) as measured by DEXA scanning following 21 day treatment period in 
streptozotocin-induced diabetic mice. Values are mean ± SEM (n=6). * p<0.05 and ** p<0.01 
compared to the lean group. Δ p<0.05 compared to streptozotocin group. 
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Figure 6.54: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on bone 




























































































Effect of daily oral administration of saline (0.9%), Abn-CBD (0.1μmol/kg body weight) or Abn-
CBD (0.1μmol/kg BW) in combination with Sitagliptin (50mg/kg body weight) on (A) bone mineral 
content and (B) bone mineral density as measured by DEXA scanning following 21 day treatment 
period in streptozotocin-induced diabetic mice. Values are mean ± SEM (n=6). ΔΔ p<0.01 and ΔΔΔ 
p<0.001 compared to the streptozotocin group. 
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Figure 6.55: Effects of long term daily oral treatment of GPR55 agonist Abn-CBD on bone 






































































































Effect of daily oral administration of saline (0.9%), Abn-CBD (0.1μmol/kg body weight) or Abn-
CBD (0.1μmol/kg body weight) in combination with Sitagliptin (50mg/kg body weight) on (A) 
bone mineral density and (B) bone mineral content in the femur as measured by DEXA scanning 
following 21 day treatment period in streptozotocin-induced diabetic mice. Values are mean ± SEM 
(n=6). ΔΔ p<0.01 and ΔΔΔ p<0.001 compared to the streptozotocin group. 
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Figure 6.56: Effects of long term oral treatment of GPR55 agonist Abn-CBD on plasma 






























































































Effect of daily oral administration of saline (0.9%), Abn-CBD monotherapy (0.1μmol/kg body 
weight) and Abn-CBD (0.1μmol/kg BW) combination therapy with Sitagliptin (50mg/kg body 
weight) on (A) triglycerides and (B) total cholesterol following 21 day treatment period in 
streptozotocin-induced diabetic mice. Values are mean ± SEM (n=6). *** p<0.001 compared to the 
lean group.  
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Figure 6.57: Effects of long term oral treatment of GPR55 agonist Abn-CBD on LDL and 




























































































Effect of daily oral administration of saline (0.9%), Abn-CBD monotherapy (0.1μmol/kg body 
weight) and Abn-CBD (0.1μmol/kg BW) combination therapy with Sitagliptin (50mg/kg body 
weight) on (A) HDL cholesterol and (B) LDL cholesterol following 21 day treatment period in 
streptozotocin-induced diabetic mice. LDL was calculated using the Friedewald equation (LDL 
cholesterol = Total cholesterol – HDL cholesterol – (Triglycerides/5)). Values are mean ± SEM 










Determination of the effects of GPR119 
activation on gastrointestinal hormone 











7.1: Overview of results 
GPR119 was identified through bioinformatical analysis and found to be present in various genomes 
including those of fish. The discovery of GPR119 in animal genomes allowed for the identification 
of receptor ligands both in vitro and in vivo. Both endogenous and synthetic ligands have now been 
identified for GPR119. GPR119 has been identified in various cells in the body including the β-
cells of the pancreas and the L and K cells of the intestine. The location of GPR119 has led to 
interest in its role in treating metabolic disorders such as Type 2 Diabetes. 
The aim of this study was to examine the effect of GPR119 activation on gastrointestinal hormone 
and insulin secretion. GLUTag, pGIPneo STC-1 and BRIN-BD11 cells were treated with a range 
of concentrations (10-12 to 10-4M) of GPR119 agonist OEA, PEA and AS1269574. The effects of 
this treatment on cytotoxicity was assessed via MTT assay for GLUTag and pGIPneo STC-1 cells 
while Alamar blue assay was used in BRIN-BD11 cells. Double immunohistochemistry was carried 
out both ex vivo and in vitro in order to determine the cellular localisation of GPR119 in the L and 
K cells of the intestine. Gene expression was further assessed using qPCR. qPCR analysis quantified 
the expression of GPR119 in the small intestine while double immunohistochemistry was used to 
determine the co-localisation of GPR119 with GLP-1, GIP and PYY. Acute in vivo effects of the 
agonists AS1269574 and OEA was studied at 0.1μmol/kg body weight in lean mice (n=6). The 
biological effects of chronic AS1269574 and AS1269574 in combination with Sitagliptin treatment 
was assess in streptozotocin induced diabetic mice (n=6). 
In GLP-1 secreting GLUTag cells PEA increased GLP-1 secretion 1.3 to 2.5-fold (p<0.01-p<0.001) 
at concentrations of 10-8M to 10-4M while OEA (10-6 to 10-4M), increased GLP-1 secretion 1.8 to 
2.0-fold (p<0.001). AS1269574 increased GLP-1 secretion 1.6-fold (10-6M, p<0.01). The secretory 
ability of PEA on GLUTag cells was reduced 1.3 to 1.8-fold (10-8M to 10-4M, p<0.05 to p<0.01) 
when cells were treated in combination with Exendin-9 while the secretory ability of OEA was 
reduced 1.2 to 2.0-fold (10-8M to 10-4M, p<0.05-p<0.001). Exendin-9 reduced AS1269574 secretory 
action 2.0-fold at 10-6M (p<0.05).  
GPR119 agonists increased GIP secretion in pGIPneo STC-1 cells. PEA increased GIP secretion 
1.1 to 1.8-fold increase (10-8M to 10-6M, p<0.05). In the presence of 10-7M Exendin-9, this action 
was decreased 1.6-fold (10-6M, p<0.05). OEA increased GIP secretion with a 1.9-fold at 10-6M 
(p<0.01) while Exendin-9 reduced this effect 1.5-fold (p<0.05). 
In 5.6mM glucose AS1269574 stimulated insulin secretion 1.3 to 2.4-fold (10-8-10-4M, p<0.01-
p<0.001) from BRIN-BD11 cells while OEA demonstrated a 1.4 to 2.2-fold increase (10-8-10-4M, 
p<0.05-p<0.001). PEA augmented insulin secretion 1.1 to 1.5-fold (p<0.05-p<0.001) at 
concentrations of 10-8 to 10-4M. AS1269574 (EC50 = 1.17x10-7M) was the most potent agonist tested 
in 5.6mM glucose followed by PEA (EC50 = 1.60x10-7M) and OEA (EC50 = 2.83x10-7M). 
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In 16.7mM glucose, AS1269574 increased insulin secretion 1.2 to 2.4-fold (10-8-10-4M, p<0.01-
p<0.001) from BRIN-BD11 cells. OEA demonstrated a 1.1 to 1.7-fold (10-10-10-4M, p<0.05-
p<0.001) increase while PEA demonstrated a 1.2 to 1.7-fold increase (10-8-10-4M, p<0.05-p<0.001). 
PEA demonstrated the highest potency (EC50 = 7.7x10-8M) whilst OEA (EC50 = 1.3x10-7M) 
demonstrated a greater potency than AS1269574 (EC50 = 1.3X10-7M) in 16.7mM glucose. All 
agonists tested demonstrated no adverse effects on cell viability or proliferation at both 
concentrations of glucose tested as measured by MTT. 
Immunohistochemistry in both lean and HFF mouse small intestine and GLUtag cells determined 
the localisation of GPR119 and GLP-1 in the L-cells of the intestine as well as GIP and GPR119 in 
intestinal K cells. The presence of GPR119 in the L-cells of the intestine as co-localisation was 
observed between GPR119 and PYY in STC-1 cells and both lean and HFF NIH Swiss mouse small 
intestine. Gene expression analysis of NIH Swiss mouse small intestine via qPCR showed that a 
HFF diet increases GPR119 expression 1.2-fold compared to lean (p<0.05). GPR119 OEA and PEA 
demonstrated no effect on GPR119 gene expression in GLUTag cells while AS1269574 
demonstrated a 1.4-fold increase (p<0.05). 
Oral administration of AS1269574 and OEA (0.1μmol/kg BW) to fasted male Swiss TO mice 
resulted in acute improved glucose homeostasis. AS1269574 reduced blood glucose 45.6 and 34.8% 
(p<0.001) 15 and 30 mins post administration while AS1269574 in combination with Sitagliptin 
reduced blood glucose 37.6%, 56.4%, 44.6% and 38.8% at 15, 30, 60 and 90 mins respectively 
(p<0.05-p<0.001). OEA administration reduced blood glucose by 40.7% and 36.2% at 30 and 60 
mins (p<0.05-p<0.001) post administration while the addition of Sitagliptin to OEA administration 
resulted in a 34.2% and a 51.3% reduction in blood glucose (p<0.05-p<0.001. Administration with 
Exendin-9 reduced the effect of AS1269574 by 49.7% at 15 min. OEA administered in combination 
with Exendin-9 had reductions of 36.8% and 31.5% at 30 and 60 mins post administration (p<0.05-
p<0.01). Sitagliptin alone reduced glycaemic excursion 30.9% at 30 mins and 54.8% at 90 mins 
post administration. AS1269574 demonstrated a 1.6 (p<0.05) to 3.4-fold increase in insulin 
secretion (p<0.001) 15 and 30 mins post administration. OEA increased insulin secretion 3.4-fold 
30 mins post administration (p<0.001). AS1269574 in combination with Sitagliptin increased 
insulin secretion 2.7-fold (p<0.001) 30 mins post administration. OEA administered in combination 
with Sitagliptin also demonstrated insulinotropic effects 30 mins post administration with an 
increase of 3.1-fold being observed (p<0.001).The addition of 0.1μmol/kg BW Exendin-9 reduced 
the insulin secretory effect of AS1269574 and the effects of OEA were decreased 1.9-fold 
(p<0.001).  
AS1269574 administered orally increased GLP-1 secretion 2.5 and 4.9-fold 15 and 30 mins post 
administration (p<0.001). OEA increased GLP-1 secretion 2.7-fold 30 mins post administration 
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(p<0.001). Overall AS1269574 increased GLP-1 secretion 1.9-fold compared to OEA (p<0.01). 
AS1269574 increased GIP secretion 2.7-fold (p<0.001) while OEA exhibited a 3.0-fold (p<0.001) 
increase 15 mins post administration. The overall effect of OEA on GIP secretion was 1.2-fold 
higher than AS1269574 (p<0.05). 
Chronic oral treatment with AS1269574 (0.1μmol/kg body weight) decreased blood glucose 35.4% 
(p<0.01) while AS1269574 combination therapy with Sitagliptin reduced blood glucose 32.3% 
(p<0.001). Plasma insulin was increased 2.0-fold (p<0.001) in mice treated with AS1269574 while 
mice that received AS1269574 combination therapy exhibited an increase of 1.9-fold (p<0.001) 
compared to streptozotocin induced diabetic mice. Chronic treatment with AS1269574 and 
AS1269574 in combination with Sitagliptin increased plasma incretin hormone levels compared to 
both lean and streptozotocin induced diabetic mice treated with saline. AS1269574 monotherapy 
increased plasma GLP-1 levels 2.0 and 2.5-fold compared to diabetic mice after 12 and 21 days of 
treatment respectively (p<0.001). AS1269574 combination therapy increased plasma GLP-1 levels 
2.3-fold after 21 days of treatment (p<0.001). AS1269574 in combination with Sitagliptin increased 
plasma GIP levels 2.9-fold compared to diabetic mice after 21 days of treatment (p<0.001). 
AS1269574 monotherapy produced a 2.2-fold increase after 21 days of treatment (p<0.001). 
Oral glucose tolerance tests showed that AS1269574 treated mice had a 1.7-fold (p<0.001) overall 
reduction in blood glucose when compared to streptozotocin mice. AS1269574 in combination with 
Sitagliptin reduced hyperglycaemia 1.9-fold (p<0.001). Overall chronic AS1269574 treatment led 
to a 1.4-fold increase in insulin secretion (p<0.01) and AS1269574 combined with Sitagliptin 
increased insulin secretion 1.4-fold compared to streptozotocin treated mice (p<0.01). Treatment 
with AS1269574 and AS1269574 in combination with Sitagliptin had no effect on insulin 
sensitivity. 
Daily oral administration of AS1269574 decreased body weight 1.2-fold (p<0.05) compared to 
diabetic mice. AS1269574 in combination with Sitagliptin had increased lean mass with a 1.2-fold 
(p<0.05) increase being observed compared to streptozotocin treated mice. AS1269574 treatment 
had a 2.1-fold (p<0.05) reduction in fat mass. In mice treated with AS1269574, bone mineral density 
of the femur was reduced 1.1-fold (p<0.05) compared to lean mice but increased 1.3-fold compared 
to streptozotocin induced diabetic mice treated with saline (p<0.001). AS1269574 combination 
therapy increased bone mineral content 1.4-fold compared to diabetic mice treated with saline 
(p<0.001) 
This study determines the role of GPR119 activation in gastrointestinal hormone secretion 
suggesting GPR119 have an important therapeutic role in the treatment of Type 2 Diabetes and 





GPR119 was first identified via bioinformatical analysis along with 6 other receptors (Fredriksson 
et al. 2003c). This analysis mapped the human gene for GPR119 to chromosome 26 which codes 
for a 335 amino acid long protein. The mouse ortholog, which is the same length as the human 
protein, has 82% amino acid sequence homology with the human protein. An ortholog in pufferfish 
was found during this analysis suggesting that GPR119 was present in early vertebrates more than 
450 million years ago.  
Following the identification of GPR119, it was one of many receptors which were of interest to 
researchers looking at the activation of orphan GPCRs with a view to using them as novel therapies. 
Research into GPR119 then focused on its deorphanisation which was achieved when 
lysophosphatidylcholine was discovered as a GPR119 agonist with the ability to increase insulin 
secretion from the β-cells of the pancreas (Soga et al. 2005). This work was further supported by 
the discovery of OEA as an endogenous ligand for the receptor (Overton et al. 2006). The 
identification of OEA as an endogenous ligand for GPR119 allowed the same researchers to develop 
a novel synthetic selective ligand for GPR119 known as PSN632408. This work focused on the 
appetite reducing effects of GPR119 agonists which suggests a role for GPR119 activation in 
reducing obesity and obesity related disorders such as Type 2 Diabetes, thus supporting the earlier 
research which had been carried out. It also confirmed the presence of higher levels of GPR119 
gene expression in the islets of the pancreas compared with whole pancreas suggesting that GPR119 
may have a role in the regulation of metabolic disorders. 
The action of activated GPR119 can be blocked by a number of antagonists. One such antagonist, 
TM43718, blocked the action of AS1269574 and AR231453 (Engelstoft et al. 2014). AR436352 
was also identified as an antagonist against the action of OEA and both antagonists acted as inverse 
agonists for GPR119 in the absence of GPR119 agonists (Engelstoft et al. 2014). Other GPR119 
agonists that have been identified include Compound 8 and the partial antagonist Compound 1 
(McClure et al. 2011). The GLP1R antagonist Exendin 9-39 has also demonstrated the ability to 
antagonise GPR119 and has also been used in studies involving glucose homeostasis (Moran et al. 
2014a, McKillop et al. 2016).  
Research by (Soga et al. 2005) and (Overton et al. 2006) identified GPR119 as a receptor which 
works through the activation of adenylate cyclase leading to the production of intracellular cAMP. 
(Sakamoto et al. 2006) complimented these results by determining that GPR119 was bound to a Gαs 
protein inside the cell. However, other studies have also shown that GPR119 can increase insulin 
secretion through the voltage gated calcium ion channels as GPR119 activation has led to an 
increase in intracellular calcium (Ning et al. 2008, Moran et al. 2014a).  
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Further research focused on the localisation of GPR119 within the islet (Sakamoto et al. 2006). 
Using immunohistochemistry it was determined that GPR119 was co-localised with PPY in the PP-
cells of the islet. However, gene expression studies confirmed the presence of GPR119 in the insulin 
secreting MIN6 and glucagon secreting αTC1.9 cell line suggesting that GPR119 is present in both 
the α and β cells of the islet. The effects of GPR119 activation on insulin secretion have since been 
tested in BRIN-BD11 cells (Moran et al. 2014a), MIN6 cells (Ning et al. 2008), NIT-1 cells 
(Yoshida et al. 2011) and HIT-T15 cells (Oshima et al. 2013) as well as in vivo (Moran et al. 2014a, 
Oshima et al. 2013, Yoshida et al. 2011). 
In order for GPR119 to be used as a target in the regulation of metabolic disorders, it is important 
that insulin secretion is glucose-dependent. This was tested in relation to GPR119 activation in 
MIN6 cells (Lan et al. 2012). This study determined that the increase in insulin secretion mediated 
by GPR119 is glucose dependent. Furthermore this study also determined that activation of GPR119 
can increase GLP-1 secretion from the intestinal L-cells. This effect was found to be independent 
on insulin levels and was thought to be due to higher basal calcium levels in L-cells compared to β-
cells. GPR119 mediated GLP-1 secretion was confirmed in insulin resistant mice (Ahlkvist, Brown 
& Ahren 2013) which further the supports the concept that GPR119 activation can be used as a 
therapeutic treatment for metabolic disorders. 
The presence of GPR119 in GIP secreting K-cells of the intestine has previously been determined 
(Parker et al. 2009). However, a contrasting study found no GPR119 present in GIP secreting cells 
in rat duodenum (Chu et al. 2008) using in situ hybridisation. Remarkably the same study found 
that oral gavage of GPR119 agonist AS231453 increased plasma GIP and that this effect was lost 
in GPR119 knockout mice. This is further supported as GLP1R knockout mice had significantly 
increased levels of GIP when treated orally with AS231453 (Flock et al. 2011). There was not such 
a significant increase in plasma GIP in wild type mice upon GPR119 activation which suggests that 
GPR119 mediated GLP-1 secretion may have an effect on GIP secretion in vivo. 
As GPR119 has shown the ability to augment the incretin hormones, further research has looked at 
other intestinal hormones which regulate insulin secretion or may play a role in metabolic disorders. 
One such hormone is PYY. Activation of GPR119 with GSK263 was shown to have a 5-fold 
increase on PYY compared to placebo in humans (Nunez et al. 2014a). Interestingly this study 
found that GPR119 activation by GSK263 had no effect on GLP-1 or GIP secretion. This is further 
supported by work in PYY knockout mice which showed that there was no effect on PYY secretion 
upon GPR119 activation while orally delivered GPR119 agonists reduced blood glucose in wild 
type mice (Cox et al. 2010) suggesting that GPR119 mediates PYY secretion. 
GPR119 activation has been shown to play a role in glycaemic control through various methods as 
mentioned above. This study identifies the effects of GPR119 activation on insulin, GLP-1, GIP 
275 
 
and PYY secretion both in vitro and in vivo. This was achieved using the endogenous agonists OEA 
and PEA and the synthetic agonist AS1269574 and a range of cell lines along with Swiss TO mice. 
The effects of these agonists on the genes which code for these hormones along with the expression 
of the receptor itself was determined by qPCR. Immunohistochemistry determined the cellular 
localisation in all cell lines used along with lean and HFF diet mice. Both OEA and AS1269574 
were then further investigated in vivo. 
 
7.3: Materials and methods 
 
7.3.1: Materials 
OEA (ab141141), PEA (ab120345) and were purchased from Abcam (Cambridge, UK). 
AS1269574 was purchased from R & D Systems (Minnesota, USA). Multi species GLP-1 total and 
rat/mouse GIP total ELISA kits were purchased from Merck Millipore (Watford, UK). 
 
7.3.2: Acute hormone secretion from intestinal cell lines 
GLUTag or pGIPneo STC-1 cells were seeded into 24-well plates with 150000 cells per well which 
were incubated overnight in 1ml of culture medium (as described previously in Chapter 2, section 
2.1) at 37°C and 5% CO2. To ensure that cells grew in monolayers, they were pipetted up and down 
vigorously to ensure proper mixing before seeding. After overnight incubation and preincubation 
with 1.1mM glucose for 40 mins, acute incubations were carried out at 37°C 5% CO2 for 2 hrs in 
2mM glucose in KRBB buffer supplemented with 10-12 to 10-4M concentrations of AS1269574, 
OEA and PEA. After incubations, supernatants (950μl) were collected and frozen at -20°C until 
ELISA could be carried out. 
 
7.3.3: Acute insulin secretion from pancreatic BRIN-BD11 cells 
Cells were seeded into 24-well plates with 150000 BRIN-BD11 cells per well and incubated 
overnight in 1ml of RPMI 1640 media at 37°C and 5% CO2. Following this incubation, cells were 
preincubated with 1.1mM glucose for 40 mins with subsequent acute incubations being carried out 
at 37°C 5% CO2 for 20 mins in 5.6mM and 16.7mM glucose in KRBB buffer supplemented with 
10-12 to 10-4M concentrations of AS1269574, OEA and PEA with 10mM alanine as a positive 
control. After incubations, supernatants (950μl) were collected and frozen at -20°C until 
radioimmunoassay could be carried out. 
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7.3.4: Acute effects of GPR119 agonists on cell toxicity 
Cells were seeded in 96-well plates with 40000 cells per well of BRIN-BD11, GLUTag or pGIPneo 
STC-1 cells and incubated overnight in cell culture media (as described in Chapter 2, section 2.1) 
in an atmosphere of 5% CO2 at 37°C. After 20 hrs, BRIN-BD11 cells were preincubated with 
1.1mM glucose for 40 mins with subsequent acute incubations being carried out at 37°C 5% CO2 
for 20 mins in 5.6mM and 16.7mM glucose in KRBB buffer supplemented with 10-12M to 10-4M 
concentrations of GPR119 agonist with 1mM H2O2 as a cytotoxic control (n=3). After 48hrs, 
GLUTag and pGIPneo STC-1 cells were preincubated with 1.1mM glucose for 40 mins with 
subsequent acute incubations being carried out at 37°C 5% CO2 for 2 hrs in 2mM in KRBB buffer 
supplemented with 10-12M to 10-4M concentrations of GPR119 agonists with 1mM H2O2 as a 
cytotoxic control (n=3). After incubation, supernatant was decanted, cells were washed with HBSS 
and 0.5mg/ml MTT was added for 2 hrs. Following MTT incubation, supernatant was discarded 
and DMSO was added to solubilise crystals. Optical density was subsequently measured at 570nm 
and 630nm using the Flexstation 3 (Molecular Devices, CA, USA).  
 
7.3.5: Immunofluorescence staining in GLUTag, pGIPneo STC-1, STC-1 cells and lean and HFF 
NIH Swiss mouse small intestine 
GLUTag, pGIPneo STC-1 and STC-1 cells were seeded at a density of 40000 cells on to polylysine 
coated slides overnight at 37°C in an atmosphere of 95% air and 5% CO2 as described in Chapter 2, 
section 2.1. Swiss TO mice were anesthetised by isoflurane and killed by cervical dislocation. 
Pancreas and intestine was excised as described in Chapter 2, section 2.6.3. Immunohistochemistry 
was carried out by incubating with rabbit polyclonal anti-GPR119 and goat polyclonal anti-GLP-1, 
goat polyclonal anti-GIP or goat polyclonal anti-PYY with the dilutions outlined in Chapter 2, Table 
2.1. 
 
7.3.6: Quantitative real-time PCR (qPCR) 
qPCR was performed using LightCycler® 480 SYBR Green I Master. Reactions were performed 
using 4.5μl of 2x concentrated SYBR green, 1μl of forward and reverse primers (primer sequences 
are listed in Chapter 2, Table 2.2), 1μl of cDNA and 3μl of RNase free water (n=3). All reactions 
included a negative template control with RNase free water added instead of cDNA (n=3). The 
reactions were carried out in 8-well real-time PCR Tube Strips and Masterclear™ Cap Strips 
(Eppendorf, HAM, DE). Amplification conditions were 5 mins initial denaturation at 95°C, 
followed by 40 cycles of 30 secs denaturation at 95°C, 30 secs annealing at 58°C and 30 secs 
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extension at 72°C and a final elongation step for 5 mins at 72°C. Reactions included melting curve 
analysis with temperature range of 60 °C to 90 °C. All reactions were carried out using the 
MiniOpticon two colour real time PCR detection system (BioRad, UK). Analysis of results was 
performed using the Livak method and the mRNA levels of all genes were normalised using the 
housekeeping gene GAPDH. 
 
7.3.7: Acute in vivo glucose tolerance tests 
Male Swiss TO mice were housed as described in Chapter 2, section 2.7. The effects GPR119 
agonists AS1269574 and OEA (0.1μmol/kg BW), as well as in combination with Sitagliptin 
Phosphate (50mg/kg BW) in lean male Swiss TO mice were investigated. Before test compounds 
were administered mice were fasted for 18 hrs and blood subsequently collected (t=0). Test 
compounds were administered orally in glucose (18mmol/kg BW), and blood was collected at 15, 
30, 60, 90 and 120 mins along with blood glucose measurements. Collected blood was centrifuged 
at 13200rpm for 5 mins at 4°C using a Beckman centrifuge (Beckman Instruments, UK). Plasma 
was stored at -20°C until hormone measurements by RIA or ELISA as described in Chapter 2, 
section 2.2 and 2.3. 
 
7.3.8: Multiple low dose streptozotocin induced-diabetic mice 
Age-matched (26 wks), male Swiss TO mice were sourced from Envigo (Huntingdon, UK). Mice 
were housed in single cages and were supplied drinking water and standard rodent maintenance diet 
(60% carbohydrate, 30% protein, 10% fat (12.99 kJ/g), Trouw Nutrition, Cheshire, UK) ad libitum. 
Diabetes was chemically induced in 4 hr fasted Swiss TO mice through 4 intraperitoneal injections 
of streptozotocin (40mg/kg body weight, 0.1M sodium citrate, pH 4.5) which were received on 
alternate days. Diabetes was confirmed through an oral glucose tolerance test (OGTT) which was 
performed 14 days after the first injection of streptozotocin injection (day 0) on 18 hr fasted Swiss 
TO mice.  
 
7.3.9: Treatment procedure and parameters assessed  
The long term effects of oral AS1269574 (0.1µmol/kg BW) or saline (0.9% w/v NaCl) in multiple 
low dose streptozotocin-induced diabetic Swiss TO mice (n=6) was assessed over a period of 21 
days. Hyperglycaemia was confirmed in diabetic mice through an oral glucose tolerance test which 
was performed 14 days after the first streptozotocin injection (day 0) on 18 hr fasted NIH Swiss 
mice as previously described (Chapter 2, section 2.8.2). Fluid intake, food intake, body weight, non-
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fasted blood glucose, insulin, GLP-1 and GIP concentrations were monitored every 3 days. Blood 
was collected via tail vein bleeding of conscious mice and was collected and analysed for blood 
glucose, insulin, GLP-1 and GIP as described in Chapter 2, section 2.8.4. After the testing period, 
glucose tolerance tests (18mmol/kg body weight) were carried out to assess glucose tolerance on 
18 hr fasted streptozotocin treated mice and Swiss TO mice on standard rodent maintenance diet as 
outlined in Chapter 2, Section 2.8.2. 
 
7.3.10: Insulin sensitivity   
Prior to the injection of insulin, blood glucose was measure in non-fasted Swiss TO mice via tail 
vein bleeding using the Bayer Contour glucose meter. Bovine insulin (25U/kg) in 0.9% saline was 
administered using intraperitoneal injection of bovine insulin (25U/kg) and blood glucose was 
monitored at 30 and 60 mins post injection.   
 
7.3.11: Dual energy X-ray absorption (DEXA)  
Non-fasted Swiss TO mice were culled by cervical dislocation after being anesthetised using 
isoflurane, and subsequently arranged on the specimen tray to ensure both limbs and tail were 
extended away from the body. In order to ensure calibration and quality control, 25 measures of the 
aluminium/lucite phantom (0.069g/cm2, 12.0% fat) were taken using a Lunar PIXImus Dual energy 
X-ray absorption (DEXA) system (software version 1.4x) before any specimens were measured. 
DEXA scanning was performed on all carcasses as per manufacturer’s guidelines. The Lunar 
PIXImus DEXA system measures percentage body fat as well as bone mineral density (BDM, 
g/cm3) and bone mineral content (BMC, g) using a fully integrated densitometer.  
 
7.3.12: Measurement of plasma hormones 
Blood was collected via tail vein bleed on conscious mice every 3 days for biochemical analysis on 
a variety of hormones. Blood glucose determination was performed using a Bayer Contour Next 
meter (Leverkusen, DE) every 3 days. Plasma insulin was quantified using insulin RIA as 
previously described in Chapter 2, section 2.2. Rat/mouse GIP total ELISA kit (Millipore, Watford, 
UK) was used to measure total GIP concentrations in mouse plasma following chronic treatment. 
Multi species GLP-1 total ELISA was used to measure total GLP-1 content of mouse plasma. These 




7.3.13: Assessment of plasma lipid profiles  
Plasma triglyceride and HDL cholesterol concentrations were measured using an I-lab 650 clinical 




7.4.1: Effects of GPR119 agonists and antagonist Exendin-9 on GLP-1 secretion from intestinal 
GLUTag cells 
The intestinal GLP-1 secreting GLUTag cell line was treated with the GPR119 agonists tested 
above. In order to determine the selectivity of each agonist for GPR119, cells were treated with 
agonist and GPR119 antagonist Exendin-9.  
Of the agonists tested, PEA demonstrated the greatest GLP-1 secretory ability demonstrating a 1.3 
to 2.5-fold (p<0.01-p<0.001) increase compared to basal control (Figure 7.3A) at concentrations of 
10-8M to 10-4M. When administered in combination with 10-7M Exendin-9, the secretory effect of 
PEA was reduced 1.3 to 1.8-fold (10-8M to 10-4M, p<0.05 to p<0.01). Addition of 10-7M Exendin-
9 did not completely prevent PEA from increasing GLP-1 secretion, with secretion being increased 
1.4 and 2.0-fold when 10-6M and 10-4M PEA was added in the presence of Exendin-9. 
The other endogenous GPR119 agonist tested, OEA, increased GLP-1 secretion 1.8 to 2.0-fold 
(p<0.001, Figure 7.2A). The addition of 10-7M Exendin-9 along with OEA reduced its GLP-1 
secretory ability 1.2 to 2.0-fold (10-8M to 10-4M, p<0.05-p<0.001) when compared to agonist treated 
cells alone. As seen with PEA, the presence of Exendin-9 did not completely prevent OEA from 
having a secretory effect on GLUTag cells. 10-4M OEA in the presence of 10-7M Exendin-9 
increased GLP-1 secretion 1.4-fold. 
Synthetic agonist AS1269574 (Figure 7.1A) demonstrated a 1.6-fold increase in GLP-1 secretion 
when compared to basal control (10-6M, p<0.01). In the presence of Exendin-9, the secretory action 
of AS1269574 was reduced 2.0-fold at 10-6M (p<0.05).  
AS1269574 was the most potent agonist which had an effect on GLP-1 secretion with an EC50 of 





7.4.2: Effects of GPR119 agonists and antagonist Exendin-9 on GIP secretion from intestinal 
pGIPneo STC-1 cells 
In order to assess the ability of GPR119 activation in the K cells of the intestine, pGIPneo STC-1 
cells were treated with GPR119 agonists. As also used in GLUTag cells, Exendin-9 determined 
agonist selectivity for GPR119.  
AS1269574 demonstrated no secretory effect on GIP compared to 2mM basal control (Figure 7.4A). 
Interestingly, at the lowest AS1269574 concentration tested, 10-8M, the presence of Exendin-9 
reduced GIP secretion 1.1-fold (p<0.05). However, endogenous GPR119 agonist PEA 
demonstrated GIP secretory action with a 1.1 to 1.8-fold increase (10-6M to 10-4M, p<0.05, Figure 
7.6A). In the presence of GPR119 agonist 10-7M Exendin-9, this action was decreased 1.6-fold (10-
4M, p<0.05). All agonists tested demonstrated no cytotoxic effects as measured by MTT assay 
(Figures 7.4B-7.6B). The other endogenous agonists tested, OEA, increased GIP secretion 1.9-fold 
10-4M, p<0.01, Figure 7.5A). In the presence of Exendin-9 this effect was reduced 1.5-fold (p<0.05). 
 
7.4.3: Effects of GPR119 agonists on insulin secretion from pancreatic BRIN-BD11 cells 
The insulinotropic ability of synthetic GPR119 agonist AS1269574 and endogenous agonists OEA 
and PEA in clonal BRIN-BD11 cells were tested at both normal and hyperglycaemic conditions 
(Figures 7.7-7.12). AS1269574 (Figure 7.7A) stimulated insulin secretion from 1.3 to 2.4-fold (10-
8-10-4M, p<0.01-p<0.001) whilst OEA (Figure 7.9A) demonstrated a 1.4 to 2.2-fold increase in a 
dose dependent manner (10-8-10-4M, p<0.05-p<0.001). A 1.1 to 1.5-fold increase in insulin secretion 
from BRIN-BD11 cells was observed from BRIN-BD11 cells treated with PEA (Figure 7.11A) at 
concentrations of 10-8 to 10-4M (p<0.05-p<0.001).  
AS1269574 (Figure 7.8A) augmented insulin secretion 1.2 to 2.4-fold (10-8-10-4M, p<0.01-
p<0.001) in hyperglycaemic conditions whilst OEA (Figure 7.10A) demonstrated a 1.1 to 1.7-fold 
(10-10-10-4M, p<0.05-p<0.001) increase. PEA (Figure 7.12A) demonstrated a 1.2 to 1.7-fold 
increase (10-8-10-4M, p<0.05-p<0.001) in 16.7mM glucose.  
The calculation of the EC50 value for each agonist was used as a measure of potency. In 5.6mM 
glucose (Figure 7.13A), all agonists tested had very similar potencies with AS1269574 having an 
EC50 of 1.17x10-7M, OEA demonstrating an EC50 of 2.83x10-7M and the EC50 of PEA being 
calculated as 1.60x10-7M. However in hyperglycaemic conditions (Figure 7.13B), PEA 
demonstrated the highest potency (7.7x10-8M) whilst OEA (1.3x10-7M) demonstrated a greater 
potency than AS1269574 (1.3X10-7M). Both AS1269574 and OEA demonstrated lower potency in 
16.7mM glucose compared to 5.6mM glucose while the reverse was observed for PEA. All agonists 
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tested demonstrated no adverse effects on cell viability or proliferation (Figures 7.7B-7.12B) at both 
concentrations of glucose tested. 
 
7.4.4: Distribution of GPR119 and GLP-1 in intestinal GLUTag cells and lean and HFF NIH Swiss 
mouse small intestine 
Immunohistochemistry in both lean and HFF mouse small intestine and GLUtag cells determined 
the localisation of GPR119 and GLP-1 in the L-cells of the intestine. GLP-1 was found to be 
expressed mainly inside clumps of L-cells (Figure 7.14B) while its presence was confirmed in both 
lean and HFF NIH Swiss mice small intestine (Figure 7.15B and 7.16B). GPR119 was found to 
widespread throughout GLUTag cells (Figure 7.14C). It was also found to be present alongside 
GLP-1 in both lean and HFF small intestinal L-cells (Figure 7.15D and 7.16D). Gene expression 
analysis of NIH Swiss mouse small intestine via qPCR showed that a HFF diet increases GPR119 
expression 1.2-fold compared to lean (p<0.05, Figure 7.17). 
 
7.4.5: Distribution of GPR119 and GIP in intestinal pGIPneo STC-1 cells and lean and HFF NIH 
Swiss mouse small intestine 
Similarly to intestinal L-cells, immunohistochemistry of both lean and HFF mouse small intestine 
(Figure 7.19 and Figure 7.20) and pGIPneo STC-1 cells (Figure 7.18) was carried out to determine 
the cellular localisation of GPR119 and GIP. GIP was present in the majority of pGIPneo STC-1 
cells (Figure 7.18B) while GPR119 was present at lower levels (Figure 7.18C). The presence of 
GPR119 and GIP was confirmed in both lean and HFF NIH Swiss mouse small intestine (Figures 
7.19B and 7.20B). GPR119 was confirmed to be present in the intestine of both lean and HFF mice 
(Figure 7.19C and 7.20C) and double immunofluorescence determined the presence of GPR119 and 
GIP in the same K-cells (Figure 7.19D and Figure 7.20D).  
 
7.4.6: Distribution of GPR119 and PYY in intestinal STC-1 and lean and HFF NIH Swiss mouse 
small intestine 
The presence of GPR119 in intestinal L-cells was proven with double immunohistochemistry for 
both GLP-1 and GPR119. Double staining was then carried out to determine if GPR119 is present 
in PYY secreting L-cells in both lean and HFF mouse small intestine. This was confirmed 
demonstrating that GPR119 activation may have an effect on PYY secretion (Figure 7.22 and Figure 
7.23). STC-1 cells are a PYY secreting cell line and double immunohistochemistry was carried out 
to determine their suitability in the study of the effects of GPR119 on PYY secretion (Figure 7.21). 
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Both GPR119 and PYY were found throughout STC-1 cells confirming their suitability for future 
in vitro experiments (Figure 7.21). 
 
7.4.7: Effects of GPR119 agonists on GPR119 gene expression in intestinal GLUTag cells 
The effects of GPR119 agonist treatment on GPR119 gene expression in GLUTag cells was 
assessed using qPCR (Figure 7.24). Endogenous GPR119 agonists OEA and PEA demonstrated no 
effect on GPR119 gene expression compared to vehicle control. AS1269574 exhibited a 1.4-fold 
increase in GPR119 expression when compared to 2mM glucose control (p<0.05). 
 
7.4.8: Acute effects of GPR119 agonists on incretin hormones in male Swiss TO mice 
In order to assess the effects of GPR119 agonists on GLP-1 and GIP secretion, both OEA and 
AS1269574 were administered orally and secretion levels were checked after 0, 15 and 30 mins 
respectively. GPR119 agonist AS1269574 demonstrated the greatest increase in GLP-1 secretion 
with a 2.5 and 4.9-fold increase being observed 15 and 30 mins post administration (p<0.001, Figure 
7.25A). The endogenous GPR119 agonist OEA only increased GLP-1 secretion 30 mins post 
administration with a 2.7-fold increase being observed (p<0.001). Overall AS1269574 increased 
GLP-1 secretion 1.9-fold compared to OEA (p<0.01, Figure 7.25B). 
Both AS1269574 and OEA increased GIP secretion 15 mins post administration with GIP secretion 
returning to basal levels 30 mins post administration (Figure 7.26A). OEA demonstrated the greatest 
increase on GIP secretion potentiating GIP secretion 3.0-fold (p<0.001). GIP secretion was 
increased 2.7-fold when AS1269574 was administered after 15 mins (p<0.001). The overall effect 
of OEA on GIP secretion was 1.2-fold higher than AS1269574 (p<0.05, Figure 7.27B). 
 
7.4.9: Acute effects of GPR119 agonists on blood glucose and insulin in male Swiss TO mice 
AS1269574 and OEA (0.1μmol/kg BW) were orally administered to fasted male Swiss TO mice. 
AS1269574 reduced blood glucose at 15 and 30 mins post administration (Figure 7.27A) when 
compared to glucose administration alone. Glycaemic excursion was reduced 45.6 and 34.8% 
respectively at these time points (p<0.001). To ensure the specificity of AS1269574 for GPR119, 
AS1269574 and OEA were administered in conjunction with GPR119 antagonist Exendin-9. 
Administration with Exendin-9 reduced the effect of AS1269574 by 49.7% at 15 min. Both agonists 
were also tested along with the DPP-IV inhibitor Sitagliptin Phosphate. Sitagliptin alone reduced 
glycaemic excursion 30.9% at 30 mins and 54.8% at 90 mins post administration. AS1269574 
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administered along with Sitagliptin reduced blood glucose from 15 mins until 90 mins post 
administration. Glycaemic excursion was reduced 37.6%, 56.4%, 44.6% and 38.8% at 15, 30, 60 
and 90 mins respectively (p<0.05-p<0.001). No effect was observed after 120 mins.  
The effects of oral administration of AS1269574 on insulin secretion were observed both 15 and 30 
mins post administration (Figure 7.29A). Insulin secretion from male fasted Swiss TO mice was 
increased 1.6-fold 15 mins post administration (p<0.05) while this was increased to a 3.4-fold 
increase (p<0.001) compared to glucose control. AS1269574 in combination with Sitagliptin 
increased insulin secretion 2.7-fold (p<0.001). The addition of 0.1μmol/kg BW Exendin-9 reduced 
the insulin secretory effect of AS1269574, however it was not completely diminished with a 1.7-
fold increase in insulin secretion being observed 30 mins post administration (p<0.05). Overall 
AS1269574 increased insulin secretion 1.5-fold (p<0.001, figure 7.29B) while combination of 
Sitagliptin and AS1269574 increased insulin secretion 1.3-fold (p<0.001). Compared to the effects 
of Sitagliptin treatment alone, AS1269574 in combination with Sitagliptin and AS1269574 
treatment alone had no significant effect on insulin secretion. 
Oral OEA administration reduced blood glucose by 40.7% and 36.2% at 30 and 60 mins (p<0.05-
p<0.001) post administration (Figure 7.28A). GPR119 agonist Exendin-9 reduced the effect of OEA 
by 36.8% and 31.5% at 30 and 60 mins post administration (p<0.05-p<0.01). The addition of 
Sitagliptin to OEA administration lead to a 34.2% and a 51.3% reduction in blood glucose (p<0.05-
p<0.001).  
OEA increased insulin secretion 3.4-fold 30 mins post administration (p<0.001, Figure 7.30A). 
OEA administered in combination with Sitagliptin also demonstrated insulinotropic effects 30 mins 
post administration with an increase of 3.1-fold being observed (p<0.001). The presence of 
Exendin-9 reduced the insulin secretory effects of OEA, with an overall decrease of 1.9-fold being 
observed (p<0.001, Figure 7.30B).  
 
7.4.10: Acute effects of GPR119 agonists on feeding 
GPR119 agonists were orally administered orally to male Swiss TO mice which were trained to eat 
for 3 hrs daily. GPR119 agonists were also administered in combination with Sitagliptin. 
AS1269574 was unable to reduce feeding over the course of 3 hrs while AS1269574 in combination 
with Sitagliptin reduced appetite 1.2-fold 3 hrs post administration (p<0.05, Figure 7.31A).  
The endogenous GPR119 agonist OEA caused an initial 1.5-fold reduction in appetite (p<0.001, 
Figure 7.31B) 30 mins post administration. Although there was no reduction in feeding 60 mins 
post administration, appetite was reduced 1.2-fold 90, 120, 150 and 180 mins post administration 
(p<0.05-p<0.01). OEA in combination with Sitagliptin did not have an initial reduction in feeding 
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as seen with OEA, however appetite was reduced from 90 mins post administration. OEA in 
combination with Sitagliptin reduced appetite 1.2-fold (p<0.01) 90 mins post administration with 
decreases in appetite of 1.2, 1.2 and 1.3-fold being observed 120, 150 and 180 mins post 
administration. 
 
7.4.11: Effects of multiple low dose streptozotocin on blood glucose and plasma insulin in male 
Swiss TO mice 
Male Swiss TO mice administered multiple low dose streptozotocin via intraperitoneal injection 
had their blood glucose observed for 14 days after initial injection (Figure 7.34A). Streptozotocin 
induced diabetes caused a 1.6-fold reduction in blood glucose 2 days after the initial streptozotocin 
injection (p<0.001). Compared to lean mice, streptozotocin treated mice had a 1.3 and a 1.7-fold 
increase in blood glucose compared to lean mice 7 and 11 days post initial injection (p<0.01-
p<0.001). Seven days after the initial streptozotocin injection blood glucose had not increased 
however 11 days post initial injection there was a 1.5-fold (p<0.001) compared to initial levels. 
Lean mice underwent no changes in blood glucose for the duration of saline injections. 
In order to confirm impaired glucose regulation in streptozotocin induced diabetic mice, both lean 
and mice treated with multiple low dose streptozotocin were fasted for 18 hrs and underwent an oral 
glucose tolerance test (Figure 7.32A). Streptozotocin induced diabetic mice had increased blood 
glucose compared to lean mice before glucose was administered with a 1.7-fold increase being 
observed (p<0.01). Oral administration of 18mmol/kg BW glucose increased blood glucose in both 
lean and streptozotocin induced mice. Streptozotocin induced diabetic mice had higher blood 
glucose levels than lean mice with increases of 1.3, 1.6, 163, 1.8 and 1.9-fold at 15, 30, 60, 90 and 
120 mins post administration respectively (p<0.05-p<0.001). The overall increase in blood glucose 
of streptozotocin induced diabetic mice was 1.6-fold as determined by AUC (Figure 7.32B). 
Non-fasting blood glucose was also monitored before treatment started with streptozotocin induced 
diabetic mice having increased non-fasting blood glucose compared to lean mice with a 2.2-fold 
(p<0.001) increase in being observed (Figure 7.33A). Before treatment, streptozotocin treated mice 
were split into groups with no significant difference in blood glucose levels (Figure 7.33B). 
Mouse were fasted for 4 hrs before streptozotocin injection and streptozotocin treatment resulted in 
a reduction in body weight (Figure 7.35A) with a 1.1-fold decrease being observed on the last day 
of streptozotocin injection (p<0.01) and a 1.1-fold decrease being observed 14 days after the first 
injection (p<0.001). Lean mice had no reduction in body weight (Figure 7.35B) while the reduction 
in body weight in streptozotocin treated mice did not result in significant body weight differences 
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with lean mice before grouping (Figure 7.36A). After grouping, streptozotocin induced diabetic 
mice had no significant difference in body weight before treatment (Figure 7.36B). 
 
7.4.12: Effects of AS1269574 on non-fasting GIP and GLP-1 levels 
Treatment of streptozotocin induced diabetic mice with AS1269574 and AS1269574 in 
combination with Sitagliptin led to increased plasma incretin hormone levels compared to both lean 
and streptozotocin induced diabetic mice treated with saline (Figures 7.40A and 7.41A). 
AS1269574 treatment alone had the greatest effect on circulating GLP-1 levels with a 2.0 and 2.5-
fold increase compared to diabetic mice after 12 and 21 days of treatment respectively (p<0.001, 
Figure 7.40A). AS1269574 combination therapy increased plasma GLP-1 levels 2.3-fold after 21 
days of treatment (p<0.001). 
AS1269574 in combination with Sitagliptin increased plasma GIP levels 1.5-fold compared to 
diabetic mice after 12 days of treatment (p<0.05, Figure 7.41A). After 21 days of treatment, 
circulating GIP levels were increased 2.9-fold (p<0.001). AS1269574 treatment alone produced a 
1.5-fold increase after 12 days of treatment (p<0.01) and a 2.2-fold increase after 21 days of 
treatment (p<0.001). 
 
7.4.13: Effects of GPR119 agonist AS1269574 on body weight, fluid intake, non-fasting blood 
glucose and plasma insulin 
Mice with streptozotocin induced diabetes had increased blood glucose before treatment (Figure 
7.43A). AS1269574, AS1269574 with Sitagliptin and saline treated streptozotocin induced diabetic 
mice had increased blood glucose 6 days after oral treatment (p<0.001). After 9 days of oral 
treatment, mice treated with AS1269574 and Sitagliptin still had increased glucose compared to 
lean mice (AS1269574), however mice treated with AS1269574 had no significant difference 
compared to lean mice. After 12 days of treatment both AS1269574 and AS1269574 combination 
therapy treated mice had a 1.7 and 1.6-fold reduction in blood glucose compared to streptozotocin 
induced diabetic mice treated with 0.9% saline (p<0.05). These effects were maintained for the 
duration of the treatment with AS1269574 administration reducing blood glucose 1.8, 1.7 and 1.9-
fold compared to mice treated with saline (p<0.05-p<0.01) after 15, 18 and 21 days of treatment 
respectively. AS1269574 in combination with Sitagliptin reduced blood glucose 1.8, 2.1 and 1.7-
fold at the same time points (p<0.05-p<0.001). 
The body weight of streptozotocin mice treated with AS1269574 was reduced after 21 days of 
treatment (Figure 7.37A). AS1269574 monotherapy reduced body weight 18.7% (p<0.05) 
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compared to diabetic mice treated with saline. Interestingly both AS1269574 monotherapy and 
combination therapy with Sitagliptin reduced appetite (Figure 7.38B). AS1269574 combination 
therapy reduced appetite after 15 days of treatment with reductions of 23.0%, 34.4% and 27.2% 
(p<0.01 to p<0.001) after 15, 18 and 21 days respectively compared to diabetic mice administered 
saline. AS1269574 monotherapy displayed reductions of 27.1% and 30.4% (p<0.01 to p<0.001). 
AS1269574 monotherapy was also the only treatment to reduce fluid intake (Figure 7.39A) with a 
2.5-fold (p<0.001) reduction being observed after 21 days. 
 
7.4.14: Effects of AS1269574 on glucose tolerance and insulin sensitivity 
In order to assess the effects of daily oral administration of AS1269574 or AS1269574 in 
combination with Sitagliptin, oral glucose tolerance tests were performed after 21 days of treatment 
(Figures 7.44A and 7.45A). Both AS1269574 and AS1269574 combination treatment reduced 
blood glucose over the course of the test (Figure 7.44A). Overall, AS1269574 treated mice had a 
1.7-fold overall reduction in blood glucose when compared to streptozotocin mice dosed with saline 
over the course of the study (Figure 7.44B, p<0.001). AS1269574 in combination with Sitagliptin 
also had a reducing effect on hyperglycaemia with an overall decrease in blood glucose of 1.9-fold 
being observed (p<0.001).  
Both AS1269574 and AS1269574 in combination with Sitagliptin had an insulinotropic effect 
compared to streptozotocin mice when administered glucose orally (Figure 7.45A). AS1269574 in 
combination with sitagliption increased insulin secretion 1.4 and 1.4-fold 15 and 30 mins post 
administration (p<0.05-p<0.01). AS1269574 treated mice had a 1.3-fold increase in insulin 
secretion compared to streptozotocin treated mice (p<0.05). Lean mice demonstrated increased 
insulin secretion compared to streptozotocin induced diabetic mice treated with saline at all time 
points except for 60 mins post administration (p<0.01 to p<0.001). Overall AS1269574 treatment 
lead to a 1.4-fold increase in glucose stimulated insulin secretion (p<0.01) and AS1269574 
combined with Sitagliptin increased insulin secretion 1.4-fold (p<0.01) compared to streptozotocin 
treated mice (Figure 7.45B). Treatment with AS1269574 and AS1269574 in combination with 
Sitagliptin had no effect on insulin sensitivity (Figure 7.46). 
 
7.4.15: Effects of AS1269574 as measured by DEXA 
Streptozotocin induced diabetic mice had the highest body weight with a 1.1-fold increase compared 
to lean mice (Figure 7.48A, p<0.05). Daily oral administration of AS1269574 decreased body 
weight 1.2-fold (p<0.001) compared to diabetic mice treated with saline, with a 1.1-fold reduction 
being observed when compared to lean mice (p<0.01). Mice treated with AS1269574 combination 
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therapy displayed a 1.1-fold reduction in body weight compared to diabetic mice (p<0.05). This 
same treatment increased lean mass (Figure 7.48B) with AS1269574 in combination with 
Sitagliptin increasing lean mass 1.2-fold compared to streptozotocin treated mice (p<0.05) The 
reduction in body weight of AS1269574 mice was likely to reduced fat mass (Figure 7.49A) with 
this treatment reducing fat mass 2.1-fold (p<0.05). This resulted in a 1.4-fold decrease in body fat 
% (Figure 7.49B, p<0.05).  
AS1269574 treatment had no effect on overall bone mineral density (Figure 7.50B) while 
streptozotocin treated mice had the highest overall bone mineral content (Figure 7.50A). The results 
for bone mineral content were confirmed when focusing on the femur (Figure 7.51A), however 
bone mineral density was reduced in diabetic mice which displayed a reduction of 1.4-fold 
compared to lean mice (Figure 7.51B, p<0.001). In mice treated with AS1269574, bone mineral 
density of the femur was reduced 1.1-fold (p<0.05) compared to lean mice but increased 1.3-fold 
compared to streptozotocin induced diabetic mice treated with saline (p<0.001). AS1269574 
combination therapy increased bone mineral content 1.4-fold compared to diabetic mice treated 
with saline (p<0.001) 
 
7.4.16: Effects of chronic AS1269574 treatment on lipid profile 
Strepotozotocin treatment resulted in reduced triglycerides for all treatment groups (Figure 7.52A). 
Saline treated diabetic mice had a 2.9-fold (p<0.001) reduction in triglycerides compared to lean 
mice. AS1269574 monotherapy and combination therapy exhibited reductions of 2.4-fold and 2.1-
fold (p<0.001) compared to lean mice. Chronic treatment with AS1269574 had no effect on total 
cholesterol (Figure 7.52B) or HDL cholesterol levels (Figure 7.53B). All diabetic mice had reduced 
LDL levels compared to lean mice (Figure 7.53A) with saline treated mice having a 1.9-fold 
reduction (p<0.001) and AS1269574 combination therapy exhibiting a reduction of 2.1-fold 
(p<0.001). AS1269574 monotherapy reduced LDL cholesterol 3.3-fold (p<0.001) compared to lean 
mice and 1.7-fold (p<0.001) compared to diabetic mice treated with saline. 
 
7.5: Discussion  
Current therapies for Type 2 Diabetes include drugs such as metformin which have the ability to 
reduce circulating glucose levels in the blood. GPR119 has previously demonstrated the ability to 
increase insulin secretion and thus blood glucose (Moran et al. 2014a) while knockout of GPR119 
has reduced GLP-1 secretion in vivo (Moss et al. 2015). As a result, attention has focused on 
activating GPCRs such as GPR119 in the search for better anti-diabetic therapies. Some GPR119 
agonists have even made it into clinical trials (Nunez et al. 2014a). This study demonstrated that 
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GSK1292263 did not improve incretin hormone secretion or the glycaemic control of individuals 
with Type 2 Diabetes but did show that it increased plasma PYY levels in the same individuals. The 
ability of GPR119 to regulate glucose homeostasis and the lack of improved glucose homeostasis 
in diabetics treated with GSK1292263 mean the identification of novel GPR119 agonists which can 
increase incretin hormone secretin and improve glucose homeostasis are an exciting target with a 
view to Type 2 Diabetes therapeutics. 
The effects of GPR119 activation on insulin, GLP-1 and GIP secretion in vitro and in vivo was 
investigated in this study. GPR119 was first described in the pancreatic polypeptide secreting cells 
of the pancreatic islets (Sakamoto et al. 2006) however further studies described the expression of 
GPR119 in insulin secreting β-cells (Chu et al. 2008). Activation of GPR119 by the agonist 
AS1535907 has also previously been shown to increase insulin secretion (Yoshida et al. 2011). 
Therefore activation of GPR119 by fatty acids became a novel target for those looking to identify 
possible new drug targets for Type 2 Diabetes (Madiraju, Poitout 2007). In this study, the 
insulinotropic effects of GPR119 by both synthetic and endogenous agonists was investigated in 
the clonal BRIN-BD11 cell line at both normal and hyperglycaemic conditions. All agonists tested 
increased insulin secretion at both 5.6mM and 16.7mM glucose, confirming the insulinotropic effect 
of GPR119 agonists which had been described previously (Moran et al. 2014a). In terms of insulin 
secretion, the synthetic GPR119 agonist AS1269574 demonstrated the greatest ability to elicit an 
insulin secretory response in normal conditions. OEA was the best performing endogenous agonist 
in normal conditions followed by PEA. In order to determine the potency of each agonist, EC50 
values were calculated. In normal conditions, all agonists tested had similar potencies. 
In hyperglycaemic conditions, AS1269574 demonstrated the greatest insulinotropic ability whilst 
OEA and PEA had the same response at the highest concentration tested. However, OEA did 
demonstrate an insulin secretory effect at lower concentrations when compared to PEA. The 
determination of EC50 values for each agonist showed that PEA had the greatest potency for 
GPR119 despite the lower insulinotropic effect and OEA also demonstrated greater potency than 
the synthetic agonist AS1269574. 
As well as the insulin secretory effect described above, GPR119 activation has shown to have a 
positive effect on GLP-1 secretion from the intestine (Lan et al. 2012, Moss et al. 2015, Panaro et 
al. 2017a). In order to determine the effects of GPR119 activation on GLP-1 secretion by both 
endogenous and synthetic agonists, GLUTag cells were treated with AS1269574, OEA and PEA. 
Double immunohistochemistry for GLP-1 and GPR119 confirmed the expression of GPR119 in 
GLUTag cells which confirms results which have been described previously (Lan et al. 2012). The 
endogenous agonist PEA demonstrated the greatest GLP-1 secretory ability followed by 
endogenous agonist OEA and the synthetic agonist AS1269574. Treatment of GLUTag cells with 
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GPR119 agonists OEA and AS1269574 along with Exendin-9 confirmed their selectivity for 
GPR119. EC50 values determined that AS1269574 was the most potent agonist in GLUTag cells 
followed by OEA and then PEA. This confirms previous work which has shown OEA increases 
GLP-1 secretion in GLUTag cells and mice after intraluminal administration (Lauffer, Iakoubov & 
Brubaker 2009). The same study demonstrated that PEA has no effect on GLP-1 secretion in 
GLUTag cells however this was at lower concentrations than those used in this study. The 
selectivity of OEA for GPR119 was also confirmed using gene knockdown. This selectivity has 
been confirmed in the colon of GPR119 knockout mice (Moss et al. 2015). AS1269574 has also 
previously shown the ability to increase GLP-1 secretion in vitro in STC-1 cells (Chepurny et al. 
2016).  
Further to the secretory tests, gene expression analysis was carried out on GLUTag cells treated 
with GPR119 agonists. The effects of GPR119 activation on proglucagon, PC1 and GPR119 was 
assessed. Treatment of GLUTag cells with endogenous GPR119 agonists OEA and PEA had no 
effect on GPR119 expression when compared to vehicle control. However, synthetic agonist 
AS1269574 upregulates GPR119 gene expression in intestinal L cells. This is similar to results 
demonstrated previously which showed that this agonist increased the proglucagon gene promoter 
activity in the same cell line (Chepurny et al. 2013) Need to add more here on the significance of 
these findings. 
GPR119 has previously been shown to be present in K cells of the intestine at similar levels to that 
seen in L cells (Parker et al. 2009, Reimann, Gribble 2016) and GPR119 agonists have previously 
been shown to increase GIP secretion (Chu et al. 2008, Flock et al. 2011, Patel et al. 2014). The in 
vitro effects of GPR119 activation on GIP secretion was determined through treatment of pGIPneo 
STC-1 cells with GPR119 agonists. As with GLUTag cells, double immunohistochemistry was first 
carried out to ensure the presence of both GIP and GPR119. AS1269574 demonstrated no ability to 
increase GIP secretion in vitro. However, endogenous GPR119 agonists OEA and PEA stimulated 
GIP secretion. Treatment of pGIPneo STC-1 cells with PEA and GPR119 agonist Exendin-9 
confirmed the selectivity of PEA for GPR119. 
To complement the in vitro studies, mice were administered with either OEA or AS1269574 orally. 
Oral administration was chosen in order to further study the effects of GPR119 activation on 
intestinal hormone secretion. These agonists have been administered previously via intraperitoneal 
injection to confirm their insulinotropic and glucose regulatory effects (Moran et al. 2014a). Further 
work using incretin receptor knockout mice suggested a role for AS1269574 in GLP-1 secretion as 
Gipr knockout mice retained their insulinotropic ability while Glp1r knockout mice did not 
(McKillop et al. 2016). In this study acute male fasted Swiss TO mice received 0.1μmol/kg body 
weight gavage of either AS1269574 or OEA. AS1269574 demonstrated a greater effect at reducing 
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blood glucose compared to OEA. However the effects of OEA were observed later than those seen 
with AS1269574. In order to preserve and/or enhance the incretin effect, both agonists were also 
tested along with the DPP-IV inhibitor Sitagliptin Phosphate. AS1269574 administered along with 
Sitagliptin had a more pronounced and longer lasting effect than OEA and Sitagliptin combined. 
Both agonists tested increased incretin hormone secretion with AS1269574 having a greater effect 
on GLP-1 secretion than OEA while OEA had a greater effect on GIP secretion. This confirms 
previous work demonstrating that AS1269574 may have an effect in vivo on GLP-1 secretion 
(McKillop et al. 2016). Interestingly AS1269574 also increased GIP secretion in vivo despite having 
no effect in vitro. This is also the first study to investigate these effects as a combination therapy 
with Sitagliptin. 
For further confirmation of the effects displayed acutely in vivo, AS1269574 and AS1269574 in 
combination with Sitagliptin were administered chronically to mice induced with diabetes through 
multiple low doses of streptozotocin. This diabetic animal model exhibits moderate 
hyperglycaemia, hypoglycaemia and moderate levels of insulin secreting cells. Mice treated with 
streptozotocin demonstrated increased non-fasting hyperglycaemia, food intake, fluid intake, 
hyperglycaemia when challenged with glucose and body weight. Insulin secretion in response to 
glucose, plasma insulin, insulin sensitivity and femur bone mineral density were all reduced.  Daily 
treatment with AS1269574 decreased non-fasting hyperglycaemia, body weight, food intake, fluid 
intake and body fat. Plasma insulin, plasma GLP-1, plasma GIP, femur bone mineral density and 
insulin secretion in response to glucose challenge were all increased. AS1269574 combination 
therapy decreased non-fasting blood glucose, food intake, hyperglycaemia in response to glucose 
and body weight were all decreased. Plasma insulin, femur bone mineral density, lean mass, insulin 
response to glucose challenge, plasma GLP-1 and plasma GIP were all increased with this treatment. 
The results described in this study confirm results seen previously for AS1269574 (Moran et al. 
2014a, McKillop et al. 2016). This is the first study to describe the effects of these treatments on 
incretin hormones as well as the combination therapy of AS1269574 with Sitagliptin. Further 
studies using GPR119 knockout mice are required to further confirm the selectivity of AS1269574 
for GPR119. These results also need to be studied in other diabetic animal models such as high fat 
fed animals. 
In conclusion, the insulinotropic effects of GPR119 agonists in BRIN-BD11 cells were confirmed. 
Swiss TO mice administered GPR119 agonists orally had improved glucose homeostasis both 
acutely in lean mice and chronically in a Type 2 Diabetic animal model. GPR119 agonists 
demonstrated an ability to increase incretin hormone in vitro from GLUTag and pGIPneo STC-1 
cells as well as acute and chronic studies in vivo. These findings provide further credence towards 




Figure 7.1: Effects of AS1269574 on GLP-1 secretion and cell viability in intestinal GLUTag 




















Effect of GPR119 agonist AS1269574 (10-10-10-4M) and GPR119 antagonist Exendin-9 (10-7M) on 
GLP-1 secretion (A) and cell viability (B) at 2mM glucose in GLUTag cells. Cell viability was 
measured using MTT. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. * 
p<0.05, ** p<0.01 and *** p<0.001 compared to basal glucose control for GLP-1 secretion and 



























































































































































Effect of GPR119 agonist OEA (10-10-10-4M) and GPR119 antagonist Exendin-9 on GLP-1 
secretion (A) and cell viability (B) at 2mM glucose in GLUTag cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. * p<0.05, ** 
p<0.01 and *** p<0.001 compared to basal glucose control for GLP-1 secretion and media non-



















































































Effect of GPR119 agonist PEA (10-10-10-4M) and GPR119 antagonist Exendin-9 (10-7M) on GLP-
1 secretion (A) and cell viability (B) at 2mM glucose in GLUTag cells. Cell viability was measured 
using MTT. Results are mean ± SEM (n=3) for GLP-1 secretion and cell viability. * p<0.05, ** 
p<0.01 and *** p<0.001 compared to basal glucose control for GLP-1 secretion and media non-











































































































Figure 7.4: Effects of AS1269574 on GIP secretion and cell viability in intestinal pGIPneo 





















Effect of GPR119 agonist AS1269574 (10-10-10-4M) and GPR119 antagonist Exendin-9 (10-7M) on 
GIP secretion (A) and cell viability (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was 
measured using MTT. Results are mean ± SEM (n=3) for GIP secretion and cell viability. *** 
p<0.001 compared to basal glucose control for GIP secretion and media non-toxic control for cell 



























































































Figure 7.5: Effects of OEA on GIP secretion and cell viability in intestinal pGIPneo STC-1 





















Effect of GPR119 agonist OEA (10-12-10-4M) and GPR119 antagonist Exendin-9 (10-7M) on GIP 
secretion (A) and cell viability (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was 
measured using MTT. Results are mean ± SEM (n=3) for GIP secretion and cell viability. * p<0.05, 
** p<0.01 and *** p<0.001 compared to basal glucose control for GIP secretion and media non-
























































































Figure 7.6: Effects of PEA on GIP secretion and cell viability in intestinal pGIPneo STC-1 





















Effect of GPR119 agonist PEA (10-12-10-4M) and GPR119 antagonist Exendin-9 (10-7M) on GIP 
secretion (A) and cell viability (B) at 2mM glucose in pGIPneo STC-1 cells. Cell viability was 
measured using MTT. Results are mean ± SEM (n=3) for GIP secretion and cell viability. * p<0.05, 
** p<0.01 and *** p<0.001 compared to basal glucose control for GIP secretion and media non-

























































































Figure 7.7: Effects of AS1269574 on insulin secretion and cell viability in pancreatic BRIN-






























































































5.6mM Glucose + AS1269574












Effect of AS1269574 (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose 
in BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± 
SEM (n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 





Figure 7.8: Effects of AS1269574 on insulin secretion and cell viability in pancreatic BRIN-






























































































16.7mM Glucose + AS1269574
200M STZ












Effect of AS1269574 (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose 
in BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± 
SEM (n=8) for insulin secretion and (n=3) for cell viability. **p<0.01 and *** p<0.001 compared 





Figure 7.9: Effects of OEA on insulin secretion and cell viability in pancreatic BRIN-BD11 





























































































5.6mM Glucose + OEA












Effect of OEA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 
























































Figure 7.10: Effects of OEA on insulin secretion and cell viability in pancreatic BRIN-BD11 


















































16.7mM Glucose + OEA












Effect of OEA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 






















































Figure 7.11: Effects of PEA on insulin secretion and cell viability in pancreatic BRIN-BD11 


















































5.6mM Glucose + PEA












Effect of PEA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 5.6mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, ** p<0.01 and *** p<0.001 























































Figure 7.12: Effects of PEA on insulin secretion and cell viability in pancreatic BRIN-BD11 



















































16.7mM Glucose + PEA












Effect of PEA (10-12-10-4M) on insulin secretion (A) and cell viability (B) at 16.7mM glucose in 
BRIN-BD11 cells. Cell viability was measured using Alamar Blue Assay. Results are mean ± SEM 
(n=8) for insulin secretion and (n=3) for cell viability. * p<0.05, **p<0.01 and *** p<0.001 







Figure 7.13: EC50 of GPR119 agonists AS1269574, OEA and PEA in BRIN-BD11 cells 
A.








-7  1.1 M
PEA EC50 1.60x10
-7  1.0 M
OEA EC50 2.83x10
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-6  1.4 M
PEA EC50 7.70x10
-8  1.4 M
OEA EC50 1.3x10
-7  1.5 M




























EC50 values for GPR55 agonists AS1269574, OEA and PEA in BRIN-BD11 cells in 5.6mM glucose 
(A) and 16.7mM glucose (B). 
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Figure 7.14: Immunofluorescence staining of GLP-1 and GPR119 in intestinal GLUTag cells 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR119 and (D) combined fluorescence of GLP-1 and 
GPR119 in GLUTag cells. Images are taken at x200 magnification and examples of positive staining 



















Figure 7.15: Immunofluorescence staining of GLP-1 and GPR119 in lean NIH Swiss mouse 
small intestine 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR119 and (D) combined fluorescence of GLP-1 and 
GPR119 in lean NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 
















Figure 7.16: Immunofluorescence staining of GLP-1 and GPR119 in HFF NIH Swiss mouse 
small intestine 
 
Distribution of (A) DAPI, (B) GLP-1, (C) GPR119 and (D) combined fluorescence of GLP-1 and 
GPR119 in HFF NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 


































































Effect of HFF diet on GPR119 gene expression in male NIH Swiss mouse small intestine (n=6). 


















Figure 7.18: Immunofluorescence staining of GIP and GPR119 in pGIPneo STC-1 cells 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR119 and (D) combined fluorescence of GIP and 
GPR119 in pGIPneo STC-1 cells. Images are taken at x200 magnification and examples of positive 












Figure 7.19: Immunofluorescence staining of GIP and GPR119 in lean NIH Swiss mouse small 
intestine 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR119 and (D) combined fluorescence of GIP and 
GPR119 in lean NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 













Figure 7.20: Immunofluorescence staining of GIP and GPR119 in HFF NIH Swiss mouse 
small intestine 
 
Distribution of (A) DAPI, (B) GIP, (C) GPR119 and (D) combined fluorescence of GIP and 
GPR119 in HFF NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 














Figure 7.21: Immunofluorescence staining of PYY and GPR119 in STC-1 cells 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR119 and (D) combined fluorescence of PYY and 
GPR119 in STC-1 cells. Images are taken at x200 magnification and examples of positive staining 












Figure 7.22: Immunofluorescence staining of PYY and GPR119 in lean NIH Swiss mouse 
small intestine 
 
Distribution of (A) DAPI, (B) PYY, (C) GPR119 and (D) combined fluorescence of PYY and 
GPR119 in lean NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 

















Distribution of (A) DAPI, (B) PYY, (C) GPR119 and (D) combined fluorescence of PYY and 
GPR119 in HFF NIH Swiss mouse small intestinal tissue. Images are taken at x200 magnification 





































































Effects of GPR119 agonists on the expression of the GPR119 gene in intestinal GLUTag cells at 
2mM glucose (n=3). ** p<0.01 and ** p<0.01 compared to untreated media control. ∆ p<0.05 and 





























































































Glucose (18mmol/kg BW) or glucose in combination with a GPR119 agonist (0.1μmol/kg BW) 
were administered orally to male Swiss TO mice (n=6). (A) Plasma GLP-1 of mice treated with 
GPR119 agonists (B) AUC of A. * p<0.05 and ***p<0.001 compared to glucose treatment alone. 











































































Glucose (18mmol/kg BW) or glucose in combination with a GPR119 agonist (0.1μmol/kg BW) 
were administered orally to male Swiss TO mice (n=6). (A) Plasma GIP of mice treated with 
GPR119 agonists (B) AUC of A. **p<0.01 and ***p<0.001 compared to glucose treatment alone. 






Figure 7.27: Effects of AS1269574 on blood glucose in male Swiss TO mice 
A. 






Glucose + 50mg/kg Sitagliptin
0.1mol/kg AS1269574
0.1mol/kg AS1269574 + 50mg/kg Sitagliptin





























































































Glucose + 50mg/kg Sitagliptin
0.1mol/kg AS1269574
0.1mol/kg AS1269574 + 50mg/kg Sitagliptin



































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with AS1269574 (0.1μmol/kg BW), glucose in combination with 
AS1269574 and the GPR119 antagonist Exendin-9 (0.1μmol/kg BW), glucose in combination with 
AS1269574 and Sitagliptin Phosphate or saline (0.9% NaCl (w/v)) in combination with AS1269574 
were all administered orally to male Swiss TO mice. (A) Blood glucose of mice treated with 
AS1269574 (B) AUC of A. * p<0.05, ** p<0.01 and *** p<0.001 compared to glucose alone. Δ 
p<0.05 and ΔΔΔ p<0.001 compared to glucose and Sitagliptin. 
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Figure 7.28: Effects of OEA on blood glucose in male Swiss TO mice 
A.  








Glucose + 50mg/kg Sitagliptin
0.1mol/kg OEA
0.1mol/kg OEA + 50mg/kg Sitagliptin



















































































Glucose + 50mg/kg Sitagliptin
0.1mol/kg OEA
0.1mol/kg OEA + 50mg/kg Sitagliptin



































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with OEA (0.1μmol/kg BW), glucose in combination with OEA and the 
GPR119 antagonist Exendin-9 (0.1μmol/kg BW), glucose in combination with OEA and Sitagliptin 
Phosphate or saline (0.9% NaCl (w/v)) in combination with OEA were all administered orally to 
male Swiss TO mice. (A) Blood glucose of mice treated with OEA (B) AUC of A. * p<0.05, ** 

























































































































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with AS1269574 (0.1μmol/kg BW), and glucose in combination with 
AS1269574 and Sitagliptin Phosphate were all administered orally to male Swiss TO mice (n=6). 
(A) Plasma insulin of mice treated with AS1269574 (B) AUC of A. * p<0.05, ** p<0.01 and *** 



















































































































Glucose (18mmol/kg BW), glucose in combination with Sitagliptin Phosphate (50mg/kg BW), 
glucose in combination with OEA (0.1μmol/kg BW), and glucose in combination with OEA and 
Sitagliptin Phosphate were all administered orally to male Swiss TO mice (n=6). (A) Plasma insulin 
of mice treated with OEA (B) AUC of A (C) Plasma insulin of mice treated with OEA (D) AUC of 
C. * p<0.05, ** p<0.01 and *** p<0.001 compared to glucose alone. ΔΔΔ p<0.001 compared to 




Figure 7.31: Effects of GPR119 agonists on feeding in trained male Swiss TO mice 
A. 












0.9% NaCl + 0.1mol/kg BW AS1269574
0.9% NaCl + 50mg/kg BW Sitagliptin + 0.1mol/kg BW AS1269574
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0.9% NaCl + 0.1mol/kg BW OEA























Saline (0.9%), saline and a GPR119 agonist (0.1μmol/kg BW), saline with a GPR119 agonist and 
Sitagliptin (50mg/kg BW) or saline and Sitagliptin were administered orally to Swiss TO mice 
which had been trained to eat for 3 hrs daily (n=8). * p<0.05, **p<0.01 and **p<0.001 compared 






Figure 7.32: Effect of multiple low dose streptozotocin on blood glucose and insulin in male 
Swiss TO mice 
A. 




































































In order to induce diabetes, 4 hr fasted male Swiss TO mice were administered streptozotocin 
(40mg/kg BW, 0.1M sodium citrate, pH 4.5) via intraperitoneal injection. Reduced glucose 
tolerance was confirmed 14 days after the initial injection of streptozotocin (day 1) via oral glucose 
tolerance test. Glucose (18mmol/kg body weight) was administered orally to either lean or 
streptozotocin treated Swiss TO mice (n=6 for lean mice, n=12 for streptozotocin treated mice). (A) 




Figure 7.33: Effect of multiple low dose streptozotocin on non-fasting blood glucose in male 
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In order to induce diabetes, 4 hr fasted male Swiss TO mice were administered streptozotocin 
(40mg/kg BW, 0.1M sodium citrate, pH 4.5) via intraperitoneal injection. Non-fasting blood 
glucose was measured 14 days after initial injection (n=6 for lean and n=12 for streptozotocin 
induced diabetic mice) (A) Non fasting blood glucose of mice 14 days after initial treatment (B) 
Non-fasting blood glucose levels between treatment groups of streptozotocin treated mice when 
separated 14 days after initial treatment. Mice were separated to ensure no significant differences 

































Figure 7.34: Effects of multiple low dose streptozotocin on blood glucose in 4 hr fasted male 





































Male Swiss TO mice were fasted for 4 hrs prior to streptozotocin treatment to induce diabetes 
(n=32) or 0.9% saline (n=6) via intraperitoneal injection. Blood glucose was measured prior to 
injection. **p<0.01 and ***p<0.001 compared to lean blood glucose. ΔΔΔ p<0.001 compared to 




























































































Body weights of both streptozotocin treated (A) and lean male Swiss TO mice (B) was monitored 
prior to injection (n=32 for streptozotocin treated mice, n=6 for lean mice). Lean mice received 




Figure 7.36: Differences in body weight between treatment groups of streptozotocin induced 



























































Body weight was compared between lean and streptozotocin treated mice 14 days after initial 




Figure 7.37: Effects of long term daily oral treatment of GPR119 agonist AS1269574 body 







0 3 6 9 12 15 18 21-14 -12

































































Effect of daily oral administration of saline (0.9%), AS1269574 monotherapy (0.1μmol/kg body 
weight) and AS1269574 (0.1μmol/kg body weight) combination therapy with Sitagliptin (50mg/kg 
body weight) on body weight. (A) Body weight (B) AUC of A. Parameters obtained before and 
during the 21 days treatment period (indicated by the horizontal black bar). Values are mean ± SEM 
(n=6). Δ p<0.05 compared to streptozotocin induced diabetic mice 
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Figure 7.38: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on food 
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Effect of daily oral administration of saline (0.9%), AS1269574 monotherapy (0.1μmol/kg body 
weight) and AS1269574 (0.1μmol/kg body weight) combination therapy with Sitagliptin (50mg/kg 
body weight) on food intake. (A) Food intake (B) AUC of A. Parameters obtained before and during 
the 21 days treatment period (indicated by the horizontal black bar). Values are mean ± SEM (n=6). 
* p<0.05, ** p<0.01 and *** p<0.001 compared to lean mice. ΔΔ p<0.01 and ΔΔΔ p<0.001 
compared to streptozotocin induced diabetic mice. 
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Figure 7.39: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on fluid 
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Effect of daily oral administration of saline (0.9%), AS1269574 monotherapy (0.1μmol/kg body 
weight) and AS1269574 (0.1μmol/kg body weight) combination therapy with Sitagliptin (50mg/kg 
body weight) on fluid intake. (A) Fluid intake (B) AUC of A. Parameters obtained before and during 
the 21 days treatment period (indicated by the horizontal black bar). Values are mean ± SEM (n=6). 
* p<0.05 and *** p<0.001 compared to lean mice. Δ p<0.05 compared to the streptozotocin group. 
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Figure 7.40: Effects of long term oral daily treatment of GPR119 agonist AS1269574 on 



















































































AS1269574 (0.1μmol/kg BW) in 0.9% saline or AS1269574 (0.1μmol/kg body weight) in 
combination with Sitagliptin Phosphate (50mg/kg body weight) were administered orally to male 
Swiss TO mice (n=6). Lean and streptozotocin induced diabetic mice were administered 0.9% saline 
orally (n=6). Effects of daily administration on (A) plasma GLP-1(B) AUC of plasma GLP-1. * 
p<0.05, **p<0.01 and ***p<0.001 compared to lean mice. Δ p<0.05 and ΔΔ p<0.01 compared to 
streptozotocin induced diabetic mice treated with 0.9% saline. 
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Figure 7.41: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on 






































AS1269574 (0.1μmol/kg BW) in 0.9% saline or AS1269574 (0.1μmol/kg body weight) in 
combination with Sitagliptin Phosphate (50mg/kg body weight) were administered orally to male 
Swiss TO mice (n=6). Lean and streptozotocin induced diabetic mice were administered 0.9% saline 
orally (n=6). Effects of daily administration on (A) plasma GIP (B) AUC of plasma GIP. * p<0.05, 
**p<0.01 and ***p<0.001 compared to lean mice. Δ p<0.05, ΔΔ p<0.01 and ΔΔΔ p<0.001 
compared to streptozotocin induced diabetic mice treated with 0.9% saline. 
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Figure 7.42: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on blood 
glucose in multiple low dose streptozotocin mice 
A. 











































































































AS1269574 (0.1μmol/kg BW) in 0.9% saline or AS1269574 in combination with Sitagliptin 
Phosphate were administered orally to male Swiss TO mice (n=6). Lean and streptozotocin induced 
diabetic mice were administered 0.9% saline orally (n=6). Effects of daily administration on (A) 
Blood glucose (B) AUC of A. **p<0.01 and ***p<0.001 compared to lean mice. Δ p<0.05, ΔΔ 




Figure 7.43: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on 
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AS1269574 (0.1μmol/kg BW) in 0.9% saline or AS1269574 (0.1μmol/kg body weight) in 
combination with Sitagliptin Phosphate (50mg/kg body weight) were administered orally to male 
Swiss TO mice (n=6). Lean and streptozotocin induced diabetic mice were administered 0.9% saline 
orally (n=6). Effects of daily administration on (A) Plasma insulin (B) AUC of A. * p<0.05, 
**p<0.01 and ***p<0.001 compared to lean mice. Δ p<0.05, ΔΔ p<0.01 and ΔΔΔ p<0.001 
compared to streptozotocin induced diabetic mice treated with 0.9% saline. 
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Figure 7.44: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on 
glucose tolerance in multiple low dose streptozotocin mice 
A. 
























































































































Mice treated with orally with GPR119 agonist AS1269574 (0.1μmol/kg body weight) or 
AS1269574 (0.1μmol/kg body weight) in combination with Sitagliptin (50mg/kg body weight) and 
mice treated with saline (0.9%) underwent an oral glucose tolerance test (18mmol/kg body weight) 
21 days after treatment. Mice were fasted for 18 hrs before glucose administration. (A) Blood 
glucose, (B) AUC of blood glucose. Results are the mean ± SEM (n=6). * p<0.05, ** p<0.01 and 
*** p<0.001 compared to lean mice.  
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Figure 7.45: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on acute 
insulin secretion in multiple low dose streptozotocin mice 
A. 













































































































Mice treated with orally with GPR119 agonist AS1269574 (0.1μmol/kg body weight) or 
AS1269574 (0.1μmol/kg body weight) in combination with Sitagliptin (50mg/kg body weight) and 
mice treated with saline (0.9%) underwent an oral glucose tolerance test (18mmol/kg body weight) 
21 days after treatment. Mice were fasted for 18 hrs before glucose administration. (A) Plasma 
insulin, and (B) AUC of plasma insulin. Results are the mean ± SEM (n=6). * p<0.05, ** p<0.01 





Figure 7.46: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on 













STZ + 0.1mol/kg BW AS1269574
STZ + 0.1mol/kg BW AS1269574 and 50mg/kg BW sitagliptin




















































































Non fasted Swiss TO mice were administered insulin via intraperitoneal injection (25 U/kg body 
weight, dissolved in 0.9% NaCl) 21 days after treatment with saline (0.9%), AS-1269574 
(0.1μmol/kg body weight) or AS1269574 (0.1μmol/kg body weight) in combination with Sitagliptin 
(50mg/kg body weight). (A) Blood glucose, (B) AUC of blood glucose. Results are the mean ± 
SEM (n=6). * p<0.05, ** p<0.01 and *** p<0.001 compared to lean mice. ΔΔ p<0.01 and ΔΔΔ 





Figure 7.47: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on 


























































































Non fasted Swiss TO mice were administered insulin via intraperitoneal injection (25 U/kg body 
weight, dissolved in 0.9% NaCl) 21 days after treatment with saline (0.9%), AS-1269574 
(0.1μmol/kg body weight) or AS1269574 (0.1μmol/kg body weight) in combination with Sitagliptin 
(50mg/kg body weight). (A) Blood glucose (% change), and (B) AUC of blood glucose (% change) 




Figure 7.48: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on body 






















































































Effect of daily oral administration of saline (0.9%), AS-1269574 (0.1μmol/kg body weight) and 
AS1269574 (0.1μmol/kg body weight) in combination with Sitagliptin (50mg/kg body weight) in 
Swiss TO mice on (A) body weight and (B) lean mass as measured by DEXA scanning following 
21 day treatment. Values are mean ± SEM (n=6). * p<0.05 and ** p<0.01 compared lean mice. Δ 
p<0.05 and ΔΔΔ p<0.001 compared to streptozotocin induced diabetic mice. 
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Figure 7.49: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on fat 













































































Effect of daily oral administration of saline (0.9%), AS-1269574 (0.1μmol/kg body weight) and 
AS1269574 (0.1μmol/kg body weight) in combination with Sitagliptin (50mg/kg body weight) in 
Swiss TO mice on (A) Fat mass and (B) % body fat as measured by DEXA scanning following 21 
day treatment. Values are mean ± SEM (n=6). * p<0.05 and ***p<0.001 compared lean mice. ΔΔ 
p<0.01 compared to streptozotocin induced diabetic mice. 
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Figure 7.50: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on bone 


























































Effect of daily oral administration of saline (0.9%), AS-1269574 (0.1μmol/kg body weight) and 
AS1269574 (0.1μmol/kg body weight) in combination with Sitagliptin (50mg/kg body weight) in 
Swiss TO mice on (A) bone mineral content (B) bone mineral density as measured by DEXA 
scanning following 21 day treatment. Values are mean ± SEM (n=6). ** p<0.01 compared lean 

















































Figure 7.51: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on bone 






























































Effect of daily oral administration of saline (0.9%), AS-1269574 (0.1μmol/kg body weight) and 
AS1269574 (0.1μmol/kg body weight) in combination with Sitagliptin (50mg/kg body weight) in 
Swiss TO mice on (A) bone mineral content (B) bone mineral density in the femur as measured by 
DEXA scanning following 21 day treatment. Values are mean ± SEM (n=6). * p<0.05 and *** 


















































Figure 7.52: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on 
































































































Effect of daily oral administration of saline (0.9%), AS1269574 monotherapy (0.1μmol/kg body 
weight) and AS1269574 (0.1μmol/kg body weight) combination therapy with Sitagliptin on (A) 
triglycerides and (B) total cholesterol following 21 day treatment period in streptozotocin-induced 
diabetic mice. Values are mean ± SEM (n=6). * p<0.05 compared to the lean group. Δ p<0.05, ΔΔ 
p<0.01 compared to the streptozotocin group. 
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Figure 7.53: Effects of long term daily oral treatment of GPR119 agonist AS1269574 on LDL 





























































































Effect of daily oral administration of saline (0.9%), AS1269574 monotherapy (0.1μmol/kg body 
weight) and AS1269574 (0.1μmol/kg body weight) combination therapy with Sitagliptin on (A) 
HDL cholesterol and (B) LDL cholesterol following 21 day treatment period in streptozotocin-
induced diabetic mice. LDL was calculated using the Friedewald equation (LDL cholesterol = Total 
cholesterol – HDL cholesterol – (Triglycerides/5)). Values are mean ± SEM (n=6). * p<0.05 and 





























8.1: GPCR-based therapies 
There are over 860 GPCRs present in the human genome which are expressed at low levels 
throughout the body (Fredriksson, Schioth 2005). GPCRs are of particular interest with 36% of 
FDA approved drugs targeting GPCRs (Rask-Andersen, Almen & Schioth 2011). Rhodopsin-like 
Class A receptors are highly targeted as they are the most prevalent GPCR superfamily in a range 
of genomes (Fredriksson, Schioth 2005). There is further pharmaceutical interest in the 
identification of novel GPCRs as well as new GPCR ligands as only 10% of currently identified 
GPCRs are targeted by drugs (Garland 2013). Therefore a large number of GPCRs may still be 
targeted for therapies for a range of syndromes. 
Over 150 GPCRs are described as orphan receptors with no identified ligands (Ngo et al. 2016). 
The identification of endogenous and synthetic GPCR ligands requires better understanding of the 
physiological, pharmacological and pathological properties of these receptors. Advances in receptor 
overexpression or artificially expressed receptor technologies as well as in vitro and in vivo 
knockout technologies have helped to identify new GPCR ligands (Davenport et al. 2013). The 
identification and utilisation of novel GPCR ligands is also an area of research for new therapies 
for a range of diseases. 
Type 2 Diabetes is usually treated with an initial prescription of metformin followed by metformin 
in combination with a sulphonylurea and finally insulin after the progressive loss of pancreatic β-
cell mass (Matthews, Wallace 2005, Bailey, Turner 1996). However, some of the currently 
approved therapies include the targeting of the GLP1R with both exenatide and liraglutide (Kendall 
et al. 2005, Buse et al. 2010, Shyangdan et al. 2011). The majority of GPCRs targeted by drugs are 
Class A rhodopsin-like receptors, however GLP1R is a Class B receptor (de Graaf et al. 2016). 
Another GPCR of interest in the treatment of Type 2 Diabetes is GIPR. The insulinotropic effect of 
GIP in individuals with Type 2 Diabetes is diminished (Nauck et al. 1993). However when 
individuals with Type 2 Diabetes were administered a bolus injection of GIP, the insulinotropic 
effect of GIP was observed (Meier et al. 2004) demonstrating that the GIPR on pancreatic β-cells 
can be activated and targeted in the treatment of Type 2 Diabetes. This is further confirmed as the 
insulinotropic effect of GIP returns upon stabilisation of blood glucose to normal levels (Höjberg 
et al. 2009). In fact a novel long acting GIPR agonist known as AC163794 has been developed and 
this may have potential in the treatment of Type 2 Diabetes (Tatarkiewicz et al. 2013). Finally, 
while the GIP effect on insulin secretion is diminished in individuals with Type 2 Diabetes, GIPR 
knockout prevented weight gain, reduced insulin resistance and adiposity and antagonistic targeting 




The receptors for incretin hormones are not the only GPCRs which have been targeted for the 
treatment of Type 2 Diabetes. One receptor which has generated significant interest is GPR40. This 
receptor was targeted due to its ability to increase glucose-stimulated insulin secretion upon 
activation by long chain fatty acids (Itoh et al. 2003b). A number of GPR40 agonists have been 
used in clinical trials with fasiglifam reaching stage 3 clinical trials but these were stopped due to 
concerns over liver toxicity (Li et al. 2015). Other GPR40 agonists which have underwent clinical 
trials as possible Type 2 Diabetes therapies include JTT-851, which has underwent phase 2 clinical 
trials (Watterson et al. 2014), ASP5034, LY2881835 and AMG837 all of which have been used in 
clinical trials but have not progressed past phase 1 (Houze et al. 2012, Krasavin et al. 2016). Further 
research into GPR40 agonists could include agonists which elicit an incretin response such as AM-
1638 and AM-6226 possibly in combination with a DPP-IV inhibitor (Luo et al. 2012). GPR120 is 
also activated by long chain fatty acids however it has not received the same interest as GPR40 as 
its expression in β-cells has been questioned and it has reduced overall expression in the pancreas 
compared to GPR40 (Amisten et al. 2013, Stone et al. 2014). Previous research in our lab has shown 
that GPR120 activation has an insulinotropic effect on the pancreas (Moran et al. 2014b). The 
presence of GPR120 has been well established in the L and K cells of the intestine and may have 
effects on the incretin hormones as well as other endocrine hormones of the intestine (Reimann, 
Gribble 2015) . The presence of GPR120 in the endocrine cells of the intestine and pancreas make 
it an interesting target for the treatment of Type 2 Diabetes. Another fatty acid receptor which has 
been used in clinical trials for the treatment of Type 2 Diabetes is GPR119. Within healthy human 
volunteers the GPR119 agonist JNJ-38431055 demonstrated an ability to increase incretin and PYY 
secretion after a single dose and exhibited insulinotropic ability upon infusion (Katz et al. 2011). 
However in individuals with Type 2 Diabetes these effects were ablated (Katz et al. 2012). Other 
GPR119 agonists which have been used in clinical trials include APD-597, MBX-2982, 
GSK1292263 and PSN-821 with most agonists making it to phase 2 trials (Cornall et al. 2013, 
Witkamp 2010). GSK1292263 showed no effects on circulating glucose or insulin but increased 
circulating PYY which mean that it may play a role in the reduction of obesity and other metabolic 
disorders (Nunez et al. 2014b). Further understanding of GLP1R and GIPR signalling may be 
required to utilise this agonist as a diabetic therapy due to its incretin secreting ability. A final GPCR 
which has been targeted for the treatment of Type 2 Diabetes is TGR5 due to the ability of this 
receptor to increase GLP-1 secretion upon activation (Duan et al. 2015). The presence of this 
receptor in the heart and gallbladder has led to severe side effects and it has been less extensively 





8.2: GPCRs activated by peptides 
The work described in Chapter 3 in this thesis outlines how a GPCR present in the β-cells of the 
pancreas can be activated by a peptide resulting in increased insulin secretion. One of the main 
complications in Type 2 Diabetes is the control of hyperglycaemia and a direct effect of GPCR 
agonists on the pancreas will lead to a reduction in circulating glucose as observed when 
administering sulphonylureas or GLP1R agonists. The use of a GPCRs targeted by peptides as a 
possible therapy for Type 2 Diabetes is supported by the evidence described above. Activation of 
GPR75 by CCL5 led to increased insulin secretion both in vitro and in vivo. Direct binding studies 
have not been able to prove the association between GPR75 and CCL5 (Southern et al. 2013) 
however the work carried out in this study and others have provided evidence that CCL5 activates 
GPR75 (Ignatov et al. 2006, Liu et al. 2013).  
CCL5 increased insulin secretion confirming results seen previously (Liu et al. 2013). CCL5 was 
shown to be expressed in the β-cells of the pancreas in both lean and HFF mice providing evidence 
that the insulinotropic effect of this agonist is through direct action on GPR75. The increased 
expression of this receptor in HFF mice make it an attractive therapeutic target due to the close 
relationship between Type 2 Diabetes and obesity, however these results will need to be confirmed 
in human cell lines and subjects. While previous work has demonstrated an effect of CLL5 on the 
pancreas, this study is the first study to identify the presence of GPR75 in the enteroendocrine cells 
of the intestine. Therefore this agonist may have potential as an oral anti-diabetic therapy. Both oral 
and IP administration of CCL5 elucidated an insulinotropic response in vivo. The results in this 
study demonstrate the suitability of GPR75 activation as a potential therapy for the treatment of 
Type 2 Diabetes. 
 
8.3: GPCRs activated by monatomic ions 
GPCRs have a range of ligands including ions (Kobilka 2006) which are unable to enter the cell 
through the tightly bound seven transmembrane domain configuration of these receptors (Ji, 
Grossmann & Ji 1998). Previous research has shown that activation of GPCR with monatomic ions 
has an insulinotropic effect in vitro and in vivo (Moran et al. 2016b). This study identified the effects 
of GPR39 activation on intestinal hormone secretion. The only GPR39 agonist which demonstrated 
a secretory effect on GLP-1 in vitro was CuCl2 while all agonists tested demonstrated an effect on 
GIP secretion. This was confirmed with immunocytochemistry which failed to show GPR39 in 
GLP-1 secreting cells, however it was found to be present in both PYY and GIP secreting cells. 
Both PYY and GLP-1 are secreted from the L cells of the intestine, therefore activation of GPR39 
may still lead to GLP-1 secretion. This was confirmed with in vivo studies which showed both CuCl2 
and ZnCl2 increased GLP-1 and GIP secretion confirming previous research demonstrating that oral 
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administration of GPR39 agonists reduced blood glucose and increased insulin secretion (Moran et 
al. 2016b). Only one GPR39 agonist which increased GLP-1 secretion has been previously 
described (Peukert et al. 2014) and the research carried out in this study demonstrates two more 
GPR39 agonists with this action. This is also the first study to assess the ability of these agonists to 
increase incretin hormone secretion as well as being the first study to assess the acute effects of 
GPR39 agonists in combination with Sitagliptin in vivo. 
 
8.4: GPCRs activated by fatty acids 
Previous work has shown that GPR55, GPR119 and GPR120 can be activated by fatty acids of 
varying lengths and that this can lead to increased insulin secretion from the pancreas (McKillop et 
al. 2013, McKillop et al. 2016, Moran et al. 2014a, Moran et al. 2014b). Chapter 5 confirmed the 
insulinotropic effect observed when GPR120 is activated in the pancreas. GPR120 was found to be 
expressed in the small intestine (Hirasawa et al. 2005a) and the work carried out in Chapter 5 
describes the expression of GPR120 in both the L and K cells of the small intestine. Both GPR120 
and GPR40 can be activated by long chain fatty acids, however studies using si and shRNA has 
demonstrated that the agonists used in the studies performed in Chapter 5 are specific for GPR120 
(Hirasawa et al. 2005, Tanaka et al. 2008). With the expression of GPR120 in both the pancreas 
and small intestine established, the study carried out in Chapter 5 determined that GPR120 
activation by long chain fatty acids resulted in increased insulin and incretin secretion in vitro.  
GW9508 was the only GPR120 agonist to increase both GLP-1 and GIP secretion in vitro while 
both ALA and DHA increased GLP-1 secretion. For this reason GW9508 was chosen for further in 
vivo analysis along with DHA. Previously, intraperitoneal administration of GPR120 agonists has 
demonstrated their direct effect on the pancreas (Moran et al. 2014b). In order to assess the effects 
of GPR120 agonists on incretin secretion, GPR120 agonists were administered in vivo via oral 
gavage. Agonists were also administered with the DPP-IV inhibitor Sitagliptin to try and prolong 
the effects of these hormones. Both agonists tested demonstrated the ability to increase insulin, 
GLP-1 and GIP secretion in vivo. Both DHA and GW9508 in combination with Sitagliptin reduced 
appetite. Overall these results show that GPR120 can be activated in both the intestine and pancreas 
and may be targeted for the regulation of glucose homeostasis. 
Along with the previous research showing that GPR55 may be activated directly in the pancreas to 
increase insulin secretion, work carried out in incretin receptor knockout mice suggests that GPR55 
activation may play a role in incretin hormone secretion (McKillop et al. 2016). The work carried 
out in Chapter 6 was designed to assess the ability of GPR55 agonists to increase intestinal hormone 
secretion both in vitro and in vivo. The only previously work in this are studied the effect of GPR55 
agonist LPI on GLP-1 secretion while there are no currently published studies which have looked 
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at direct GPR55 activation on GIP secretion. GPR55 is an interesting target for metabolic disorders 
as it has been described as a putative cannabinoid receptor and may be used to reduce appetite while 
it is also a fat sensing receptor like GPR119, GPR120 and GPR40 (Henstridge, Brown & Waldhoer 
2016). The work described in Chapter 6 confirmed the previously described effects of GPR55 
activation on pancreatic β-cells. GPR55 has previously been shown to be present in the L-cells of 
the intestine (Harada et al. 2017) however this is the first study to describe the presence of GPR55 
in the K cells of the intestine. It is also the first study to describe the ability of Abn-CBD, OEA and 
PEA to activate GPR55 and increase GLP-1 and GIP secretion in vitro. The presence of GPR55 in 
the L cells of the intestine was further confirmed as it is co-localised with PYY and this is the first 
study to describe this.  
Previous work used intraperitoneal injection of GPR55 agonists to demonstrate their effect in vivo 
while oral administration of these agonists in incretin receptor knockout mice demonstrated a 
possible incretin effect (Moran et al. 2014b, McKillop et al. 2016). The in vivo work carried out in 
Chapter 6 involved oral administration of GPR55 agonists to confirm this incretin effect. Agonists 
were administered in combination with Sitagliptin. Oral administration of Abn-CBD and AM251 
confirmed the previously seen insulin stimulating effects while also describing the ability of these 
agonists to increase GLP-1 and GIP for the first time. Abn-CBD administration alone reduced 
appetite while AM251 administration in combination with Sitagliptin had a similar effect. The 
results described in Chapter 6 suggests that GPR55 can be targeted to help regulate the impaired 
glucose homeostasis seen in Type 2 Diabetes.  
A direct effect of GPR119 in the β-cells has been described (Moran et al. 2014a, McKillop et al. 
2016), however there is also evidence that the ability of GPR119 agonists to reduce blood glucose 
and increase insulin secretion is dependent on the incretin response (Panaro et al. 2017b). The 
expression of GPR119 in the endocrine cells of the intestine has previously been described (Nunez 
et al. 2014a, Parker et al. 2009) and the work described in Chapter 7 confirmed the presence of 
GPR119 in the K and L cells of the intestine. Knockout of GPR119 has shown to ablate the ability 
of GPR119 agonists to increase GLP-1 secretion (Moss et al. 2015) and the study which was 
conducted confirmed the ability of GPR119 agonists to increase GLP-1 secretion in vitro. The 
effects of GPR119 agonists on GIP secretion was also described in vitro and these results were in 
agreement with the effects of GPR119 activation which have previously been published (Flock et 
al. 2011, Patel et al. 2014, Chu et al. 2008). 
Previous in vivo work has shown that GPR119 agonists have a direct effect on the pancreas (Moran 
et al. 2014a). Later work in incretin receptor knockout mice suggested that GPR119 agonists may 
have the ability to increase incretin hormone secretion in vivo (McKillop et al. 2016). Therefore the 
in vivo studies carried out in Chapter 7 involved oral administration of GPR119 agonists so that the 
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effects of these agonists on incretin secretion could assessed directly. Both AS1269574 and OEA 
increased insulin secretion, reduced blood glucose and increased incretin hormone secretion. These 
agonists were administered in combination with Sitagliptin which helped to further reduce blood 
glucose. Both agonists in combination with Sitagliptin reduced feeding. Long term administration 
of AS1269574 mirrored these effects.  
Overall, the results from the studies described above show that fatty acid agonists can be used to 
target GPCRs in the intestine and the pancreas to regulate glucose homeostasis through a variety of 
mechanisms and thus have potential as a therapy for the treatment of Type 2 Diabetes. 
 
8.5 Conclusions and Limitations of the studies described in this thesis 
The work described in this thesis leads to the following conclusions: 
 GPCRs are present in the gastrointestinal tract and can be activated by a range of fatty acid, 
peptide based and monoatomic ion based agonists 
 Activation of gastrointestinal GPCRs can increase GLP-1 and GIP secretion and this is 
achieved through a range of GPCRs as well as a range of agonists 
 GPCR agonists can also have a direct effect on the pancreas and directly stimulate insulin 
secretion 
 Long term oral administration of fatty acid based agonists can improve glucose homeostasis 
and demonstrates the potential of GPCR activation for the treatment of Type 2 Diabetes 
The work described in this thesis also has several limitations. These are as follows: 
 There are no direct binding studies performed to demonstrate agonist specificity for the 
GPCR being targeted 
 Some agonists target a number of GPCRs 
 siRNA knockodown was not used and this would have helped to determine agonist 
specificity 
 While the studies discussed in this thesis were being performed, the CRISPr Cas9 knockout 
system was described and this would be a useful tool in the future to confirm agonist 
specificity 
 
8.6: Mode of action of GPCRs studied in this thesis 
Previous research has shown that the GPCRs studied in this thesis may regulate glucose homeostasis 
through direct action on the pancreas, however work in incretin receptor knockout mice suggests 
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that these GPCRs play a role in incretin hormone secretion as well as (McKillop et al. 2013, Liu et 
al. 2013, Moran et al. 2014b, Moran et al. 2014a, Moran et al. 2016b, McKillop et al. 2016). The 
work described in this thesis demonstrates a direct action of GPCR agonists on the enteroendocrine 
cells of the intestine. The ability of these receptors to increase intestinal and pancreatic hormone 
secretion and their role in glucose homeostasis are seen in Figure 8.1. Activation of intestinal 
GPCRs increases GLP-1 secretion which increases satiety due to its ability to cross the blood brain 
barrier. The brain returns a signal to the intestine to slow gastric emptying. Increased GLP-1 will 
also activate the GLP1R in the pancreas resulting in increased insulin secretion. GPCR agonists also 
have an insulinotropic effect through direct action on the GPCRs present in the pancreatic endocrine 
cells. Increased GLP-1 will also help to increase the β-cell mass of the pancreas. Increased GIP 
secretion from intestinal K cells will also demonstrate an insulinotropic effect in individuals without 
diabetes. The result of this process is a reduction in body weight, increased glucose tolerance and 
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GW9508 Oral GPR120 30 mins; *** Oral 15 to 30 mins; *** 15 mins; *** 
 
The in vivo effects of the GPCR agonists used in this study on GLP-1, GIP and insulin secretion. * p<0.05, ** p<0.01 and *** p<0.001. 
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Figure 8.1 Mechanism of action of intestinal and pancreatic GPCRs as well as the incretin 
hormones, GLP-1 and GIP 
 
 
8.7: Limitations and complications of currently approved therapies for Type 2 Diabetes 
Many of the current therapies used in the treatment of Type 2 Diabetes are able to regulate glucose 
homeostasis in diabetic individuals, however they are unable to prevent the macrovascular 
complications which are caused by the associated chronic obesity (Cade 2008). If left untreated, 
these macrovascular complications will result in increased risk of mortality (Panzram 1987) 
however these effects on both mortality and morbidity can be reduced when therapies focus on 
regulation of blood pressure rather than hyperglycaemia (King, Peacock & Donnelly 1999). 
Intensive anti hyperglycaemic therapies have only been shown to reduce microvascular 
complications but have no effect on the macrovascular complications and individuals with 
hypertension were heavier and had higher plasma triglyceride levels (Diabetes Control and 
Complications Trial Research Group et al. 1993). The first generation of sulphonylurea therapies 
were also linked to increased mortality due to adverse cardiovascular events which may be due to 
the inhibition of vasodilation due to ischemia (Ashford et al. 1994). This was similar to the observed 
effects of the first generation of biguanide therapies which increased mortality due to adverse 
cardiovascular events. Administration of these biguanides also conferred an increased risk of lactic 
acidosis as discussed in Chapter 1. The inability of hypertension therapies to correct hyperglycaemia 
and the inability of hyperglycaemic medication to correct hypertension mean that one of the main 
challenges in antidiabetic therapies is the development of treatments which can reduce both the 
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microvascular and macrovascular complications which occur in people with Type 2 Diabetes due 
to the combined effects of hyperglycaemia and hypertension. 
Treatment of hyperglycaemia in individuals with Type 2 Diabetes reduces the microvascular 
complications of the disease with the biggest reductions seen in surgeries to reduce complications 
of diabetic retinopathy (King, Peacock & Donnelly 1999). A study comparing the main treatments 
for hyperglycaemia compared sulfonylurea and insulin therapy to metformin and found that obese 
people administered metformin had fewer complications such as hyperglycaemia and weight gain. 
This is one of the many reasons why metformin is normally the first therapy used in the treatment 
of Type 2 Diabetes over other available therapeutics. The differences between metformin and other 
therapies may be due to the differing mechanisms through which metformin reduces 
hyperglycaemia. Despite being the first choice drug for the treatment of Type 2 Diabetes, there are 
still instances when administration of metformin is not recommended. Individuals with impaired 
kidney or liver function would not be suitable for treatment with metformin (Bailey, Turner 1996). 
While these drugs may reduce hyperglycaemia, their effect diminishes over time due to the 
destruction of pancreatic β-cells (Matthews, Wallace 2005, Bailey, Turner 1996). The progressive 
loss of β-cell mass means that all Type 2 Diabetes sufferers will end up on insulin therapy after 
having the disease for a long period of time. The limitations of antidiabetic and antihypertensive 
medications mean that affected individuals need to be prescribed various medications which will 
likely lead to lower compliance with prescribed guidelines. Therefore there is a need to develop 
new Type 2 Diabetes therapeutics which can reduce both hyperglycaemia and hypertension and 
which will prevent the progressive loss of pancreatic β-cell mass. The UKPDS has indicated that 
beta cell dysfunction begins at an early stage, prior to changes in blood glucose. Therefore better 
therapies for Type 2 Diabetes are required to tackle beta cell dysfunction. The ideal therapy would 
prevent diabetes and obesity due to the complications of hyperglycaemia and hypertension which 
are present in both of these syndromes. This therapy could be administered before the onset of β-
cell dysfunction. 
 
8.8: Future research 
Previous research has described the presence of 293 GPCRs in the pancreas of mice (Amisten et al. 
2013). These receptors have been further compared to those present in the human pancreas (Amisten 
et al. 2017). The identification of the different GPCRs in both humans and mice will be beneficial 
in future research for the identification of appropriate in vivo models as well as the identification of 
appropriate GPCR targets that are present in the human genome. In order to further understand the 
effect of GPCRs in the intestine the GPCRs present in the intestine would need to be identified, as 
seen with the pancreas. This presents its own challenges due to the differences between the main 
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sections of the intestine as well as the variety of cells scattered throughout the intestine, however ex 
vivo methods such as intestinal organoids (Fatehullah, Tan & Barker 2016) may be utilised to try 
and limit these to cells solely with an open confirmation and access to the lumen of the intestine. 
Furthermore there are a wide variety of hormones secreted from a wide variety of enteroendocrine 
cells in the intestine and the effects of GPCR activation on hormones such as PYY, CCK, ghrelin, 
gastrin and obestatin need to be further understood in order to further understand how receptors in 
the intestine can be targeted for the regulation of glucose homeostasis. 
Much of the research described above has looked at the acute effects of GPCR activation except for 
the chronic effects on Abn-CBD and AS1269574 described in Chapters 6 and 7. Chronic treatment 
of these agonists has been described previously (McKillop et al. 2016), however this is one of the 
first studies to assess chronic administration of GPCR agonists in combination with Sitagliptin in 
order to try and better utilise the incretin effect. Previous chronic studies have been carried out for 
GPR40 and GPR119 (Li et al. 2015, Katz et al. 2011, Katz et al. 2012) but there are not many 
published chronic studies which combine GPCR agonists with other drugs for Type 2 Diabetes. 
There are still a lot of GPCR agonists which are yet to be identified and of those which have been 
identified there are still questions regarding long term administration which need to be answered.  
One of the most important questions regarding research into GPCRs is surrounding the specificity 
of agonists for the receptor being studied. Previous studies include direct binding studies as well as 
blocking of the receptor with antagonists as well as knockdown with siRNAs. With the development 
of in vitro knockout technologies such as CRISPR (Zhang, Wen & Guo 2014) it is now possible to 
knockout the receptor to assess ligand binding. These techniques now allow researchers to assess 
the specificity of agonists for receptors before moving to in vivo models and will likely be a large 
area of research for those interested in GPCRs.  
As described previously in this thesis, one of the main complications in Type 2 Diabetes is 
cardiovascular events caused by hypertension. A possible area of research would be to identify 
GPCRs which can help reduce hypertension and regulate glucose homeostasis as the same time. It 
would also be beneficial if GPCRs which can help to reduce inflammation are identified as this is 
another complication of Type 2 Diabetes. The difficulties with the current therapies for Type 2 
Diabetes have also been described and these difficulties mean that there is a need to develop better 
therapies. The work described in this thesis describes how GPCRs can be targeted to help regulate 
glucose homeostasis through intestinal hormone secretion. GPCRs have already shown the potential 
to treat diabetes with the currently available Liraglutide and Exenatide. Fatty acid GPCRs have been 
further studied in clinical trials and the identification of new receptors or agonists for these receptors 
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